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ANGLIA RUSKIN UNIVERSITY 
ABSTRACT 
FACULTY OF MEDICAL SCIENCE 
DOCTOR OF PHILOSOPHY 
A LONGITUDINAL MONITORING STUDY OF 
CARDIOVASCULAR HEALTH IN THE ESSEX REGION 
LEON WEBSTER 
August 2017 
This thesis investigates the risk factors associated with adverse outcomes following 
percutaneous coronary intervention (PCI) for patients reporting to the Essex 
Cardiothoracic Centre (ECTC). The risk prediction model NWQIP (North West Quality 
Improvement Programme), for in-hospital Major Adverse Cardiac Events (MACE), 
comprising of at least one of four types of event (Q-wave myocardial infarction, death, 
emergency coronary artery bypass graft surgery, and cerebrovascular accidents), was 
externally validated on the ECTC PCI procedure database, using data from 2007 to 2015, 
to evaluate its effectiveness in a different era of stenting and a different geographical 
location. It was found the NWQIP model requires recalibration and hence no longer 
predicts such MACE events accurately. A custom risk prediction model was designed for 
the outcome of 30-day mortality. This incorporates novel risk factors (pre-operation 
ventilation and peripheral vascular disease) that were not featured in the NWQIP model. A 
subsequent analysis was performed on stable (elective) patients to identify those that are 
likely to either die or require a subsequent coronary revascularisation within three years. 
These two novel risk models should be tested on PCI cohorts external to the ECTC to 
identify how effective they are, and if they perform well, then possibly adopted into modern 
PCI practice for usage by consultants, operators, or patients for informed consent. 
Key words: percutaneous coronary intervention; major adverse cardiac events; 30-day 
mortality; repeat revascularisation; North West Quality Improvement Programme; Essex 
Cardiothoracic Centre  
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From the second study within this Thesis (Chapter 5, 30-day mortality prediction), an 
article was written and published to a peer-reviewed cardiovascular intervention journal as 
referenced below. 
Webster, L., van der Linde, I., Davies, J.R., Hampton-Till, J., 2015. Evaluation of the North 
West Quality Improvement Programme risk prediction model as a 30-day mortality 
predictor. Interv. Cardiol., 7(5), pp. 431-442 
In summary, the research article externally evaluates an established risk prediction model, 
NWQIP, for in-hospital complications (MACE) and 30-day mortality following 
percutaneous coronary intervention. This was performed on a modern PCI database for a 
cohort of patients at the Essex Cardiothoracic Centre (ECTC), part of Basildon and 
Thurrock NHS University Hospital. Following this, a risk model for predicting 30-day 
mortality in modern PCI cohorts was developed. The three co-authors of this research 
article are the three members of the supervisory team for this Thesis. 
At the time of writing this thesis, a journal article from the third study within this thesis 
(Chapter 6, Three-Year Repeat Revascularisation or Death) is in the final production 
stage and is intended to be submitted to a peer-reviewed interventional cardiology journal. 
Two abstracts were submitted in successive years (2014, and 2015) for presentation at 
the Anglia Ruskin University Student Research conferences. The abstracts received a 
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This thesis investigates patient outcomes following coronary revascularisation procedures 
for patients presenting with cardiovascular disease (CVD) at the Essex Cardiothoracic 
Centre (ECTC). The ECTC is a tertiary cardiac referral centre that is part of the Basildon 
and Thurrock University Hospital NHS Foundation Trust (BTUH), located in the county of 
Essex within the south-east of the United Kingdom (UK). 
1.1 Purpose 
The purpose of this research project was to identify whether the use of a contemporary 
cardiovascular patient database can be utilised to assist in the prediction of useful clinical 
outcomes (in-hospital complications, short and long-term mortality, repeat and 
revascularisation) for patients within the Essex region following percutaneous coronary 
intervention (PCI). It was also conducted to ascertain whether any prediction models could 
be developed that performed to accuracy and thus might be adopted and utilised by not 
only clinicians and interventional cardiologists at the ECTC, but also those at other 
hospitals and cardiac referral centres within the UK. 
By identifying a set of risk factors (characteristics) which exhibit a strong relationship with 
adverse outcomes following cardiovascular intervention, certain subgroups of patients 
most at risk could be determined and subsequently additional care, planning and 
resources could be allocated to such patients. Conversely, it may be the case that the 
clinical and procedural characteristics recorded in modern cardiovascular patient 
databases do not fully explain the important outcomes and hence may have very weak 
relationships thus rendering the usefulness of any such prediction models as poor. 
Whilst there are many published peer-reviewed journal articles (Singh & Lennon et al., 
2002; Grayson et al., 2006; Singh & Gersh et al., 2007; Madan et al., 2008; Ranucci et al., 
2009; Maluenda et al., 2010; Peterson et al., 2010; Hannan et al., 2013) on the subject of 
outcome risk prediction following PCI or coronary artery bypass graft (CABG) surgery, 
there are several important reasons why the studies in this thesis were performed, and 
why they contribute to knowledge of the field. 
There have been numerous changes in different aspects of cardiovascular intervention 
since many of these risk prediction models were developed, some of which are over a 
decade old, and consequently their performance may have deteriorated due to several 





The majority of the peer reviewed research on risk prediction models for outcomes 
following coronary revascularisation procedures that were identified in this thesis were 
developed by researchers at hospitals and cardiac centres within the United States (US). 
The US healthcare system has many differences (McCarthy, 2014; Ham, 2005; Pritchard 
and Wallace, 2011; Tyrrell, 2016; Jick, 2012) compared to the British National Health 
Service (NHS). Such differences may include the classification of intervention indications 
and reasons for performing (or not) PCI or CABG procedures for certain subgroups of 
patients, and hence the associations between mortality and other important outcomes 
may be impacted by such differences in healthcare practice. In addition to this, differences 
in population demographics (Cherlin, 2010) are also present, including but not limited to 
ethnic background (Chaturvedi, 2003), obesity levels (Poirier et al, 2006), socioeconomic 
status (Clark et al, 2009), these of which have been identified as having a relationship with 
developing cardiovascular disease. As well as differences between these factors for 
comparing countries it is also anticipated that internal differences exist, i.e. states within 
the US and counties within the UK (Braveman et al, 2010; ONS, 2016). It may also be the 
case that differences are present within regions, i.e. between towns, primary care trusts 
(PCTs) or clinical commissioning groups (CCGs). 
Increasing Life Expectancy 
In England, the average life expectancy in years has increased (ONS, 2016) from 75.9 in 
1990 to 81.3 in 2013 (Newton et al., 2015). With increasing age, so too has the incidence 
of coronary artery disease (CAD) and hence inpatient episodes, caused by CAD (BHF 
CVD Statistics, 2014). During 2012/13 this figure was 404,000. For many PCI mortality 
and/or adverse complication risk prediction models, patient age is one of the components 
whereby an increased risk of adverse events is generated, in general, as age increases. 
The advanced age tends to act as a surrogate predictor for frailty (Murali-Krishnan et al, 
2015). With increasing life expectancy (Leon, 2011) is it anticipated that more elderly 
patients would be presenting for coronary revascularisation, and hence would affect the 
overall mortality and complication rates negatively. The increase in the population 
reporting to PCI centres and hospitals would likely cause a burden on the healthcare 
system, possibly resulting in lower risk patients with cardiovascular disease having to wait 
longer for the appropriate procedure. This increased 'load' may alter the decision making 
process for cardiology consultants, i.e. would a low-risk patient (such as stable angina) 
now instead be given pharmacological therapy instead of a PCI. 
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Other Demographic and Comorbidity Trends 
In addition to increasing life expectancy there have been trends identified specifically in 
the UK population rates relating to increasing CVD, diabetes, other comorbidities, and 
prior PCI. These rates may simply be explained because they are diagnosed at a far 
earlier stage than previously. For example, individuals with hypertension and renal 
disease may have a more rapid identification of subsequent cardiovascular disease 
symptoms and hence a more rapid referral to a consultant cardiologist. Sociodemographic 
factors may also have an influence on the outcomes following PCI, for example the ECTC 
is based in the south-east of England, and it has been identified that a north/south divide 
is present whereby those in the north of England were found to have a lower life 
expectancy than the southern counterparts (ONS, 2013). 
Cardiac Centres and Operators 
In the UK there has been a steady increase in the number of cardiac centres and hence 
locations which perform PCI procedures. This increased from approximately 52 in 1996 to 
119 in 2014. This corresponded with an increased number of interventional operators from 
approximately 300 in 2001 to 731 in 2014 (BCIS Audit, 2015). In 2014, 96,143 PCIs were 
performed on patients with CAD (BCIS Audit, 2015) at NHS centres. 
Clinical Syndrome 
The clinical syndrome UK patients are presenting to PCI centres with, when broken down 
into acute coronary syndromes (ACS) and the counterpart, stable syndromes shows a 
steady trend over time. ACS has increased from approximately 44% in 2005 to 65% in 
2014, and corresponding to this, the stable syndrome decreased from approximately 56% 
in 2005 to 35% in 2014 (BCIS Audit, 2014). 
Stenting Technology and Dual Antiplatelet Therapy (DAPT) 
The devices used during modern coronary revascularisation, most notably PCI 
procedures, have experienced big changes over the last few decades (Simard et al, 2014; 
Ernst, 2014). One of these biggest changes is the evolution from standard balloon 
angioplasty to the usage of bare metal stents (BMS), to the usage of drug-eluting stents 
(DES), subsequent generations of DES (Akin et al, 2011), followed more recently by 
global clinical trials of bioabsorbable stents, such as the Absorb stent manufactured by 
Abbott Laboratories. These bioabsorbable stents were developed to address the 
drawbacks/limitations of current generation metallic stents. They are constructed from a 
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polylactide material and can be fully absorbed into the coronary artery, usually after a 
period of 2-3 years. The main aim is to prevent very late stent thrombosis, whereby blood 
clots form around metallic stents in 1-2% of patients, and thus can cause subsequent 
adverse events for the patient such as death, myocardial infarctions, or the need for 
subsequent treatment (target lesion revascularisation, TLR). Once the stent has fully 
dissolved, it is proposed that the coronary vessel can resume its natural movement, i.e. 
vasodilation and vasoconstriction. This also should result in the patient not needing to 
dual anti-platelet therapies (DAPT) for as long as they would if they had a metallic stent. 
The DAPT combine the usage of aspirin with a stronger aspirin-like drug (e.g. Clopidogrel, 
Prasugrel, and Ticagrelor), the purpose of its usage is to reduce the risks of future 
myocardial infarctions (MIs), and blood clotting around the inserted stent (ACC, 2016). 
These differences in the stent technology such as material, thickness, and drug coating 
may exhibit differences in restenosis and other adverse events (Smits, 2010; Navarese et 
al, 2014) for different patient subgroups at the ECTC following PCI, such events may 
include mortality (all or cardiac-related), myocardial infarction (MI), TLR, or target vessel 
revascularisation (TVR). As mentioned above, related to the stent type is the post-
procedure pharmacological therapy provided to the patient, namely the amount and 
duration of DAPT (Kereiakes et al, 2015; Tantry et al, 2006). 
Recently (September 2017), Abbott Laboratories announced they were ceasing the 
commercial sales of their first generation Absorb stent (Abbot 2017). They will focus on a 
next generation bioabsorbable stent by addressing some of the reported limitations 
including: cost; thickness of the stent (additional polymer is required to make the stent 
strong compared to metallic stents); long insertion times; inability to use the stent (due to 
size) on small coronary vessels (< 2.5 mm diameter); recoil issues following expansion; 
and faster absorption rates. Additionally, there has been a lack of results from trials 
reporting clear benefits in terms of MACE rates compared to DES (Pandya et al., 2016; 




1.2 Risk Prediction Models 
Risk prediction models exist in many different industries and are used to estimate the 
likelihood of different events occurring. For example, in medicine models exist to predict 
long-term mortality for patients which have undergone coronary bypass graft surgery (Wu 
et al, 2012), many others exist that are non-cardiac related also; for example, predicting 
mortality following kidney transplantation (Jassal et al, 2005), or liver transplantation (Pan 
et al, 2014). Typically, the models are constructed using a comprehensive database 
incorporating demographics, procedural, and clinical variables where applicable. The 
myriad of models in published peer-reviewed journals allow clinicians and researchers to 
externally validate them on their own cohorts to verify the performance level of the model, 
and hence if the model performs well enough to be adopted in clinical practice. 
The models incorporate risk factors/characteristic variables which are assigned specific 
weights based on their statistical association with the event/outcome (e.g. three-year 
mortality), typically, the more risk factors within a prediction model that the patient 
exhibits, the higher the probability of experiencing the adverse outcome. Variables are first 
identified in a univariate test with their association for the specific outcome. Those which 
exhibit a strong statistically significant relationship are then used as candidates for a 
multivariate logistic regression analysis. In doing so, this eliminates those risk factors with 
high correlation with each other, i.e. those with high multicollinearity, to ensure the risk 
model is as parsimonious as possible. 
Risk models provide numerous benefits that warrant their research, construction, and 
subsequent adoption in clinical practice. They can inform consultants and operators or 
likely outcomes for a patient that exhibits certain characteristics. A model can estimate a 
probability of an adverse event which could assist in justification of whether to proceed 
with a certain type of treatment. 
Related to the previous benefit, the model could be useful for elective patients such that 
they can be informed of the likely outcomes should they choose to receive a certain 
treatment. For example, if a risk model estimated a 95% probability of death within 30 
days based on various characteristics exhibited by the patient, they may not want to 
proceed with such a high risk treatment. 
Usage of risk models can allow more efficient planning and management strategies to be 
implemented for high-risk patients. For example, the highest risk subgroups of patients 
could be provided more care by the hospital rehabilitation teams or given an increased 
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hospital length of stay to facilitate their recovery, conversely patients at a very low-risk of 
adverse events could be discharged more rapidly, this is especially beneficial given 
shortage of hospital beds (Chang et al., 2002; Kramer and Zimmermant, 2010; Ong and 
Pua, 2013). 
They also have the potential to identify adverse practices. For example, given the release 
of operator outcomes to the public (BCIS Operator Results, 2015) it allows comparisons 
between operators and hospitals for complications/mortality to ascertain which are 
performing above or below national rates (i.e. using a 95% confidence interval). It allows 
the following points to be addressed: (I) Are certain operators/hospitals unnecessarily 
putting patients at high risk that should not be. (ii) Whether treatment for certain patients is 
being avoided to covertly reduce mortality rates. Any significant departures from the 





1.3 Outcomes Analysed and Hypotheses 
The important clinical outcomes featured in this thesis were chosen because they are 
measures considered important with regards to interventional cardiology, and hence why 
they are selected in a myriad of previous published research studies on outcomes 
following coronary revascularisation. The outcomes are described briefly below. 
In-hospital major adverse cardiac events (MACEs) 
This is a composite outcome of the occurrence of at least one of the following events 
during a patient's index admission at the ECTC: (I) death – this can be any cause even if it 
is unrelated to an underlying cardiovascular cause; (II) emergency CABG surgery 
performed; (III) cerebrovascular accident (stroke); (IV) a Q-wave MI in which a heart 
attack has occurred that produces a new Q-wave on an electrocardiogram (ECG) and 
whereby certain elevated cardiac biomarkers are detected in the patient (Thygesen et al, 
2007). The outcome of in-hospital MACE was particularly important because it is the 
featured outcome of the widely recognised NWQIP model (North West Quality 
Improvement Programme, Grayson et al, 2006) developed by a consortium of UK 
hospitals. The NWQIP model is a multivariate logistic regression model whereby several 
risk factors are given different weightings based on the strength of their association with 
the in-hospital MACE outcome and these are combined to generate an odds metric which 
represents the likelihood that patient with a given set of risk factors, would go on to 
experience the in-hospital MACE outcome. The risk factors incorporated into the NWQIP 
model are: age; female gender; stroke; cardiogenic shock; PCI priority; and lesion type 
treated (i.e. LMS or graft). 
30-Day Mortality 
This includes a patient's death occurring up to and including 30 days from the date of an 
index PCI procedure. This measure includes both patients that died pre-discharge and 
post-discharge so long as the death is within the specified time period of 30 days. This 
outcome includes all-cause mortality, not just cardiac-related deaths.  
Repeat Revascularisation 
The type of repeat revascularisation investigated in this thesis is whereby a patient is 
given a subsequent unplanned coronary revascularisation procedure within three years, 
whether this is another PCI or a CABG following an initial PCI at the ECTC. The 
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unplanned classification is where their subsequent revascularisation procedure has not 
been foreseen, arranged or known about at the time of their initial PCI. 
A subset of repeat revascularisation is target vessel revascularisation (TVR) whereby a 
subsequent unplanned revascularisation procedure is performed on the same coronary 
vessel as was treated during their index PCI. This does not necessarily have to be a 
single coronary vessel revascularisation for both procedures, as long as the same vessel 
was treated during the index PCI and the subsequent PCI/CABG then it is classified as a 
TVR. The vessels that are treated can be one of the following: right coronary artery 
(RCA); left circumflex (LCX); left main stem (LMS/Lmain); left anterior descending artery 
(LAD); or a previously grafted vessel. 
 
1.3.1 Hypotheses 
By analysing the specified the outcomes of in-hospital MACE, 30-day mortality, and 
repeat revascularisation or death it allowed the following hypotheses to be tested. These 
hypotheses were formulated from the described limitations in section 1.1. In summary, the 
factors which influenced the development of the hypotheses are: 
 Increasing life-expectancy of the UK population (ONS, 2016).  
 Increasing overweight and obesity rates amongst the UK population (ONS, 2017) 
 Other differences between the characteristics (demographic, clinical, and 
procedural) between the original NWQIP PCI cohort and the ECTC cohort (as 
documented in section 3.6). 
 high proportions of emergency PCI procedures being performed (e.g. critically ill 
patients, such as those which have experienced an out-of-hospital myocardial 
infarction) as reported by the British Cardiovascular Intervention Society (2016) 
 Increased numbers of UK cardiac centres/hospitals performing PCI (and CABG) 
 Increased numbers of operators/interventional cardiologists (BCIS, 2016) 
 Technological evolution in stent design and material (e.g. drug-eluting stents and 
successive generations such as bioabsorbable materials), which are claimed to 




Hypothesis 1: The NWQIP risk model is outdated and will not perform as effectively as it 
did in its original setting (Grayson et al., 2006), or as it did in the external validation study 
(Kunadian et al., 2008), when tested on a modern PCI centre patient database. 
Hypothesis 2: Relating to hypothesis 1, not all of the NWQIP model risk factors (i.e. age, 
gender, cerebrovascular disease, cardiogenic shock, PCI priority, left main stem lesions, 
and graft lesions) will exhibit significant univariate associations with in-hospital MACE. 
Therefore, it is theorised that due to both increasing numbers and more experienced 
operators (higher volumes of PCIs performed), performing PCI on patients with such 
NWQIP risk factors is effectively 'safer' than previously. This therefore suggests that a 
'new' risk prediction model will not incorporate all of the NWQIP risk factors. 
Hypothesis 3: By performing a multivariate logistic regression analysis on the modern, 
comprehensive, ECTC PCI database (CVIS), novel risk factors not present in the NWQIP 
model will be discovered that exhibit a significant association with important clinical 
outcomes following PCI and hence could lead to the development of risk prediction 
models that perform well for both discrimination (Hanley & McNeil., 1982; Park et al., 




1.4 Limitations and Considerations 
Risk prediction models are not perfect, especially in medicine. It is extremely unlikely that 
a mortality prediction model for a certain procedure would produce perfect discrimination. 
When constructing or using pre-existing risk prediction models there are many potential 
pitfalls and limitations that should be considered when interpreting results and as such 
highlighted during the production of this thesis. These are briefly described below. 
Variable Definitions and Data Completeness 
The variables or 'risk factors' should be easily defined and recognised. For example, the 
exact definition of various comorbidity classifications such as hypertension or diabetes 
should be consistent throughout different hospitals and cardiac centres. By 
misclassification of variables, it will worsen the performance of any association with 
measured outcome and hence either overestimate or underestimate the strength of the 
relationship, which subsequently makes any findings less accurate and hence reduces the 
accuracy of any prediction model. Fortunately, for the studies featured here this is 
somewhat mitigated by the UK NHS having a similar system of classification regardless of 
the hospital. This point would be more evident if for example, a risk prediction model were 
developed in a foreign health service setting (e.g. United States) and then used in a UK 
hospital or vice versa. An issue also arises if different institutions do not enforce good data 
completion policies, however with regards to the UK, having a central body that examines 
each hospital's or cardiac centre’s data completeness somewhat addresses this limitation, 
in the case of the PCI procedures, the British Cardiovascular Intervention Society is 
responsible for this (BCIS, https://www.bcis.org.uk).  
Variable Selection 
The risk model should be as parsimonious as possible, whereby only the core set of most 
important predictors or risk factors are present, and none that do not significantly 
contribute to the model's performance. The variables utilised in any model should also 
have a high data completion rate in any database used to develop the model. For 
example, even though a specific variable yields a very high association with a certain 
outcome, it may be the case than the given variable is only recorded for a small 
percentage of patients/procedures and thus for the rest the value of such a variable is 
unknown. It should also include only those variables that do not incur any significant cost 




If certain comorbidities such as diabetes, peripheral vascular disease (PVD), or chronic 
obstructive pulmonary disease (COPD) are identified to be significant predictors of a given 
outcome (e.g. mortality or in-hospital complications) then it may be the case that many 
patients which have not been diagnosed with the condition at the time of their PCI are 
afflicted with it but it is not known, for example it was estimated that 590,000 adults had 
undiagnosed Type 2 diabetes in 2013-14 within the UK (Diabetes UK, 2015). If this issue 
was constant over time then any model would be less affected, but if differences in 
percentages of patients are correctly diagnosed with/without a certain comorbidity then 
comparing patient populations over different time periods would be inaccurate thus limiting 
the effectiveness of the model as a decision making tool for clinicians and patients. 
Multicollinearity 
This occurs when two or more variables/risk factors in a prediction model are highly 
correlated with each other such that the strength of each predictor cannot be separated. 
Between these risk factors, one may be linearly predicted from the other, when this is the 
case the standard error of the variables will be high and thus affect the overall 




1.5 Objectives Summary 
There are five main objectives which this thesis sets out to complete in order to test the 
stated hypotheses (section 1.3), these objectives were formulated following review of 
existing literature, analysis of what was missing, what has changed, and what novel risk 
factors from the available data might be worthy of analysing for possible associations with 
adverse outcomes. These intended objectives were selected following synthesis of the 
information provided in 1.1 to 1.3, and are briefly described below.  
(1) To investigate the important clinical outcomes following PCI procedures (as discussed 
in 1.3) at the ECTC, by using data from the patient PCI database. Such data contained 
within the database includes demographic, clinical, angiographic, procedural, and 
mortality data. 
(2) To externally validate the NWQIP risk prediction model using the ECTC PCI patient 
cohort, and to assess its level of performance on a different geographical area within the 
UK (i.e. South-East England instead of North-West England), and a different era of PCI, 
namely the NWQIP study was performed in an era of higher BMS usage compared with 
the modern high usage of DES at the ECTC. Following analysis of the NWQIP 
performance, identification of any multivariate risk factors that have major changes to the 
strength of their association with the in-hospital MACE, as an outcome will be 
investigated. 
(3) Extending the analysis above (objective 2), investigate which risk factors within the 
NWQIP model may no longer be useful in predicting in-hospital MACE, and which risk 
factors not present in the model are significantly associated with the outcome and should 
potentially be considered for incorporation into a new risk prediction model that would 
improve performance on a modern PCI cohort. 
(4) As it is already known following many published studies and audit reports of outcomes 
following PCI that in-hospital MACE events occur at very low rates in elective (stable) 
patients, identification of other important outcomes would be identified such as extending 
the in-hospital mortality component of MACE to 30-day mortality. It may be identified that 
if patients survive the first 30 days following their PCI, then the risk decreases. 
Identification of such risk factors could then be incorporated into a new risk prediction 
model and be assessed for its performance, i.e. discrimination and calibration capabilities. 
Depending on how it performs, it may warrant further testing by other hospitals or cardiac 
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centres for possible usage in clinical practice (i.e. decision making or better management 
of high-risk patient subgroups). 
(5) At the time of writing this, there is lots of peer-reviewed literature featuring outcomes 
following PCI such as in-hospital complications and short-term mortality (mostly from the 
United States), however there is less literature available on the outcome of repeat 
revascularisation, especially within stable (elective) patients. This study investigates the 
factors useful in predicting which subgroups of patients are likely to return to the ECTC for 
a subsequent unplanned (non-staged) revascularisation procedure within three years. Not 
only could this be useful for PCI operators, but also for patient information and more 




1.6 Thesis Structure 
The Theoretical Background (Chapter 2) provides the fundamental details of 
cardiovascular disease intervention which will be useful in understanding the context of 
this Thesis. This section briefly explains the types of treatment available for CVD, namely 
pharmacological therapy, PCI, and CABG surgery. This also includes a literature review of 
related published peer-reviewed studies analysed in preparation of this thesis, specifically, 
those with similar outcomes of interest following coronary revascularisation. 
The third chapter, General Methods and Data, lists the general analysis techniques and 
statistics tests used in this thesis. It lists the details of the cardiovascular patient database 
used and general data. The approach in designing a risk prediction model and how they 
have their performance evaluated is also explained. 
The first study within this thesis – Evaluation of NWQIP (Chapter 4) externally validates 
the established PCI risk prediction model for in-hospital complications in the form of 
MACE. Both the discrimination and calibration performance are validated using a 
contemporary PCI patient database from the ECTC. 
The second study (Chapter 5) modifies the outcome of in-hospital MACE to the more 
robust outcome of 30-day mortality and validates whether the NWQIP model is a useful 
predictor of 30-day mortality, or whether significant recalibration/re-identification of risk 
factors is necessary. A custom multivariate prediction model is then developed to attempt 
to improve the performance in predicting 30-day mortality using additional characteristics 
from the cardiovascular PCI patient database. 
The third and final study (Chapter 6) investigates three-year repeat revascularisation and 
death following an initial elective PCI at the ECTC. It aims to identify important outcomes 
for the low-risk (elective) patients as previous measures (short-term mortality, in-hospital 
complications) occur a very low rates. Knowing whether an elective patient has a high risk 
of dying or requiring a subsequent coronary revascularisation procedure (PCI or CABG) is 
extremely useful for both operators and patients. 
Since the 30-day mortality prediction model was developed (in Chapter 5), two 30-day 
mortality models have been published by other researchers in the UK (McAllister et al, 
2016; Wall et al, 2017). The major findings from these studies and how they relate to the 
model developed using the ECTC cohort, is discussed in Chapter 7 (Conclusions). 
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Section 2.1 features a very basic description of cardiovascular disease, that would be 
useful to understand (as a bare minimum) as a foundation for subsequent chapters in this 
thesis. Section 2.2 includes a basic introduction to interventional cardiology, and 
describes the percutaneous coronary intervention (PCI) and coronary artery bypass graft 
(CABG) procedures, both of which are performed at the ECTC. Having a basic knowledge 
of PCI and CABG would be beneficial in order to set the context of the three studies in 
chapters 4, 5, and 6. 
Section 2.3 begins with an introduction to the first major health related epidemiological 
study (Framingham Heart Study) conducted, and a second study of a similar nature 
(Seven Countries Study). The former led the way for longitudinal studies and provided 
useful information on population cardiovascular health, and the corresponding 
identification of risk factors and their association with cardiovascular disease. Following 
this there is a review of published literature relating to risk prediction models developed to 
estimate the likelihood of clinically important outcomes occurring following PCI. The 
literature featured here is important because they incorporate outcomes of interest in this 
thesis (e.g. in-hospital MACE, mortality, and repeat revascularisation) and this provided a 




2.1 Cardiovascular Disease 
The cardiovascular system is primarily responsible for circulating blood around the body 
for the delivery of oxygen and other nutrients required for powering cells, and subsequent 
removal of waste by-products such as carbon dioxide. Other functions include 
transportation of hormones to organs, temperature regulation and defending the host by 
carrying immune cells and antigens (Horton-Szar & Newby, 2012). 
The heart, a double muscular pump, for which the primary function is to collect and pump 
blood throughout the body achieves this using a combination of four chambers comprising 
two ventricles, two atria, and several valves which include the tricuspid, pulmonary, mitral, 
and aortic valves. The other components of the cardiovascular system are the arteries, 
veins, capillaries, and arterioles. 
Figure 2.1.1 shows the basic components of the heart (Adapted from Zoofari, 2010). 
 
 





In brief, the following sequence of events is performed by a functioning heart (Pappano & 
Wier, 2013, p.2). 
(1) Deoxygenated blood enters the right atrium (RA) from the superior/inferior vena cava. 
(2) The blood moves from the RA to the right ventricle (RV). 
(3) From the RV the blood is pumped to the pulmonary artery and then to the lungs. 
(4) The oxygenated blood from the lungs enters the left atrium (LA). 
(5) The blood moves into the left ventricle (LV). 
(6) The LV pumps the blood to the body via the aorta. 
In some people the ability of the cardiovascular system to function effectively and 
efficiently becomes sabotaged and can subsequently lead to a variety of health problems 
collectively termed cardiovascular disease (CVD). CVD itself, comprise of numerous 
afflictions affecting either the heart directly, or the blood vessels/arteries throughout the 
body, for which the most frequently observed types are briefly described below (Segerson 
et al., 2011, p.23;p.40;p.45;p.93;p.110;p.114). 
Coronary Heart Disease/Coronary Artery Disease (CHD/CAD) 
CHD is the biggest single cause of morbidity and mortality in the UK (British Heart 
Foundation, 2014) and the US. In the UK specifically, approximately 16% of men and 10% 
of women die from CHD. This occurs when the arteries (coronary) which supply blood to 
the heart tissue itself become occluded. Such arteries supplying blood to the heart tissue, 
which can become either partially occluded or fully blocked, include the right coronary 
artery (RCA), left anterior descending artery (LAD), left main stem (LMS), or the left 
circumflex artery (LCX). For patients who have undergone a coronary artery bypass graft 
(CABG) for a previously occluded native coronary artery, it is possible for the graft vessel 
to become occluded itself and hence require revascularisation treatment. The material 
causing the occlusion within these arteries are plaque deposits (atherosclerosis) which 
are formed as a result of fatty acid deposits that collect and accumulate on the arteries 
inner walls. When the plaques accumulate to a high degree they become part of 
structures known as atheromas which are responsible for the narrowing and constricting 
of the arteries. Insufficient blood flow to the heart tissue can result in cell death (necrosis), 
affecting the heart's electrical system and hence sabotaging the ability of the ventricles to 
contract and pump blood effectively. When partially blocked a patient may experience 
chest pain (angina), this can be stable whereby the pain is only experienced upon 
physical exertion, or unstable whereby the pain seemingly occurs at periods without much 
exertion, and is not responsive to medication. When a coronary artery becomes fully or 
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close to fully occluded a patient may experience a myocardial infarction (heart attack) 
which can be fatal, especially if not treated rapidly. 
Angina Pectoris (chest pain) 
As briefly described above, angina can occur when there is a reduction of blood flow, and 
hence oxygen supply to the tissues of the heart itself. The pain experienced by patients 
with angina can feel like a squeezing pain in the chest, and occurs because too much 
demand placed upon the heart which is not receiving adequate blood flow. Treatment in 
the form of pharmacological therapy can often be used for patients suffering with angina, 
this includes nitroglycerin which causes blood vessels to dilate, or beta-blockers which 
help control the overactivity of the heart itself. Angina is the most commonly reported 
symptom of CHD, and if appropriately managed before the patient's condition is too 
severe, a myocardial infarction can be potentially avoided, or at least have the time until 
one is experienced extended. 
Congestive Heart Failure (CHF) 
Heart failure occurs when the heart is unable to pump enough blood to meet the body's 
requirements, and is commonly caused by damage to the heart's ventricles (muscles) 
themselves. Due to the lack of circulation, sometimes blood can accumulate in the lungs, 
ankles, or legs and when this occurs it is known as CHF. Obesity is one the biggest risk 
factors for CHF, due to a patient having excessive body fat, this causes an increased 
oxygen demand and hence makes it much harder for the heart to meet such demand. 
Stroke (cerebrovascular accident) 
A stroke occurs when either a blood vessel within the brain or one supplying the brain 
becomes blocked via atherosclerosis, the corresponding tissue within the brain which is 
not getting the required supply of blood from the artery dies, i.e. necrosis. In some cases 
the stroke can be caused by an embolus, whereby a piece of atherosclerotic matter 
breaks off from another location within the body, but subsequently travels to the brain and 
clots an artery and causes tissue death. Depending on the location within the brain where 
the tissue is dying, it has the ability to cause either temporary or permanent physical or 
cognitive damage. This is especially fatal if the stroke affects the brain stem as this assists 
in regulating the heart rate, blood pressure, and respiratory system. Several symptoms of 
stroke may be present relating to both cognitive and physical functioning such as 
numbness/weakness of the face/arms/legs (especially on one side of the body), sudden 
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confusion/difficulty speaking or understanding, visual difficulty in one or both eyes, 
difficulty walking or a loss of balance, or sudden headaches with an unknown cause. 
Atherosclerosis 
As already briefly described, atherosclerotic material is a plaque which builds up within the 
inner walls/lining of the arteries, which is of additional importance when this occurs in the 
coronary arteries that supply the heart muscle tissue with blood. The build-up can cause 
the arteries to stiffen and also thicken. The deposits can be comprised of cholesterol, 
calcium, fibrin, and other cellular waste products. 
Arrhythmias 
Arrhythmias are caused by abnormalities in the heart's electrical system which 
subsequently affects the contractions of the left and/or right ventricles which pump blood 
around the body. The most common forms are tachycardia, bradycardia, and fibrillation. 
Tachycardia occurs when the heart is beating abnormally fast despite no additional 
exercise or other stimulus. Bradycardia occurs when the heart is beating abnormally slow, 
and fibrillation is when the heartbeat features a quivering pattern and is sporadic and 
uncoordinated. 
Risk Factors for Cardiovascular Disease (CVD) 
There have been many risk factors identified and verified which contribute to the 
manifestation of CVD. In general, the more risk factors a patient exhibits, the more likely 
they will develop a form of CVD. Some risk factors can be controlled such as tobacco 
consumption, physical activity, diet (e.g. saturated fat and cholesterol), weight (i.e. 
avoiding obesity), alcohol consumption, blood pressure control through the usage of 
pharmacological therapy, diabetes management, and stress management. There are 
however several risk factors that are unavoidable (Horton-Szar & Newby, 2012, p. 85) and 
hence unchangeable, such as age (increased risk as you age), gender (men have an 
increased risk even after women experience menopause), ethnicity and other heredity 
(e.g. African and Asian ethnicities have an increased risk relative to 
Caucasian/European), and family history (e.g. a parent or close relative which died of 
CVD can increase the risk for an individual).  
Patients with CVD can experience early death or other comorbidities and disabilities, 
reduction in their quality of life, myocardial infarction (heart attacks), and cerebrovascular 
accidents (stroke). Some of these symptoms can be alleviated with pharmacological 
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therapies such as aspirin, statins, beta-blockers, and nitroglycerin. However, for some the 
CVD may be so severe that a coronary revascularisation procedure in the form of 
percutaneous coronary intervene (PCI), or a coronary artery bypass graft (CABG), or 
valve surgery are required to treat the CVD effectively. PCI and CABG are described in 
brief in section 2.2. 
There are many techniques and medical imaging modalities available in modern health 
care practice for diagnosing CVD, these include an electrocardiogram (ECG) whereby the 
electrical system of the heart is analysed by placing multiple leads on various locations on 
the patient's chest and measuring activity at different time periods throughout the hearts 
contraction. This allows the strength, timing, and other characteristics to be displayed 
allowing possible diagnosis of certain abnormalities. An angiography utilises a dye that is 
injected into the body allowing the coronary vessels to become easily visible on an x-ray. 
The CT scanner performs rotations and allows occlusions and narrowing of arteries to be 
spotted. Other less frequently used technologies include positron emission tomography 
(PET), single photon emission tomography (SPECT), magnetic resonance imaging (MRI), 




2.2 Interventional Cardiology 
2.2.1 Percutaneous Coronary Intervention (PCI) 
A percutaneous coronary intervention (PCI) procedure, also known as an angioplasty, is a 
treatment which aims to clear blockages/narrowing of the heart's coronary arteries so that 
optimal blood flow to the tissues of the heart (myocardium) is restored either partially or 
fully. The PCI procedure is a non-surgical procedure as opposed to CABG surgery; 
meaning the chest and heart itself are not exposed. During the procedure an incision is 
made either into a femoral (groin) or radial (arm) artery to allow a hollow tube known as a 
catheter to be inserted via the use of a thin guide wire, allowing placement into the correct 
coronary artery which has the site of the occlusion. The catheter contains a deflated 
balloon on the tip, often (in modern practice) covered with a metallic stent consisting of a 
mesh coil. When the balloon is inflated at the site of the blockage the mesh coil remains in 
place and holds the occluded (stenotic) section of the coronary artery open, after this the 
balloon is deflated and removed (Kern, 2004, p.14). The inflation of the balloon and hence 
expansion of the stent presses against the atherosclerotic plaque causing the narrowing, 
thus allowing an increase in blood flow through that segment of the coronary artery as 
show in Figure 2.2.1 (created by the author, Webster, L., 2016). 
 
Figure 2.2.1 –Diagram of a guide catheter, balloon, and stent used during a PCI procedure (Webster, 2016) 
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It should be noted that the majority of PCIs performed in the modern era of interventional 
cardiology will use a stent. Those that do not, occur in rare circumstances and this refers 
to standard balloon angioplasty, whereby the balloon's expansion alone it used to disrupt 
the site of the plaque. Fluoroscopy, which is a special type of x-ray, assists operators in 
visualising the coronary arteries and hence allowing them to see the locations of the 
blockages or narrowing of the arteries, this technique can elucidate the approximate 
stenosis (blockage) percentage. This is achieved through the use of a radioactive contrast 
dye that enhances the arteries, allowing the vessels to be seen more easily on a screen. 
Once a stent has been inserted and expanded at the target site, tissue can soon form 
over it (within several days) following the PCI. After approximately one month the stent 
can be covered in scar tissue such that antiplatelet medication must be taken by the 
patient to decrease the 'stickiness' of the platelets within the blood to prevent clots 
occurring around the site of the stent. For the newer generations of stent, i.e. drug-eluting 
stents (DES), they are coated with a drug that slowly releases over time that inhibits the 
growth of tissue within the stent site and thus assisting to stop the artery from becoming 
narrowed again. Any narrowing of the treated artery will likely however make symptoms 
such as angina reoccur. 
The following sequence of steps briefly describes the process of performing a PCI 
procedure in the general sense, the exact steps and devices used will differ between 
hospitals and operators and depending on the type of patient and disease severity being 
treated (Kern, 2004, p.12-14; Segerson et al, 2011, p.27). 
Steps during a PCI procedure 
(1) An intravenous (IV) line is inserted into the patient’s hand or arm in order to administer 
fluids if required. 
(2) The patient is connected to an electrocardiogram (ECG) monitor to display vital signs, 
including blood pressure, heart rate, breathing rate, and oxygen level). 
(3) A sedative will be given to relax the patient. 
(4) The pulse near the insertion site for the catheter will be verified. 
(5) A local anaesthetic will be injected at the insertion site. 
(6) A sheath will be inserted into the blood vessel allowing the catheter to be threaded 
through. 
(7) The catheter is threaded through the patient into the heart and is visualised using 
fluoroscopy. 
(8) Once in place, the contrast dye is injected into the coronary arteries. 
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(9) The X-ray images of the arteries are taken rapidly. 
(10) The catheter is advanced to the correct location of the blockage. 
(11) The balloon is inflated (and hence stent is used in the PCI) 
(12) The balloon is deflated, and angiograms are taken. 
(13)The catheter and sheath are removed. 
(14) A closure device is used to seal the insertion site artery. 
Complications during and following a PCI procedure 
Patients which undergo PCI are at risk of developing certain complications either during 
the procedure itself or afterwards. Some of the complications which may be experienced 
from PCI can also be experienced by patients that undergo a CABG surgery. Most of the 
complications that occur following PCI occur almost immediately, some of the most 
frequently experienced complications are briefly described below. 
Artery closure/emergency CABG is one of the most serious complications whereby 
sudden closure of the target coronary artery occurs, this may be treated by reinserting a 
balloon/stent, or in more serious cases by performing an emergency CABG. 
Bleeding/infection at the site at which the catheter is inserted can occur, i.e. the femoral or 
radial artery. Restenosis occurs when the stent (or balloon if a standard angioplasty) fails 
to prevent the coronary artery from narrowing again. In some cases a subsequent PCI 
may be needed, or for more serious cases a CABG may be performed. Major adverse 
cardiac events (MACE) as described in Chapter 1 can occur, which include in-hospital 
death, Q-wave myocardial infarctions, emergency CABG, or cerebrovascular accidents 
(Levine & Kern, 2004, p.162-190). Other complications which are quite rare can include 
negative contrast medium reactions, stent loss, arterial perforation, or femoral 
arteriovenous fistula (Mukherjee & Bavry, 2011, p.165-174). 
In general, the PCI procedure is considered a success if certain clinical, angiographic, and 
procedural criteria are met. The PCI should be absent of in-hospital complications (i.e. 
MACE). The coronary vessel target site stenosis percentage should be substantially 
reduced relative to the pre-PCI stenosis percentage. Such a reduction in stenosis should 
relieve any symptoms such as angina either partially of fully following the PCI, after a 
sufficient recovery period. Most patients that receive PCI recover fully from the procedure 
within a few days to two weeks and can resume normal activities at a far earlier time than 
patients which undergo CABG surgery. In general, patients will be informed about lifestyle 
and diet changes which can reduce the chance of lesions and cardiovascular disease 
progression from reoccurring. Examples include cessation of smoking, obese patients 
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losing weight and eating lower-fat food, and getting more regular exercise. Most patients 
will be on some sort of cardiac rehabilitation programme whereby they will have their 
recovery monitored and suggested to take pharmacological therapy such as 
aspirin/anticoagulant medication. 
2.2.2 Coronary Artery Bypass Graft (CABG) Surgery 
The CABG surgery was the first procedure to be widely adopted by interventional 
cardiologists for coronary revascularisation. In brief, an artery or vein is removed from 
another location within the patient's body, and is subsequently surgically grafted from the 
aorta, past the blocked section of the coronary artery thereby bypassing the blocked 
segment, and allowing blood to flow again from one end of the artery to the other. During 
the surgery an incision to the sternum is made to allow the patient's chest to be opened 
for access to the heart, the heart itself is stopped temporarily to allow the graft vessel to 
be sewn on. The circulation of blood is performed mechanically using a cardiopulmonary 
bypass machine. Newer bypass procedures do not require the heart to be stopped for 
surgery however, i.e. off-pump CABG, and require smaller incisions, i.e. minimally 
invasive bypass surgery.  
Some of the indications that warrant CABG surgery are similar to PCI such as angina 
(chronic or unstable), acute myocardial infarction (AMI). However CABG in general is 
performed on patients with complex lesions such as those heavily calcified or in difficult 
locations within the coronary artery such as branches or bends. CABG also tends to be 
more popular with patients that exhibit multiple occluded coronary vessels, whereby the 
stenosis percentage is very high (e.g. 70% occluded). CABG can also be a solution for 
when a PCI has failed; this failure could be due to lesion complexity despite attempts with 
using a drill known as a rotablator to try to break up the lesion. In most cases when CABG 
is to be performed on the right coronary artery (RCA) or circumflex artery (LCX), the vein 
used for the bypass will be the saphenous vein from the patient's leg. If the target vessel 





The three most common coronary arteries requiring a bypass graft are the RCA, LAD, and 
LCX as detailed in Figure 2.2.2 (Adapted from Tidy, 2017) 
 
Figure 2.2.2 – commonly bypassed coronary arteries (Adapted from Tidy, 2017) 
 
For conventional CABG surgery, angina is relieved in approximately 90% of patients and 
80% remain free of such symptoms for at least five years following the procedure. 
Compared to PCI, CABG has a lower risk of restenosis as the graft itself should provide 
complete revascularisation compared to partial revascularisation as commonly seen in 
PCIs. PCI also has the chance of in-stent restenosis which CABG clearly cannot 
experience. It has been suggested however that after approximately 15 years, 85% of the 
vein grafts become narrowed or totally occluded and hence may require a subsequent 
revascularisation, often performed using PCI, and in rare cases another CABG is 
performed. In addition to the graft vein becoming stenotic, angina itself may recur due to 
atherosclerosis building up in other coronary vessels not originally bypassed during 
surgery. Typically about 95% of CABG patients are still alive after one year (Harlan et al, 
2008). There are some drawbacks associated with performing a CABG relative to a PCI, 
for example, the CABG can take 3-6 hours to perform and patients will require much 
longer length of stays (LOS) in intensive care units (ICUs), and overall hospital bed usage. 
CABG patients also require a much longer period of recovery usually between three to six 
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months for a full recovery. For CABG there is a considerably high risk of post-operative 
complications, affecting approximately 5-10% of patients. The main complications 
experienced are described briefly below. 
Coronary Artery Bypass Graft (CABG) Complications 
Compared to PCI, CABG patients have a much higher risk of death during the procedure 
and in the short recovery period afterwards (i.e. 30 days), especially elderly patients 
(Safaie et al., 2015). During CABG surgery there are multiple events which have high 
risks of death such as stopping the heart, surgically grafting the vein/artery onto the heart, 
and restarting the heart. A high risk of bleeding exists (approximate 30%) either during or 
after surgery subsequently warranting a blood transfusion, or in rare cases (i.e. < 2%) 
multiple transfusions and additional surgery to stop the bleeding. There is a high risk of 
bleeding for patients which have been taking blood thinning medication such as aspirin 
prior to the surgery; however this should be especially rare in elective CABG because 
cessation of such medicine before surgery is recommended. Atrial fibrillation whereby a 
fast and abnormal heart beat rhythm is present can occur in up to 40% of CABG patients, 
the irregular rhythm has the potential to cause blood clotting within the coronary vessels, 
or should an existing lesion become dislodged it has the potential to travel to another 
location, e.g. the brain and subsequently cause a stroke. A large proportion of the patients 
which experience atrial fibrillation only exhibit it temporarily, it can also be controlled with 
appropriate medicine. As with any type of surgery there is a risk of infection, in the case of 
CABG at the graft artery or vein removal site or within the exposed lungs of chest during 
surgery. Infections can affect approximately 4% of patients undergoing this procedure 
(CABG Risks, 2013). Approximately 5% of patients may experience a reduction in renal 
function, which for the majority of cases in only temporary and should resume within 
several days to weeks. Stroke and other neurological problems such as difficulty 
concentrating or memory issues can occur in approximately 5% following CABG. In rare 
circumstances this can be a permanent condition. However the patient should improve 
within months of recovery after their surgery. Stroke, which is a rare and more serious 
complication, affects approximately 1 in 50 patients and can temporarily or permanently 
affect both physical and cognitive functioning in addition to causing death. Because the 
heart and hence coronary arteries are in a vulnerable state following surgery, especially 
the sites of the attached graft vessel, there is an increased risk of a myocardial infarction, 
especially within the short period (i.e. 30 days) following surgery, this is the most common 
cause of death following CABG procedures. For patients which experience small to 
moderate myocardial infarctions, these can be detected through the usage of ECG 
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signatures and elevated levels of cardiac enzymes such as Troponin. In general, patients 
who undergo surgery to one of the coronary valves are at a higher risk than standard 
CABG patients. 
The risk factors for complications (Hawkes et al., 2006; Diodato & Chedrawy, 2014) are 
similar to patients who are more likely to exhibit complications following PCI such as old 
age, female gender (post menopause), multi-vessel disease such that the more vessels 
requiring a bypass the greater the chance of complications such as bleeding occurring, 
obese patients requiring deeper incisions hence risk of infection. Emergency CABG 
exhibits a higher risk, because there is much less time to plan the surgery and the heart 
itself may be damaged from the myocardial infarction, compared to elective patients, for 
whom no actual damage may have occurred yet. Other medical conditions such as 
diabetes, chronic obstructive pulmonary disease (COPD), peripheral vascular disease 





2.3 Related Work 
This section reviews peer-reviewed published literature relating to this thesis, including 
cardiovascular longitudinal studies, in-hospital and short-term complications following PCI, 
risk prediction models for adverse events following PCI, and the factors associated with 
repeat revascularisation following PCI. 
2.3.1 Longitudinal Cardiovascular Epidemiological 
Studies 
The Framingham Heart Study 
One of the first and most important cohort studies to prospectively collect longitudinal 
cardiovascular health data was the Framingham Heart Study (Dawber, 1980) which began 
in 1948 and is still currently active in its third generation. The study itself is named after 
the town in Massachusetts, US for which the study cohort were residents of. The study is 
now being run by the National Heart, Lung, and Blood Institute (NHLBI) and researchers 
from the Boston University School of Medicine. The study originally recruited 5209 healthy 
men and women, 5127 of these were confirmed free from cardiovascular disease (CVD). 
The individuals in the study ranged from 30 to 62 years old and were provided with free 
comprehensive physical examinations and had detailed medical history recorded. The 
cohort age ranges were chosen because it was known CVD developed in high rates for 
this group. Other laboratory tests were performed such as chest x-rays and 
electrocardiograms (ECGs) every two years. The motivation behind the study was to find 
out why CVD was responsible for increasing rates of death and why it was becoming the 
number one cause of mortality in the US. The study design was chosen because it could 
help explain the behaviour of CVD and identify the set of factors which relate to its 
manifestation. By identifying such factors it was hypothesised that is would then be 
possible to inform the public as to avoid such factors and thereby lower the rate of CVD 
and hence increase life expectancy. 
In the US in the 1950s approximately one-third of men were determined to have CVD by 
the age of 60 years, which was twice the number of people that developed cancer during 
the same period. The number of deaths relating to CVD specifically per 100,000 
individuals saw a linear increase each decade and rose 115% from approximately 260 in 
1900 to 575 in 1950. There were four main reasons hypothesised for this increase in CVD 
death rates: (1) decreased physical activity; (2) dietary changes; (3) introduction of 
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cigarettes; (4) decreased deaths from infectious diseases – more people who were alive 
would then go onto develop CVD. Relating to (4), there was a significant reduction in 
infectious disease deaths due to several reasons such as improvements in hygiene, 
tuberculosis and pneumococcal disease control, and the introduction of penicillin in 1942. 
From 1960 to 2005 the number of CVD deaths per 100,000 decreased by approximately 
63% from 560 to just over 200. Of these CVD deaths the most common was due to 
coronary artery disease (CAD), which saw a constant decline since the mid-1960s. There 
were several hypotheses for this decrease following cardiovascular research which lead to 
the following: dietary research – identification of the role of cholesterol as a risk factor; 
more accurate and faster diagnosis of CVD and hence treatment; effective therapy – such 
as beta-blockers, aspirin, diuretics which treat hypertension; The Surgeon General's 
report on the negative effects of smoking. 
The Framingham study had one major aim and two minor ones (Dawber & Moore, 1952). 
Firstly to produce epidemiological data on CVD with regards to atherosclerosis and 
hypertension. Secondly, to produce data on the prevalence of other forms of CVD in a 
cohort group that is representative of the population. Thirdly, to test the efficiency and 
accuracy of CVD diagnostic equipment, and tests. The arteriosclerosis CVD was thought 
to be caused by a loss of elasticity and thickening of the coronary and carotid artery walls. 
The study itself was a longitudinal monitoring study which observed changes and did not 
intervene with any actual treatment. The first examination provided on each of the study 
subjects was to identify whether they were free from known symptoms of CVD, those 
which were, were then used as part of the official study cohort for which the periodic 
examinations would be performed, which was planned to continue until a sufficient 
number of subjects that were re-examined went on to develop CVD, subsequently giving 
the potential to identify the risk factors which predisposed people to CVD. Over time 
different tests and measurements were included in the study such as alcohol and smoking 
status, echocardiograms, lipoproteins, exercise ECGs, fibrinogen, and apolipoprotein 
levels. These additions were made to test various new hypotheses which were formed 
following the evolution of medical science. 
Before the study officially began several hypotheses were formulated as it was assumed 
the development of CVD was not as a result of a single cause but multiple ones that 
collectively led to the disease manifesting. The set of hypotheses were developed by 
medical specialists and subsequently lead to the types of medical questions and physical 
examinations being performed to assist in proving/disproving them. The list of hypotheses 
constructed (Dawber, 1980) were (not in any particular order): 
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(1) CVD risk increases with age and occurs more frequently and earlier in men. 
(2) Elevated cholesterol level increases the risk of CVD. 
(3) Regular alcohol consumption and smoking increases the risk of CVD. 
(4) Increasing physical activity shows decreased risk of CVD development. 
(5) Decreased CVD is experienced following increased thyroid function. 
(6) Increasing body weight increases CVD risk. 
(7) CVD develops in a higher rate in those with gout. 
(8) High levels of haematocrit increases the chances of developing CVD. 
It had been hypothesised that the onset of CVD could be delayed, i.e. experienced at a 
much more advanced age than currently seen by using a preventative approach for 
certain lifestyle choices. The study was seen as significant because it helped identify that 
those which went on to develop CVD had overall a different set of characteristics to those 
which did not experience CVD. It was made apparent that poor cardiovascular health was 
not a simple consequence of ageing but also affected by the choice of lifestyle, 
inheritance, environmental factors, and other measurable risk factors. The characteristics 
defined as showing increased probability of developing CVD in the future were identified 
as: advanced age; male gender; diabetes; elevated serum cholesterol; hypertension; 
cigarette smoking; and physical inactivity. These risk factors were considered ideal 
because they meet the following characteristics: associated with the disease; frequently 
found; easily recognised/distinguished; reversible/treatable – excluding age and gender; 
the disease can be prevented if treated appropriately. Whilst the study identified the 
important set of risk factors, it did not explain the pathogenesis of CVD, i.e. the exact 
detailed biological mechanisms that result in its development. 
Of the 5000 subjects used in the study it was predicted that within five years of the first 
examination, 400 (8%) of these would develop CVD, and within ten years 900 (18%), and 
within 15 years 1500 (30%), and within the expected end date of 20 years, 2150 (43%) 
would develop CVD (Gordon & Kannel, 1968). There were drawbacks and criticism of the 
study design whereby the final cohort of subjects were considered healthier than the 
general population along with some other biases. The study also focussed on a single 
town, that being Framingham in Massachusetts (US) which was predominately white 
middle class people and therefore different ethnic groups may not have been represented 
sufficiently as well as other socioeconomic and environmental factors. The suggested 
workaround to this was to set the study up in multiple areas. Another drawback of the 
study was that it could only be used to analyse incidence rates, i.e. the number of 
individuals that went on to develop CVD within a certain time interval, however the 
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prevalence rates would not be accurate for the population because the cohort were 
healthy to begin with and thus not representative of the population of the town. 
The Seven Countries Study 
Another important longitudinal monitoring study was the Seven Countries Study which ran 
from 1958 to 1970 across multiple countries (US, Finland, Netherlands, Italy, Yugoslavia, 
Greece, and Japan), this was the first epidemiological study to be conducted across 
multiple nations and it featured 16 cohorts of men aged between 40 and 59 years that 
were engaged in traditional occupations and this cohort totalled 12,723 subjects. The 
study had a similar motivation to the Framingham Heart Study whereby it was noticed that 
an epidemic of middle-aged men were dying from heart attacks. The study found 
hypothesised this was predominately due to lifestyle choices and other changeable 
characteristics. A prior study to this conducted in Italy, Spain, Japan, and South Africa 
from 1952 to 1956 proposed that a diet and the level of serum cholesterol and the rate of 
heart attacks varied between countries, this was also found in a later study within Finland, 
Greece and Italy, which subsequently led to the development of the Seven Countries 
Study. 
By spanning the study across multiple countries, it allowed differences in culture and 
lifestyle to be identified and their apparent link to diet, cholesterol, and subsequent 
development of coronary heart disease (CHD). This study addressed the main drawback 
of the Framingham study whereby multiple populations were used rather than a single 
town in a single country. A large variation in diet, mostly linked to saturated fat was found 
between the countries, and that as the average percentage of saturated fat increased, so 
did the serum cholesterol levels, and the rates of death from CHD. The lowest levels of 
cholesterol and hence incidence of CHD were found in countries with a Mediterranean-
style diet which consisted of low animal product usage (i.e. saturated fat). The main 
source of fat in these countries came from olive oil, which is a monounsaturated fat. This 
type of diet also consists of high amounts of legumes, fruit, and fish. It was made apparent 
from this that certain dietary choices can alter an individual's risk of developing CHD. 
These findings relating to Mediterranean diet and both fatal/non-fatal CHD in middle-age 
individuals were also identified by other researchers (Martínez-González & García-López, 
2010) by observing countries in Northern Europe and the US compared to Southern 
Europe and controlling for the variables of age, blood pressure, cholesterol levels, 
physical activity, and smoking status. The study found that from five years onwards CHD 
and stroke rates were independently linked to serum cholesterol level and this was 
consistent across different ethnic cultural groups. 
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Both the Framingham and Seven Countries studies showed that cigarette smoking, i.e. 
tobacco usage, was a major predictor in developing CHD whereby those which smoked 
exhibited increased rates of angina, heart attacks, and other CVD related deaths. 
Hypertension was also again shown to increase the risk of both CHD and stroke. Both 
studies demonstrated the importance of maintaining healthy lifestyles, such as regular 
exercise and a healthy diet, in helping to avoid both dementia and CHD. Despite the 
useful findings there has been disagreement by scientists on whether cholesterol and fat 
intake can be effectively used as predictors for CHD. Some argued (Taubes, p. 1120) that 
these adverse conditions were caused by refined carbohydrates instead. Another 
researcher (Edward H Ahrens Jr) in 1957, also suggested that cholesterol might not be 
the cause, but instead carbohydrates and triglycerides. Triglycerides were identified as 
more important than cholesterol level thus saturated fat was not responsible but 
carbohydrates (Teichoz, P.58-59). It was later suggested that sugar was the main cause 
of CHD and other adverse conditions instead of fat (Yudkin, 2012). Back in 1956, John 
Godman, an expert in clinical lipidology proposed an atherogenic index that combined low 
density lipoprotein (LDL) and very low density lipoprotein (VLDL) which could predict CHD 
and the development of atherosclerosis (Gofman, 1956) and later suggested that serum 
cholesterol levels can be misleading in analysing the effect of diet upon lipids. 
Conclusions 
Both the Framingham Heart Study and the Seven Countries studies were important 
epidemiological longitudinal studies which although both had some limitations, they 
showed that this type of study design is important and can assist in identifying important 
risk factors that have high associations with the adverse outcome of CVD/CHD. These 
were useful studies which mirrored how simple, easily measurable risk factors can be 
used to predict adverse outcomes following coronary revascularisation treatment for 
patients that already have CVD/CHD as evidenced by a myriad of published peer-




2.3.2 PCI Risk Prediction Models 
Introduction 
The ability to predict the occurrence of major complications following coronary 
revascularisation procedures such as PCI or CABG is essential for interventional 
cardiologists. There are several important benefits to having effective prediction models, 
these include: a decision making tool for clinicians (i.e. is a given patient a suitable 
candidate for PCI?); decision making tool for elective patients (i.e. if they know the risks, 
do they want to proceed with a given PCI procedure?); resource planning (i.e. hospital 
staff can focus more care and resources on high risk patients); and as a comparison tool 
for operators, hospitals, and patient subgroups (especially useful for audit or performance 
reports). 
For the majority of outcomes used in interventional cardiology prediction models, the 
dependent variable is dichotomous (binary), i.e. it assumes one of two states such as: 
alive/dead after 30 days of a procedure; yes/no for experiencing an in-hospital 
complication. For these outcomes the most widely used technique for constructing 
prediction models is multivariate logistic regression, wherein the outcome of the 
regression model is an estimated probability of the outcome occurring given a set of 
predictors. 
Many risk prediction models have been developed (Moscucci, 2001; Singh, 2002; 
Qureshi, 2003; Grayson, 2006; Madan, 2008; Chowdhary, 2009; Hamburger, 2009; 
Maluenda, 2010; Peterson, 2010; Sousa, 2010; Curtis, 2012; Mrdovic, 2013) for 
estimating the risk of various adverse outcomes following PCI procedures. They all 
feature the usage of multiple risk factors, some of which are present in many different 
models, and other factors which are present in only a few. Such differences in risk factors 
among models can be explained by different cohort demographics, socioeconomic 
factors, stent technology, disease severity etc. These models generate a probability of a 
patient, given a set of risk factors, experiencing the measured adverse outcome (e.g. in-
hospital complications or mortality). One of the most commonly measured outcomes are 
the occurrence of a major adverse cardiac event (MACE), this is a composite outcome 
which includes at least one of the following four complications 
(1) In-hospital death. 
(2) Q-wave myocardial infarction. 
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(3) Cerebrovascular accident (stroke). 
(4) Emergency CABG surgery. 
 
The majority of risk prediction models in usage today use in-hospital outcomes as the 
end-point whereby mortality or MACE occurs before the patient is discharged from their 
PCI procedure. The majority of the prediction models identified in this literature review 
were internally validated, whereby the researchers split their database into a training and 
validation set, the former of which was used to develop the prediction model, and the 
latter was used to internally verify the models stability. Whilst different methods exist for 
splitting the available data into training and validation sets, doing so simply by date (i.e. 
the oldest data is used for training, and newer data for validation), it is more robust to 
trends and changes that may exist in the cohort. This is especially applicable for 
anticipated trends in the ECTC cohort such as increasing proportions of emergency PCIs, 
patients with comorbidities. Regardless of how well new risk models perform using an 
internal validation set, they should be externally validated to verify their performance, and 
hence possible adoption in clinical practice.  
The differences in the independent risk factors from the myriad of prediction models as 
stated above, can be potentially caused by the following: 
(1) Changing patient demographics and comorbidities – differences in the general 
age, priority (e.g. stable angina or acute myocardial infarction), comorbidities such as 
renal disease/peripheral vascular disease (PVD)/chronic obstructive pulmonary disease 
(COPD)/diabetes etc. could alter the regression model coefficients especially if more 
patients are living with comorbidities but have not yet had them diagnosed (e.g. type-2 
diabetes mellitus). Trends in proportions of emergency patients and increasing 
proportions of octogenarians could also affect analysis. 
(2) Intervention Technology – If the time difference of two different cohorts used to 
develop a risk prediction model is large enough, it may be the case that differences in 
intervention technologies are responsible for differences in adverse outcomes. One 
anticipated difference relates to stenting technology, for example, differences in cohorts 
with standard balloon angioplasties, bare metal stents (BMS), and drug eluting stents 




(3) Operator experience, PCI centres, and cardiovascular disease screening – It 
would be expected that increasing numbers of operators and PCI centres available to 
perform PCIs would reduce the percentage of adverse outcomes experienced. For 
emergency patients, in particular those presenting with ST-elevation myocardial infarction 
(STEMI), a faster call-to-balloon time (due to more operators and centres) would reduce 
adverse outcomes. The increase in both operators and centres in the UK has been 
reported by the British Cardiovascular Intervention Society (BCIS) in its audit reports 
(BCIS Audit Report, 2014). 
 In modern practice the risk factors for developing CVD are better known than in previous 
decades (e.g. obesity, diet, smoking, lack of exercise), the increase in referral speed for 
patients with CVD would mean a given patient is being treated (either via PCI or by 
pharmacological therapy) at an earlier stage than they would have previously and are 
hence much less likely to present with an emergency indication in the future because their 
condition has been intercepted/identified more rapidly, thus intervention measures can 
slow the rate at which a patient's cardiovascular system may deteriorate. 
Some of the risk factors which have been reported in multiple prediction models are: 
patient age; diabetes; cerebrovascular disease; cardiogenic shock; left main stem (LMS) 
lesions. The following literature review features a summary of the published peer-
reviewed research in the domain of risk prediction models for adverse outcomes following 
PCI. This includes many popular models which have been both developed and validated 
using large PCI databases, most commonly within the US health care system. Such 
literature in the UK NHS is far scarcer. However, as described in Chapter 1.6, two recent 
UK models for 30-day mortality prediction have been published. These are both further 
discussed in Chapter 7 (Conclusions). 
2.3.2.1 The North West Quality Improvement Programme (NWQIP) 
Risk Model 
The North West Quality Improvement Programme (NWQIP) was a collaboration between 
four cardiac centres in the UK, which performed PCI procedures. The centres involved 
were the Manchester Royal Infirmary, Blackpool Victoria Hospital, Wythenshawe Hospital, 
and the Cardiothoracic Centre in Liverpool. NWQIP were focussed on the collection of 
high quality clinical data (both accuracy and completeness) and subsequent validation, 
with the aim of developing techniques to analyse the data. Grayson et al. (2006) published 
a study for a prediction model which estimated the occurrence of in-hospital MACE 
following 9914 consecutive PCI procedures from August 2001 to December 2003, that 
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were performed at the four centres. This collection allowed meaningful comparisons 
between the centres and operators following appropriate adjustment of risk. 
It was important to identify whether, for a given set of patients of the same estimated risk, 
there were any differences in adverse outcome rates between the different centres. The 
study arguably improved upon existing research as it included in-hospital MACE as an 
outcome. The composite outcome allowed more useful insights than simply using 
mortality alone as an end-point. The NWQIP model was constructed from several 
independent risk factors identified using multivariate logistic regression analysis, these 
variables were:  
(1) Advanced age group (70-79 years, or ≥ 80 years). 
(2) Priority of PCI (urgent or emergency). 
(3) Female sex. 
(4) Cerebrovascular disease (stoke). 
(5) Cardiogenic shock (pre-procedural). 
(6) Location of lesions (i.e. PCI to graft lesions; or PCI to the left main stem lesions). 
The overall MACE rate using their cohort of 9914 patients was 1.3% (129 patients), this 
rate varied between the four centres from 1.1% to 1.4% although the difference was not 
statistically significant. The majority of the MACE rate was caused by death at 0.7% (66), 
followed by 0.4% (36) Q-wave myocardial infarctions, 0.15% (15) required an emergency 
CABG, and 0.2% (20) experienced a cerebrovascular accident. 
Grayson et al. (2008) tested the NWQIP model performance using the area under the 
receiver operating characteristic curve (ROC) for discrimination capability, and the 
Hosmer-Lemeshow goodness of fit statistic for calibration. They used the bootstrap 
resampling technique to internally validate the model to ensure overfitting did not occur. 
The AUROC was 0.74 indicating a good ability to discriminate (0.5 would be randomly 
guessing) between MACE occurring. The goodness of fit test was not significant (p = 0.43) 
indicating no large deviations between observed and estimated MACE within groups of 
ascending predicted risk. The 100 samples used in the bootstrap resampling produced an 
AUROC of 0.74 (Standard error, SE = 0.032). A validation set was used by Grayson et al. 
to verify the model stability on 1786 PCIs performed after December 2003, the AUROC 
was 0.72, which was close to the original. The goodness of fit statistic was not reported for 




2.3.2.2 External Validation of the NWQIP Risk Model 
The NWQIP model was externally validated by Kunadian et al. (2008), they also validated 
a model developed in the US, the Mayo Clinic Risk Score (MCRS). The performance of 
both models was assessed using the AUROC value for discrimination, and the Hosmer-
Lemeshow goodness of fit test for calibration. By externally validating these models it 
could be ascertained whether PCI cohorts separate from the original cohort (both 
geographically and over a different time period) yield stable performance and hence 
reveal the models are robust or whether the performance is negatively affected, thus 
rendering them worthless in contemporary practice, and subsequently requiring significant 
recalibration of the risk factors to become useful. The risk factors within both models and 
their corresponding odds ratios, regression coefficients, and derived integer scores (based 
closely on odds ratios) are listed in Table 2.3.1. 
     Table 2.3.1 – NWQIP and MCRS risk factors (adapted from Kunadian et al., 2008) 












Age (decades > 30)       1.37 0.313   
Age 70-79 years 2.02 0.7048 2     4 
Age ≥ 80 years 2.75 1.0106 3     5 
Female sex 1.58 0.4586 2      
Cardiogenic shock 26.14 3.2636 26 4.95 1.599 5 
Cerebrovascular 
disease 
2.37 0.8618 3 
      
Urgent PCI 1.61 0.4788 2       
Emergency PCI 3.91 1.3625 4       
Urgent or 
Emergency PCI 
      
2.13 0.758 2 
LMS lesion treated 5.21 1.6502 5       
Graft lesion treated 2.48 0.9101 3       
LMS disease       4.34 1.467 5 
Serum creatinine > 
265 µmol/l 
      
2.41 0.881 3 
NYHA class ≥ III       2.11 0.745 2 
Thrombus       1.9 0.644 2 





The external validation cohort featured 5034 consecutive PCI procedures from September 
2002 to August 2006. The baseline demographic, clinical, and procedural characteristics 
were similar to the NWQIP cohort however an increase in emergency procedures was 
observed (10.8% to 17.6% respectively), cardiogenic shock also increased from 0.7% to 
1.7%, as did the usage of the glycoprotein inhibitor IIb/IIIa from 61.8% to 76.1%. The 
percentage of patients aged ≥ 80 years increased slightly from 2.1% to 3.8%. Apart from 
this, the other characteristics were similar. 
The in-hospital MACE rate was 2% (104 complications), 1.3% (66) of patients died, and 
0.2% (11) had a Q-wave MI, 0.2% (10) experienced a cerebrovascular accident, and 0.1% 
(7) required an emergency CABG. The AUROC was 0.86 (95% CI 0.82 to 0.89) for the 
NWQIP model, and for the MCRS model this was 0.87 (0.84 to 0.90). The Hosmer-
Lemeshow test for these models were χ2 = 1.7 (p = 0.95) and χ2 = 11.7 (p = 0.16) 
respectively, the former of which reveals an excellent fit (with 1.0 being perfect). The study 
showed that the NWQIP model could discriminate in a different geographical cohort and 
time period better than in it did in the original setting. 
With regards to the NWQIP model, Kunadian et al. went a step further and performed a 
useful additional analysis technique in their study. Integer values were assigned to the 
independent risk factors within the model based closely on the odds ratios, for example in 
most cases the integer represented this rounded odds ratio value. Cardiogenic shock as 
shown in Table 2.3.1 has an odds ratio of 26.14, the integer score used for this was 
therefore 26. LMS lesions treated has an odds ratio of 5.21 therefore it was assigned an 
integer score of 5. The total value of all integer scores from the present risk factors in a 
given patient were stratified into one of five different risk groups (very low, low, moderate, 
high, and very high). The observed and estimated MACE rates were then plotted for these 
five groups. This is a similar goodness of fit test to the Hosmer-Lemeshow test. However, 
it can be more effective because in-hospital MACE occurs at such a low rate and hence 
frequencies. Some of the risk groups have a small number of events hence their accuracy 
is questionable as per the requirements of a chi-square test, for which the Hosmer-
Lemeshow test is an extension. 
The five risk score categories have the PCIs assigned by the range of the total integer 
score, this being 0-5, 6-8, 9-11, 12-14, and ≥ 14 respectively. Kunadian et al. (2008) 




Table 2.3.2 – Integer score system and results developed by Kunadian et al. (2008) 
for NWQIP 






Very low (0 to 5) 82.1% 0.8% 0.9% 
Low (6 to 8) 12.8% 3.6% 2.9% 
Moderate (9 to 11) 3.2% 7.5% 6.3% 
High (12 to 14) 0.3% 13.3% 14.4% 
Very high (> 14) 1.7% 42% 45% 
 
2.3.2.3 Other Integer Risk Score Models 
Risk scores based on integer values were not founded by Kunadian et al. (2008). One of 
the first PCI risk score models to utilise integer scoring for easy calculation without the 
need for a programmable calculator, was the Mayo Clinic Risk Score (MCRS), developed 
in the study by Singh et al. (2002). The study featured 5463 PCIs from January 1996 to 
December 1999. The outcome was the same as the NWQIP study (MACE). The model 
used a validation set of PCIs performed in 2000. The MACE rate was 4.0% (220 
procedures). The independent risk factors within the model featured several also present 
in the NWQIP model, which were cardiogenic shock, LMS (disease – not specifically 
‘lesions’), urgent/emergency PCI, old age, but also some not present in NWQIP, which 
were: severe renal disease; congestive heart failure (CHF) class III or higher, thrombus 
present, and multivessel disease. Singh et al. reported an excellent goodness of fit, 
whereby p = 0.93 (1.0 is perfect), for the Hosmer-Lemeshow test, and an area under the 
ROC curve of 0.78 (0.018) following bootstrap resampling. Despite the excellent 
goodness of fit reported, it should be noted that the observed and expected MACE rates 
for different groups of risk are extremely close in terms of frequency, for example despite 
showing an almost perfect observed vs. expected rate, several of groups are closely 
clustered together. This essentially means, for example, that groups 1 and 2 show a very 
close MACE frequency (3-8) and groups 4, 5, and 6 displays a count (20 to 25). It should 
be noted also that these values are raw frequencies, and not rates, which is unusual for 
calibration plots for risk prediction models.  





Table 2.3.3 – MACE prediction model risk factors from the Mayo Clinic Risk Score 
(Singh et al., 2002) 
Risk Factor Integer 
Age 90-99 years 6 
Cardiogenic shock 5 
LMS disease 5 
Age 80-89 years 5 
Age 70-79 years 4 
Renal disease 3 
Age 60-69 years 3 
Urgent/Emergency PCI 2 
Multivessel disease 2 
NYHA class ≥ III 2 
Thrombus 2 
Age 50-59 years 2 
Age 40-49 years 1 
In the article by Singh et al. (2002) a plot of estimated risk for the procedural 
complications based on the integer score was made. From the above table, the theoretical 
maximum total integer score is obtained from the following risk factors: Age 90-99 years 
(6), cardiogenic shock (5), LMS disease (5), renal disease (3), emergency PCI (2), 
multivessel disease (2), NYHA class ≥ III (2), and a thrombus present (2), which totals to 
an integer score of 27, this exceeds the risk graph profile (maximum 25), for which the risk 
is approximately 92.5% chance of in-hospital MACE. 
Similar to the Kunadian et al. (2008) method of classifying the integer score into five 
groups, Singh et al. (2002). did the same, except the five respective groups were 
classified by estimated percentage: ≤ 2%, 2-5%, 5-10%, 10-25%, and >25%. Only 2.1% 
were classified as very high-risk in their cohort. The model was appropriately validated 
using 1781 PCI procedures that were performed in 2000, for which there was a 3.3% (58 
procedures) MACE rate. The model performed well for the validation set for which the 
ROC curve was 0.755, and the Hosmer-Lemeshow test produced a p value of 0.64, whilst 
not as good as the training set (0.93), this still indicates little departure from observed vs. 
expected MACE. It was found that the model could discriminate best in higher-risk 
patients such as those presenting with diabetes and LMS lesions, compared to low-risk 
patients. An interesting point made by Singh et al. (2002) was that good discrimination is 
very hard to obtain for low-risk patients (i.e. elective PCI) because the MACE complication 
rate is low. 
In a more recent study by Madan et al. (2008), 9494 PCIs were analysed from January 
1996 to December 2002, this era was considered BMS dominant. As with Grayson et al., 
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Kunadian et al., and Singh et al. studies, MACE was the outcome of interest but the 
definition was slightly altered to include the following outcomes: 
(1) Death (all-cause within 30 days) 
(2) Myocardial infarction (Q-wave BCIS definition or chest pain lasting > 20 minutes) 
(3) Urgent or emergency CABG (during the index hospitalisation) 
(4) cerebrovascular accidents 
(5) Repeat PCI (during the same admission) 
In should be noted that unlike the other three studies mentioned, patients with pre-
procedural cardiogenic shock were excluded, as these were considered at very high risk 
of adverse outcomes already, hence the omission as a multivariate predictor of MACE. It 
should also be noted that the operator volume and experience was not analysed and 
hence a possible limitation of their study. 
The multivariate predictors and the corresponding model statistical properties are listed in 
Table 2.3.4. The model developed was the Texas Heart Institute risk score (Madan et al., 
2008). 
Table 2.3.4 – The Texas Heart Risk Score for MACE following PCI 
Risk Factor Integer Coefficient Odds Ratio P Value 
Unstable angina 5 0.465 1.59 (1.22-2.08) 0.0006 
Renal insufficiency 4 0.364 1.44 (1.01-2.04) 0.0431 
Hypertension 3 0.349 1.42 (1.04-1.93) 0.027 
Acute MI 4 0.424 1.53 (1.13-2.06) 0.0056 
Congestive heart failure 4 0.364 1.44 (1.03-2.02) 0.0345 
PVD 3 0.330 1.39 (1.01-1.91) 0.0417 
Urgent PCI 9 0.927 2.53 (1.62-3.93) < 0.0001 
Emergency PCI 14 1.397 4.04 (2.71-6.04) < 0.0001 
Thrombus 4 0.388 1.48 (1.01-2.15) 0.0443 
Type C lesion 4 0.389 1.48 (1.13-1.93) 0.0043 
2 stents placed 4 0.448 1.56 (1.17-2.09) 0.0023 
≥ 3 stents placed 5 0.526 1.69 (1.16-2.17) 0.0063 
Intercept NA -4.885 NA NA 
The MACE rate was 2.8% (264 procedures), the model displayed good performance with 
the ROC curve = 0.70 and the Hosmer-Lemeshow test p = 0.67 indicating a good fit of 
observed vs. expected MACE. The validation cohort featured 5545 PCIs from 2003 to 
2006, this displayed an increased MACE rate of 3.43%, and both the discrimination and 
calibration performances worsened to 0.67 (ROC) and p=0.08 respectively. The increase 
in MACE could possibly be explained by the validation cohort exhibiting a decrease of 
patients classified from low risk of 51.6% (training set) to 44.9% (validation) respectively. 
A major difference between the Singh et al. and Madan et al. studies was that the Texas 
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Heart Institute risk score model was performed in a DES dominant era that corresponded 
to a high usage of clopidogrel and glycoprotein inhibitors. 
One-Year Mortality Prediction following PCI 
Whilst the Grayson et al., Kunadian et al., Singh et al., and Madan studies, described 
previously, use the outcome of in-hospital MACE, and including 30-day death (Madan et 
al.), it is beneficial for patients and clinicians to know the likely longer-term outcomes 
following PCI, such as mortality within one year of a patient’s procedure. Whilst extending 
the ‘death’ outcome from in-hospital mortality or 30-day mortality to one year is desired, 
there are considerations which must be noted, such as whether a patient that dies 11 
months following PCI died because of a poor procedure (stent insertion) or whether it is 
completely unrelated to the PCI. When extending the outcome to long intervals such as 1-
3 years, other conditions and comorbidities also can become more prominent such as 
diabetes, PVD, COPD and renal disease, which could all affect mortality rates. 
A more recent study conducted by Maluenda et al. (2010) which incorporated a PCI 
cohort of 6932 procedures from January 2000 to December 2005, identified eight risk 
factors that were significantly associated with one-year mortality, for which the risk model 
characteristics are listed in Table 2.3.5 (Maluenda et al. 2010). 
Table 2.3.5 – Risk prediction model for one-year mortality (Maluenda et al, 2010) 
Risk Factor Integer Coefficient OR 95% OR CI P Value 
TIMI grade < 3 flow 7 2.035 7.65 5.3-10.9 < 0.0001 
Heart failure 4 1.155 3.17 2.4-4.1 < 0.0001 
LMS disease 3 0.783 2.19 1.3-3.5 0.0001 
Chronic renal failure 3 0.730 2.07 1.6-2.7 < 0.0001 
Diabetes mellitus 2 0.527 1.69 1.3-2.2 < 0.0001 
Haematocrit decrease 1 0.382 1.46 1.2-1.7 < 0.0001 
Haematocrit baseline 1 0.374 1.45 1.3-1.7 < 0.0001 
Age (decades > 40 years) 1 0.296 1.34 1.2-1.5 < 0.0001 
Intercept NA -5.276 NA NA NA 
The overall rate of one-year mortality was 5.6% (383 patients). The majority of these had 
high-risk characteristics such as multivessel disease and other comorbidities. Despite the 
PCI cohort date range being from 2000 to 2005, the DES usage was fairly high at 60%. 
Maluenda et al. (2010) reported a good performance for both discrimination and 
calibration for which the ROC curve was 0.818 (mean bootstrap resampling) and the 




The model performed well when applied to a validation PCI cohort which included 973 
procedures from January 2006 to December 2007. The one-year mortality rate was much 
greater than the training cohort at 10.3% (100 patients), for which the model accurately 
predicted 81.5% of these deaths. An improvement in discrimination was evident whereby 
the ROC curve was 0.836, although the standard deviations were not reported, it is 
assumed this difference is not statistically significant. An improvement in the goodness of 
fit was observed also, with the p = 0.573. When the model was tested with AMI patients, 
the ROC curve increased to 0.903 with p = 0.625, indicating excellent performance for 
both measures. As with the other studies, the operator volume was omitted, in addition to 
cardiogenic shock patients. This study also only featured a single-centre, which suggests 
that the model requires external validation to verify its discrimination and calibration 
performance. 
Primary PCI 30-Day MACE Prediction 
The risk prediction models reviewed previously in this thesis have included PCI patients of 
all priorities (i.e. elective, urgent, and emergency) in their analyses and subsequent 
determination of multivariate predictors. In the majority of models designed with PCI 
cohorts of all priorities, the priority of the PCI procedure in some form is represented as an 
independent risk factor, whether this is separate risk factors for urgent and emergency, or 
combined into a single risk factor (urgent or emergency PCI), relative to the elective PCIs. 
Patients presenting with elective conditions such as stable angina are, by definition, less 
likely to experience adverse outcomes (in-hospital complications or death) than their 
urgent and emergency counterparts. Indeed, every PCI study (to the author’s knowledge) 
which reports outcome rates by priority shows emergency patient cohorts report higher 
rates of adverse outcomes. Because of this, research has been conducted using only 
high-risk (emergency) patients such as those requiring primary PCI (PPCI) for conditions 
such as ST-elevation myocardial infarction (STEMI). 
In a recent study conducted by researchers in Serbia (Mrdovic et al., 2011) which 
investigated 30-day MACE following PPCI, a risk model was designed (The RISK-PCI 
score) using a PCI cohort of 2096 consecutive PPCIs from 2006 to 2009, this model also 
uses a point scoring system (decimal, in this instance). The 2096 PPCIs were split into a 
training set (80%) and validation set (20%) randomly, for which 1676 and 420 patients 
were assigned respectively. The reported definition of 30-day MACE was: death, nonfatal 
reinfarction, or cerebrovascular accident (stroke). This study also excluded patients with 
cardiogenic shock prior to their PCI procedure. Table 2.3.6 lists the risk factors that were 
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identified as independent predictors for 30-day MACE following their logistic regression 
analysis. 
Table 2.3.6 – Risk prediction model for 30-day MACE (Mrdovic et al., 2011) 
Risk Factor Coefficient Points OR 95% OR CI P Value 
Age > 75 years 0.51 1 1.66 1.02-2.65 0.05 
Prior infarction 0.76 1.5 2.13 1.37-3.39 0.005 
Anterior infarction 0.57 1 1.77 1.15-2.74 0.02 
Complete AV block (pre) 0.90 2 2.47 1.34-4.45 0.004 
Acute bundle branch block 1.68 3.5 5.37 2.63-10.96 < 0.001 
Leukocyte > 12.0 
10-9/L 0.49 1 1.63 1.11-2.39 0.01 
Creatine clearance 60-89 
ml/min 
0.62 1 1.84 1.16-2.90 0.01 
Creatinine clearance < 60 
ml/min 
0.97 2 2.65 1.50-4.68 0.001 
LVEF < 40% 0.67 1.5 1.97 1.36-2.83 0.003 
Reference diameter ≤ 25 
mm 
0.62 1 1.87 1.14-2.81 0.03 
TIMI flow 0 (pre) 0.51 1 1.66 1.08-2.55 0.02 
TIMI flow < 3 (Pre) 1.58 3.5 4.84 2.87-8.16 < 0.001 
Glucose > 6.6 mmol/L 0.46 1 1.58 1.01-2.83 0.05 
Intercept -4.27  0.14  < 0.001 
From the point scores reported in Table 2.3.6 by Mrdovic et al., the patients were 
classified into four risk groups based on the total points value of all their risk factors: low 
(0-2.5), intermediate (3-4.5), high (5-6.5), and very high (> 7), within these groups the 
observed rates of 30-day MACE were 1.9%, 5.9%, 13.3%, and 39.4% respectively. The 
RISK-PCI vs. the predicted 30-day MACE % is almost perfectly linear, the following table 
(2.3.7) displays the approximate predicted rate (based on Fig 1 from Mrdovic et al., 2011). 
Table 2.3.7 – RISK-PCI score vs. predicted 30-day MACE (Mrdovic et al, 2011) 
RISK-PCI Score 30-Day MACE RISK-PCI Score 30-Day MACE 
0 1.5% 9 40.0% 
1 2.0% 9.5 45.0% 
1.5 2.5% 10 55.0% 
2 3.0% 10.5 57.5% 
2.5 4.0% 11 63.0% 
3 5.0% 11.5 67.5% 
3.5 6.0% 12 72.5% 
4 7.5% 12.5 77.0% 
4.5 8.5% 13 80.0% 
5 10% 14.5 90.0% 
5.5 13.5% 15 92% 
6 15.0% 15.5 93.5% 
6.5 18% 16.5 95.0% 
7 22.5%   
7.5 25.0%   
8 30.0%   
8.5 35.0%   
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Within the MACE outcome, mortality with 30 days was 0%, 2.3%, 5.7%, and 32.5% 
respectively. The MACE rate for all PPCI patients was 9.1% (191), comprising 4.9% 
mortality (102), 3.3% (68) non-fatal reinfarction, and 1.0% (21) cerebrovascular accidents. 
Out of the 102 patients who died, 86.3% (88) died in hospital, meaning the rest (14) died 
following discharge but within 30 days. 
The RISK-PCI score model performed well on the 1676 PPCI training cohort exhibited 
very good discrimination (ROC = 0.83) and calibration (Hosmer-Lemeshow, p = 0.72), this 
level of performance was retained in the validation set (420 PPCIs) with the discrimination 
and calibration being 0.83 (0.77 to 0.89) and p = 0.72 respectively.  
An important point made by Mrdovic et al. (2011) was that even though emergency 
patients are by nature reasonably high risk, those presenting with STEMI which were 
classified as low-risk PPCI patients could be discharged early thus reducing costs and 
freeing up beds and staff resources, and those with an estimated high RISK-PCI score 
could be given additional length of stay or care prior to discharge. Because patients in the 
intermediate risk group (RISK-PCI score: 3-4.5) had a peak mortality count at 8 days post 
PPCI, there could be time to perform additional complete revascularisation within this 
period via elective PCI to possibly reduce the chance of subsequent MACE. Another 
interesting point made by Mrdovic et al., which has not been discussed in other published 
research papers, is that because their study distinguishes PPCI patients into different risk 
groups (from low to very high), by identifying and excluding low risk patients, future trials 
can increase their statistical power from a smaller sample size with regards to measuring 
poor outcomes in the form of MACE, whether this be post-operation drugs, or a 
comparison between new stent technology. 
Long-term Mortality Prediction in a DES Era 
An important study conducted in Australia by Wilson et al. (2011) investigated the causes, 
duration, and predictors of death after a long-term follow-up period for PCI patients. Their 
cohort of PCI patients was obtained from the Melbourne Interventional Group registry and 
was linked to the National Death Index database allowing analysis of long-term mortality 
outcomes following PCI for the first time in Australia. The cohort included 10,682 
consecutive PCI procedures performed from February 2004 to November 2009. 
Patients that underwent a BMS PCI were recommended to take both aspirin and 
Clopidogrel (antiplatelet therapy) for at least four weeks, and those which underwent a 
DES PCI were recommended to take them for at least six months following their PCI. 
Wilson et al. split their analysis into two groups:  
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(1) DES group (4662 PCIs) – at least one DES inserted  
(2) BMS group (6060 PCIs) – only BMS inserted 
The decision to use a DES for the PCI was based on least one of the following criteria: 
diabetes mellitus (all forms), target vessel diameter ≤ 2.5 mm, target lesion length ≥ 20 
mm, bifurcation lesion, ostial lesion, in-stent restenosis, long-term total occlusions. 
Table 2.3.8 (adapted from Wilson et al. 2011) displays the mortality rates for all PCIs, 
DES PCIs, and BMS PCIs by different mortality intervals (ranging from in-hospital to long-
term). 
Table 2.3.8 – Mortality rates reported by Wilson et al. (2011) 
Mortality Interval Overall  
(n = 10,262) 
DES 
(n = 4,662) 
BMS 
(n = 6,060) 
P Value 
In-hospital 1.6% 1.0% 2.1% < 0.001 
30 days 2.1% 1.3% 2.6% < 0.001 
12 months 3.9% 3.1% 4.5% < 0.001 
Long-term (median 3.2 
years) 
8.2% 7.7% 8.7% 0.072 
Unlike the other literature discussed so far whereby a risk model was constructed using 
logistic regression analysis, Wilson et al. (2011) developed a survival analysis form of 
regression using a Cox proportional hazards regression model, this does not specifically 
result in a developed model but a set of independent predictors and a corresponding 
hazard ratio (HR). The predictors and HR variables discovered by Wilson et al. are in 
Table 2.3.9 (adapted from Wilson et al., 2011, Table 5). 
Table 2.3.9 – Independent predictors of long-term mortality (Wilson et al, 2011) 
Predictor HR (95% CI) P Value 
Cardiogenic shock 4.58 (3.60-5.83) < 0.001 
Renal failure 3.14 (2.58-3.82) < 0.001 
Recent heart failure 1.97 (1.60-2.41) < 0.001 
STEMI 1.79 (1.47-2.18) < 0.001 
PVD 1.72 (1.40-2.11) < 0.001 
NSTEMI 1.58 (1.32-1.90) < 0.001 
Multivessel disease 1.47 (1.24-.1.74) < 0.001 
Current smoker 1.39 (1.12-1.71) 0.002 
Diabetes 1.36 (1.16-1.59) < 0.001 
Previous stroke 1.33 (1.06-1.60) 0.014 
Previous MI 1.24 (1.06-1.42) 0.008 
LAD vessel to be treated 1.23 (1.06-1.43) 0.005 
Hypertension (BP > 140/80 
mmHg) 
1.21 (1.01-1.45) 0.034 
Age (per year increase) 1.05 (1.04-1.06) < 0.001 
DES usage 0.85 (0.73-0.99) 0.036 
Dyslipidaemia  0.82 (0.70-0.94) 0.02 
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From the cohort of 10,682 patients, there were reasonably high percentages of 
characteristics considered to be high risk, such as 24% diabetic patients, 63% reporting 
with acute coronary syndromes (ACS), 59% presenting with multivessel disease. The 
procedures percentage of PCIS featuring exclusive DES usage was 43%. The DES group 
displayed a lower late mortality HR (0.85, 0.73 to 0.99, p = 0.04) compared to the BMS 
group yet at 30 days the rates were no different. Wilson et al. did however state that the 
difference in long-term mortality rate between the BMS and DES groups could simply be 
caused by early BMS mortality (30 day). It is important to consider that the majority of 
early deaths were cardiac-related, i.e. for in hospital, and 30 days the overall rate was 
79% and 79% respectively (BMS: 87% and 82%; DES: 82% and 77% respectively), for 
the long-term follow-up (median 3.2 years) this was 52% overall (BMS: 54%; DES: 50%). 
Only half of the long-term deaths were classified as cardiac-related. 
As with the other studies which did not exclude cardiogenic shock from their regression 
analysis and subsequent model development, it has been identified as one of the 
strongest predictors of mortality (most notably early mortality). Heart failure was identified 
as a strong predictor of long-term mortality and is associated with a poor left ventricle 
ejection fraction (LVEF), which has been a predictor in many other models of adverse 
outcomes. 
Table 2.3.10 displays a summary of the multivariate risk factors identified from PCI risk 
prediction models or Cox regression survival analysis identified from this literature review. 
Note that not all predictors increase the risk, in some cases such as ‘DES used’, the HR 




Table 2.3.10 – summary of multivariate prediction models for outcomes following 
PCI 
Risk Model/Paper Outcome Multivariate Predictors 
NWQIP IH-MACE Age, female sex, LMS lesions, graft lesions, 
urgent/emergency PCI, cardiogenic shock, 
stroke 
Kunadian (2008) IH-MACE Age, renal dysfunction, PVD, cardiogenic 
shock, AMI, thrombus, urgent/emergency PCI, 
multivessel disease 
Texas HI Risk Score IH-MACE/30-M Unstable angina, renal dysfunction, 
hypertension, AMI, CHF, PVD, 
urgent/emergency PCI, thrombus, type C 
lesions, num. of stents placed. 
Wilson et al. (2011) Long-term 
Mortality 
Cardiogenic shock, renal failure, recent HF, 
STEMI, PVD, NSTEMI, multivessel disease, 
current smoker, diabetes, prior stroke, prior 
MI, LAD vessel, hypertension, age, DES used, 
dyslipidemia  
The British Colombia 
PCI Risk Score 
30-Day Mortality Age, female sex, emergency PCI, LMS 
disease, 3-vessel disease, LVEF, NYHA ≥ 
3/CHF, critical preproc state (shock), STEMI 
ongoing/recurrent, other ACS, 
dialysis/creatinine > 200 µmol/L 
Mayo Clinic Score IH-MACE Age, cardiogenic shock, urgent/emergency 
PCI, LMS disease, serum creatinine > 265 
µmol/l, NYHA class ≥ III, thrombus, multivessel 
disease 
Singh (2002) IH-MACE Cardiogenic shock, LMS disease, serum 
creatinine > 265 µmol/l, urgent/emergency 
PCI, NYHA ≥ III, thrombus, multivessel 
disease, age 
Maluenda (2010) 1-Year Mortality TIMI flow < 3, CHF, LMS disease, chronic 
renal failure, history of diabetes, hematocrit 
drop (%), baseline hematocrit (%), age 
CathPCI Risk Score 30-Day Mortality Age, Cardiogenic shock, prior CHF, PVD, 
chronic lung disease, GFR rate, NYHA class, 
PCI status (STEMI/no-STEMI) priority 
Curtis (2012) 30-Day Mortality [STEMI/shock group] age, BMI, chronic lung 
disease, GRF rate, prior PCI, HF (admission), 
cardiogenic shock, MI status, LVEF, Priority, 
vessel, SCAI class,  
Curtis (2012) 30-Day Mortality [No STEMI/shock group] age, BMI, history 
CHF, stroke, PVD, chronic lung disease, 
diabetes, GFR rate, prior PCI, CHF, NYHA 
class, MI status, LVEF, priority, vessel, SCAI 
class 
Conclusions 
The NWQIP model was the first to be developed in a clinical setting within the UK health 
care system, and was subsequently validated and found to perform well in an external 
cohort and different geographical location within the UK. It is however unknown how it will 
perform in more modern times, i.e. post 2010 with increasing proportions of DES usage, 
and with the future potential introduction of 2nd generation bioabsorbable stents. The 
51 
 
referral systems have improved and it is anticipated that more patients would be treated at 
the ECTC as elective patients, whereas previously their disease would have worsened 
and more likely resulted in them undergoing emergency PCI following an out-of-hospital 
myocardial infarction. This thesis provides the opportunity to test this hypothesis and 
identify how well the NWQIP performs on an external cohort in a different era of 
interventional cardiology. 
2.3.2.4 Repeat Revascularisation and Target Vessel 
Revascularisation (TVR) 
Introduction 
Reintervention following coronary revascularisation procedures is an important outcome to 
consider and subsequently warrants analysis of the risk factors that predispose patients to 
undergoing future treatment (Wang et al., 2012; Taniwaki et al., 2014). If such 
characteristics (demographic, clinical, or angiographic) are identified which show a high 
association with the need for further revascularisation in the future, this can be useful for 
both interventional consultants and patients. 
As with mortality prediction, the time period analysed may weaken associations as it is 
increased, for example a patient or consultant may wish to know the probability that a new 
elective PCI patient will require another PCI or CABG within three years, however the 
accuracy and risk factor associations is much more likely to be weaker than that of a 
model which analyses one-year revascularisation. Two common measures of subsequent 
coronary revascularisation are: repeat revascularisation (RR) – which involves any type of 
coronary revascularisation whether this be PCI/CABG, to any coronary artery within a 
defined time period; target vessel revascularisation (TVR) which involves treatment to the 
same coronary vessel as the index procedure. As long as one coronary vessel is treated 
in the subsequent revascularisation procedure that was treated in the initial procedure 
then it is classified as TVR. 
With regards to predicting TVR/RR, it is important to understand that some subsequent 
procedures are planned/staged, meaning the interventional operator intentionally plans to 
treat another vessel/lesion at a later date. Commonly a patient that comes to the ECTC 
following a myocardial infarction (e.g. STEMI) will be treated for the vessel which 
caused/experienced the infarction, however during the coronary angiogram the operator 
may identify high stenosis (atheroma) in other coronary arteries, which they plan to treat 
at a later date, the stenosis is not considered high enough to require immediate 
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revascularisation so they are placed on a waiting list and are seen within six weeks for 
subsequent treatment, additionally it may be the case that the radioactive contrast dye 
would provide too much radiation within a short period of time should the patient be 
treated for the other non-infarct arteries during the index hospitalisation. It is known that 
staged/planned procedures are going to occur, and therefore they are omitted from 
analysis and are not classified within the RR/TVR category. 
In many risk models, which were constructed for repeat revascularisation or target vessel 
revascularisation, death is combined with these outcomes as simply knowing whether a 
patient has a low percentage chance of requiring a further PCI, would be deceiving if that 
patient has a high chance of dying within this period. Other models combine the use of 
myocardial infarction, target lesion failure as predictors although depending on the 
hospital setting, tracking this data may be difficult for some healthcare systems. 
In Japan a study was conducted by Shiomi et al. (2012) across 26 PCI centres, their study 
cohort featured 1005 consecutive revascularisation procedures from January 2005 to 
December 2007, 365 of these were PCI and 640 were CABG. The purpose of the study 
was to compare long-term outcomes of PCI versus CABG for patients that were treated 
for unprotected left main coronary artery disease (ULMCAD) during their first coronary 
revascularisation procedure. Patients with AMI were excluded from their analysis. The 
primary end-point for the analysis was a composite outcome of three year 
death/MI/cerebrovascular accident (stroke) but repeat coronary revascularisation was a 
peripheral end-point that was analysed. It was found that the primary end-point had a 
significantly higher rate in the PCI cohort compared to the CABG counterparts (22.7% vs. 
14.8%, p = 0.0006) but after having adjusted the risk for possible confounding variables, it 
was determined that there was no significant difference in risk (adjusted Hazard Ratio = 
1.30, 95% CI = 0.79 to 2.15, p = 0.30). 
There were significant differences in the SYNTAX score between the two methods of 
revascularisation whereby the PCI cohort had a higher percentage of low (< 23) and 
intermediate (23-33) scores, of 34.4% vs. 26.8% and 36.6% vs. 30.8% respectively, 
however the CABG cohort exhibited a higher rate of high SYNTAX scoring (> 33) patients 
with 42.3% vs. 29.1% (PCI), overall p < 0.0001. Several other important 3-year end-points 
were used in the study, these included: 
(1) All-cause death. 
(2) Cardiac death. 
(3) Myocardial infarction. 
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(4) Cerebrovascular accidents. 
(5) Coronary revascularisation (PCI or CABG). 
Both death classifications (all-cause and cardiac) showed higher rates in the PCI cohort 
(13.6% vs. 9.2%, p = 0.01; and 7.4% vs. 3.7%, p = 0.005 respectively). However, when 
risk adjustment was performed, the rates were not significantly different for either outcome 
for PCI vs. CABG (HR = 0.79, 0.40 to 1.57; and HR = 1.80, 0.64 to 5.09, p = 0.27 
respectively). 
For the myocardial infarction end-point, a higher rate was identified in the PCI cohort 
compared to the CABG group (5.5% vs. 2.3%, p = 0.003). However, following adjustment, 
this was not significant either (HR = 2.47, 0.81 to 7.54, p = 0.11). The reported rate of 
definite stent thrombosis was very low (1.5%), the rate of stent and DES usage were high 
at 98% and 78% respectively. Unlike the other outcomes (described above), the pre-
adjusted rate for stroke was not significantly different between the PCI and CABG cohorts 
(6.6% vs. 5.5%, p = 0.43; and HR = 0.79, 0.30 to 2.08, p = 0.63). The end-point of 
subsequent coronary revascularisation was the only outcome that was significantly 
different between the PCI and CABG cohorts, following risk adjustment. The PCI cohort 
exhibited almost four times the rate of further revascularisation than the CABG cohort 
(43.4% vs. 11.2%, p = 0.0001; and HR = 5.83, 3.74 to 9.09, p < 0.0001). Despite the 
overall 3-year primary end-point (death/MI/stroke) not showing a significant between PCI 
and CABG following adjustment, when the analysis was limited to patients classified into 
the high scoring SYNTAX group (> 33), a significant difference was identified even after 
adjustment (27.4% vs. 16.8%, p = 0.006; and HR = 2.61, 1.32 to 5.16, p = 0.006). No 
statistically significant differences were identified in either the low or intermediate 
SYNTAX score groups. 
As with other studies, there may have been selection bias for patients being administered 
PCI or CABG. Secondly, longer follow up periods (i.e. more than three years) may have 
been difficult to perform, but the rates may have been different and identified whether PCI 
or CABG performs better when considered over longer intervals. For example, it could be 
that the CABG cohort starts to manifest higher adverse outcome rates after three years, 
but these are not known due to the follow-up period being limited to three years. 
In a recent study by Hess et al. (2014), the end-point of target vessel revascularisation 
(TVR) within 1-year of PCI was used. The cohort included elderly patients aged ≥ 65 
years that were having de novo (not previously treated) lesions treated. The study 
included a very large sample size of 343,173 PCIs from 2005 to 2009 from more than 
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1400 hospitals in the US. One of the motivations for this study was the increase life 
expectancy and hence the proportion of elderly patients being treated with PCI. The paper 
reported that approximately 40% of the PCIs performed in the US were on those aged ≥ 
65 years. Due to increasing life expectancy, it was important to consider which of the 
patients needed subsequent treatment for the same vessel, this would allow more efficient 
planning based on estimated risk of TVR, it would be known approximately, what numbers 
of patients would be expected to be seen again within one year. Other studies have 
analysed TVR rates with regards to BMS versus DES over different time intervals and 
have typically found that patients with DES inserted during their procedure have a 
significantly reduced rate of TVR compared to BMS counterparts of a similar condition. 
Despite DES showing lower rates of TVR (e.g. from restenosis) compared to BMS, it does 
not necessarily mean DES should be favoured for all PCIs: (i) DES are more expensive 
than BMS; (ii) DES have a higher risk of very late stent thrombosis; (iii) prolonged use of 
dual antiplatelet therapy is required (or at least recommended). The rate of DES usage in 
their cohort of PCI patients was high at 76.5% (262,496). Hess et al. (2014) analysed the 
1-year TVR rates by splitting their PCI cohort into two groups: (i) BMS exclusive PCIs; (ii) 
DES exclusive PCIs. The overall TVR rate was 3.3% (11,217 patients). When grouped by 
the endpoint, i.e. 1-year TVR group vs. non-TVR group, the former exhibited (as 
expected) a higher percentage of comorbidities, most commonly hypertension, diabetes, 
prior MI, and prior revascularisation. The prior revascularisation PCIs were only those for 
which the vessel treated was different, i.e. prior TVRs were excluded from analysis. Hess 
et al. created four different TVR models using multivariate logistic regression: 
(1) BMS: pre-procedural variables only. 
(2) BMS: both pre-procedural and procedural variables. 
(3) DES: pre-procedural variables only. 
(4) DES: both pre-procedural and procedural variables. 
By producing a model featuring only pre-procedure (proc.) variables, it allows prospective 
use of a risk prediction model to be taken advantage of, which is especially useful for 
elective patients. The strongest predictors identified for each of the four models were: 
(1) BMS (pre-proc.): insulin and non-insulin-treated diabetes, and prior PCI. 
(2) BMS (pre-proc. and proc.): smallest stent diameter, longer stent length, and 
multivessel PCI. 
(3) DES (pre-proc.): prior PCI, age, insulin-treated diabetes. 
(4) DES (pre-proc. and proc.): multivessel PCI, smallest stent length, and prior PCI. 
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Once the regression models had been constructed, the estimated probabilities of TVR 
were assigned to each PCI record and then split into three groups based on the 
ascending order of estimated risk (low, medium, and high). The following table (2.3.12) 
identifies the estimated mean 1-year TVR rate and range for each group, the 
corresponding odds ratios are for the medium and high groups (the low risk group is the 
reference). 
Table 2.3.11 – estimated TVR risk for BMS and DES cohort groups (Hess et al, 
2014) 
Group Mean Risk (%) Range (%) Odds Ratio 
BMS    
Low 2.5% 0.4% to 3.2% Reference 
Medium 3.8% 3.2% to 4.5% 1.5 
High 6.2% 4.5% to 29.8% 2.6 
DES    
Low 1.6% 0.3% to 2.0% Reference 
Medium 2.4% 2.0% to 2.9% 1.5 
High 4.0% 2.9% to 18.2% 2.4 
Table 2.3.11 shows that in the highest risk group for 1-year TVR there is an apparent 
reduction from 6.2% to 4.0% for BMS vs. DES, this is an overall reduction of 35.5%. 
The BMS and DES models (pre-procedure and procedural factors) produced an AUROC 
of 0.54, 0.60, 0.57, and 0.60 respectively, in terms of discrimination performance this is 
poor compared to other important endpoints such as in-hospital MACE/mortality, and 30-
day mortality. The models used a 2:1 ratio for development and validation respectively. It 
is important to note that the study excluded the following PCIs from analysis: procedures 
without stents (e.g. standard balloon angioplasty); procedures featuring a mixture of BMS 
and DES inserted into the patient; procedures with PCIs to graft lesions; patients with 
STEMI; target vessel lesion previously treated; in-hospital deaths/CABG; and CABG 
within one year of the patient’s index PCI. Calibration goodness of fit statistics have not 
been reported (e.g. Hosmer-Lemeshow). The calibration plots present do reveal closely 
matched observed and estimated 1-year TVR however there is little differentiation 
between risk groups, with several of the models within a 2% range of each other. It would 
be beneficial if additional variables could be identified to better distinguish between risk 
groups, and hence allow better judgement of whether a patient might experience 1-year 
TVR. Other factors may have an important impact, such as the duration over which a 
patient continues their antiplatelet therapy. 
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In Sydney, Australia another study relating to TVR was conducted by Shugman et al. 
(2012). This was an investigation into a PCI cohort which had BMS inserted from 2003 to 
2010, and included 1059 PCIs in the final analysis. The study limited the indication for 
intervention to patients presenting with STEMI, as to identify whether BMS insertion into 
large infarct related arteries (IRAs) produces lower rates of TVR compared to a cohort of 
patients which experience STEMI in smaller IRAs. The study excluded patients presenting 
with stable CHD and NSTEMI, and PCIs repeated on the same patient. One of the 
reasons for conducting this study was because it was known that DES overall show 
reduced reintervention rates compared to BMS, but it was unknown whether patients who 
receive DES keep up with dual antiplatelet therapy after 12 months (from their index PCI), 
therefore would using BMS in large arteries be beneficial and produce low TVR rates. 
The BMS PCI cohort was split into three categories based on the size in millimetres of the 
IRAs: 
(1) Large artery group: ≥ 3.5 mm.  
(2) Moderate group: 3.0 mm to 3.49 mm.  
(3) Small group: ≤ 3.00 mm. 
The distributions of the PCIs performed for the three groups were 512 (48%), 333 (31%), 
and 214 (20%), respectively. The 1-year TVR overall rate was 5.8% and for the three 
groups this was 2.2%, 9.2%, and 9.0% respectively. The 1-year death/MI rate for these 
groups was 6.6%, 11.7%, and 9.0%, respectively. The predictors of 1-year TVR are listed 
in Table 2.3.12 
Table 2.3.12 – Predictors for 1-year TVR in BMS patients (Shugman et al., 2012) 
Predictor Odds Ratio 95% CI OR P Value 
Vessel diameter 4.39 2.24 to 8.60 < 0.001 
Proximal LAD lesions 1.89 1.08 to 3.31 0.027 
Hypertension 2.01 1.17 to 3.48 0.011 
Prior PCI 3.46 1.21 to 9.85 0.020 
The predictors for 1-year death/MI are listed below in Table 2.3.13. 
Table 2.3.13 – predictors for 1-year death/MI in BMS patients (Shugman et al, 2012) 
Predictor Odds Ratio 95% CI OR P Value 
Cardiogenic shock (pre-PCI) 8.16 4.16 to 16.01 < 0.001 
Age ≥ 65 years 2.63 1.58 to 4.39 < 0.001 
LAD lesions 1.95 1.19 to 3.21 0.019 
Female gender 1.93 1.12 to 3.32 0.008 
ACC/AHA Type B2 and C lesions 2.17 1.10 to 4.27 0.026 
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In summary, it was found that STEMI in IRAs ≥ 3.55mm were associated with a low 1-year 
TVR rate (2.2%) when treated with BMS, and should therefore be considered for future 
interest as this could alleviate the problems of using DES whereby patients prematurely 






Following review of the published journal articles featuring risk prediction models design 
for outcomes following PCI, it is apparent that the vast majority of the models were 
constructed by researchers outside of the UK. The original NWQIP study (Grayson et al., 
2006) and external validation study (Kunadian et al., 2008) were initially the only literature 
available that utilised a UK PCI database, however, since the completion of the studies in 
Chapters 4 and 5, two new publications (McAllister et al, 2016; Wall et al, 2017) have 
been made featuring the development of a 30-day mortality prediction model, the findings 
within this thesis and how they relate to both models is discussed in Chapter 7. This lack 
of research gives rise to the need to verify whether NWQIP performs as well as it 
originally did on PCI cohorts of a different era. In order to test the first and second 
hypothesis (section 1.3), a study utilising the ECTC's PCI cohort is performed in Chapter 
4. To restate these hypotheses in brief, it is predicted that due to the myriad of changes in 
terms of patient demographics, clinical, and procedural characteristics, that the NWQIP 
risk model will not perform as well it once did for predicting in-hospital MACE. Subsequent 
logistic regression analysis, as heavily featured in published literature relating to PCI risk 
prediction models, should allow a risk model to be constructed that can more accurately 
predict important clinical outcomes such as in-hospital MACE, or short and long-term 
mortality following PCI. Chapter 5 extends the validation study of NWQIP, to investigate 
30-day mortality, and to ascertain whether the incorporated NWQIP risk factors are 
effective predictors for all-cause death within 30 days of a patient undergoing PCI. 
At the time of writing, there is no peer-reviewed research available that has been 
conducted in the UK to examine the impact of repeat revascularisation. Similarly, there is 
little available information prediction models for longer-term outcomes for stable PCI 
patients. Hess et al. (2014) showed that DES cohorts typically have lower estimated TVR 
rates compared to BMS cohorts for the same relative risk groups (i.e. low, medium, and 
high). Both the Shugman and Hess studies yielded useful information to investigate in the 
ECTC cohort, specifically that the types lesions and vessel diameter are useful predictors 
for TVR. As with many models that report MACE/mortality, comorbidities are also 
prominent in repeat revascularisation and TVR models. Many of the different risk factors 
in these published models are available in the ECTC CVIS database and can be 
investigated in an univariate association analysis. This analysis may provide useful 
insights into which risk factors predispose patients to requiring a subsequent coronary 
revascularisation. This is especially beneficial for elective patients, whereby the other 
clinical outcomes such as in-hospital MACE, or short-term mortality (i.e. 30 days) occurs a 
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very low rates. Chapter 6 investigates the outcomes of repeat revascularisation and 










The data used in this thesis was obtained from the Essex Cardiothoracic Centre (ECTC), 
part of Basildon and Thurrock University Hospital's NHS Foundation Trust (BTUH). The 
site is located in Basildon, Essex, United Kingdom. The data was provided following 
NRES Ethical Approval (detailed in section 3.3). All patient-identifiable information was 
removed, i.e. names, addresses, contact details, dates of birth etc. The ECTC is a tertiary 
cardiac referral centre which serves the county of Essex, which includes a population of 
approximately 1.7 million people (ONS, 2014).The ECTC opened in July 2007, and 
performs coronary procedures for elective, urgent, and emergency patients, comprising 
approximately 3000 per annum. Many patients are referred to the ECTC by several district 
general hospitals (DGHs) in the county of Essex, these being Southend University 
Hospital NHS Foundation Trust (Westcliff-on-sea, Essex), Colchester Hospital University 
NHS Foundation Trust (Colchester, Essex), Princess Alexandra Hospital NHS Trust 
(Harlow, Essex), Mid Essex Hospital Services NHS Trust (Chelmsford, Essex), and 
Basildon and Thurrock NHS Foundation Trust (Basildon, Essex).The ECTC initially began 
performing elective PCI procedures when it first opened in 2007 which is why 
approximately 83% of all PCIs during that year were elective. In the third quarter of 2009 
the ECTC started its primary care activation programme whereby patients which 
experienced out-of-hospital ST-elevation myocardial infarctions (STEMI) were sent 
straight to ECTC for coronary revascularisation instead of being treated at another non-
PCI hospital with thrombolytic therapy and then transferred to the ECTC at a later stage. 
This is why from quarter three of 2009 onwards there is a rise in the proportion of 
emergency PCI procedures performed. 
The ECTC offers four principle clinical services (BTUH, 2014). These are: 
1. Cardiovascular surgery – conventional CABG, off-pump coronary bypass (OPCAB), 
minimally invasive direct coronary bypass (MIDCAB), aortic valve replacement (AVR), 
mitral valve replacement/repair, and others. 
2. Interventional Cardiology – PCI, including standard balloon angioplasty, bare metal 
stent (BMS) insertion, and drug-eluting stent (DES) insertion. 
3. Thoracic Surgery 
4. Cardiac Electrophysiology 
The ECTC facilitates for over 100 patients and includes 22 critical care beds, a 
rehabilitation gym, and a dedicated cardiac rehabilitation team (SCTS, 2014). 
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3.2 Patient Database 
The ECTC uses a cardiovascular information management system (CVIS) from Philips 
(Philips CVIS, 2014). In 2014, this was used by approximately 26% of the PCI centres in 
the UK (BCIS Audit Report, 2015). This is a comprehensive relational database system 
that performs numerous functions relating to the management of patients and coronary 
procedures in a cardiovascular treatment setting. The relational database structure 
schema itself is confidential and cannot be described in detail here. However, it contains 
common tables and fields as expected such as patient, procedure, history, devices used 
etc. The CVIS system itself is also known as Tomcat, although it is usually used to 
describe the system front-end. According to the national audit project for PCI centres, the 
British Cardiovascular Intervention Society (BCIS), CVIS/Tomcat is the most commonly 
used front-end database for PCI centres in the UK (BCIS Audit Project, p. 68, 2014). The 
total number of PCIs was 15,865 and procedure dates ranges from 2nd July 2007 to 12th 
March 2015. The CVIS application front-end supports, and hence has tailored interfaces 
for numerous specialities within cardiology such as catherisation, electrophysiology, 
echocardiography, nuclear cardiology, cardiac surgery labs, and several others. The 
system supports the scheduling of patients for treatment, the management of staff and 
resources, capturing of costs, and also allows for the rapid generation of reports. The 
CVIS application allows detailed patient information to be stored and easily retrieved for 
review, whether this be by cardiac operators, consultants, or nurses. Detailed discharge 
and treatment letters can also be created, stored, and accessed from the system. In 
addition to PCI and CABG procedures, support for other cardiovascular databases and 
imaging software is supported, thus overall allowing a single comprehensive system to be 
used for the majority of the work performed at the ECTC. There are several benefits to 
utilising a single cardiovascular information management system over using multiple 
software systems from different vendors, these include (but are not limited to) the 
following: 
Less training – it may confuse staff (operators, consultants, and nurses) if multiple 
systems were used, and utilising a single system less training may be required for 
effective usage. 
Easier backup and security – backing up a single database and implementing security 
may be more easily performed on a single database. Data managers would also only 
need to know the inner workings of a single database schema rather than multiple, which 
is beneficial should any problems or issues arise. 
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Data Redundancy – by using a single database not only will the data be up-to-date, it will 
also not be duplicated as the functionality is contained within one system and no 
overlapping of data can occur between different systems, thus reducing the resources 
required. It also reduces the risk of inconsistency. 
Centres such as the ECTC which perform procedures for patients with cardiovascular 
disease are required to submit certain data audits to various cardiovascular national audit 
projects (in England, Wales, and Northern Ireland). These audits allow various hospitals 
and cardiac centres to be compared. They also allow identification of how they performing 
compared to the national average with respect to important clinical outcomes, such as in-
hospital complications and mortality. The audits themselves specify a minimum dataset 
(list of variables required for submission) although a schema for extra data are often 
provided and appreciated. These audits allow patients to be educated on a given hospital 
or cardiac centre's performance, which may subsequently influence their decision to 
undergo a certain choice of treatment there. In addition to this it can allow the under-
performing centres to reassess their processes and attempt to improve upon their 
services. The audits have the potential to detect operators or surgeons that are 
underperforming and allow questions to be answered such as “which operators show 
unusually high associations with adverse outcomes?”. Public outcomes may also tempt 
certain operators or institutions to avoid higher-risk patients as to avoid potentially adverse 
outcomes, despite the operation being most preferred. Many of these cardiovascular 
audits are managed by the National Institute for Cardiovascular Outcomes Research 
(NICOR) which is based at University College London (NICOR, 2015). By having these 
national bodies that process and make hospital/cardiac centre and operator outcomes 
publicly available it allows patients to have a better informed consent before they undergo 
a procedure at a certain centre or with a certain operator. 
The audits which the ECTC is known to submit to national sources include: 
1. Myocardial Ischaemia National Audit Project (MINAP) – this includes data that 
relates to the management of patients which have a myocardial infarction/heart attack 
(MINAP, 2015). 
2. Society for Cardiothoracic Surgery (SCTS) – this includes data relating to all patients 
which undergo any form of cardiac surgery, such as CABG, aortic/mitral valve surgery etc. 
(SCTS, 2014). 
3. British Cardiovascular Intervention Society (BCIS) – this includes data for patients 




The primary set of data used in this thesis was acquired from the ECTC CVIS database 
through the usage of structured query language (SQL). This allowed relevant data relating 
to each patient procedure to be extracted, and stored in a spreadsheet for subsequent 
analysis. The SQL queries and construction of the corresponding spreadsheets were 
designed and executed by the ECTC Data Manager following provision of NRES ethical 
approval and data anonymisation. The majority of queries executed were already 
designed for extraction of the CVIS data for audit reports in order to submit them to the 
three national bodies above (MINAP, SCTS, and BCIS), these were modified and 
additional variables added for analysis in the studies within this thesis. The mortality data 
was extracted in the background; the CVIS database links up the BTUH PAS database 
that contains the date of death and any relevant deaths for patients that have had a PCI 
procedure at the ECTC are retrieved. The characteristics of fields relating to each of the 
three audits are listed in Appendix B. In summary, each cardiac procedure performed at 
the ECTC has a detailed set of information stored about it in the CVIS database that 
relates to: (I) patient demographics; (ii) comorbidities/medical history; (III) procedural 
aspects; (IV) and angiographic characteristics. 
This study, whilst including analysis on CABG, primarily focusses on PCI (BCIS) 
outcomes. As listed previously, BCIS are responsible for the national PCI audit. The 
audits themselves are submitted digitally following the appropriate extraction through SQL 
into a standard flat text file. The required information is specified in the BCIS dataset 
documentation version 5.6.2 (BCIS Dataset, 2014). In brief, the data required by BCIS 
includes: patient demographics; intervention indication; procedure priority; cardiogenic 
shock (pre-procedural); angina status (Canadian Cardiovascular Society Classification, 
CCS); date and times of operation/symptom onset/ambulance transport/balloon inflation; 
prior myocardial infarction/CABG/PCI; diabetes; left ventricle ejection fraction (LVEF); 
stenosis percentages of coronary vessels (left main stem, circumflex, right coronary 
artery, left anterior descending artery); number and type of stents inserted; drugs given 
pre and post-procedure; medical history; complications during and after the procedure; 
and status at discharge. 
Data Completion and Recommended Minimum Dataset for PCI Procedures 
The data is recorded by a combination of interventional operators, trained nurses, and 
junior doctors. Although not every piece of information may be recorded due to time 
constraints or a lack of training, in recent times the majority of the minimum data fields 
specified by BCIS are complete and should be encouraged for anyone recording 
procedure details.  
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Table 3.2.1 lists the minimum dataset standard for audit submission as specified by 
NICOR. Some of the data is only required depending on the PCI type and this has 
remained a requirement since November 2010. It is also a requirement that at least 90% 
of the following data fields are complete upon submission. The 'All PCIs' type represents 
every single PCI procedure performed, 'Primary PCI' type represents PCIs performed on 
STEMI patients, and the 'ACS PCI Types' represents any procedure performed on acute 
coronary syndrome patients (i.e. non-stable patients). 
Table 3.2.1 – Recommended minimum PCI procedure audit submission dataset 
Field Code Field Name PCI Type 
1.03 NHS Number All PCIs 
1.06 Birth Date All PCIs 
1.07 Sex All PCIs 
2.03 Procedure Urgency All PCIs 
2.04 Cardiogenic shock (Pre-PCI) All PCIs 
2.07 Date/Time of symptom onset ACS PCI Types 
2.08 Date/Time arrival at first hospital ACS PCI Types 
2.16 Diabetes All PCIs 
2.18 Weight All PCIs 
3.02 Consultant Responsible Name All PCIs 
3.09 Vessels Attempted All PCIs 
3.26 Date/Time of first balloon inflation Primary PCIs 
4.01 PCI Hospital Outcome All PCIs 
4.03 Status at discharge All PCIs 
4.04 Discharge date All PCIs 
5.05 Medical History All PCIs 
5.06 History of renal disease All PCIs 
5.26 Date/Time of arrival at PCI hospital ACS PCI Types 
5.27 Date/Time call for help ACS PCI Types 
5.30 Location of Patient at STEMI onset Primary PCIs 
5.31 Consultant Responsible GMC Number All PCIs 
5.35 Creatinine All PCIs 
In this study, the NHS Number, Consultant Responsible GMC Number, and Birth Date 
were not available or needed in this dataset due to confidentiality and ethical approval 
reasons. The age in years was however available and represented the patient's age at the 
time of their procedure.  
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Table 3.2.2 lists the minimum required variable as specified in Table 3.2.1 and the 
percentage completeness from July 2007 to March 2015, which were provided from the 
CVIS database for analysis. 
Table 3.2.2 – ECTC CVIS Data completeness (BCIS minimum dataset) 
Variable 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Age 100 100 100 100 100 100 100 100 100 
Sex 100 100 99.9 100 100 100 100 100 100 
Status at 
Discharge 
62.3 99.5 94.6 97.6 98.8 98.1 97.7 94.2 91.7 
Shock  28.4 97.4 86.1 93.2 94.2 92.1 96.4 97.4 97.8 
Urgency 94.4 99.9 99.7 99.8 100 99.9 100 99.8 100 
Medical 
History 
88.8 98.6 92.1 92.05 98.8 92.6 97.2 91.7 92.4 
Discharge 
Date 
59.8 99.7 90.1 98.0 98.9 97.9 98.7 85.0 77.3 
Diabetes 91.3 91.5 95.5 96.6 98.5 95.2 96.8 95.1 94.6 
Weight 65.4 31.5 48.7 42.7 42.3 22.7 22.2 37.7 68.6 
Vessels 
Attempted 
29.3 99.8 97.8 98.09 99.3 99.1 99.6 98.5 99.1 
Consultant 
Responsible 



















22.2 81.9 54.2 43.2 39.3 47.8 39.3 40.6 55.5 
D/T arrival 
PCI hospital 
5.5 63.7 49.2 67.9 76.9 81.2 85.7 83.6 78.3 
PCI Hospital 
Outcome 





As expected the age and sex data are fully complete. Several of the variables show very 
high completion rates overall, these being pre-procedural cardiogenic shock, procedure 
priority, coronary vessel(s) attempted, date/time of first balloon inflation, and the 
consultant responsible. Those which show relatively low data completion rates were 
discharge date, patient weight, date/time of arrival at first hospital, date/time arrival at PCI 
hospital. It should be noted that in 2015 for some variables there is a reduction in 
completion rate that could be explained by staff not completing fields by the time the data 
was provided for this Thesis. For example, the latest month in the 2015 data is March and 
therefore there may have been some patients not discharged, or at least there discharge 
date was not completed and recorded in the data immediately thus why a drop from 85% 
in 2014 to 77% in 2015 exists. In some cases an apparent low data completion rate such 
as the date/time arrival at first hospital can be explained by the fact that it is required for 
'ACS PCI Types' however, this is explained by the fact than patients with an ACS type 
since the third quarter of 2009 are sent directly to the ECTC, therefore this is somewhat 
overridden by the date/time arrival at first PCI hospital variable, which exhibits a much 
higher data completion rate compared to the former, at 55.5% and 78.3% respectively. 
Other variables completion rates can also be related to the type of priority, for example, 
the patient weight variable although it exhibits a sudden rise from 37.7% in 2014 to 68.7% 
in 2015, this would mostly be completed in elective patients. For emergency procedures 
the planning and information about a patient (i.e. from their general practitioner) is scarcer 
relative to the elective counterparts, which is why weight would be missing. 
ECTC Data Completion Profile Compared to Other PCI Centres 
The BCIS audit reports, provide statistics from the UK PCI centres allowed comparisons 
to be made between the ECTC PCI profile (patients and procedure characteristics), other 
national centres, and the national averages for certain variables and data completion 
rates. By having data available allowing certain comparisons between centres it can 
reveal information about how closely patients and procedures match, and possibly explain 
differences in outcomes, for example if a centre had an overall very high rate of 
emergency/STEMI patients versus another centre which exhibited a very high rate of 
elective/stable patients then the anticipated difference in overall adverse outcomes would 
be easily deduced simply by procedure priorities. In summary, these comparisons using 
audit data allow more accurate comparisons and conclusions to be made with regards to 
certain outcomes.  
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In the PCI audit report (BCIS Audit Report 2014) the ECTC is listed on various figures as 
'BAS' and its data completion is classified as 'Almost Excellent' with only the following 
fields exhibiting a completeness below 90%. 
 Medical history – 88.14% 
 Renal disease – 85.49% 
 Weight – 40.3% 
Approximately 62% (2000) of the ECTC PCIs were performed on ACS patients. This is 
slightly below the national average of 65.1% (BCIS, 2014). Of the 119 UK PCI centres, 
only seven of these perform a greater number of PCIs on ACS patients than the ECTC. 
The entire ECTC cohort of PCI patients are on average older at approximately 65.6 years 
compared to the national average of 65.1 years. 
Data Accuracy/Validity 
When analysing the ECTC CVIS dataset it was important to consider accuracy, validity, 
and completeness of data. If such considerations were ignored it may result in false 
conclusions being drawn from the data. During the undertaking of this project certain 
issues were discovered with some data fields, either from discussions with interventional 
cardiologists, or by observations of the database. It is unknown whether these issues exist 
at other UK centres, but if the same level of staff inputting data into the system exists, 
then it is likely it is not limited to the ECTC. By highlighting such issues it might prove 
useful in the future for educating hospital staff on what should be input in certain data 
fields and the use of having accurate and complete data for risk prediction models. 
Several methods exist for handling missing data such as multiple imputation, whereby an 
unknown/missing variable is predicted by using multiple others that show a high 
association as detailed for its usage by Sterne et al. (2009) for epidemiological and clinical 
research usage. This technique was considered for usage where appropriate in the 
analysis of the ECTC CVIS data for this thesis. 
Many of the input fields relating to procedures are drop down boxes and therefore feature 
a limited number of possible values for selection (e.g. 'yes', 'no', blank) thus avoiding free 
text problems such as 'y','yes','Y','YES', all representing the same value 'yes' in the data. 
Within the database, there is a field that represents medical notes/history for each 
patient's procedure. This field is free text and therefore among difference operators, 
consultants and staff this has many different formats, and short-hand words thus making 
automatic extraction very difficult. 
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Examples of such a notes issue are the pre-procedural patient symptoms, 
pharmacological therapies administered, cardiovascular disease present in relatives, etc. 
For this reason, and the fact that the medical notes could contain confidential information 
(i.e. patient names etc.) this was not available in the dataset for analysis. 
Detailed information relating to the procedure is also displayed on a discharge letter, and 
other documents, one of which features a graphic diagram of the coronary arteries and 
the location of the lesions detected, and subsequently where the stents (if applicable) 
have been inserted. Some of the information in the discharge letter and other documents 
are also free text and therefore is not specifically listed in any separate data field. 
It has been made known from some of the interventional cardiologists at the ECTC that 
certain data fields within CVIS may not be correct in the sense that the field might only be 
set to 'Yes' if the patient experiences/has a certain characteristic. Therefore in some 
cases instead of entering 'No' the field is left blank. Two common examples of this are 
cardiogenic shock (pre-procedural), and ventilation (pre-procedural) both of which are 
associated with the emergency/STEMI patients. In these cases because both these 
conditions are very important, for analysis the blank fields are interpreted as 'No' as 
recommended by the ECTC staff that were consulted with. 
For the coronary 'vessels attempted' field it was determined that there were differences in 
how graft vessels treated were stored. For example, if the PCI was being performed on a 
graft vessel during the procedure then the 'vessels attempted' field should include the 
value 'Graft(s)' to indicate this. The actual graft vessel to which the PCI was administered 
to had to be identified from another field (not originally available in the provided dataset), 
this was the 'Events' field, which would list details such as 'PCI to RCA Graft', in a small 
percentage of cases with Graft(s) listed it was found that the value also listed the graft 
vessel beside the 'Graft(s)' value, e.g. 'Graft(s), RCA', however this in most cases would 
represent multi-vessel PCI, whereby the 'RCA' native vessel is different from the graft 
vessel being treated. These were manually corrected by reading the 'Event' and 'Event 
failures' fields for the correct graft vessel (if it existed). 
An issue with the 'Devices' field was identified whereby it listed every device used/planned 
to be used during the procedure (i.e. stent, balloon catheter, sheath, and guide wire) 
regardless of whether it was inserted into the patient, i.e. if a stent did not get inserted due 
to not being able to bypass/penetrate the lesion, it would still be listed in this field. To 
remedy this issue, the field was cross referenced with the following fields: 'stents used'; 
'stents successful'; and 'event failures'. 
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Where available the body mass index (BMI) was calculated (NHS BMI Calculator, 2016) 
using the patient's weight and height by dividing the weight in kilograms (Kg) by the height 
in metres, squared. In the CVIS dataset the patient's height and weight at the time of their 
procedure is stored in centimetres (cm) and kilograms respectively. It was determined that 
a small proportion of records (< 1%) displayed unusually high or low values for either one 
of both of the weight and height fields. The cause of this was due to staff inputting the 
values in the incorrect measurement type (e.g. pounds or stone instead of kilograms), or 
inputting the decimal place incorrectly (e.g. 18.2 cm instead of 182 cm), these are clearly 
erroneous and were manually amended to the value assumed to be correct. Similar 
issues were found with the weight field. Without amending these erroneous values, this 
affected the calculated BMI metric. 
During the initial basic analysis of the dataset, suspiciously long length of stay (LOS) 
durations where discovered, i.e. this is supposed to represent the interval in days between 
the operation date and the discharge date. Usually for elective patients presenting with 
low-risk conditions such as stable angina, they are discharged the same day or the 
following day. Critically ill patients such as those treated with primary PCI (PPCI) for 
STEMI, they may be expected to have longer LOS, of a few days. The only factor in the 
dataset which helped explain certain long LOS intervals was the presence of certain PCI 
complications. It was determined that several records had a discharge date that had more 
than likely been incorrectly input. For example, a PCI procedure may have been 
performed on 16/06/2009 and the discharge date was set to 17/06/2010, thus resulting in 
a LOS of 366 days, the discharge date should have however been set to 17/06/2009, thus 
being a single day LOS. Where an error in the input date was likely, thus was manually 
changed in the dataset after first having been confirmed using the CVIS front-end to view 
the discharge letter details. 
Another important point to consider in the interpretation of the data was that comorbidities 
were not backdated (and correctly so), for example, if a patient underwent a PCI in 2009 
and their diabetes status was unknown, then they came back in 2012 for another PCI but 
their diabetes status had in this interim been tested (positive), then only the 2012 PCI data 
would have diabetes listed in medical history, and not the 2009 data, even though 
technically the patient may have been diabetic during the 2009 procedure. 
In a very small number of records (< 0.1%) the priority was unknown because despite 
being transferred from another hospital (before September 2009 when the ECTC started 
the primary care activation pathway) it was unknown whether these patients were 
classified as urgent or emergency due to the use thrombolytic agents provided elsewhere 
71 
 
and the duration since their myocardial infarction. They may have been classified as 
emergency patients when they arrived at another hospital, but when they were transferred 




3.3 Ethical Approval 
The data used for this Thesis was provided following the ethical approval granted by the 
Solihull Research Ethics Committee (REC) after the submission of an application through 
the Integrated Research Application System (IRAS) website. The application allowed the 
use and access to the CVIS database, along with subsequent publication of research 
findings in peer-reviewed journals. Following REC approval, the appropriate authorisation 
was granted by the Basildon and Thurrock NHS University Foundation Trust. The 
procedure records were anonymised prior to access so that no patient-identifiable 
information was available or used, i.e. no names, addresses, contact details, date of 
births, or any other identifiers were ever provided. The REC reference number for the 




3.4 Statistical Analysis 
Integer variables such as the patient age (in years) are expressed using the mean and 
standard deviation (SD), and discrete variables such as the patient age group are 
represented as a percentage. Univariate analysis was performed to identify which 
variables in the dataset, comprising demographic, procedural, clinical were significantly 
associated (i.e. p < 0.05 unless stated elsewhere) with the outcomes featured in this 
thesis (in-hospital MACE, 30-day mortality, and three-year repeat revascularisation or 
death). Nominal variables were analysed using chi-square tests of Fisher’s exact test 
where appropriate, and continuous data was tested using the Student’s t-test. The odds 
ratios, corresponding 95% confidence limits, and significance values were calculated for 
each variable and displayed in a column for each corresponding univariate association 
table displayed in the results sections. 
The variables from the univariate association analysis that exhibited a p value that was 
considered statistically significant, in addition to those considered clinically important 
predictors, were used as candidates for entry into subsequent multivariate logistic 
regression analysis (Sperandei, 2014), using the forward stepwise selection technique. 
This uses the Wald test to assess whether the presence of the candidate variable 
significantly contributes to the model whilst also controlling for covariates already 
accepted into the model. This is done by dividing the coefficient of the candidate by its 
standard error, then retaining the variable as a risk factor if the significance is p < 0.05. By 
using the Wald test, it reduces the likelihood of candidate predictors incorrectly being 
regarded as significant by statistical chance (i.e. type I errors), and hence avoids potential 
incorrect conclusions about which characteristics are truly associated with the measured 
outcome. At the end of this regression analysis, only the variables that contain a 
significant relationship with the outcome should be retained. The Wald test is one of the 
available correction tools incorporated into the statistical analysis software package 
(SPSS) that used for the analyses in this thesis. The assumptions for the logistic 
regression analysis (Burns & Burns, 2009) in brief are: no linear association between the 
dependent and independent variables; dependent variable is dichotomous/binary (i.e. one 
of 2 categories); no assumptions of normal distribution, equal variance, or linear 
relationships in the independent variables; the independent variable groups must be 
mutually exclusive (i.e. a patient can only be in a single age group, not multiple); large 





When creating multivariate regression models it is important to detect variables which 
exhibit high collinearity and multicollinearity with others in the same model and to handle 
this appropriately. Multicollinearity will always be present however the degree to which 
must be investigated to determine whether this causes any issues, in some cases even 
small levels has the potential to cause problems. It occurs when two or more of the 
predictor variables in the model are correlated with each other such that it is difficult to 
determine each individual predictor’s effects on the dependent variable alone, hence 
making the model less accurate along with the statistical power of the estimates whilst 
making the standard error large. In an ideal risk model the predictors should possess a 
strong variance with the dependent (outcome) variable but a low variance with each of the 
other predictors. 
A simple potential indicator of high multicollinearity is to iterate through each predictor and 
remove/drop it from the model whilst retaining all others and observe any large changes in 
the estimated regression coefficients. Ideally for a model with low multicollinearity, these 
changes should be minute. Whilst there is no gold standard, there are two collinearity 
diagnostic measures (Baguley, 2012) which can be used to identify how severe the issue 
of multicollinearity is. These are tolerance and variance inflation factor (VIF). The 
tolerance statistic in brief represents the amount of unique information which a given 
predictor is responsible for in the regression model. The tolerance value itself in essence 
reports the amount of information the multicollinearity is responsible for in the analysis. It 
is calculated using the proportion of a predictor’s variance which overlaps with the other 
predictors; this is then subtracted from 1.0. If other predictors in the model explain 65% of 
a predictor’s variance then the tolerance value of that predictor is 1.0 – 0.65 = 0.35. If the 
calculated tolerance value is 0.35 this means that the predictor estimates and their 
corresponding confidence intervals are using only 35% of the available information to 
explain the dependent variable. The perfect tolerance value would be 1.0 although this 
unlikely in the real world, as this would indicate no multicollinearity for the predictor at all, 
conversely the worst value would be 0.0 or any values close to this, indicating a strong 
level of multicollinearity. The VIF in brief, is the factor which the sample size needs to 
increase to be considered free from multicollinearity, for example, if the VIF were 2.7 then 
this means a sample size 2.7 times greater than the actual one used in the multiple 
regression analysis would be needed to overcome the level of multicollinearity. The VIF is 
calculated by 1/tolerance, for example if the tolerance were 0.35 then the VIF would be 
1/0.35 = 2.86. 
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In this thesis, unless otherwise stated a VIF ≥ 4.0 and/or a tolerance < 0.2 were 
considered indicator threshold values for concern regarding multicollinearity (Van Steen et 
al., 2002) and thus warranted attention in how to handle the issue. 
There is no gold standard for how to handle predictors which exhibit a low tolerance value 
or a high VIF. Several approaches exist and are widely used however no method is 
perfect, each has its own limitation. One method is to simply remove/drop the predictor (or 
one of) however this can be argued that it is hiding the issue rather than actually solving 
the problems caused by the multicollinearity, and it could be misleading when testing any 
hypotheses about predictors. Secondly the predictors can be combined or transformed as 
done by factor analysis, by either adding or average the predictors, this obviously cannot 
be done if the majority of the dataset contains nominal variables. Using weightings or the 
difference between predictors can also be utilised. The other method is to simply leave the 
predictors which exhibit high multicollinearity in the model and report this in the 
accompanying literature whilst stating more data is desired to distinguish the individual 
effects apart effectively, as small samples sizes cause poor estimates of the individual 
effects. 
Software 
Data were analysed using the statistical analysis software SPSS for Windows, release 




3.5 Risk Prediction Model Testing 
Multivariate logistic regression risk prediction models have three widely reported 
measures that can be used to assess and compare their performance levels, these are 
discrimination, calibration, and pseudo R2. 
Discrimination 
Two important measures for binary/dichotomous classification tests are sensitivity and 
specificity. In the context of this thesis the sensitivity, also known as the true positive rate 
(TPR), is the percentage of patients which are correctly classified as experiencing a given 
outcome (e.g. in-hospital MACE, or 30-day mortality, or repeat revascularisation within 
three years). The specificity, also known as the true negative rate (TNR), is the 
percentage of patients which do not experience the outcome and have been correctly 
predicted as not. The false positive (FP) measurement refers to the patients that did not 
experience the outcome which were incorrectly predicted to, and conversely the false 
negative (FN) measurement is the patients which experienced the outcome but were 
incorrectly predicted not to. The equations for both measures are as follows: 
Equation 1. (Sensitivity) 
Sensitivity = TP / (TP + FN)  
 
 
Equation 2. (Specificity) 
 
 Specificity = TN / (TN + FP) 
Clearly the ideal risk prediction model would have both 100% sensitivity and specificity 
(i.e. only true positives and true negatives) although this is highly unlikely in the real world 
of clinical medicine, especially when related to mortality prediction following a given 
procedure. The effect of having a poor sensitivity and specificity could be the failure to 
provide the correct type of treatment to a patient. 
With these measures there is a trade-off, one commonly used technique to visualise this 
and identify an optimal cut-off is the receiver operator characteristic curve (ROC), 
specifically the measurement of the area under the curve is reported (AUROC). The ROC 
curve itself is a plot of the sensitivity (TP rate) against 1-specificity (FP rate) (Hanley & 
McNeil, 1982; Park et al, 2004). Any test which produces an equal rate of TP and FP 
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would display a 45° diagonal from the origin. The optimal cut-off point on a ROC curve is 
the point closest to the upper left corner, i.e. the highest sensitivity and lowest FP rate, 
this will yield the largest AUROC. The usage of the AUROC statistic can be used to 
compare different risk prediction models; generally the one which yields the higher 
AUROC would be preferred (Hajian-Tilaki, 2013). 
The AUROC will be in the range from 0.5 to 1.0 whereby the latter is desired, and the 
former shows a poor performance that is no better than randomly guessing/classifying a 
patient's predicted outcome. Whilst the AUROC ranges depend on the type of prediction 
model and the outcome used, other peer-reviewed literature have suggested the following 
ratings for the AUROC ranges (Metz, 1978; Obuchowski, 2003; Ludemann et al., 2006). 
 0.5 to 0.6 – Failed 
 0.6 to 0.7 – Poor 
 0.7 to 0.8 – Fair 
 0.8 to 0.9 – Good 
 0.9 to 1 – Excellent 
Calibration 
The calibration refers to how well the observed and estimated outcomes rates match 
across different risk groups. Typically, from the estimated outcome probabilities, patients 
are ordered by ascending risk and placed in one of several risk equally sized (if possible) 
groups (e.g. eight). A goodness of fit test (Hosmer & Lemeshow, 2013), commonly the 
Hosmer-Lemeshow test, which is an extension of the chi-square test it used for logistic 
regression model goodness of fit testing. The test produces an overall significance value, 
i.e. a p value for which values lower than 0.05 indicating a large deviation between 
observed and estimated rates. The closer the p value is to 1.0, the better the calibration. A 
risk model that has a p = 1 means across every risk group, the observed and estimated 





An example of a calibration plot and ROC curve example are displayed in Figure 3.5.1. 





The perfectly calibrated risk model would see all data points fall across the line (y = x), 





3.6 General Data 
Listed below are the details of the basic descriptive statistics of the entire PCI dataset (n = 
15,865) by year of PCI. By visualising differences in demographic, clinical, and procedural 
characteristics over time, certain trends may be identified about the PCI patient cohorts in 
modern times. All figures and tables in section 3.6 display percentages relative to the non-
missing data unless otherwise stated. 
3.6.1 PCIs by year 
Table 3.6.1 and Figure 3.6.1 display the total number of PCIs performed each year at the 
ECTC from 2007 to 2015 (2007 and 2015 are partial years). 
Table 3.6.1 – PCIs by year 
Year Count Percentage 
2007 162 1.02% 
2008 1708 10.77% 
2009 1980 12.48% 
2010 2303 14.52% 
2011 2440 15.38% 
2012 2351 14.82% 
2013 2198 13.85% 
2014 2260 14.25% 
2015 463 2.92% 
 




The number of PCI procedures performed at the ECTC peaked in 2011 wherein 2440 
were carried out. This has seen a slight decrease in successive years. This could be for a 
variety of reasons such as faster diagnosis of CVD by general practitioners and hence 
some patients could be treated with pharmacological therapy at an earlier stage in their 
disease progression and hence avoid the necessity of having a PCI, although this is just 
one possible explanation. 
3.6.2 PCIs by yearly quarter 
Table 3.6.2 and Figure 3.6.2 show the quarterly breakdown of PCIs (January-March, April-
June, July-September, and October-December). This allows identification of whether 
certain periods within the year show increased rates of PCIs performed. Years 2007 and 
2015 have been excluded from the figure because they are partial years. 
Table 3.6.2 – PCIs by yearly quarter 
Year Q1 Q2 Q3 Q4 
2007 - - 134 62 
2008 367 429 437 475 
2009 457 456 518 549 
2010 575 563 552 613 
2011 600 622 609 609 
2012 597 595 577 582 
2013 581 519 535 563 
2014 538 536 618 568 
2015 463 - - - 
 
Figure 3.6.2 – PCIs by yearly quarter (bars from left to right: Q1, Q2, Q3, Q4) 
There is little variation in breakdown by quarter however 2008, 2009, and 2014 show a 
slight increase in the number of PCIs performed in the last two quarters of the year. 
82 
 
3.6.3 PCIs by Priority 
Table 3.6.3 and Figure 3.6.3 details the breakdown by PCI year and procedure priority 
(elective, urgent, or emergency). 
Table 3.6.3 – PCIs by priority 
Year All PCIs Elective (%) Urgent (%) Emergency (%) 
2007 162 127 (83%) 23 (15.0%) 3 (2.0%) 
2008 1708 1103 (64.6%) 400 (23.4%) 204 (12.0%) 
2009 1980 844 (42.8%) 724 (36.7%) 406 (20.6%) 
2010 2303 935 (40.7%) 619 (26.9%) 745 (32.4%) 
2011 2440 977 (40.0%) 680 (27.9%) 783 (32.1%) 
2012 2351 919 (39.1%) 680 (28.9%) 752 (32.0%) 
2013 2198 879 (40.0%) 613 (27.9%) 706 (32.1%) 
2014 2260 883 (39.1%) 629 (27.9%) 745 (33.0%) 
2015 463 175 (37.8%) 131 (28.3%) 157 (33.9%) 
 
Figure 3.6.3 – PCIs by priority 
The proportion of elective PCIs by year, shows an almost (excluding year 2013) year-on-
year decrease from 83% in 2007 to 37.8% in 2015. A sudden jump from 64.6% in 2008 to 
42.8% in 2009 can be explained by the fact that the ECTC started the primary care 
activation programme towards the latter part of 2009 and hence a rapid increase of 
emergency patients were treated. The proportion of urgent PCIs performed remains fairly 




3.6.4 Indication for PCI 
Table 3.6.4 and Figure 3.6.4 represent the breakdown of PCIs by the indication (or 
reason), these are classified into one of four categories: (1) STEMI; (2) Unstable 
angina/NSTEMI; (3) Stable angina; (4) Other. 
Table 3.6.4 – Indication for PCI 









2007 0 3 26 2 0.00% 9.68% 83.87% 6.45% 
2008 13 436 1101 156 0.76% 25.56% 64.54% 9.14% 
2009 260 773 810 95 13.42% 39.89% 41.80% 4.90% 
2010 661 646 897 59 29.21% 28.55% 39.64% 2.61% 
2011 652 770 962 26 27.05% 31.95% 39.92% 1.08% 
2012 646 730 897 16 28.22% 31.89% 39.19% 0.70% 
2013 601 699 873 17 27.44% 31.92% 39.86% 0.78% 
2014 654 697 834 13 29.75% 31.71% 37.94% 0.59% 
2015 127 141 155 4 29.74% 33.02% 36.30% 0.94% 
 
Figure 3.6.4 – Indication for PCI 
As expected, in 2009 there is a sudden rise in the proportion of PCIs for the STEMI 
indication from 0.76% in 2008 to 13.4% in 2009, and again to 29.21% in 2010, this as 
previously mentioned is when the ECTC started treating STEMI patients directly on its 
primary care activation programme. The proportion of urgent patients or those with non-
ST elevation myocardial infarctions/unstable angina has remained fairly consistent from 
2010 (28.6%) to 2015 (33.0%). Again, the number of stable PCIs has decreased almost 
year-on-year from 83.9% in 2007 to 36.3% in 2015, which as previously explained could 
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be simply explained by a sudden increase in emergency patient numbers and hence rates 
thus amending the relative proportions. 
3.6.5 Average patient age 
Table 3.6.5 and Figure 3.6.5 display the mean PCI patient age and standard deviation for 
each year. 
Table 3.6.5 – Mean (SD) PCI patient age 
Year Age (Mean) SD 
2007 64.52 10.85 
2008 64.64 11.07 
2009 64.78 11.70 
2010 65.65 12.03 
2011 66.00 11.98 
2012 65.80 12.11 
2013 65.29 11.99 
2014 65.70 12.19 
2015 65.32 12.08 
 
Figure 3.6.5 – Mean (SD) PCI patient age 
The average (mean) age of the PCI patients remains fairly static from 2007 to 2015. The 
standard deviations are large therefore indicating a wide range (variation) in patient ages. 




3.6.6 Average patient age by Priority 
The following table (3.6.6) and figure (3.6.6) display the mean patient age (SD) split by the 
priority of PCI (i.e. elective, urgent, or emergency).  
Table 3.6.6 – mean (SD) PCI patient age by priority 
Year Elective SD Urgent SD Emergency SD 
2007 65.35 10.33 61.26 12.34 55.67 10.02 
2008 65.33 10.55 63.87 11.83 62.30 11.86 
2009 65.57 10.82 64.42 11.85 63.72 13.04 
2010 66.64 10.49 65.21 12.14 64.79 13.60 
2011 66.17 10.36 67.06 12.15 64.87 13.54 
2012 67.02 10.90 65.67 12.31 64.39 13.15 
2013 65.92 10.98 65.53 12.31 64.30 12.85 
2014 66.94 11.05 66.20 12.43 63.74 12.99 
2015 65.83 11.47 66.48 12.17 63.88 12.57 
 
Figure 3.6.6 - mean (SD) PCI patient age by priority 
When breaking the PCIs down by priority and mean patient age there no significant 
differences between the mean ages either within the same year versus the other priorities, 
or for the same priority over time. The error bars have been omitted from Figure 3.6.6.  
However, they are present in Table 3.6.6. Whilst not statistically significant the mean age 
of emergency patients is slightly lower each year than the elective and urgent 
counterparts. The exact reason behind this is unknown, it could be that younger 
individuals are more likely to survive an out-of-hospital myocardial infarction and make it 
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to the ECTC for emergency treatment relative to elderly individuals who might die from the 
myocardial infarction before an ambulance arrives, or whilst on route to the ECTC, and 
hence do not undergo an actual PCI. 
3.6.7 Gender by Priority 
The overall (all priorities of PCI) percentage of male and female PCI patients remains 
fairly consistent with approximately 3:1 ratio (i.e. 75% male and 25% female). Table 3.6.7 
and Figure 3.6.7 break this down by the priority of PCI to identify whether there are any 
hidden differences at this level. 
Table 3.6.7 – Gender by priority 
 
Elective Urgent Emergency 
Year Male (%) Female Male (%) Female Male (%) Female 
2007 91 (71.65%) 36 15 (65.22%) 8 0 (0%) 3 
2008 825 (74.80%) 278 293 (73.25%) 107 161 (78.92%) 43 
2009 648 (76.87%) 195 545 (75.28%) 179 302 (74.38%) 104 
2010 709 (75.83%) 226 456 (73.67%) 163 542 (72.75%) 203 
2011 761 (77.89%) 216 496 (72.94%) 184 573 (73.18%) 210 
2012 725 (78.89%) 194 491 (72.21%) 189 566 (75.37%) 185 
2013 671 (76.34%) 208 463 (75.53%) 150 512 (72.52%) 194 
2014 690 (78.14%) 193 461 (73.29%) 168 525 (70.56%) 219 
2015 134 (76.57%) 41 95 (72.52%) 36 123 (78.85%) 33 
 




As previously mentioned, the emergency PCIs are low in 2007 because the ECTC only 
just opened and hence almost all priorities were either elective or urgent. There are no 
statistically significant differences in the gender proportions across time. 
3.6.8 Emergency priority by PPCI vs. Non-PPCI 
Table 3.6.8 and Figure 3.6.8 display the indications within the emergency PCIs, 
i.e. a breakdown of Primary PCI (for STEMI) versus non-PPCI (e.g. unstable 
angina, NSTEMI etc.). 
Table 3.6.8 – Emergency priority by PPCI vs. Non-PPCI 
Year PPCI Non-PPCI Emergency PPCI (%) 
2007 0 3 3 0.00% 
2008 13 191 204 6.37% 
2009 260 146 406 64.04% 
2010 661 84 745 88.72% 
2011 651 132 783 83.14% 
2012 646 105 751 86.02% 
2013 601 105 706 85.13% 
2014 653 91 744 87.77% 
2015 127 29 156 81.41% 
 
Figure 3.6.8 – Emergency priority by PPCI rates 
In the third quarter of 2009 the ECTC began their primary care activation programme for 
treating patients with STEMI hence the sudden rise from 6.4% in 2008 to 64.0% in 2009, 
and the subsequent rise to 88.7% in 2010. The proportion of PPCI from 2010 onwards 




3.6.9 Average Total Stent Length 
Table 3.6.9 and Figure 3.6.9 detail the total average length of the stents which were used 
in the PCI procedures at the ECTC, the data represents those procedures for which at 
least one stent was used (i.e. PCIs with no stent usage such as standard balloon 
angioplasty are excluded). 
Table 3.6.9 – Average total stent length (mm) 
Year Total PCIs PCIs ≥ 1 stent Stent used (%) Mean SD 
2007 162 136 83.95 30.51 17.39 
2008 1708 1627 95.26 31.21 20.38 
2009 1980 1853 93.59 31.93 20.57 
2010 2303 2126 92.31 30.9 19.45 
2011 2440 2238 91.72 30.61 18.97 
2012 2351 2169 92.26 30.09 19.2 
2013 2198 1964 89.35 29.42 19.58 
2014 2260 1994 88.23 31.48 21.24 
2015 463 421 90.93 33.79 24.48 
 
Figure 3.6.9 – Average total stent length (mm)  
The standard deviations for all average total stent lengths are large and hence represent a 
wide variety of stent lengths used in the PCI procedure. There are no statistically 
significant differences across the years. This could mean that single-vessel PCIs are still 
as common as multi-vessel PCIs, if not it would be anticipated that the average total stent 
length increase, i.e. more vessels treated results in increased total stent length. 
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3.6.10 Average Total Stent Length by Priority 
Table 3.6.10 and figure 3.6.10 detail the average total stent length across the three 
different PCI priorities to identify whether there are any differences present. 
Table 3.6.10 – Average total PCI stent length (mm) by priority 
 
Elective Urgent Emergency 
Year n 
Mean 
(mm) SD n 
Mean 
(mm) SD n 
Mean 
(mm) SD 
2007 107 30.56 17.61 17 30.94 18.54 3 21.00 9.54 
2008 1048 30.86 20.39 386 32.59 20.91 192 30.43 19.28 
2009 771 33.19 21.56 705 30.93 19.81 372 31.03 19.75 
2010 866 31.83 21.04 590 30.32 18.99 669 30.20 17.66 
2011 909 31.21 20.69 631 30.92 18.78 698 29.53 16.64 
2012 853 31.81 21.33 632 29.20 18.53 683 28.81 16.73 
2013 780 31.81 23.26 566 28.30 18.24 618 27.43 14.85 
2014 761 34.86 24.24 572 29.83 19.71 659 29.04 18.14 
2015 161 35.66 27.88 120 36.34 26.95 139 29.59 16.37 
 




The mean (SD) total stent length in millimetres (mm) for elective, urgent and emergency 
priorities were 32.19 (21.9), 30.39 (19.52), and 29.28 (17.26) respectively. A one-way 
ANOVA was conducted on the total mean stent length for each priority to identify whether 
a significant difference in total stent length was present, F(2,14507) = 27.47 and p < 
0.001, this indicated a significant difference between at least one of the priorities. To 
further identify which groups, a t-Test was performed (assuming unequal variances) 
between each group: elective-urgent, t(9693) = 4.4, p < 0.001; elective-emergency, 
t(9878) = 7.49, p < 0.001; and urgent-emergency, t(8202) = 2.72, p = 0.006. Each group 
showed a significant difference in total stent length, this however is likely to be explained 
by the fact that emergency/STEMI patients may have a myocardial infarction in a single 
coronary vessel and hence only one vessel gets treated during the procedure, whereas 
elective patients are more likely to have multivessel PCI, because the procedure is 
planned in advance, and hence this may be why the mean total stent length increases 
between elective, urgent, and emergency priorities. Following an emergency PCI in a 
single vessel, lesions may be found in other coronary arteries that are not immediately 





3.6.11 Stent Type Used 
Table 3.6.11 and Figure 3.6.11 detail the PCI procedures when classified into categories 
based on the type of stent used. These categories are: (1) exclusive BMS usage; (2) 
exclusive DES usage; (3) a combination of BMS and DES usage. The percentages 
displayed are relative to all PCI procedures (n = 15,865), not just the three categories 
(hence why they do not add up to 100%). 
Table 3.6.11 – Stent Type Used 
Year 
Total 
PCIs BMS (%) DES (%) Mixed (%) 
2007 162 64 (39.51%) 56 (34.57%) 16 (9.88%) 
2008 1708 745 (43.62%) 752 (44.03%) 130 (7.61%) 
2009 1980 624 (31.52%) 1137 (57.42%) 92 (4.65%) 
2010 2303 583 (25.31%) 1446 (62.79%) 97 (4.21%) 
2011 2440 458 (18.77%) 1655 (67.83%) 125 (5.12%) 
2012 2351 335 (14.25%) 1812 (77.07%) 22 (0.94%) 
2013 2198 214 (9.74%) 1718 (78.16%) 32 (1.46%) 
2014 2260 143 (6.33%) 1837 (81.28%) 14 (0.62%) 
2015 463 22 (4.75%) 394 (85.10%) 5 (1.08%) 
 
Figure 3.6.11 – Stent type used 
The proportion of PCIs which feature DES exclusively increases in a linear fashion from 
34.6% in 2007 to 85.1% in 2015. The opposite trend exists with BMS, whereby a high 
usage of 39.5% in 2007 drops almost year-on-year to 4.8% in 2015. The proportion of 
mixed stent procedures drops to circa 1% in 2015 from 9.9% in 2007. If the usage of BMS 
stents themselves are reducing then so would 'mixed' procedures. Whilst not listed here, 
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when the above three stent categories are broken down by PCI priority, similar trends are 
exhibited between the elective, urgent, and emergency groups respectively. 
3.6.12 Average Minimum Stent Diameter 
Table 3.6.12 and Figure 3.6.12 display the average smallest stent diameter (smallest if 
multiple used) used in the PCI procedure in millimetres (mm) by stent type group (i.e. 
BMS, DES, or mixed). 
Table 3.6.12 – average minimum stent diameter (mm)  
Year 
Total 








2007 162 136 2.983 0.423 3.133 0.456 2.893 0.343 
2008 1708 1627 2.977 0.459 3.224 0.463 2.775 0.338 
2009 1980 1853 2.926 0.449 3.191 0.470 2.803 0.375 
2010 2303 2126 2.907 0.471 3.231 0.504 2.789 0.395 
2011 2440 2238 2.887 0.476 3.257 0.550 2.796 0.403 
2012 2351 2169 2.882 0.467 3.205 0.498 2.825 0.435 
2013 2198 1964 2.891 0.479 3.304 0.556 2.842 0.442 
2014 2260 1994 2.926 0.489 3.357 0.634 2.892 0.458 
2015 463 421 2.911 0.499 3.545 0.751 2.876 0.458 
 
Figure 3.6.12 – Average minimum stent diameter (mm)  
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Whilst the SD error bars are not listed, there were no significant differences in minimum 
stent diameter however in general the BMS PCIs did have larger minimum stent 




3.6.13 Average Minimum Stent Diameter by Priority 
Table 3.6.13 and Figure 3.6.13 display the average minimum stent diameter (mm) by 
priority of PCI. 
Table 3.6.13 – average minimum stent diameter (mm) by priority  
 
Elective Urgent Emergency 
Year n Diameter SD n Diameter SD n Diameter SD 
2007 107 2.97 0.40 17 2.96 0.35 3 3.00 0.00 
2008 1048 2.95 0.44 386 2.98 0.47 192 3.13 0.48 
2009 771 2.88 0.43 705 2.92 0.45 372 3.04 0.46 
2010 866 2.84 0.46 590 2.88 0.46 669 3.02 0.48 
2011 909 2.83 0.46 631 2.84 0.48 698 3.01 0.48 
2012 853 2.82 0.46 632 2.87 0.47 683 2.97 0.45 
2013 780 2.81 0.47 566 2.91 0.49 618 2.98 0.46 
2014 761 2.82 0.45 572 2.92 0.51 659 3.05 0.48 
2015 161 2.85 0.56 120 2.84 0.40 139 3.04 0.49 
 
Figure 3.6.13 – average minimum stent diameter (mm) by priority 
The SD error bars have been omitted for clarity, however, there are no statistically 
significant differences each year between any of the PCI priorities in terms of average 
minimum stent diameter. Emergency PCIs do in general exhibit larger average minimum 
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stent diameters compared to both urgent and emergency PCIs. Whilst not displayed here, 
when these procedures are broken down into stent type group (BMS, DES, or mixed) the 
BMS category in all priorities show increased minimum diameters although this too is not 
statistically significant. The reason for emergency showing larger diameters could be 
because there is not sufficient time to determine the optimal size. 
 
3.6.14 Number of Stents Used 
Table 3.6.14 and Figure 3.6.14 show the numbers of stent used for each PCI procedure 
within the year when classified into one of three categories: 1, 2, 3 or more stents. 














≥ 3 stents 
(%) Total 
2007 162 79 31 26 48.77% 19.14% 16.05% 83.95% 
2008 1708 887 427 313 51.93% 25.00% 18.33% 95.26% 
2009 1980 1020 521 312 51.52% 26.31% 15.76% 93.59% 
2010 2303 1209 600 317 52.50% 26.05% 13.76% 92.31% 
2011 2440 1248 665 325 51.15% 27.25% 13.32% 91.72% 
2012 2351 1273 598 298 54.15% 25.44% 12.68% 92.26% 
2013 2198 1206 534 224 54.87% 24.29% 10.19% 89.35% 
2014 2260 1233 507 254 54.56% 22.43% 11.24% 88.23% 




Figure 3.6.14 – Number of stents used 
Throughout the years from 2007 to 2015 there has not been much of a fluctuation in the 
number of stents used for each PCI procedure overall. The majority of PCIs have a single 
stent (approx. 53%) followed by approx. one quarter of PCIs using two stents, and approx. 
15% using three or more stents. A lot of the single stent PCIs for as explained previously 
are likely to be emergency PCIs. 
 
3.6.15 Vessels Treated 
Table 3.6.15A, 3.6.15B and Figure 3.6.15 display the coronary vessels treated. It should 
be noted that each represents at least one of the vessels treated this does not mean the 
vessel has been exclusively treated. For example, a multivessel PCI (such as RCA and 
LAD) would count twice, once for RCA and once for LAD. 
Table 3.6.15A –Vessels treated (frequencies) 
 






Figure 3.6.15 – vessels treated (not mutually exclusive) 
The LAD was the most commonly treated coronary vessel in each year by at least 10% 
since 2008 with approximately 50% of all PCIs involving this vessel. The RCA is the 
second most frequently treated vessel with approximately 36% of PCIs treating this 
vessel, and thirdly, the LCX with approximately 22% of PCIs. 
 
3.6.16 LAD Vessel by Priority 
Table 3.6.16 and Figure 3.6.16 display the PCIs involving the LAD vessel being treated 
when broken down by PCI priority. 






Figure 3.6.16 – LAD vessel treated by priority 
From 2008 the percentage of all PCIs each year that feature the LAD vessel being treated 
remain fairly stable, elective PCIs in general have a slightly higher percentage treated that 
the other priorities. However, they all range from approximately 42% to 53%. 
 
3.6.17 RCA Vessel by Priority 
Table 3.6.17 and Figure 3.6.17 display the PCIs featuring treatment to the RCA vessel 
when broken down by priority of PCI. 
Table 3.6.17 – RCA vessel by priority 
Year Elective (%) Urgent Emergency 
2007 13 (10.24%) 0 (0.00%) 1 (33.33%) 
2008 379 (34.36%) 147 (36.75%) 88 (43.14%) 
2009 279 (33.06%) 285 (39.36%) 160 (39.41%) 
2010 303 (32.41%) 211 (34.09%) 310 (41.61%) 
2011 340 (34.80%) 237 (34.85%) 316 (40.36%) 
2012 309 (33.62%) 223 (32.79%) 321 (42.69%) 
2013 317 (36.06%) 192 (31.32%) 330 (46.74%) 
2014 311 (35.22%) 206 (32.75%) 316 (42.42%) 





Figure 3.6.17 – RCA vessel by priority 
As with the LAD, the RCA PCIs remain fairly stable over the years, however in this 
instance the RCA vessel has a higher percentage of PCIs under the emergency priority 
classification in contrast to elective as with the LAD. 
 
3.6.18 LCX Vessel by Priority 
Table 3.6.18 and Figure 3.6.18 display the third most commonly treated coronary vessel, 
the LCX by PCI priority. 





Figure 3.6.18 – LCX vessel by priority 
As with the LAD and the RCA coronary vessels, the LCX PCIs remain fairly stable over 
the years when broken down by PCI priority. In this instance the urgent PCIs show the 
highest percentage treated relative to the elective and emergency PCIs 
 
3.6.19 LMS Vessel by Priority 
Table 3.6.19 and Figure 3.6.19 display the LMS PCIs by priority of PCI. 
Table 3.6.19 – LMS vessel by priority 
Year Elective (%) Urgent (%) Emergency (%) 
2007 2 (1.57%) 0 (0.00%) 0 (0.00%) 
2008 17 (1.54%) 5 (1.25%) 2 (0.98%) 
2009 21 (2.49%) 10 (1.38%) 9 (2.22%) 
2010 17 (1.82%) 16 (2.58%) 10 (1.34%) 
2011 24 (2.46%) 14 (2.06%) 20 (2.55%) 
2012 22 (2.39%) 23 (3.38%) 15 (1.99%) 
2013 15 (1.71%) 15 (2.45%) 14 (1.98%) 
2014 29 (3.28%) 23 (3.66%) 11 (1.48%) 






Figure 3.6.19 – LMS vessel by priority 
There is a slight increase in the overall percentage of PCIs which feature treatment to the 
LMS, from approximately 1% in 2008 to 3% in 2015. There are no major differences 
between any of the PCI priorities with regards to treatment of the LMS. The slight increase 
can be explained by more complex PCIs (i.e. multivessel) being utilised, whereas 
previously lesions in the left main stem may have been treated with CABG, now it may be 
the case that PCI is more preferred in some of these LMS cases. 
 
3.6.20 Graft Vessels by Priority 
Table 3.6.20 and Figure 3.6.20 display the PCIs to coronary vessels that have previously 
been grafted, i.e. the patient has had a prior CABG. In the available dataset the exact 
native vessel that was grafted was not available, neither was the type/location the graft 




Table 3.6.20 – Graft vessels by priority 
Year Elective (%) Urgent (%) Emergency (%) 
2007 0 (0%) 0 (0%) 0 (0%) 
2008 1 (0.09%) 0 (0%) 0 (0%) 
2009 9 (1.07%) 13 (1.80%) 4 (0.99%) 
2010 11 (1.18%) 10 (1.62%) 7 (0.94%) 
2011 17 (1.74%) 19 (2.79%) 11 (1.40%) 
2012 14 (1.52%) 19 (2.79%) 7 (0.93%) 
2013 19 (2.16%) 22 (3.59%) 7 (0.99%) 
2014 12 (1.36%) 13 (2.07%) 10 (1.34%) 
2015 3 (1.71%) 3 (2.29%) 2 (1.27%) 
 
Figure 3.6.20– Graft vessels by priority 
Treatment to graft vessels represents a small proportion of the total PCIs (i.e. less than 
2.8% over all priorities). There is not much fluctuation between the priorities however 
those classified as urgent have a slight increase in rate relative to elective and 
emergency. 
 
3.6.21 Number of Lesions Attempted 
Table 3.6.21 and Figure 3.6.21 represent the number of lesions that were attempted, they 
may not have all actually been treated, but it is the number the operator(s) anticipated 
treating before the actual PCI started. These are broken down into three categories: 1 
lesion; 2 lesions; three or more lesions. 
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Table 3.6.21 – Number of lesions attempted  
 
 
Figure 3.6.21 – Number of lesions attempted  
 
The majority of PCI procedures feature treatment to a single lesion only. Although the 
information is similar to the number of stents used, there is a slight difference. A coronary 
vessel may have multiple lesions within it separated by a short distance and hence only a 





3.6.22 Prior PCI 
Table 3.6.22 and Figure 3.6.22 show whether the patients given PCI have had at least 
one previous PCI performed at the ECTC. 
Table 3.6.22 – Prior PCI status 
 
 
Figure 3.6.22 – Prior PCI status 
The proportion of patients receiving PCI, which have previously had a PCI (at the ECTC) 
remains fairly stable over years at approximately 75%. Almost one quarter have 
previously had a PCI there and a likely explanation for most of these is that they 
previously had an emergency PCI possibly due to a STEMI and had the causative lesion 
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treated but it was also discovered that other coronary vessels have high stenosis and thus 
they were scheduled for a subsequent elective PCI in the future. 
3.6.23 Prior CABG 
Table 3.6.23 and Figure 3.6.23 show the prior CABG status. Note this does not 
necessarily mean that the PCI will be treating a graft vessel, it simply means that at least 
one coronary vessel in the patient's heart has been previously grafted. 
Table 3.6.23 – Prior CABG status  
 
 
Figure 3.6.23 – Prior CABG status  
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As anticipated, the vast majority (approx. 92%) of PCI patients did not have any prior 
CABG surgery. Only a small proportion did (approx. 7%) and this figure remains fairly 
stable over the years. 
 
3.6.24 Prior MI 
Table 3.6.24 and Figure 3.6.24 represent the PCIs which feature patients that have had a 
prior myocardial infarction (heart attack), this prior MI does not necessarily mean this is 
the reason they are requiring a PCI, it could be the case that many years ago they had a 
MI and the current PCI is to a completely different coronary vessel than previously treated. 
Table 3.6.24 – Prior MI status 
 
 
Figure 3.6.24 – Prior MI status 
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The majority of patients approximately (70%) have not have a prior MI, there is a jump 
from 58% in 2008 to 70% in 2009 which is explained by the ECTC starting their primary 
care activation programme in 2009 and hence beginning to directly treat STEMI patients 
as opposed them being treated elsewhere and transferred to the ECTC as urgent 
patients. Approximately 27% have had prior myocardial infarctions, again the resolution at 
this level does not explain whether it is directly responsible for the current PCI or not. 
3.6.25 Diabetes Mellitus 
Table 3.6.25 and Figure 3.6.25 list the patients diagnosed with any form of diabetes 
mellitus. The table also breaks this down further by display the type (e.g. Type 1 or Type 
2). 






Figure 3.6.25 – PCIs to diabetic patients 
The majority of patients (approx. 78%) presenting for PCI treatment were not diagnosed 
as diabetic. Less than 19% of patients each year were diagnosed as having a type of 




3.6.26 Cerebrovascular Disease 
Table 3.6.26 and Figure 3.6.26 display information relating to the patients that have had a 
prior cerebrovascular accident (stroke). It should be noted that the timing of the stroke is 
irrelevant, i.e. it may have happened many years prior to the PCI procedure. 
Figure 3.6.26 –PCIs to cerebrovascular disease patients 
Year PCIs Missing No Stroke Stroke 
Missing 
(%) No (%) Stroke (%) 
2007 162 18 144 0 11.11% 88.90% 0.00% 
2008 1708 23 1649 36 1.35% 96.56% 2.11% 
2009 1980 156 1730 94 7.88% 87.37% 4.757% 
2010 2303 183 2025 95 7.95% 87.93% 4.13% 
2011 2440 29 2299 112 1.19% 94.22% 4.59% 
2012 2351 173 2114 64 7.36% 89.92% 2.72% 
2013 2198 61 2068 69 2.78% 94.09% 3.14% 
2014 2260 187 2013 60 8.27% 89.07% 2.66% 
2015 463 35 408 20 7.56% 88.12% 4.32% 
 
Figure 3.6.26 – PCIs cerebrovascular disease patients 
As expected the proportion of patients which have had a prior cerebrovascular accident is 




3.6.27 Renal Dysfunction 
Table 3.6.27 and Figure 3.6.27 represent those patients with renal dysfunction. This is 
classified as either chronic or acute renal failure, or abnormally high creatinine (i.e. ≥ 200 
umol/L or < 200 umol/L but the estimated glomerular filtration rate, GFR < 60 mL/min). 
The remaining values not under the missing, normal, or renal disease dysfunction 
categories are functioning transplant patients (i.e. 8 overall, or 0.05%). 
Table 3.6.27 – PCIs to renal dysfunction patients 
 
 
Figure 3.6.27 – PCIs to renal dysfunction patients 
There is an almost (except for year 2013) year-on-year increase in the patients presenting 
with renal dysfunction over the years. This increases from 4% in 2007 to 16% in 2015. 




3.7 National PCI Information and Audit 
Data 
The following information relates to the national audit PCI data, as reported by BCIS in 
their audit report of 2014 (BCIS, 2015). Information about national PCI activity in 2014 is 
listed here, and where possibly yearly trends. This is compared in 3.8, where available, to 
the corresponding ECTC PCI database listed in 3.6. 
3.7.1 National PCI Activity 
In 2014, there were 96,143 PCIs performed within 119 UK centres that performed PCIs. In 
1991, there were fewer than 60 PCI centres. During this interval there has been a steady 
increase in almost every year, apart from a few years in which a PCI showed an apparent 
reduction (e.g. 1996, 2001, and 2013). Of these 119 PCI centres, 100 are provided by the 
NHS, and 19 are private. The number of centres, PCIs performed, and population 
estimates are broken down by country in Table 3.7.1. In mid-2014 figure for the entire UK 
was estimated as 64.5 million. 
Table 3.7.1 – UK PCI activity by country in 2014 




PCIs Rate  
(per population) 
England 86 16 54.32 million 79,352 0.15% 
Northern Ireland 4 0 1.84 million 4,235 0.23% 
Scotland 6 2 5.35 million 8,499 0.16% 
Wales 4 1 3.09 million 4,057 0.13% 
There are 63 centres in UK which provide angiography services without performing PCI 
procedures. This is a reduction from approximately 90 centres in 2006. In 2014, 
angiography was performed 40,322 times in these 63 centres, and 207,041 times in the 
119 PCI centres. 
The number of interventional consultants increased from 621 in 2012, to 659 in 2014. 
Although not displayed, there is an expected general trend whereby the more consultants 
employed at a particular PCI centre, the higher the number of PCIs performed at that 
centre. The majority of the PCI centres in 2014 had less than 10 consultants and most of 
these centres performed less than 1500 PCIs. The average number of consultants per 
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NHS centre in 2014 was 7.3. In 2000, this was approximately 5.5. The average number of 
PCIs per operator was 123, in the three years prior to this (2011, 2012, and 2013) this 
was 127, 131, and 130, respectively. 
From 2005 to 2013 there has been a year-on-year increase in the percentage of PCIs 
performed on acute patients from approximately 44% to 65.7% (in 2014 this reduced to 
65.1%). Corresponding to this increase, the proportion of stable PCIs reduced from 
approximately 56% in 2005 to 34.4% in 2013. In 2014 there was a slight increase to 
34.9%. 
The indication for PCI is broken down by year in Figure 3.7.1. 
 
Figure 3.7.1- National Indication for PCI by year (BCIS, 2015) 
As expected, the proportion of PCIs for STEMI has increased from only 11% in 2006, to 
27.2% in 2014. Corresponding to this increase is a decrease in the proportion of stable 





In 2014, the average (mean) age of the patients that underwent a PCI procedure in the 
UK was 65.1. Approximately three quarters were male (74.3). Table 3.7.2 lists the basic 
national average demographic trends. 
Table 3.7.2 – reported demographic figures from BCIS Audit Report (BCIS, 2015). 
Year 2007 2008 2009 2010 2011 2012 2013 2014 
Age (mean) 64.3 64.4 65.0 65.1 65.3 64.9 64.9 65.1 
Male (%) 73.6% 73.8% 73.9% 74.0% 74.0% 74.1% 74.3% 74.3% 
Previous MI 29.5% 30.2% 28.8% 28.4% 27.6% 26.8% 27.2% 27.4% 
Previous PCI 18.6% 21.1% 22.3% 22.6% 22.7% 23.5% 24.7% 25.6% 
Previous CABG 8.5% 9.1% 8.6% 8.4% 7.9% 8.9% 8.6% 8.4% 
Pre-PCI ventilated 
(emergency only) 
N/A 3.5% 3.9% 3.8% 4.5% 5.1% 5.5% 5.8% 
Because it was known that female sex is a NWQIP model risk factor for in-hospital MACE 
following PCI, it was useful to further breakdown the patients by age and gender. It was 
hypothesised that in general women undergoing PCI were more elderly than men and 
hence why it was used as a risk factor. Table 3.7.3 displays the age group classification 
by gender breakdown (relative to the same gender only). 
Table 3.7.3 – Age group distribution by gender in 2014 (BCIS, 2015). 
Age (years) Male (%) Female (%) P Value 
≤ 50 9,856 (14.03%) 2,102 (8.64%) < 0.001 
51-60 18,189 (25.89%) 4,037 (16.60%) < 0.001 
61-70 21,005 (29.89%) 6,585 (27.08%) < 0.001 
71-80 15,185 (21.61%) 7,413 (30.48%) < 0.001 
≥ 81 6,031 (8.58%) 4,182 (17.20%) < 0.001 
The chi-square statistic was χ2 = 2962.61, p < 0.001 indicating significant differences in 
age groups between the two genders. As anticipated, female patients exhibit a much 





3.7.3 Procedural Characteristics 
The percentage of PCI procedures using stents has remained above 90% since 2003, 
with it being at 91.7% in 2014. As expected, in the 1990s it was low, which corresponds to 
an era when PCIs were primarily conducted using standard balloon angioplasties and did 
not involve stent insertion. The approximate rates in the years 1993, 1994, 1995, 1996, 
1997 were 5%, 12.5%, 27.5%, 46%, and 60%, respectively. Figure 3.7.2 displays the 
mean percentage usage of drug-eluting stents (DES) for PCIs by each year. 
 
Figure 3.7.2 – mean DES usage by UK PCI centres (BCIS, 2015) 
 
The breakdown of coronary vessel type treated by presenting syndrome (Stable, NSTEMI, 
or Primary PCI) is shown in Figure 3.7.3. 
The LAD vessel is the most commonly treated for each syndrome (for Primary PCI, the 
RCA vessel is rounded up from 39.6%). For all syndromes, the 2nd most common vessel 











From inspection of the ECTC PCI database and the national audit reports published by 
BCIS, it is apparent that the ECTC is one of the higher-volume PCI centres in the UK. In 
2014, the majority of the national centres performed less than 1500 PCIs compared to the 
2260 identified in the ECTC data. Both nationally, and at the ECTC there has been a 
general trend of increasing emergency PCI proportions, and hence a reduction in elective 
(stable) PCIs. In 2014, the most recent complete year for which both sets of data were 
available, the ECTC had a STEMI PCI percentage of 29.8% compared to the national 
average of 27.2%. As anticipated, and one of the justifications for externally validating the 
NWQIP on modern era, is the fact that the emergency proportions nationally have 
increased, therefore more operators are performing PCIs on patients that are at higher 
risk due to their coronary syndrome than previously.  
Although the standard deviation was not reported in the latest BCIS audit report the 
previous years, the average (mean) age in years of patients has increased. In 2007 this 
was 64.3 years, and in 2014 it was 65.1 years. At the ECTC these figures were 64.5 and 
65.7 years, respectively. There was no statistically significance difference in mean age 
over the years at the ECTC cohort. 
As expected with the evolution of stent type, the percentage usage of DES used during 
PCIs has increased from approximately 34.6% in 2008 to 81.3% in 2014 at the ECTC. 
This increase is apparent nationally also, with a 57% usage in 2008 to 85.7% in 2014. 
The three most commonly treated vessels for both the ECTC cohort and the national 
average were the LAD, RCA, and LCX, respectively. Almost half of all PCIs in both 
cohorts featured treatment to the LAD, followed by approximately one-third to the RCA, 
and approximately one-fifth to the LCX. Lesions to left main stem were treated in less than 
3% of all PCIs at the ECTC, and 4% nationally. The graft vessels were the least treated 
type in both cases, in which the figures were less than 2.5% at the ECTC and 2% 
nationally.  
Overall, the ECTC and national average exhibit similar trends over recent years, most 
notably from 2008 to 2014 in terms of patient demographics, clinical, and procedural 
characteristics. The similarity may allow any such risk prediction models for various 
outcomes constructed using the ECTC PCI cohort to be validated externally by other UK 
PCI centres to see if such incorporated risk factors are stable nationally, and hence verify 
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the authenticity of the model and possible subsequent adoption as a tool in clinical 
practice. 
Addition demographic, clinical, and procedural characteristics for the ECTC cohort are 
reported in the three following study chapters (4, 5, and 6). The following studies 
investigate the different important clinical outcomes following PCI at the ECTC. They 
feature different inclusion/exclusion criteria for the entire dataset of 15,865 PCI records at 




Chapter 4: External Validation of 
the North West Quality 






The first published, peer-reviewed research, on in-hospital complications following 
percutaneous coronary intervention (PCI) in the UK was conducted by Grayson et al. 
(2006). Their research was conducted by a consortium of four cardiac centres/hospitals in 
the north-west of England in a time of predominantly high bare-metal stent (BMS) usage, 
and from this research a multivariate logistic regression model was developed, this being 
the North West Quality Improvement Programme (NWQIP) risk model. Before this, the 
majority of the published studies were conducted by researchers in the United States, 
which has a health care system with considerable differences to the UK. The NWQIP 
study utilised 9914 consecutive PCI patients in their analysis using PCI procedures from 
1st August 2001 to 31st December 2003. The outcome of interest was in-hospital major 
adverse cardiac events (MACE), which is a composite outcome of death, Q-wave 
myocardial infarction, emergency coronary artery bypass graft (CABG) surgery, or a 
cerebrovascular accident. In some cases a patient may experience multiple components 
of MACE. A beneficial point about the NWQIP risk model is that the incorporated risk 
factors (age, female sex, cerebrovascular disease, cardiogenic shock, PCI priority, and 
LMS or graft lesion treatment) are all variables that are likely to have high data completion 
rates in UK PCI centres, especially with the advent of the minimum dataset specified by 
the British Cardiovascular Intervention Society (BCIS). These variables are also simple to 
identify, i.e. they can be recognised and recorded by staff fairly easily and the definition of 
them is likely to be consistent between different hospitals and different staff inputting the 
data. Of the independent risk factors within the NWQIP model, the presence of pre-
procedural cardiogenic shock has the highest regression coefficient weighting and hence 
patients with this risk factor are as expected, at high risk of experiencing in-hospital 
MACE. The two other risk factors with high coefficients are emergency PCI and treatment 
to left main stem (LMS) lesions. 
Grayson et al. (2006) reported an overall in-hospital MACE rate of 1.3% (129 patients). 
This was broken down into 0.7% (66) deaths, 0.4% (36) Q wave myocardial infarctions, 
0.15% (15) emergency CABG surgeries, and 0.2% (20) cerebrovascular accidents. The 
discrimination performance was assessed using the area under the receiver operating 
characteristic (ROC) curve for which the value was 0.76, indicating a fair ability to 
discriminate between in-hospital MACE occurring or not occurring. When their PCI cohort 
were classified into one of eight risk groups based on the estimated probabilities of 
experiencing MACE, the Hosmer-Lemeshow goodness of fit statistic produced p = 0.43, 
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indicating only a small difference between estimated and observed MACE across the risk 
groups. The NWQIP model was then tested using 1786 consecutive PCIs from 1st January 
2004 to 31st December 2004. The ROC curve for this validation set of PCIs was 0.72, 
which again represents a fairly good ability to discriminate. The patient demographics, 
clinical, and procedural characteristic were not reported for the validation PCI cohort, and 
hence it cannot be determined how closely these characteristic match the original 9914 
patient. 
The NWQIP risk model was more recently externally validated by Kunadian et al. (2008) 
using a PCI cohort of 5034 patients between September 2002 and August 2006. Their 
cohort reported an overall in-hospital MACE rate of 2.0% (104 patients). This was broken 
down into 1.3% (66) deaths, 0.22% (11) Q-wave myocardial infarctions, 0.20% (10) 
cerebrovascular accidents, and 0.14% (7) emergency CABG surgeries. Both studies 
reported similar rates for cerebrovascular accidents (0.20% and 0.20% respectively) and 
emergency CABG surgery (0.15% and 0.14% respectively) however there was a lower 
rate of death (0.7% versus 1.3%) which could be explained by the fact that the external 
study performed emergency PCIs in 17.6% relative to the 10.8% in the NWQIP study and 
hence more patients are at higher risk of dying. The ROC curve was 0.87 (95% 
confidence limits were 0.82 to 0.90) which indicates a better ability to discriminate than in 
the original NWQIP PCI cohort. The calibration of observed versus estimated MACE was  
p = 0.95, indicating an almost perfect fit among the different risk groups. In summary, it 
was found that the NWQIP model performed very well in terms of both discrimination and 
calibration for an external PCI cohort, and a different location (Midlands instead of north-






Despite the external validation of NWQIP (Kunadian et al., 2008) verifying the model's 
performance as a predictor for in-hospital MACE, in terms of discrimination and 
calibration, there are reasons why subsequent external validation of this model is 
required. These are described in section 1.1, but in addition, differences in characteristics 
are listed in Table 4.1.1. This shows the percentage of each characteristic between the 
ECTC, original NWQIP cohort (Grayson et al., 2006), and the external validation cohort 
(Kunadian et al., 2008). Such differences in characteristics along with technology 
evolution (i.e. higher modern DES usage), and increased numbers of cardiac centres and 
PCI operators are theorised to manifest as a performance alteration in the effectiveness of 
the NWQIP risk prediction model. Although the DES usage for both the NWQIP and 
external cohorts are not reported, the general usage of BMS in the UK in these era was 
low, i.e. less than 40% (BCIS, 2016). 
Table 4.1.1 – prominent differences in characteristics between the ECTC, NWQIP, 
and external validation PCI cohorts 
Characteristic ECTC cohort NWQIP cohort External cohort p Value 
DES usage 68.5% N/A N/A N/A 
Age ≥ 70 years 38.8% 20.4% 26.4% < 0.001 
Diabetes mellitus 17.5% 13.2% 14.7% < 0.001 
Emergency PCI 30.0% 10.8% 17.6% < 0.001 
Previous PCI 22.3% N/A 12.6% < 0.001 
Cardiogenic shock 2.9% 0.7% 1.7% < 0.001 
LMS lesions 2.2% 1.1% N/A < 0.001 
In general, from the characteristics in Table 4.1.1, the ECTC cohort appear to be at higher 
risk, i.e. higher percentage of elderly, diabetic, emergency, cardiogenic shock, previous 
PCIs and LMS lesions. It may be the case however that higher proportions of non-stable 
patients means that the operators gain more experience in treating higher risk individuals 





4.1.2 Hypothesis and Objectives 
It is hypothesised that the NWQIP risk model will not perform as effectively as it did in the 
original or external validation studies. The theorised reason for the degradation of 
performance is that due to the combination of changes (specified in section 4.1.1) not all 
the incorporated risk factors (age, gender, PCI priority, cardiogenic shock, 
cerebrovascular disease, LMS lesions, or graft lesions) will exhibit significant associations 
with the outcome of in-hospital MACE, and therefore their incorporation into such a risk 
model is obsolete and thus affects the estimated probability. 
The following objectives were created in order to test the hypothesis: 
(1) Using the NWQIP risk model coefficients, generate the estimated probability of each 
patient experiencing in-hospital MACE based on the presence of the incorporated risk 
factors. 
(2) To identify which patients experienced in-hospital MACE by extracting the relevant 
information from the mortality or complication data fields. 
(3) Using the generated NWQIP probabilities and in-hospital MACE outcome data (from 
objective 1 and 2), Verify the NWQIP model performance (calibration and discrimination) 
by utilising the ECTC PCI cohort, which is based in a different location (south-east 
England) to the original NWQIP cohort (north-west England), and the external PCI cohort 
(Midlands), and also in a different era of stenting (i.e. a higher DES usage for PCIs). 
(4) To attempt to explain the causative reasons for any performance changes in the 
NWQIP model for the ECTC PCI cohort relative to the original cohort (Grayson et al., 





4.2.1 Patient Data 
The general PCI patient dataset available for this study is described in Chapter 3 (General 
Methods and Data). The entire range of PCIs (15,865) was considered for analysis (July 
2007 to March 2015). The only PCI procedure records which were excluded from analysis 
were those missing crucial data from either: (1) an NWQIP model risk factor; (2) 
complication data. Cardiogenic shock (pre-procedural) was the only variable for which a 
blank field was assumed to be 'No', as recommended by consultant interventional 
cardiologists at the ECTC as this was stated that it was common practice to leave this 
field blank and only set it to 'Yes' if the patients were in cardiogenic shock. 
The CVIS/ECTC dataset contained variables which represent all of the NWQIP risk 
factors, the risk factor and its corresponding field name and data type in the dataset are 
listed below in Table 4.2.1. 
Table 4.2.1 – NWQIP risk factors and CVIS data fields 
NWQIP Risk Factor CVIS Data Field CVIS Data Type Example(s) 
Age 70-79 years Age Integer (positive) {71, 76} 
Age ≥ 80 years Age Integer (positive) {80, 89} 
Female sex Sex Character {M, F} 
Cerebrovascular disease Medical History String {Cerebrovascular 
event} 
Cardiogenic shock Cardiogenic Shock String {Yes, No} 
Urgent PCI Procedure Urgency String {Urgent} 
Emergency PCI Procedure Urgency String {Emergency} 
LMS lesions treated Vessels Attempted String {Lmain} 
Graft lesions treated Vessels Attempted String {Graft(s)} 
Relating to the above NWQIP variables, and outcome data (procedural complications, 
status at discharge), the following records were excluded, as the estimated NWQIP 
probabilities of experiencing in-hospital MACE could not be calculated. The number of 




Table 4.2.2 –NWQIP risk factor fields with missing data 
Risk Factor Missing (n) Missing (%) 
Age 0 0% 
Sex 1 < 0.01% 
Procedure Urgency 23 0.15% 
Vessels Attempted 283 1.78% 




The records with a 'Medical History' set to blank ('##') were excluded from analysis 
because it is unknown whether the patient may have had a previous cerebrovascular 
accident (stroke), and this could affect the performance testing of the NWQIP risk model 
had these records remained and were simply assumed as not having a prior stroke. Whilst 
not listed here, no significant differences were identified in the general characteristics for 
the records retained in the analysis versus those excluded because of missing NWQIP 
risk factors. The number of records missing one of the NWQIP risk factors, and hence 
excluded from analysis, totalled 978 (6.16%). The second group of data fields that were 
investigated for missing data were the complication/outcome fields as listed in table 4.2.3 
below. 
Table 4.2.3 – CVIS outcome/complication fields needed for the NWQIP model 
Outcome Type Missing (n) Missing (%) 
Post Procedure Complication 1716 10.82% 
PCI Hospital Outcome 1448 9.13% 
PCI Hospital Outcome or Post 
Procedure Complication 
2132 13.44% 
The records with missing risk factor or outcome/complication data in Tables 4.2.2 and 
4.2.3 were not mutually exclusive. However, some records had multiple missing values for 
each. In total, including the valid NWQIP risk factor variables and the 
complication/outcome fields, there were 13,202 PCI records retained in the analysis, 
resulting in 2,663 (16.79%) of the records being omitted. 
Because the complication/outcome information is scattered over multiple data fields in the 
CVIS database, the task of extracting the relevant data was broken down into the 
following sequence of steps. The fields checked were 'Post Procedural Complications' and 





(1) Check of 'Post Procedural Complications' field is blank, if so invalidate the record. 
(2) Check if 'PCI Hospital Outcome' field is blank; if so invalidate the outcome record. 
(3) Check for 'Cerebrovascular accident' or 'CVA' MACE component. 
(4) Check for 'Q-wave MI' MACE component. 
(5) Check for 'In-hospital death' or 'death' for in-hospital death MACE component. 
(6) Check for 'Pre-discharge emergency coronary surgery' or 'emergency CABG' MACE 
component. 
(7) If either steps 3 to 6 are identified as present then set the current record to 'MACE'. 
 
4.2.2 NWQIP Estimated Risk Calculation 
The NWQIP risk model logistic regression coefficients (listed below in Table 4.2.4) that 
were reported by Grayson et al. (2006) were used to generate the estimated odds of each 
PCI patient experiencing in-hospital MACE. From these odds values, the estimated 
probabilities of MACE occurring was then generated 
Table 4.2.4 - NWQIP risk factors and coefficient values (Grayson et al, 2006) 
NWQIP Risk Factor Coefficient 
Age 70-79 years 0.7048 
Age ≥ 80 years 1.0106 
Female sex 0.4586 
Cerebrovascular disease 0.8618 
Cardiogenic shock 3.2636 
Urgent PCI 0.4788 
Emergency PCI 1.3625 
LMS lesions treated 1.6502 
Graft lesions treated 0.9101 
(Intercept) -5.4959 
The estimated odds of experiencing MACE for a given patient were calculated using 
Equation 3, which utilises the logistic regression coefficients (Table 4.2.4). 
(Equation 3. NWQIP calculation for odds of in-hospital MACE) 
Odds = exp(-5.4959 + {age 70-79 years × 0.7048} + {age ≥ 80 years × 1.0106} + {female 
sex × 0.4586} + {cerebrovascular disease × 0.8618} + {cardiogenic shock × 3.2636} + 
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{urgent PCI × 0.4788} + {emergency PCI × 1.3625} + {LMS lesions treated × 1.6502} + 
{Graft lesions × 0.9101}) 
The estimated probability of a patient experiencing in-hospital MACE is then calculated 
using the odds value as shown in Equation 4. 
(Equation 4. MACE percentage risk calculation from odds ratio) 
MACE percentage = [odds / (1+odds)] ×100 
The following examples of PCI patients and the presence of certain NWQIP risk factors 
show the generated odds and probabilities of experiencing in-hospital MACE. 
Example 1: Female patient, 82 years old, emergency priority, PCI to graft lesions. 
Odds = exp(-5.4959 + {female sex × 0.4586} + {age ≥ 80 years × 1.0106} + {emergency 
PCI × 1.3625} + {graft lesions × 0.9101}) = 0.173062. 
Percentage probability of experiencing in-hospital MACE: [0.173062 / (1+0.173062)] ×100 
= 14.75% 
Example 2: Male patient, 76 years old, cardiogenic shock, emergency priority, PCI to 
LMS. 
Odds = exp(-5.4959 + {age 70-79 years × 0.7048} + {cardiogenic shock × 3.2636} + 
{emergency PCI × 1.3625} + {LMS lesions × 1.6502}) = 4.415848/ 





4.3.1 Univariate Associations with in-hospital MACE 
The patient demographic, clinical and procedural characteristics for the valid PCI 
procedures included in the analysis are listed in Tables 4.3.1 and 4.3.2 below. The 
percentages represented in the tables are relative to all data (i.e. including those missing). 
In total 13,202 records with a known MACE/non-MACE end-point were included in the 
analysis. 
Table 4.3.1 – demographic and procedural univariate associations with in-hospital 
MACE 
Risk Factor Patients (%) MACE (%) OR (95% CI) P Value 
Age (years) 
    < 50 10.5% 0.7% Reference < 0.001 
50-59 20.0% 0.7% 0.987 (0.417 to 2.336) 0.977 
60-69 30.6% 0.9% 1.206 (0.548 to 2.654) 0.642 
70-79 25.6% 1.8% 2.442 (1.150 to 5.185) 0.02 
>= 80 13.2% 3.5% 4.945 (2.329 to 10.492) < 0.001 
Gender 
    Male 75.3% 1.1% 0.507 (0.363 to 0.710) < 0.001 
Female 24.7% 2.2% Reference 
 Priority 
    Elective 40.3% 0.2% Reference < 0.001 
Urgent 29.7% 0.5% 2.272(0.993 to 5.199 < 0.001 
Emergency 30.0% 3.9% 18.971 (9.624 to 37.394 < 0.001 
Cardiogenic shock 
    No 97.1% 0.9% Reference 
 
Yes 2.9% 17.1% 
27.719 (15.109 to 
31.221) < 0.001 
Prior CABG 
    No 93.1% 1.5% Reference 
 Yes 6.9% 0.7% 0.485 (0.198 to 1.187) 0.106 
Prior MI 
    No 74.0% 1.5% Reference 
 Yes 26.0% 1.1% 0.735 (0.491 to 1.100) 0.133 
Prior PCI 
    No 77.7% 1.5% Reference 
 Yes 22.3% 1.0% 0.640 (0.405 to 1.011) 0.054 
Cerebrovascular 
disease 
    No 95.8% 1.2% Reference 
 Yes 4.2% 3.9% 3.244 (1.904 to 5.526) < 0.001 
Renal dysfunction 
    No 95.1% 1.4% Reference 
 Yes 4.9% 1.3% 0.925 (0.406 to 2.110) 0.853 
COPD 
    No 95.8% 1.4% Reference 
 Yes 4.2% 1.2% 0.904 (0.368 to 2.221) 0.825 
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Valvular heart disease 
    No 98.8% 1.4% Reference 
 Yes 1.2% 0.0% 0.986 (0.984 to 0.989) 0.211 
peripheral vascular 
disease 
    No 96.5% 1.3% Reference 
 Yes 3.5% 3.3% 2.546 (1.397 to 4.639) 0.002 
Hypercholesterolaemia 
    No 42.5% 1.6% Reference 
 Yes 57.5% 1.2% 0.747 (0.529 to 1.055) 0.096 
Hypertension 
    No 45.4% 1.6% Reference 
 Yes 54.6% 1.2% 0.763 (0.550 to 1.058) 0.103 
Diabetes 
    No 82.5% 1.4% Reference 
 Yes 17.5% 1.5% 1.140 (0.747 to 1.741) 0.544 
Asthma 
    No 96.6% 1.4% Reference 
 Yes 3.4% 0.6% 0.431 (0.106 to 1.750) 0.226 
Renal disease 
    No 86.2% 0.8% Reference 
 Yes 13.8% 1.6% 2.132 (1.244 to 3.652) 0.005 
Dyspnoea class 
    *I 37.6% 1.1% Reference 0.779 
II 29.8% 0.9% 0.825 (0.474 to 1.434) 0.495 
III 13.8% 0.8% 0.763 (0.363 to 1.604) 0.476 
IV 18.8% 0.8% 0.749 (0.385 to 1.459) 0.396 
Angina class 
    0 15.4% 1.7% Reference 0.017 
I 9.2% 1.4% 0.796 (0.373 to 1.700) 0.555 
II 25.5% 0.7% 0.398 (0.202 to 0.787) 0.008 
III 20.2% 0.7% 0.396 (0.190 to 0.823) 0.013 
IV 29.7% 0.8% 0.442 (0.235 to 0.833) 0.012 
Ventilated pre-op 
    No 98.1% 1.3% Reference 
 Yes 1.9% 15.4% 14.210 (9.059 to 22.290) < 0.001 
Biomarkers raised 
    No 15.9% 0.6% Reference 
 Yes 84.1% 1.0% 1.829 (0.555 to 6.028) 0.314 
Table 4.3.2 – procedural univariate associations with in-hospital MACE 
Risk Factor Patients (%) MACE (%) OR (95% CI) P Value 
Ejection fraction 
    < 30% 4.1% 6.9% 21.040 (10.569 to 41.889) < 0.001 
30-50% 32.1% 0.9% 2.660 (1.359 to 5.206) 0.004 
>= 50% 63.8% 0.4% Reference < 0.001 
Graft Lesion 
    No 97.4% 1.4% Reference 
 Yes 2.6% 1.1% 0.788 (0.249 to 2.487) 0.683 
LMS Lesion 
    No 97.8% 1.4% Reference 
 Yes 2.2% 4.0% 3.016 (1.516 to 6.000) 0.001 
Glycoprotein used 
    No 86.5% 1.1% Reference 
 Yes 13.5% 3.4% 3.113 (2.190 to 4.426) < 0.001 
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From both tables of associations (4.3.1. and 4.3.2) the risk factors which exhibit a 
statistically significant univariate association (p < 0.05) with in-hospital MACE are: age 
group; gender; PCI priority; cerebrovascular disease; peripheral vascular disease; renal 
disease; pre-operation ventilation; ejection fraction; LMS lesions; and glycoprotein 
inhibitor IIb/IIIa usage. 
4.3.2 In-hospital MACE Outcomes 
Of the 13,202 PCI records included in the analysis, 193 (1.46%) experienced in-hospital 
MACE. The breakdown of these MACE events is displayed in Table 4.3.3. 
Table 4.3.3 – In-hospital MACE outcome events for ECTC patient cohort 
MACE Component Patients (n) Patients (%) 
Death 146 1.11% 
Q-wave myocardial infarction 25 0.19% 
Cerebrovascular accident 16 0.12% 
Emergency CABG 12 0.09% 
The majority of the patients which developed in-hospital MACE did only experience a 
single type, however as seen in Table 4.3.3 the total number of events is 199 meaning a 
few exhibited multiple MACE outcomes. Figure 4.3.1 displays the MACE rate by year of 
PCI procedure. 
 




The MACE rate in 2007 was 0% because only 16 valid PCIs were performed during this 
year and most of these were stable patients and hence unlikely to experience adverse 
outcomes. From the BCIS Audit Report released in 2014 the national average MACE 
rates across each year (2007 to 2014) can only be seen by individual MACE components. 
These rates are displayed in Table 4.3.4. 
Table 4.3.4 – national average MACE component rates (BCIS Audit Report, 2014) 




2007 0.92% 0.15% 0.05% 0.08% 
2008 1.03% 0.14% 0.08% 0.07% 
2009 1.24% 0.11% 0.09% 0.08% 
2010 1.5% 0.18% 0.12% 0.05% 
2011 1.6% 0.13% 0.08% 0.05% 
2012 1.9% 0.11% 0.09% 0.05% 
2013 1.8% 0.09% 0.09% 0.05% 
2014 1.9% 0.13% 0.09% 0.06% 
The ECTC overall outcomes for years (2007 to 2015) as listed in Table 4.3.3 shows that 
the outcome rate for death (1.11%) is lower than the national average in all years from 
2009 onwards. The Q-wave MI (0.19%), cerebrovascular accident (0.12%), and 
emergency CABG (0.09%) components see minor increases in the ECTC average cohort 
relative to each national average audit year. 
Table (4.3.5) and Figure (4.3.2) display the breakdown of PCIs by year and priority. The 
figure was generated to ascertain whether fluctuations in MACE rate over the years (i.e. 
figure 4.3.1) could simply be explained by fluctuations in PCI priority.  






Figure 4.3.2 – ECTC PCIs by Priority 
There is a general trend of decreasing proportion of elective PCIs over the years from 
approximately 69% in 2007 to 37% in 2015. A sudden rise in the number and hence 
proportion of emergency PCIs is seen in 2009 which can be explained by the ECTC 
activating its primary care pathway whereby out-of-hospital STEMI patients are treated 
directly at the ECTC instead of being treated elsewhere and then transferred to the ECTC 
as urgent patients. The emergency proportion has remained fairly stable from 2010 
onwards and has been between 31.3% and 34.6%. 
The estimated overall in-hospital MACE rate was obtaining by summing the NWQIP 
generated probabilities for each record. The summed probabilities of all 13,202 PCI 
records were 363.84. This represents the total number of predicted MACE outcomes for 
the 13,202 PCIs, expressed as a percentage this is 2.76%. The NWQIP model estimated 
MACE rate and observed MACE rate was 2.76% and 1.46% respectively. The standard 
deviation of the NWQIP probabilities was 7.6. Table 4.3.6 and Figure 4.3.3 show the 




Table 4.3.6 – Observed and Estimated in-hospital MACE rates for ECTC PCI cohort 
Year Observed (%) Estimated (%) 
2007 0.00 0.75 
2008 2.31 1.44 
2009 1.77 2.31 
2010 1.82 2.86 
2011 1.14 3.18 
2012 1.21 3.11 
2013 1.38 2.84 
2014 1.16 2.92 
2015 1.06 2.45 
 





4.3.3 Calibration of NWQIP 
As detailed in Chapter 3 (General Methods and Data), the NWQIP was tested for its 
goodness of fit using the Hosmer-Lemeshow test. Eight risk groups were generated based 
on the record numbers and estimated probability distribution. The group information and 
statistics are listed in Table 4.3.8.The risk groups which exhibit the largest Hosmer-
Lemeshow test statistic value correspond with the poorest fit of observed and expected in-
hospital MACE rates. The degrees of freedom (df), chi-square value, and p value are 
listed in Table 4.3.7. 
Table 4.3.7 – Hosmer-Lemeshow outcome measures for goodness of fit test 
Measure Calculation/Function Value 
Degrees of freedom Number groups - 2 6 
χ
2
 Sum of group 1-8 H&L value 94.48 





















1 7 2964 0.24% 0.45% 99.55% 13.4 2957.6 3.09 
2 13 2816 0.46% 0.73% 99.27% 20.5 2808.5 2.79 
3 7 1190 0.58% 1.15% 98.95% 13.8 1183.2 3.38 
4 5 620 0.80% 1.35% 98.65% 8.4 616.6 1.4 
5 15 2099 0.71% 1.59% 98.41% 33.7 2080.3 10.52 
6 18 1426 1.25% 2.28% 97.72% 32.9 1411.1 6.93 
7 23 1199 1.88% 3.98% 96.02% 48.7 1173.3 14.08 
8 105 695 13.13% 24.05% 75.95% 192.4 607.6 52.28 
The p value is below 0.05 indicating that there is a very large difference in at least one of 
the groups with regards to observed and estimated rates of in-hospital MACE, and hence 
because of this the model's suitability based on the calibration should be rejected. The 
poorest fitting groups based on the Hosmer-Lemeshow statistic are groups 5, 7, and 8 
respectively as these show the biggest differences between observed and estimated 
MACE. The four highest groups also exhibit the poorest fits whereby groups 5 to 8 have 




Figure 4.3.4 – MACE NWQIP estimated and observed rates (%) 
 
An overestimation of approximately 50% (relative to the observed MACE %) can be seen 
in most of the eight risk groups. Following this, a subsequent calibration test (Table 4.3.9) 
was performed after having divided the estimated NWQIP % by 2, to identify how the 
calibration changes taking into account this 50% overestimation. 
 
Table 4.3.9 – Hosmer-Lemeshow Calibration testing for ECTC Cohort dividing the 
estimated NWQIP risk by 2 to account for overestimation 
   
 
The Hosmer-Lemeshow test was non-significant (χ2 = 2.23, p = 0.89, df =6), meaning a 
good fit of estimated versus observed MACE is present. Each risk group still features the 

















1 7 2964 0.24% 0.23% 99.77% 6.7 2964.3 0.01
2 13 2816 0.46% 0.36% 99.64% 10.3 2818.7 0.73
3 7 1190 0.58% 0.58% 99.42% 6.9 1190.1 < 0.01
4 5 620 0.80% 0.67% 99.33% 4.2 620.8 0.15
5 15 2099 0.71% 0.80% 99.20% 16.8 2097.2 0.2
6 18 1426 1.25% 1.14% 98.86% 16.5 1427.5 0.14
7 23 1199 1.88% 1.99% 98.01% 24.3 1197.7 0.07
8 105 695 13.13 12.02% 87.98% 92.2 703.8 0.91
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4.3.4 Discrimination Performance of NWQIP 
The area under the ROC curve (AUROC) for the 13,202 PCIs in the ECTC cohort is 
shown in Figure 4.3.5. The discrimination input was the generated NWQIP probabilities 
and the outcome was the presence of in-hospital MACE. 
 
Figure 4.3.5 – ROC curve for estimated NWQIP probability of MACE 
The AUROC was 0.83, the 95% confidence limits for this were 0.79 to 0.86 and the 
corresponding standard error was 0.017.  
The AUROC was recalculated following the recalibration changes in Table 4.3.9, this was 
identical to the AUROC prior to recalibration (ROC = 0.83), as anticipated, as the patients 
are still in the same risk groups and hence the cut-off point during the sensitivity and 





The NWQIP risk prediction model was externally tested on the ECTC PCI cohort. This set 
of PCI procedures were performed in a different part of the UK (south-east) compared to 
the original NWQIP study and external validation study by Kunadian et al. (2008). The 
ECTC cohort is more recent compared to the original NWQIP study. Such differences in 
eras provide several important changes that can potentially alter adverse outcome rates 
amongst PCI patients. For example, modern cohorts are more likely to use a higher 
proportion of DES (and subsequent generations of DES) whereas in prior years there 
would have been a higher usage of BMS or, if you go back further in time, just standard 
balloon angioplasty with no stent insertion. Pharmacological therapy such as dual 
antiplatelet therapy (DAPT) may also be responsible. As reported in the BCIS Audit (2015) 
there has been an increase in the number of PCI centres and operators which could result 
in a faster treatment window for emergency patients. The ECTC cohort featured a much 
higher proportion of elderly patients, for example patients aged 70 years or above 
represented 38.8% overall compared to 20.4% in the original NWQIP study. The ECTC 
cohort also has an approximate additional 5% of male patients (at 75.3% relative to 
70.9%). The ECTC cohort included more diabetic patients (17.5% relative to 13.7%) and 
of crucial importance, the ECTC involved more emergency patients (30.0% relative to 
10.8%) and conversely a lower proportion of elective patients (40.3% relative to 56.3%). A 
lot of these characteristics would suggest that a higher rate of in-hospital MACE should be 
expected, but that was not observed. 
The NWQIP risk model estimated an overall in-hospital MACE rate of 2.76% (364 
patients) in the ECTC cohort of 13,202 PCIs, the actual MACE rate was only 1.46% (193 
patients) however therefore suggesting that NWQIP overestimates the number of adverse 
outcomes by almost double. The majority of the eight risk groups seemed to feature this 
50% increase in estimation. By dividing the estimated NWQIP probabilities by 2 (Table 
4.3.9) and testing the calibration, the goodness of fit became non-significant, as expected 
with a p = 0.89, indicating close to a perfect fit, however it should be noted that this is 
essentially rescaling the estimated risk and does not yield any information whatsoever 
about which of the NWQIP risk factors have changed in terms of the association with in-
hospital MACE. The readjustment of the NWQIP probabilities in this manner also does not 
change the low distribution of observed risk amongst the groups, i.e. risk groups 1 to 5 
have the observed rates of 0.24%, 0.46%, 0.58%, and 0.80% respectively, thus 
distinguishing between a patient in risk group 2 with another in group 3 becomes difficult. 
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The area under the ROC curve was 0.83 which indicates a good ability to discriminate 
overall between patients experiencing/not experiencing MACE. However when the cohort 
of patients were ordered by estimated NWQIP risk of MACE and places into separate risk 
groups, the fit of estimated versus observed MACE was poor in most groups, especially 
the higher risk groups. The Hosmer-Lemeshow χ2 = 94.48 (df = 6) and the p = 3.54×10-18. 
A perfect calibration of observed and estimated MACE rates would be p = 1 and clearly 
the small p value suggests a very poor fit overall. Of the risk factors within the NWQIP 
model, only treatment to graft vessels no longer had a statistically significant univariate 
association with in-hospital MACE, this may be because operators are more experienced, 
or it may be due to operators not attempting to perform PCI to these vessels on given 
patients, as they may have done in the past. This suggests that it be omitted from future 
risk prediction models. The other variables in the NWQIP model, whilst significant, saw a 
reduction in the observed MACE race hence favouring recalibration of the coefficients. 
Tables 4.3.3 and 4.3.4 show that the ECTC has a lower in-hospital death rate (1.11%) 
than the national average from years 2009 onwards, however, the Q-wave MI, 
cerebrovascular accident, and emergency CABG events exhibit slightly increased risks 
than the national average, this however, is likely to be explained by the fact that not all 
cardiac centres perform PCIs on high volumes of emergency patients like the ECTC does, 
this is consistent with the ECTC beginning its primary PCI treatment activation. Another 
possible explanation is that patients which exhibit a non-death MACE component at the 
ECTC, may have died had they been treated at a certain other cardiac centre, whereas at 
the ECTC they survived death but this resulted in another MACE component from 
occurring although this is not possible prove and it just a possible explanation. Overall, the 
MACE component rates are similar to the national averages across each year. 
4.4.1 Limitations 
A potential limitation is that it is assumed the staff (operators, consultants, and nurses) at 
the ECTC are appropriately skilled and trained to record complications correctly in the 
appropriate fields, i.e. if certain staff members are not storing all of the in-hospital MACE 
complications accurately this could lead to an underestimation of MACE events and hence 
influence the verification of the NWQIP model on the ECTC cohort. However, this 
potential limitation is minor would be present at every other cardiac centre and hospital. It 
was not possible to identify whether all staff were trained correctly or whether the 
complications, if any such occurred, were recognised. Clearly two of the four MACE 
components are easily recognisable, these being emergency CABG surgery and death, 
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but it may be the case that not all cerebrovascular accidents (stroke) or Q-wave MIs were 
recognised and hence recorded in the database. 
4.4.2 Conclusions 
The first hypothesis (section 1.3) in this thesis predicted that the NWQIP would not 
perform as effectively as it did on the original cohort (Grayson et al., 2006), or external 
validation study (Kunadian et al., 2008). This was proved to be true, despite the 
discrimination resulting in AUROC = 0.83, the calibration of observed and estimated 
groups was extremely poor ( χ2 = 94.48, df = 6, p = 3.54×10-18) due to large differences in 
multiple risk groups. This negatively affects the usefulness of the model on the ECTC 
cohort. It is anticipated that subsequent external validation of the NWQIP model will 
confirm the findings of this study, that it may produce a satisfactory discrimination 
performance (i.e. AUROC = 0.8) but will also however exhibit a poor calibration for 
different risk groups. 
Differences in the NWQIP estimated in-hospital MACE rate and the observed rates are 
difficult to ascertain the exact reason. It is however hypothesised that the cause is due to 
multiple reasons some of which have already been explained. In summary it anticipated 
that the following are all responsible however to isolate each them and to identify to what 
degree is difficult. Given the increase in certain characteristics predisposed to adverse 
outcomes such as in-hospital MACE it would be logical to assume higher risk estimation, 
as generated in the ECTC dataset using the NWQIP model, however a much lower 
observed risk was observed. 
Firstly, the higher usage of DES may have a protective effect on complications. Typically it 
may be the case that smaller stents can be inserted into the coronary arteries than with 
BMS. Another reason may be that more PCI centres and registered operators means 
more emergency patients can be reach a PCI centre and subsequently be treated 
compared with previously where patients which had an out-of-hospital myocardial 
infarction could have been more likely to die before an ambulance reached them or if alive 
whilst an ambulance arrived, less likely to reach the PCI centre alive, because this data 
was not available for analysis it is difficult to verify. It may also be the case that operators 
are better trained now compared with previously, higher frequencies of patients receiving 
PCIs (of all priorities) may allow better training for junior doctors/operators and hence 
increase their efficiency and speed of performing PCI, this would obviously be of 
paramount importance in emergency procedures, as restoring blood flow to the tissues of 
the heart faster would result in less cardiac tissue dying.  
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The NWQIP risk model may benefit from recalibration of its incorporated risk factors. One 
approach would be simply to regenerate the logistic regression coefficients by using a 
modern PCI cohort. However a better solution may be to perform a completely new 
multivariate logistic regression analysis on a modern dataset, whilst utilising all available 
data fields, such as demographic, clinical, and procedural characteristics. Because of 
national bodies suggesting minimum dataset for PCIs and CABG surgery, modern PCI 
databases are more likely to be complete (i.e. little missing data) and have more data 
fields stored compared to the era when the NWQIP risk model was developed. By 
performing a new regression analysis it could potentially identify novel risk factors that had 
not previously been linked to adverse outcomes following PCI. It would be useful to also 
investigate whether increasing rates of comorbidities have an effect on elective patients, if 
previously diagnosed with cardiovascular disease a patient now may more likely be 
treated with pharmacological therapy (e.g. aspirin or clopidogrel) and hence only more 
seriously ill elective patients might go on to receive a PCI at the ECTC. 
4.4.3 Future Work 
In-hospital MACE rates occur at low frequencies, therefore for future work it would be 
beneficial if such data were available to extend the outcome period from in-hospital only to 
30 day or one-year. Previous studies have suggested that if an emergency patient 
survives the first 30 days following their PCI procedure they have a good chance of 
surviving the near future. Unfortunately the dataset for this study did not have post-
discharge complications available or the date at which they occurred. An issue with using 
in-hospital MACE as the outcome is that complications may not be recorded or recognised 
as easily, it is obvious that if a patient died or needs to undergo emergency CABG that 
these MACE components are easily known, but Q-wave myocardial infarctions and 
cerebrovascular accidents are more complicated to recognise and hence be recorded 
accurately in the database. It would be beneficial to see if robust and clear outcomes such 
as short to long-term mortality be investigated, this way high data completion rates would 
be expected and it can be assumed to be more accurate than complications fields, for 
example, some Q-wave myocardial infarction complications may be incorrectly recorded 
as non-Q-wave myocardial infarctions in the database and hence affecting the accuracy of 
risk prediction models. The benefit of looking at outcomes such as 30-day mortality, for 
example, is that some patients may survive the PCI procedure but exhibit complications 
shortly after they are transferred to another hospital. The useful outcome of 30 days 
bypasses this issue as regardless of where the patient dies, they will be reported as dead 
in ECTC database and hence provide a more robust and reliable outcome. 
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The analysis from Chapter 4, the evaluation of the North West Quality Improvement 
Programme (NWQIP) risk prediction model (Grayson et al, 2006), found that the NWQIP 
model could discriminate well using the outcome of in-hospital major adverse cardiac 
events (MACE) in a modern PCI cohort that was in a different geographical area (i.e. 
south-east England instead of north-west). The area under the receiver operating 
characteristic (ROC) curve was 0.83 (95% CI 0.79 to 0.86), this value is considered 'good' 
(Metz, 1978; Obuchowski, 2003; Ludemann et al., 2006). The calibration, which is a 
goodness of fit between observed and estimated in-hospital MACE rates amongst 
different risk groups based on ascending level of risk, was poor however (χ2 = 94.4, df = 6, 
p < 0.001). The small p value indicates that there were very large differences in at least 
one risk group with regards to observed and estimated rates. The analysis found that the 
four highest risk groups (out of a total of 8) had large differences between observed and 
estimated rates, thus affecting the risk models usefulness as a prediction tool for in-
hospital MACE following PCI. There were many differences between the PCI 
characteristics (demographics, comorbidities, and procedural) of the original NWQIP 
cohort, the external validation study by Kunadian et al. (2008), and the ECTC PCI cohort. 
These differences are theorised to be responsible for the NWQIP risk model's calibration 
performance worsening on the modern ECTC cohort. In addition to these characteristics, 
differences in stenting technology (i.e. subsequent generations of drug-eluting stents, 
DES) and pharmacological therapies (dual antiplatelet and aspirin) are thought to be 
responsible. 
Table 5.1.1 summarises the prominent differences between the three cohorts with regards 
to characteristics in the datasets. 
Table 5.1.1 – Prominent characteristic differences between PCI cohorts 
Characteristic NWQIP (2006) Kunadian (2008) ECTC 
Age ≥ 70 years 20.4% 26.4% 38.8% 
Emergency PCI 10.8% 17.6% 26.9% 
Prior PCI NA 12.6% 20.1% 
Diabetes 13.2% 14.7% 17.4% 
Renal dysfunction 0.9% 1.6% 4.4% 
Cardiogenic shock 0.7% 1.7% 2.5% 
ACS/AMI 10.3% 16.1% 56.0% 
It is anticipated that the manifestation of different comorbidity rates identified in modern 
UK populations may affect the adverse complication outcome rates, for example 
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increasing rates of diabetes mellitus, peripheral vascular disease (PVD), chronic 
obstructive pulmonary disease (COPD), renal disease etc. 
As Chapter 4 determined in the analysis, graft lesions were no longer significant in their 
univariate association with in-hospital MACE, and that would suggest that recalibration of 
the NWQIP model using a modern PCI cohort is warranted. The NWQIP model 
overestimated the in-hospital MACE rate by predicting 2.76% when the actual rate was 
1.46%. It could be the case than advances in interventional technology (i.e. higher usage 
of DES stents) or an increase in cardiac centres and hence more rapid revascularisation 
for emergency patients, be responsible for changes in adverse outcome rates. 
By performing a multivariate logistic regression analysis on the contemporary ECTC PCI 
cohort of patients it may allow for improved discrimination and calibration in the modern 
era of PCI intervention, and thus provide a useful prediction tool for hospitals and cardiac 
centres, replacing the need for older models such as the NWQIP risk model which do not 
appear to be highly calibrated on the modern ECTC cohort. The in-hospital MACE 
outcome incorporates some components which occur at very low rates. These rates 
among the three PCI cohorts (original NWQIP training set, external validation cohort 
study, and the ECTC cohort) are listed in Table 5.1.2. 
Table 5.1.2 – in-hospital MACE components (excluding death) for the NWQIP, 
external validation study and ECTC cohorts 
MACE Component NWQIP Kunadian ECTC 
Emergency CABG 0.15% 0.14% 0.09% 
Cerebrovascular disease 0.2% 0.20% 0.12% 
Q-wave MI 0.4% 0.22% 0.19% 
The in-hospital MACE components (apart from death) occur at such low rates it makes 
identifying statistically significant associations between them and certain characteristics 
difficult. Another issue with three of the MACE components (emergency CABG less so) is 
that they require accurate and timely identification of their occurrence, which inevitably will 
lead to some data inaccuracies. This is especially likely to occur when patients are 
transferred out of the ECTC to general hospitals following their PCI procedure. A more 
robust and informative outcome of interest is 30-day mortality, which is defined as death 
within 30 days of a patient's PCI procedure date, this does not factor length of stay (LOS) 
as patients of different priorities and conditions are likely to exhibit different LOS. The 
outcome of 30-day mortality is also more useful for patients and clinicians as the 30-day 
period has been defined as significant with regards to predicting recovery from the PCI 
procedure. In addition to these benefits of 30-day mortality versus in-hospital MACE, the 
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former is also likely to occur at a much higher rate thus increasing the statistical power 
and hence strength of univariate and multivariate associations. 
The original NWQIP study was performed on a PCI cohort from August 2001 to December 
2003, and consequently reports less variables tested for their univariate association than 
are typically recorded in modern PCI practice within the UK. The main reason for more 
variables and also increased data completeness is that the national audit body, the British 
Cardiovascular Intervention Society (BCIS), specify a minimum dataset which all PCI 
centres must provide (BCIS Dataset version 5.6.2). Identification of novel associations 
from previously untested characteristics may reveal several important new predictors of 
adverse outcomes which were discovered during the original NWQIP study era. 
 
5.5.1 Hypothesis and Objectives 
The hypothesis for this study is that a multivariate logistic regression model can be 
constructed to predict 30-day mortality. Due to the comprehensive ECTC PCI database, 
novel risk factors will be discovered 30-day mortality that were not present in the original 
NWQIP model, additionally, not all of the NWQIP risk factors will still be useful in 
predicting in-hospital MACE, or 30-day mortality and hence not required in modern risk 
prediction models. Usage of the 30-day mortality endpoint is predicted to be more robust 
(i.e. easily recognisable and hence recorded in the database) and hence it is anticipated 
that that risk models predicting this outcome could achieve good discrimination and 
calibration. 
This study has the following objectives, which aim to test the specified hypothesis: 
(1) Evaluate the NWQIP prediction model for 30-day mortality (i.e. instead of in-hospital 
MACE). 
(2) Construct a prediction model for 30-day mortality using multivariate logistic regression 
analysis. 
(3) Produce an integer-based scoring system for easy calculation of risk. 
(4) Test the discrimination and calibration performance (training set). 
(5) Verify the discrimination and calibration performance on an internal validation set. 
(6) Identify the possible reasons behind any performance changes (for better or worse). 





Many of the methods utilised in this study have been detailed in the General Methods and 
Data Chapter (3), but are also briefly described again here. 
5.2.1 Database and Study Population 
This study was a retrospective cohort study of data collected prospectively and recorded 
in the ECTC’s comprehensive cardiovascular patient information management database 
(CVIS, Philips). The data was collected for all patients that have been to the ECTC for 
percutaneous coronary intervention (PCI) from 1st July 2007 to 31st January 2015. The 
entire database available for analysis comprises 13,938 consecutive PCI procedures 
featuring all levels of priority (elective, urgent, emergency, and salvage) and hence 
includes weekend and out of hours procedures. Within the entire set of 13,938 
procedures, 3.9% (540 PCIs) contained missing data for a NWQIP risk factor (LMS lesion, 
graft lesion, cerebrovascular disease, or priority), a custom 30-day mortality independent 
predictor, or outcome data (i.e. in-hospital MACE or 30-day mortality) and consequently 
had to be excluded from analysis, otherwise comparing performance of NWQIP versus a 
custom prediction model would not be fair because different data would have been used 
to generate the performance metric results (discrimination and calibration). Repeat PCI 
procedures occurring within 30 days of the initial procedure were excluded. 
The number of records retained in the final analysis was 13,398. This cohort of valid PCIs 
was further split into a training/development set and a validation set using a ratio of 
approximately 2:1, based on the date of the procedure. The date was chosen as the 
method of splitting over a random allocation because it would be more robust to future 
trends, for example, if a set of independent predictors are identified through the analysis 
of the training set and these are subsequently validated as predictors in the validation set 
then it proves they are robust to future trends/changes that may exist in the data. The 
training set contained 9279 PCIs from 1st July 2007 to 31st December 2012, and the 
validation cohort featured 4119 PCIs from 1st January 2013 to 31st January 2015. 
The characteristics relating to the PCI procedures are listed in General Methods (Chapter 
3) and Appendix B1. In brief, the following sets PCI characteristics were available for 




Dates and Times 
PCI operation, symptom onset (ACS only), arrival at first hospital (ACS only), arrival at 
PCI hospital (ACS only), first balloon inflation, admission, waiting list, arrival, discharge 
date, length of stay duration. 
Staff Details 
Consultant responsible, primary operation, primary operator status, second operator, 
consultant, reported by, reported by position, authorised by, authorised by position. 
Demographic/History Characteristics 
Age in years (time of procedure), sex, test reason, ethnic group, priority, intended and 
actual procedures, prior MI/CABG/PCI, renal disease history, LVEF category, diabetes 
status, medical history (e.g. Hypercholesterolaemia, hypertension, COPD, PVD, stroke 
etc.), cardiogenic shock (pre-procedure), stenosis percentages of LMS/LAD other/LAD 
proximal/RCA/LCX, number of grafts present, TIMI flow, clinical syndrome, indication for 
intervention, arterial access method, smoking status, BMI classification, CAD family 
history, renal problems. 
Angiographic and Procedural Characteristics 
Vessel(s) attempted, graft vessels attempted, number of CTOs attempted, number of 
lesions attempted, number of lesions successful, largest balloon/stent used, indication for 
stent, number restenoses attempted, number in-stent stenosis attempted, number stents 
used, number DES used, longest stented/treated segment, procedural complications, 
arterial complications, Post procedural complications, GP IIb/IIIa used during procedure, 
discharge status, drugs used, devices used, presenting ECG (ACS only), cardiac 
enzymes/markers raised, CCS angina status, NYHA dyspnoea status, ventilated pre-
operation, rotablation, multivessel disease, pressure wire, IVUS, discharge location, ECG 
ischemia, heparin administered, bival administered. 
Outcome/Complication Characteristics 
Procedural complications, (e.g. coronary dissection, cardiac arrest), post-procedural 
complications, hospital outcome complications (e.g. blood transfusion, Q-wave MI), death 




5.2.2 External Validation of NWQIP 
As detailed in Chapter 4, the reported logistic regression coefficients from the NWQIP risk 
model (Grayson et al, 2006) were used to calculate the predicted probability of in-hospital 
MACE for the training set, so that fair performance comparisons can be made between 
the NWQIP model and custom prediction model. Subsequent validation was performed 
using the AUROC (Hanley & McNeil, 1982) for assessing discrimination performance. The 
calibration, which is a fit between observed and predicted outcomes for different groups 
ordered by ascending risk, was assessed using the Hosmer-Lemeshow goodness of fit 
test (Hosmer & Lemeshow, 2013). First, the performance was tested using the in-hospital 
MACE outcome, defined as the occurrence of at least one of the following: in-hospital 
death (during the same admission of the PCI regardless of the cause); emergency CABG 
surgery; Q-wave MI, defined as a new pathological Q wave with creatine kinase (CK) 
more than twice the laboratory upper limit, or normal with elevated CK-MB or troponin T 
(BCIS Dataset, 2014); cerebrovascular accident (stroke). Second, the estimated 
probabilities were used with the 30-day mortality outcome, defined as death from any 
cause up to and including 30 days following the date of the PCI. For deaths which 
occurred following a patient’s discharge, these were reported by a national data source, 
the linked HES-ONS (hospital episode statistics-office for national statistics; NHS Digital, 
2017) mortality which tracks patients deaths and is updated internally on a monthly basis. 
 
5.2.3 Statistical Methods 
Continuous variables are represented using the mean and standard deviation (SD), and 
categorical/discrete variables such as procedure priority are expressed as a percentage. 
Univariate analysis was performed to identify the set of variables in the CVIS database 
that were significantly associated with 30-day mortality, the significance criteria for the 
univariate analysis was p < 0.1, this value is adopted in many studies including the original 
NWQIP analysis (Grayson et al., 2006) to identify potential predictors that may have low 
odds ratios (relative to emergency PCI for example), but do have a measurable effect. 
Subsequent regression analysis then only retains these predictors if p < 0.05 in the 
multivariate model (Bursac et al., 2008; Hannan et al., 2013). The nominal/categorical 
variables were analysed using chi-square test of Fisher’s exact test where appropriate 
(i.e. variables which had small frequency counts), continuous data were tested using the 
Student’s t-test. The odds ratios, 95% odds ratio confidence limits, and significance (p 
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value) were calculated for each variable with regards to their 30-day mortality association. 
The significant variables (p < 0.1) and those considered clinically important predictors 
were used as candidate variables for entry into the multivariate logistic regression analysis 
using forward selection. Following the regression analysis, the set of candidate predictors 
which exhibited a significance of p < 0.05 were retained and used in the final regression 
model. The bootstrap resampling technique (Efron & Tibshirani, 1986) was performed to 
generate 200 random samples with replacement from 70% of the training set population, 
this resampling allows relatively unbiased approximations of the predictive performance 
(discrimination), meaning it identifies whether the training set AUROC is stable. 
In several PCI risk prediction models, such as the Toronto score (Chowdhary et al, 2009), 
and New York State Risk Score (Hannan et al, 2013), an additive integer score system 
was created as a simple tool for clinicians allowing an easier way of calculating a patient’s 
risk without the need for a calculator or computer. In brief, a positive integer is assigned to 
each of the independent risk factors in the given multivariate regression model based 
closely on the odds ratio, often rounded to the nearest integer value. A similar scoring 
method has been adopted in the multivariate model developed for this study, utilising 
rounding up at .5. Patients were classified into one of five different risk groups based on 
the total integer score of their combined risk factors in the multivariate model (Table 
5.2.1). 
Table 5.2.1 – Integer risk score groups for multivariate 30-day mortality risk model 
Risk Group Integer Score (range) 
Very low 0 to 9 
Low 10 to 14 
Moderate 15 to 19 
High 20 to 24 
Very high ≥ 25 
To detect possible multicollinearity between the risk factors within the custom multivariate 
logistic regression model, the variance inflation factor (VIF) and tolerance were calculated 
for each variable, a VIF of ≥ 4.0 and/or a tolerance of < 0.2 were considered 
thresholds/indicators for cause for concern (As described in 3.4). 
Data were analysed using the statistical analysis software package SPSS for Windows 





5.3.1 Outcomes following PCI 
In the training set of 9279 PCI operations there were 128 (1.4%) in-hospital MACE 
complications. These are displayed in table 5.3.1 along with the corresponding validation 
set (4119 PCIs) outcomes. Within the MACE outcome there were: 96 (1.0%) in-hospital 
deaths; 20 (0.2%) Q-wave MIs; 10 (0.1%) emergency CABGs; and 6 (< 0.1%) 
cerebrovascular accidents.  
Table 5.3.1 – in-hospital MACE and 30-day mortality outcomes for the ECTC 
training set (n = 9279) and validation set (n = 4119) 
Outcome Count Percentage 
Training Set (n = 9279) - - 
In-hospital MACE total 128 1.4% 
In-hospital death 96 1.0% 
Q-wave MI 20 0.2% 
Emergency CABG 10 0.1% 
Cerebrovascular accident 6 < 0.1% 
30-day mortality 197 2.1% 
Validation Set (n = 4119) - - 
In-hospital  MACE total 45 1.1% 
In-hospital death 31 0.8% 
Q-wave MI 8 0.2% 
Emergency CABG 4 0.1% 
Cerebrovascular accident 2 < 0.1% 
30-day mortality 84 2.0% 
The in-hospital MACE complications reported above were not mutually exclusive. The 
majority of patients exhibiting in-hospital MACE did only develop a single component of 
MACE. The 30-day mortality count was 197 (2.1%) and within this end-point 101 (1.1%) 
died following discharge from the ECTC, but within the 30-day period. Of the 101 patients 
which survived to discharge, 36 of these died within seven days of their discharge date. 
The mean age (SD) of the training set cohort was 65.4 years (11.8), 74.7% of the patients 
were male. The most common indication for PCI as classified by the BCIS specification 
(BCIS Dataset, 2014) was stable angina (3869 patients, 41.7%), followed by ‘Unstable 
angina/NSTEMI/convalescent STEMI’ (2909, 31.4%), and Primary PCI (1984, 21.4%). 
The remaining 5.5% of indications comprise: rescue PCI, reinfarction PCI, 
unlisted/unspecified, bail out interventions. Table 5.3.2 reports the in-hospital MACE and 
30-day mortality rates by priority of PCI for both the training and validation sets. As 




Table 5.3.2 – in-hospital MACE and 30-day mortality outcomes by PCI priority 
Outcome Elective (n) Urgent (n) Emergency (n) 
Training Set (n = 9279) - -  
In-hospital MACE total 0.5% (22) 0.6% (15) 3.6% (91) 
30-day mortality 0.4% (17) 0.9% (25) 6.1% (155) 
Validation Set (n = 4119)    
In-hospital MACE total <0.1% (1) 0.9% (10) 2.4% (34) 
30-day mortality 0.3% (4) 1.0% (11) 4.9% (69) 
Stent usage was high at 93.4% with 30.7% (2852 PCIs) having DES stents exclusively 
inserted, and 62.5% (5824) underwent PCI with at least one BMS stent inserted, and 
6.5% (603) did not have any stents used, i.e. just standard balloon angioplasty may have 
been used. 
5.3.2 Univariate Associations with In-hospital MACE 
Whilst the primary outcome of interest in this analysis was 30-day all-cause mortality, the 
in-hospital MACE univariate analysis produced the following significant univariate 
associations. Table 5.3.3 displays the characteristic, odds ratio, and corresponding p 
value. 
Table 5.3.3 –significant univariate associations with in-hospital MACE (training set) 
Characteristic Odds Ratio P Value 
Age group 70-79 years 2.94 0.008 
Age group ≥ 80 years 5.97 < 0.001 
Female gender 2.70 < 0.001 
Peripheral vascular 
disease 
2.94 < 0.001 
Renal disease 2.13 0.004 
Prior CABG 0.30 0.030 
Emergency PCI Priority 7.87 < 0.001 
Cerebrovascular disease 3.22 < 0.001 
Cardiogenic shock 27.29 < 0.001 
Pre-operation ventilation 19.10 < 0.001 
LVEF 30-50% 2.78 0.002 
LVEF < 30% 20.35 < 0.001 
TIMI flow grade < 3 3.59 < 0.001 





5.3.3 Univariate Associations with 30-Day Mortality 
The baseline characteristics (demographic, clinical and procedural) from the training set 
are displayed in tables 5.3.5 and 5.3.6, respectively. Both of the tables display the 
associations with 30-day all-cause mortality end-point, including the odds ratios, 95% 
confidence intervals, and p values. The patient percentage columns represent the 
percentage relative to the valid data, i.e. it excludes the missing records. The missing 
column represents the raw count of missing/blank records in the training set. The 
characteristics which exhibited a univariate association with 30-day mortality that had a 
significance of p < 0.1 were used as candidates for entry into the subsequent multivariate 
regression analysis. These characteristics were: age group (by decade); sex; PCI priority; 
diabetes mellitus; prior PCI; prior CABG; PVD; renal disease; cerebrovascular disease; 
cardiogenic shock (pre-procedural); COPD; pre-operation ventilation; LMS lesions; 
Despite TIMI flow grade, LVEF, and angina status classification (Canadian Cardiovascular 
Society) exhibiting significant relationships with 30-day mortality (p < 0.001; p < 0.001; 
and p < 0.001 respectively), these were excluded from the regression analysis because of 
the high percentage of missing data. TIMI flow grade and LVEF showed high odds ratios 
and contained 72.9% and 34.5% missing data respectively. 
Table 5.3.4–significant univariate associations with 30-day mortality (training set) 
used as candidates for multivariate analysis 
Characteristic Odds Ratio P Value 
Age group 70-79 years 3.33 0.001 
Age group ≥ 80 years 9.40 < 0.001 
Female gender 2.23 < 0.001 
Peripheral vascular 
disease 2.84 < 0.001 
Renal disease 3.28 < 0.001 
Prior CABG 0.47 0.044 
Urgent PCI Priority 2.47 0.003 
Emergency PCI Priority 16.18 < 0.001 
Cerebrovascular disease 2.47 0.003 
Cardiogenic shock 27.26 < 0.001 
Pre-operation ventilation 24.66 < 0.001 
LVEF 30-50% 4.78 < 0.001 
LVEF < 30% 31.17 < 0.001 
TIMI flow grade < 3 6.81 < 0.001 
Left main stem lesions 2.87 < 0.001 
Prior PCI 0.54 0.004 
COPD 1.76 0.043 




Table 5.3.5– univariate associations of 30-day mortality with ECTC training set (n = 








(n) OR (95% CI) P Value Missing (n) 
Age (years) 


























(4.0) 82 (7.0) 9.40 (4.53 to 19.53) < 0.001 
 Sex 












(2.7) 92 (3.8) 2.23 (1.74 to 3.02) < 0.001 
 Diabetes 












(1.7) 44 (2.7) 1.42 (1.01 to 1.99) 0.045 
 Hypertension 












(1.3) 113 (2.2) 0.98 (0.74 to 1.30) 0.908 
 PVD 






(1.4) 185 (2.1) Reference 
  
Yes 336 (3.6) 
13 
(3.9) 19 (5.7) 2.84 (1.75 to 4.61) < 0.001 
 Renal 
Disease 












(1.8) 35 (3.5) 3.28 (2.18 to 4.91) < 0.001 
 Renal 
Dysfunction 






(1.5) 189 (2.1) Reference 
  Yes 413 (4.4) 5 (1.2) 15 (3.6) 1.73 (1.01 to 2.96) 0.042 
 Prior CABG 






(1.5) 195 (2.2) Reference 
  Yes 674 (7.0) 3 (0.4) 7 (1.0) 0.47 (0.22 to 0.99) 0.044 
 Prior MI 






(1.3) 143 (2.1) Reference 


















(1.0) 24 (1.3) 0.54 (0.35 to 0.83) 0.004 
 Priority 


















(3.9) 167 (6.4) 
16.18 (9.92 to 
26.37) < 0.001 
 Cerebrovascu
lar disease 






(1.3) 186 (2.1) Reference 
  
Yes 360 (3.9) 
15 
(4.2) 18 (5.0) 2.47 (1.51 to 4.06) < 0.001 
 Cardiogenic 
shock 






(1.0) 143 (1.5) Reference 
  
Yes 240 (2.5) 
50 
(20.8) 71 (29.6) 
27.26 (19.74 to 
37.64) < 0.001 
 COPD 






(1.4) 190 (2.1) Reference 
  Yes 380 (4.1) 5 (1.3) 14 (3.7) 1.76 (1.01 to 3.05) 0.043 
 VHD 






(1.5) 200 (2.2) Reference 
  
Yes 95 (1.0) 
0 
(0.0%) 4 (4.2) 1.98 (0.72 to 5.43) 0.178 
 Ventilated 
(pre-op) 






(1.2) 176 (1.8) Reference 
  
Yes 120 (1.2) 
23 
(19.2) 38 (31.7) 
24.66 (16.33 to 
37.26) < 0.001 
 Coronary 
Syndrome 












(2.2) 196 (3.6) 
8.85 (5.45 to 






Table 5.3.6– univariate associations of 30-day mortality with ECTC training set (n = 








(%) OR (95% CI) P Value Missing 
LVEF 








(31.0) 21 (1.1) 38 (1.9) 4.78 (2.69 to 8.49) < 0.001 
 
< 30% 245 (3.9) 18 (7.3) 28 (11.4) 
31.17 (16.80 to 
57.81) < 0.001 
 TIMI Flow 








(61.6) 67 (4.2) 113 (7.0) 6.81 (3.65 to 12.71) < 0.001 
 Graft lesions 




(97.5) 137 (1.5) 208 (2.2) Reference 
  Yes 238 (2.5) 2 (0.8) 6 (2.5) 1.14 (0.50 to 2.60) 0.749 
 LMS lesions 




(98.1) 133 (1.4) 203 (2.1) Reference 
  Yes 186 (1.9) 7 (3.8) 11 (5.9) 2.87 (1.54 to 5.37) < 0.001 
 Multivessel 
PCI 








(14.7) 26 (1.9) 30 (2.2) 0.98 (0.66 to 1.45) 0.924 
 CTO 




(92.7) 123 (1.4) 194 (2.2) Reference 






5.3.4 External Validation of NWQIP 
Using the ECTC training set (n = 9279), the NWQIP risk prediction model was validated 
for two outcomes of interest. Firstly, the outcome it was originally designed to predict (in-
hospital MACE), and secondly the outcome of interest in this study, 30-day all-cause 
mortality. For in-hospital MACE the ROC curve (Figure 5.3.1) was 0.81 (standard error, 
SE = 0.022, 95% CI = 0.77 to 0.86). The Hosmer-Lemeshow goodness of fit test was 
significant, p < 0.001 (χ2 = 58.06, df = 6) this indicates a major difference between 
observed and estimated in-hospital MACE outcomes for the eight risk groups (number of 
groups = df + 2). 
 
Figure 5.3.1 – ROC curve for NWQIP estimated probabilities for in-hospital MACE and 30-day mortality 
For 30-day all-cause mortality the ROC curve (Figure 5.3.1) was 0.86 (SE = 0.014, 95% 
CI = 0.83 to 0.89). This improvement compared to in-hospital MACE (0.82) was not 
however statistically significant. The Hosmer-Lemeshow test was also significant, p = 
0.028 (χ2 = 14.20, df = 6), again indicating a poor fit of observed and estimated outcomes. 
Despite both end-points showing good discrimination (ROC > 0.8), the NWQIP model is 
poorly calibrated when ordered by estimated risk from the regression probabilities. 
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The external validation study by Kunadian et al. (2008) assigned integer scores based on 
the odds ratio values, essentially rounding them to the closest integer. These values for 
each of the NWQIP risk factors are shown in Table 5.3.7. 
Table 5.3.7– NWQIP risk factors and corresponding regression coefficients, odds 
ratios and integer score (as reported by Kunadian et al, 2008) 
Variable Coefficient Odds Ratio Integer Score 
Age 70-79 0.7048 2.02 2 
Age ≥ 80 years 1.0106 2.75 3 
Female sex 0.4586 1.58 2 
Urgent PCI 0.4788 1.61 2 
Emergency PCI 1.3625 3.91 4 
LMS lesion 1.6502 5.21 5 
Graft lesion 0.9101 2.48 3 
Cardiogenic shock 3.2636 26.14 26 
Cerebrovascular disease 0.8618 2.37 3 
Intercept -5.4959 NA NA 
The calibration was additionally tested by using these reported integer scores. The 
patients were classified into one of five risk groups based on the total integer score of their 
risk factors. The five groups along with the integer score range, patient distribution and 
outcome rates are displayed in Table 5.3.8. 
 
Table 5.3.8 – Integer score groups for the NWQIP risk model and corresponding In-
hospital MACE and 30-day mortality rates 









Very low 0 to 5 78.5% 0.52% 0.60% 
Low 6 to 8 15.4% 1.47% 3.16% 
Moderate 9 to 11 3.1% 6.19% 10.65% 
High 12 to 14 0.5% 8.89% 15.56% 
Very high > 14 2.5% 20.09% 28.83% 
 
The observed and NWQIP predicted/estimated outcome rates, along with the in-hospital 





Figure 5.3.2 – NWQIP estimated outcome probabilities including observed in-hospital MACE and 30-
day mortality rates 
The 95% confidence limits for the predicted probabilities for each of the five groups are 
displayed in Table 5.3.9. 
Table 5.3.9 – 95% confidence intervals for estimated NWQIP probabilities of in-
hospital MACE 
Group 95% CI Estimated 
NWQIP Probability 
Very low 0.92% to 0.94% 
Low 3.18% to 3.26% 
Moderate 6.92% to 7.26% 
High 15.97% to 18.43% 
Very high 41.25% to 45.91% 
For in-hospital MACE there was an overestimation within every risk group, and for 30-day 
mortality the 'Low' risk group was the only one within the 95% CI range. This suggests 
that the NWQIP model estimated probabilities are actually closer to the observed 30-day 




5.3.5 Multivariate Predictors of 30-Day Mortality 
The candidate variables which displayed a significance of at least p < 0.1 in the univariate 
association with 30-day mortality were used in the multivariate logistic regression analysis. 
Those which retained a statistical significance of p < 0.5 in the final multivariate prediction 
model are displayed in Table 5.3.10, also reported are the corresponding regression 
coefficients, odds ratios, 95% confidence intervals for the ORs, standard errors (SE), and 
p values. The vast majority of the ECTC PCI patients (91.4%, 8481) had an estimated 
probability of experiencing 30-day all-cause mortality of ≤ 5% and only a very small group 
(1.8%, 167) had an estimated probability of ≥ 20%.  
Table 5.3.10 – multivariate predictors of 30-day all-cause mortality generated from 
logistic regression analysis 
Risk Factor Coefficient SE p Value 
Odds 
Ratio OR 95% CI 
Integer 
Score 
Age 60-69 years 1.102 .300 < 0.001 3.011 1.67 to 5.42 3 
Age 70-79 years 1.642 .292 < 0.001 5.166 2.91 to 9.16 5 
Age ≥ 80 years 2.452 .294 < 0.001 11.607 6.53 to 20.65 12 
Female sex .453 .167 .007 1.573 1.13 to 2.18 2 
Cardiogenic shock 1.990 .216 < 0.001 7.314 4.79 to 11.18 7 
Cerebrovascular 
disease 
.733 .294 .013 2.082 
1.17 to 3.70 2 
Urgent PCI .698 .318 .028 2.009 1.08 to 3.75 2 
Emergency PCI 2.326 .268 < 0.001 10.232 6.05 to 17.30 10 
Peripheral vascular 
disease 
.870 .306 .004 2.388 
1.31 to 4.35 2 
Ventilated (pre-op) 1.603 .296 < 0.001 4.966 2.78 to 8.87 5 
Intercept -7.150    
  
The equation to calculate the estimated probabilities of 30-day mortality using the 
multivariate predictors in Table 5.3.10 is identical to that which was reported by Grayson 
et al. (2006) for in-hospital MACE, and this equation is listed in Chapter 4. Whilst not listed 
here, none of the predictors exhibited a variance inflation factor (VIF) or tolerance which 
would indicate high levels of multicollinearity. 
The independent set of multivariate risk factors for 30-day mortality was similar to those 
reported in the NWQIP model for in-hospital MACE. Peripheral vascular disease (PVD) is 
a novel risk factor not present in the NWQIP model, and neither was pre-operation 
ventilation. Lesions in graft vessels or the left main stem (LMS) were not considered risk 




5.3.6 Performance of the Multivariate Model 
The area under the ROC curve (Figure 5.3.3) was 0.88 (SE = 0.014, 0.85 to 0.91) 
indicating a very good ability to discriminate between those patients which died within 30 
days of their PCI and those which were alive after 30 days. The Hosmer-Lemeshow 
goodness of fit test produced a non-significant p value (p = 0.67), χ2 = 5.801, df = 8. This 
indicates a good calibration of observed and estimated 30-day mortality rates across 
different risk groups. 
 
Figure 5.3.3 – receiver operating characteristic (ROC) curve for the 30-day risk prediction model using 




5.3.7 Integer Scores for 30-Day Mortality Prediction 
Each of the PCI patient records were classified into one of five risk groups (very low to 
very high) as done by Kunadian et al. (2008), the combined integer score of the risk 
factors identifies which of these groups they are classified under. The coefficients for the 
multivariate predictors (Table 5.3.9) are rounded to the closest integer and combined. The 
approximate risk score distributions across these five groups were 64% (5944), 21% 
(1921), 10% (903), 5% (427), and 0.1% (84) respectively as listed in Table 5.3.11. 
Table 5.3.11 – Integer score risk groups with patient distribution and 30-day 
mortality rates 
Risk Group Patients (%) 30-Day Mortality (%) 
Very low 5944 (64.06%) 23 (0.39%) 
Low 1921 (20.70%) 28 (1.46%) 
Moderate 903 (9.73%) 38 (4.21%) 
High 427 (4.60%) 72 (16.86%) 
Very High 84 (0.91%) 36 (42.86%) 
The majority (64%) of the patients as expected are classified in the lowest risk that has a 
30-day mortality rate of 0.39%, conversely a small proportion (0.91%) were classified into 
the highest risk group, however the 30-day mortality in this cohort was 42.86%. 
 
5.3.8 Internal Validation of the 30-Day Mortality Model 
The validation (n = 4119) PCI patient baseline characteristics (i.e. clinical, demographic, 
procedural) although they are not listed here they were similar to the training set (n = 
9729). The majority of the characteristics had small deviations in rates compared to the 
two that were lower than 1.5%. The characteristics which exhibited the largest differences 
in rates in the validation set were renal disease (5.1% +), hypertension (1.7% +), prior MI 
(1.7% -), prior PCI (2.5% +), multi-vessel PCI (2.7% -), and PCI priority (elective 5.2% -; 
urgent 1.2% -; emergency 6.4% +). 
In this set, 45 (1.1%) patients experienced in-hospital MACE and 84 (2.0%) died within 30 
days of their PCI, of these, 53 died after discharge, with 19 of the 53 (35.8%) dying within 
seven days. 
The bootstrap resampling (with replacement) technique was used on the training set and 
200 samples were generated that contained a mean (SE) ROC curve of 0.879 (0.0153) 
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indicating a very good ability to discriminate between 30-day all-cause mortality occurring 
and not occurring. Following the generation of a stable average ROC curve, the 
multivariate logistic regression coefficients (Table 5.3.9) were used to generate the 
estimated probability of 30-day mortality for each record in validation set of 4119 PCI 
records. The ROC curve was 0.891 (SE = 0.021, 0.850 to 0.932), the improvement in 
discrimination compared to the training set was not statistically significant. The Hosmer-
Lemeshow test was not significant, p = 0.2682 (χ2 = 9.9553, df = 8), indicating little 
departure from the perfect fit as shown in Figure 5.3.4. 
 
Figure 5.3.4 – calibration plot of observed and estimated 30-day mortality for the validation dataset (n 





The integer score risk groups of observed and estimated 30-day mortality rates are 
displayed in Figure 5.3.5. The distribution of patients into these five risk groups was 
56.5% (2325), 25.7% (1058), 11.6% (479), 4.7% (194), and 1.5% (63) respectively which 
compared to the training set distributions show an increased rate in all groups except for 
the 'very low' risk group, which sees a corresponding reduction from 64.1% to 56.5%. 
 
Figure 5.3.5 – observed and estimated 30-day mortality for the validation dataset (n = 4119) 
 
There was a slight absolute overestimation for each of the five risk groups. The relative 
difference between the observed and predicted/estimated 30-day mortality rates for each 





As with the study in Chapter 4, this study showed that the NWQIP risk prediction model, 
originally designed for predicting in-hospital MACE, could discriminate more effectively 
that it did in its original setting (Grayson et al., 2006) the ROC curve was 0.81 (95% CI = 
0.77 to 0.86), compared to the original ROC curve of 0.76. This improvement in 
discrimination for the NWQIP model on an external cohort of PCI patients was also 
reported by Kunadian et al. (2008), where the ROC curve was 0.86 (0.82 to 0.90). 
When the NWQIP model was used as a tool for predicting 30-day all-cause mortality, 
there was a small increase in discrimination performance (ROC = 0.86, 0.83 to 0.89) 
although this improvement compared to in-hospital MACE was not statistically significant. 
Both the in-hospital MACE and 30-day mortality ROC curves suggest NWQIP continues to 
discriminate well despite being tested on: (i) a modern PCI cohort; (ii) different 
geographical location (south of England). It is suspected that the primary reason for this 
improvement in discrimination is the more robust nature of the outcome of 30-day 
mortality outcome compared to MACE. For in-hospital complications, the NWQIP model 
requires accurate and timely reporting of these events, and any such under-reporting in 
higher-risk cohorts could weaken the models ability to discriminate. Because the majority 
of the MACE events in our cohort (as in many other cohorts) was in-hospital death, it is 
not surprising that when focusing solely on 30-day death the model performs well, i.e. 
possibly suggesting that the other MACE events (Q-wave MI, stroke, emergency CABG) 
are less easy to predict, so, by removing these events as outcomes, the model becomes a 
stronger predictor. 
The rate of in-hospital MACE in the ECTC PCI cohort (1.4%) was similar to the original 
NWQIP cohort (1.3%) despite the former exhibiting over a 12% increase in number of 
urgent and emergency patients reporting for PCI. If all other variables remained constant 
and there was an increase in non-stable PCIs it would be expected that the rate of MACE 
would increase as urgent/emergency patients are most at risk of adverse outcomes 
compared to stable (elective) patients. The similar in-hospital MACE rates seen between 
the two cohorts of PCI patients could possibly suggest that based on the same risk 
factors, fewer patients that underwent PCI almost a decade ago would now experience in-
hospital MACE in the modern era of PCI practice. 
The outcome of 30-day all-cause mortality is obtained from the hospital’s patient 
administration system database following monthly updates from a national data source, 
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and hence is less likely to be wrong than MACE events. In the ECTC training and 
validation datasets the 30-day mortality rates were 2.0% and 2.1%, respectively. Table 
5.4.1 lists the ECTC 30-day mortality rate across each year (training set: 2007-12, 
validation set: 2013-14), and the national average 30-day tracked mortality (via ONS-
HES) for all PCIs for audit years 2007 to 2014 (BCIS Audit Report, 2015). 
Table 5.4.1 – ECTC and national average 30-day mortality rates following PCI (BCIS 
Audit Report, 2015) 
Year 2007 2008 2009 2010 2011 2012 2013 2014 
National 30-day 
mortality 
1.5% 1.6% 2.0% 2.1% 2.4% 2.7% 2.7% 2.8% 
ECTC 30-day 
mortality 
0% 1.6% 1.8% 2.6% 2.6% 2.1% 2.2% 2.0% 
In 2007, the ECTC opened and therefore the majority of procedures were stable (elective) 
hence the 30-day mortality rate of 0%. In 2010 there is a sudden increase at the ECTC to 
2.6% (from 1.8% in 2009), the cause of this is believed to be due to the ECTC activating 
the primary care pathway, and hence the beginning of more emergency patients being 
treated, and hence a much higher risk of 30-day mortality relative to stable patients. From 
2012 onwards the ECTC rate remains lower than the national average rate. 
The other metric for assessing performance, calibration, a fit of observed versus predicted 
outcomes across multiple groups ordered by ascending risk, did not perform well. The p 
values for NWQIP with the in-hospital MACE and 30-day mortality outcomes were p < 
0.001, and p < 0.028 respectively, in both cases this represents a very large difference in 
observed versus predicted rates in at least one of the risk groups. 
The cause of a poor calibration performance is likely due to changing patient 
demographics and an increase in the proportion of emergency PCIs performed on 
critically ill patients such as those presenting with STEMI, and pre-procedural cardiogenic 
shock and ventilation. The ECTC cohort of PCI patients in general exhibited a greater 
proportion of high-risk procedural and clinical characteristics than both the original NWQIP 
study (Grayson et al, 2006) and the external validation study by Kunadian et al. (2008). In 
the ECTC cohort, 12.1% of the patients were classified as octogenarians (aged 80 to 89 
years) or nonagenarians (aged 90-99 years) which is a very high proportion relative to the 
other studies (2.1% and 3.8% respectively). It is known that the life expectancy is 
increasing in the UK, thus in the future the figure may increase beyond 12.1%. It is also 
commonly known that elderly patients in general recover more slowly than their younger 
counterparts to treatment. The percentage of emergency PCIs in the ECTC cohort also 
represents a larger proportion (26.9%) of procedures relative to the other two studies of 
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10.8% and 17.6% respectively. Other increases in characteristics considered to be 
important include renal dysfunction, which is 4.4% compared to 0.9% and 1.6% 
respectively. Diabetes mellitus increased slightly to 17.4% compared to 13.2% and 14.7% 
respectively. Of the patients reporting for PCI at the ECTC, 20.1% had prior PCI (either at 
the ECTC or another hospital/cardiac centre) compared to 12.6% in the Kunadian study 
(2008), the prior PCI percentage was not reported in the original NWQIP study although it 
is anticipated to be lower than both the ECTC and Kunadian cohorts. Pre-procedural 
cardiogenic shock was more prominent in the ECTC cohort at 2.5% compared to 0.7% 
and 1.7% respectively it would be anticipated that a larger proportion of emergency PCIs 
should correspond with a relative increase in cardiogenic shock patients. 
The multivariate logistic regression analysis identified two additional risk factors that were 
significantly associated with 30-day mortality, which were not present in the original 
NWQIP risk prediction model. These were peripheral vascular disease (PVD), also 
reported by Peterson et al. (2010) and hence incorporated into their NCDR CathPCI Risk 
Score System, and pre-operation ventilation. The pre-operation ventilation figures were 
not reported in either the original NWQIP study or the external study. It is however 
possible that this was either not reported or tested as a potential risk factor of in-hospital 
MACE because of the high percentage of elective patients (at 56.3%), i.e. almost no 
elective patients would be ventilated before their PCI, as pre-operation ventilator usage is 
largely associated with patients that experience out-of-hospital cardiac arrest following a 
myocardial infarction. 
PVD was present in a smaller proportion of patients in the ECTC cohort at 3.6% 
compared to 6.3% and 7.5% respectively. PVD was identified as a multivariate predictor 
by Kunadian et al. (2008) and showed similar odds ratios to the model developed using 
the ECTC data for the 30-day mortality outcome (2.135, p = 0.013; and 2.388, p = 0.004 
respectively). 
This multivariate analysis has confirmed that certain risk factors for adverse outcomes 
following PCI, such as advanced age, female gender, urgent/emergency priority, 
cerebrovascular disease and pre-procedural cardiogenic shock, have remained useful 
predictors over the last decade, at least in a UK clinical setting. It is also important to note 
that some of these predictors have similar univariate and adjusted multivariate odds 
ratios. In the custom multivariate model constructed from the ECTC cohort, the patient 
age group 60-69 years old became a significant predictor and hence was incorporated 
into the final model. The age group did become a more powerful multivariate predictor in 
the custom prediction model compared to the NWQIP model for in-hospital MACE, i.e. for 
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NWQIP the odds ratios for 70-79 years, and ≥ 80 years was 2.02 and 2.75 respectively 
compared to 5.17 and 11.07 respectively.  
Unlike the NWQIP model, PCI to the left main stem (LMS) lesions or graft lesions were 
not significant predictors for either in-hospital MACE or 30-day mortality, for the former 
outcome Kunadian also did not list these in their multivariate predictor table. It can only be 
speculated as to the reason why these are no longer significant predictors of adverse 
short-term outcomes following PCI, but it could be that interventional cardiologists have 
greater experience in treating LMS disease, due to increasing levels of PCIs being 
performed. It is also possible than an improvement in stenting technology, the usage of 
intravascular medical imaging and embolic protection devices, and more effective 
pharmacological therapy has contributed to a dramatic reduction in risk associated with 
treating LMS and graft lesions. 
The multivariate prediction model for 30-day mortality exhibits very good discrimination 
(ROC = 0.88) and calibration of observed versus predicted outcomes of different risk 
groups (p = 0.67), this performance was confirmed using the internal validation set from 
the ECTC cohort data (ROC = 0.89, p = 0.26). From the five integer score groups (very 
low, low, moderate, high, very high), the internal validation did exhibit relative 
overestimates of 21%, 49%, 48%, 21%, and 17% respectively. However, because the 
frequencies of 30-day mortality are very small relative to the entire dataset size (4119) this 
is likely to occur when classifying patients into multiple risk groups on an outcome that 
occurs at a low rate. The actual frequencies of 30-day mortality in these five groups were: 
23; 28; 38; 72; and 36. Certain characteristics currently not recorded or measured by 
hospitals or cardiac centres may improve the overall calibration, for example, quality of 
life, diet, and exercise. In the future, genetic characteristics may be easily used as risk 
factors, for example identification of genetic differences related to the development 
(speed) of lesions, effectiveness of drugs (aspirin, clopidogrel etc.). 
 
5.4.1 Limitations 
The primary outcome of interest in this study was 30-day all-cause mortality, but both the 
original NWQIP study (Grayson et al, 2006) and the corresponding external validation 
study (Kunadian et al, 2008) did not report this outcome and therefore straightforward 




The rate of in-hospital MACE and 30-day mortality should be low, at any well-established 
PCI centre in the developed world, as such it would have been beneficial to have access 
to a larger sample size of PCIs available for analysis, especially considering certain 
comorbidities such as diabetes mellitus (p = 0.072), renal disease (p < 0.001), and COPD 
(p = 0.071) were identified as good candidates from the univariate association analysis 
with 30-day mortality using a significant threshold of p < 0.1. Researchers in the US in 
particular have been able to take advantage of larger datasets for either development of 
risk prediction models, or external testing. For example, a study by Singh et al. (2008) 
utilised 370,793 CABG procedures for externally validating a PCI mortality prediction 
model. This limitation warrants other PCI centres in the UK, especially to externally 
validate the multivariate model developed in this study. 
Approximately 4% of the PCIs in the ECTC cohort contained missing data for either a 
NWQIP risk factor, custom multivariate model risk factor, or event outcome data (in-
hospital MACE or 30-day mortality) and therefore had to be omitted from analysis. The 
missing data for clinically important risk factors should however become less frequent in 




The final hypothesis (section 1.3) stated that logistic regression analysis could identify 
useful predictors for other important outcomes following PCI. This study proved it to be 
true by the construction of a risk prediction model for 30-day all-cause mortality. It 
identified novel predictors, not incorporated in the NWQIP model (pre-operation ventilation 
and peripheral vascular disease), and also found that graft lesions and LMS lesions were 
not significant predictors and thus could be omitted from a new risk model. The model was 
internally tested using a validation dataset and found to have both stable calibration and 
discrimination. 
In the current era of PCI practice the NWQIP risk prediction model for in-hospital MACE 
continues to provide good discrimination performance, however, this study demonstrated 
that the risk model requires considerable recalibration to render the model useful for 
individual patients. Matheny et al. (2005) also identified improvements in discrimination 
but poor calibration in other published risk prediction models when applied to their cohort 
of PCI patients. In this study the model has been refined by including two novel risk 
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factors, not present in the NWQIP model, most notably pre-procedural ventilation, which is 
clearly extremely important given its strong association with 30-day mortality (odds ratio = 
23.7, p < 0.001). Ventilation prior to a PCI procedure is largely a surrogate marker for out-
of-hospital cardiac arrest, and it is therefore not surprising that critically ill patients have a 
higher probability of an adverse outcome. This study has confirmed the ability of the 
custom multivariate risk model to predict the 30-day mortality outcome in a contemporary 
UK population at a cardiac centre performing a high rate of emergency PCI procedures. It 
is hoped that the proposed multivariate prediction model for 30-day mortality will prove 
useful for comparing performance of operators, cardiac centres, and for clinically 




5.4.3 Future Work 
External validation of the risk prediction model should be conducted using a contemporary 
cohort of patients (i.e. high DES usage era) preferably outside of the South East of 
England to verify the geographic stability of the incorporated risk factors, meaning does it 
generalise to the other geographic locations within the UK. This analysis also identifies the 
importance of including comorbidities in future risk prediction model design, this will be 
more applicable when referral systems improve, meaning such comorbidities are 
diagnosed prior to a patient’s first PCI.  
Additionally, it would be interesting and useful to investigate other important outcomes, 
especially those appropriate for elective (stable) patients. Both the in-hospital MACE 
events and 30-day mortality occurred at very low rates in the ECTC cohort, as shown in 
Table 5.4.2 
Table 5.4.2 – in-hospital MACE and 30-day mortality rates for the ECTC training and 
validation PCI cohorts 
Outcome Overall Elective Emergency 
Training set (n = 9279    
In-hospital MACE 1.4% 0.5% 3.6% 
30-day mortality 2.1% 0.4% 6.1% 
Validation set (n = 4119)    
In-hospital MACE 1.1% 0.1% 2.4% 
30-day mortality 2.0% 0.3% 4.9% 
The outcome rates occur at extremely low rates, especially for elective patients and hence 
would not provide much useful information for these low-risk patients. Identification of 
adverse outcomes which occur at higher frequencies should be investigated. Such 
outcomes may include long-term mortality, i.e. three years instead of 30 days, or the 
likelihood that a patient may require a future coronary revascularisation procedure. Such 
outcomes are useful for predicting the future workload of cardiac centres, and for 
informing patients of likely outcomes, i.e. what is the probability they will require another 




Chapter 6: Three-Year Repeat 
Revascularisation or Death in 






The 30-day mortality study conducted in Chapter 5 analysed the following popular end-
points of interest after PCI. In-hospital complications in the form of major adverse cardiac 
events (MACEs) – a composite outcome of at least one of the following: (i) all-cause 
death; (ii) Q-wave myocardial infarction; (iii) emergency CABG surgery; and (iv) 
cerebrovascular accident. The second outcome was 30-day all-cause mortality, which is 
defined as death within 30 days of a patient’s index PCI procedure. Both of these end-
points are important for both clinicians and patients for justifying whether revascularisation 
by PCI should be performed, and for educating patients on the risk of adverse outcomes 
should they proceed with the PCI procedure. Table 6.1.1 displays the overall rates of in-
hospital MACE and 30-day all-cause mortality were identified in the Chapter 5. 
Table 6.1.1 – In-hospital MACE and 30-day mortality rates for ECTC training and 
validation sets 
Outcome Rate (%) Dataset Total PCIs 
In-hospital MACE 1.4% Training (1/7/07 to 31/12/12) 9279 
30-day mortality 2.1% Training (1/7/07 to 31/12/12) 9279 
In-hospital MACE 1.1% Validation (1/1/13 to 31/1/15) 4119 
30-day mortality 2.0% Validation (1/1/13 to 31/1/15) 4119 
As seen in Table 6.1.1 both the in-hospital MACE and 30-day mortality end-points exhibit 
low rates in both the training and validation sets generated from the ECTC cohort. When 
focussing solely on elective PCI patients the rate of both MACE and 30-day mortality as 
expected is much lower. Table 6.1.2 displays the elective cohort rates for both outcomes 
and datasets. 
Table 6.1.2 – In-hospital MACE and 30-day mortality rates for elective patients 
within the ECTC dataset 
Outcome Rate (%) Dataset Total PCIs 
In-hospital MACE 0.54% Training (1/7/07 to 31/12/12) 4070 
30-day mortality 0.42% Training (1/7/07 to 31/12/12) 4070 
In-hospital MACE 0.06% Validation (1/1/13 to 31/1/15) 1556 






The previous analysis, described in section 6.1.1, investigated the outcomes in-hospital 
MACE and 30-day mortality. Due to both of these outcomes occurring at very low rates 
among patients of elective priority, it is necessary to consider other important outcomes 
which are useful for clinicians and patients but occur at higher rates as this may allow 
better prediction models to be designed for elective patients. 
 
6.1.3 Hypothesis and Objectives 
The hypothesis for this study is that risk factors in the form of comorbidities will be 
identified following via the logistic regression analysis. As described in Chapter 2, certain 
studies (depending on the outcome of interest following PCI) have identified comorbidities 
as risk factors, especially relating to mortality, such as diabetes, COPD, PVD, and renal 
disease etc. Therefore, because death is a component of interest, at least one of these 
comorbidities will be identified as a significant multivariate predictor.  
The main objective of this study was to identify the demographics, clinical, or procedural 
characteristics and hence patient subgroups which are most at risk of experiencing either: 
(i) all-cause death; or (ii) repeat revascularisation. Both of these end-points are within 
three years. This is for a given patient’s first elective PCI procedure at the ECTC. By 
identifying the set of important factors associated with this 3-year end-point it could allow 
a prediction model to be constructed to estimate the approximate risk of a given patient of 
similar characteristics experiencing an adverse outcome within 3 years. The 
characteristics determined to have a significant multivariate relationship with repeat 
revascularisation or death can then be compared to those found in similar studies, most 
notably conducted in the US clinical setting to determine if existing literature is consistent 





6.2.1 Patient Database 
As detailed in section 3.2, the entire ECTC database comprised 15,865 PCI records, and 
also included 3,339 coronary artery bypass graft (CABG) surgery records. The date of 
these interventional procedures was performed ranges from July 2007 to March 2015. A 
number of these records however were excluded from analysis following certain exclusion 




Repeat revascularisation (RR) is defined as any subsequent coronary revascularisation 
procedure on a patient which has had an initial PCI at the ECTC. The subsequent 
revascularisation procedure (if applicable to a given patient) may be in the form of another 
PCI, CABG surgery (alone), or CABG surgery combined with valve surgery (e.g. aortic or 
mitral valves). The three-year event includes any repeat revascularisation within three 
years of the initial PCI, and also includes all-cause mortality.  
A staged procedure is a subsequent revascularisation, most likely to be a PCI whereby 
the procedure itself is planned prior to the execution of an initial PCI. For example, an 
elective patient may have multiple coronary vessels diseased and hence require multiple 
stents to be inserted. Some operators will insert the stents over two PCI procedures rather 
than one. It may be that one vessel requires immediate revascularisation and another can 
be delayed for several weeks when the patient has had time to recover, or the operations 
may be also be split to reduce the radiation dosage administered. Because these staged 
procedures are already known to occur to both the cardiologists and patients the need to 
predict there occurrence is obsolete and hence this is why they are excluded from 
analysis. 
Staged procedures are not consistently labelled in the CVIS database, some are identified 
via a ‘Test Reason’ field, and others are defined in an ‘Indication for Intervention’ field. It is 
known from operator experience that many staged procedures exist but are not defined 
using either of these two data variables. Some of these staged procedures can be 
identified from the discharge letters however a lot of procedures, especially those from 
173 
 
2007 to 2008 did not contain any discharge letters in the CVIS database. Rather than 
having to manually search, load, read potentially thousands of discharge letters (if they at 
all existed) the following criteria was applied to flag up likely staged procedures. A lot of 
the records which are not correctly listed as staged have been labelled as ‘Stable angina’ 
in the test reason and/or indication for intervention fields. If the subsequent PCI was 
classified as both of the following then they were classified as ‘Staged’ in this study. 
(1) Elective Priority 
(2) Interval (in days)s between the initial PCI discharge date and the next PCI waiting list 
date was one week or less then it is an indication of staged. 
In total for the three-year outcome, 60 additional PCI repeat revascularisations were 
flagged as staged procedures using the above criteria that were not labelled as such in 
the test reason or indication for intervention fields. 
 
6.2.3 Inclusion/Exclusion Criteria 
This analysis investigates the repeat revascularisation or death outcomes within three-
years for patients which have had an elective initial PCI only. Patients which have had an 
initial urgent or emergency priority PCI are excluded from analysis. However urgent and 
emergency procedures are included in the subsequent repeat revascularisation 
procedure. As listed in the definitions, staged procedures were not included as repeat 
revascularisation procedures. 
 
6.2.4 Repeat Revascularisation Search Program 
The code which performs the task of analysing the database of PCI and CABG 
procedures for the next repeat revascularisation was written using Visual Basic for 
Applications (VBA), the source code is listed in Appendix C. In summary, the code iterates 
through each PCI record and firstly identifies whether it is a valid record for analysis. If 
valid, it looks for all other PCIs for the same patient (using an anonymised ID unique to 
patient), and determines whether a match is found. If a match is detected then the 
base/index PCI has the repeat revascularisation PCIs details copied to its row for 
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subsequent analysis (i.e. procedure ID, procedure Date, procedure priority, vessels 
attempted etc.). 
The VBA code makes use of a data structure called a ‘Dictionary’, which is an array of 
keys and values. In this scenario each key of the dictionary represents the patient ID, and 
the corresponding value represents the spreadsheet row number in the Excel document 
that the first valid record is stored on. By using this data structure it allows almost 
instantaneous lookup of whether a patient exists, this lookup is performed at a later stage 
of the analysis. Two dictionaries were used, one for PCI procedures and one for CABG 
surgery procedures. 
The following represents tasks performed by the VBA code prior to searching for repeat 
revascularisations. The code has two input parameters which will alter the type of repeat 
revascularisations being searched for. 
Search Type – this can be set to find any ‘repeat revascularisations’ as in this study, or it 
can be limited to only search for subsequent ‘target vessel revascularisations’, the latter 
represents revascularisation procedures that are performed on at least one of the 
coronary vessels treated during the patient’s initial/index PCI at the ECTC. 
Priority Filter – This input parameter controls whether the base/index/initial PCI is (i) 
elective; (ii) all priorities (elective, urgent, or emergency). In this analysis the priority filter 
is set to elective PCIs only, therefore urgent/emergency initial PCIs were excluded from 
analysis. 
The Excel file with the procedure data contains two sheets which represent PCI 
procedures (BCIS) and CABG surgery (SCTS), each sheet has been initially manually 
sorted by (i) Patient ID; and (ii) Date of operation. The sorting resulted in every patient 
having all their PCI procedures clustered together (if they had more than one procedure) 
and ordered by date of their PCIs from earliest to most recent. This sorting was performed 
to make the subsequent processing faster and allowed debugging/verification that the 








Task 1: Iterate through each PCI record in the BCIS (PCI) data sheet, upon a patient’s 
first elective PCI, insert the patient ID (and row number) into the PCI dictionary data 
structure. In total, there were 6,115 unique patients that had at least one elective PCI at 
the ECTC. 
 
Task 2: Iterate through each CABG record in the SCTS data sheet, upon a patient’s first 
CABG procedure, insert the ID (and row number) into the CABG dictionary data structure. 
 
In total, there were 3,335 unique patients that had at least one CABG procedure at the 
ECTC. 
Task 3: Iterate through each unique patient in the PCI dictionary data structure (6,115 in 
total). 
Task 3.1: Exclude the record from analysis if ‘vessel attempted’ for the index/next PCI are 
missing. 
Task 3.2: Start on the next row number (+1) of the patient’s base record, if it is a different 
patient then restart the search on the next patient in the dictionary data structure, as no 
subsequent PCI procedures were found for this patient. 
Task 3.3: If the same patient ID is found, check the PCI is not ‘Staged’. If it is then skip to 
the next patient. 
Task 3.4: For the vessels attempted column (index PCI and next PCI) convert the 
‘LADproximal’ and ‘LADother’ into a single ‘LAD’ vessel. This is because the CVIS 
database represents them as two distinct vessels, yet for analysis they are considered a 
single vessel only. 
Task 3.6: Copy the next (non-staged) PCI details to the index/base elective PCI row. The 
following information is copied across, for subsequent analysis. 
 Operation date 
 Indication for Intervention 
 Test Reason 
 Vessels attempted 
 Priority of the repeat revascularisation PCI 
 Repeat revascularisation PCI procedure ID 
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Once the first repeat revascularisation PCI has been found the VBA code then repeats the 
same sequence of steps for the remaining unique patients in the PCI dictionary data 
structure. 
 
Task 4: This group of tasks are concerned with looking for any intermediate CABG 
surgery procedure which occurs between the index/base elective PCI and the next PCI 
recorded (if such a PCI was found previously). The details of any valid intermediate CABG 
replace the next PCI details. 
 
Task 4.1: Iterate through each unique patient in the CABG dictionary data structure and 
check whether the patient has had a PCI at the ECTC (regardless of the operation date). 
This checks whether the same patient also exists in the PCI dictionary data structure. If no 
match is found, then the code moves on to the next patient in the CABG dictionary data 
structure. If a match is found the next task is performed (4.2). 
Task 4.2: Check whether the base/index PCI has been populated with a repeat 
revascularisation PCI, if no such PCI is found then skip to the next patient in the CABG 
dictionary. If such a PCI is found then the next task is performed (4.3). 
Task 4.3: Iterate through each CABG record for the same unique patient (starting with 
earliest procedure date) and check whether the CABG operation date is between the 
base/index PCI and the date of the repeat revascularisation PCI. If the date is not within 
the range then move on to the next CABG for this patient (if multiple exist) and repeat the 
comparison. If the date is within the range then perform the next task (4.4). 
Task 4.4: Populate the index/base PCI record with the CABG details (i.e. the CABG 
replaces the next revascularisation PCI details). The following CABG procedure data is 
copied across. 
 CABG Procedure Date 
 CABG Procedure ID 
 CABG Priority  
 CABG vessel(s) 




Task 5: This set of tasks is responsible for populating the index/base PCI records which 
have not had a subsequent PCI; or hence been replaced by an intermediate CABG. 
Task 5.1: Iterate through each unique patient in the PCI dictionary data structure and if a 
patient has no repeat revascularisation (PCI or CABG) currently populated then check 
whether the patient has a CABG recorded in the CABG dictionary data structure. If a 
CABG has been found and it occurs after the date of the base/index PCI procedure then 
populate the CABG details into the base/index PCI record. 
 CABG Procedure Date 
 CABG Procedure ID 
 CABG Priority 
 CABG vessel(s) 
 CABG type: (i) CABG alone; (ii) CABG and Valve surgery within the same 
procedure. 
 
6.2.5 Custom Spreadsheet Formulas 
The following formulas were used following the completion of the VBA code execution. 
The formulas listed here calculate useful information for working out which PCIs count as 
a repeat revascularisation and death outcome, or those that require excluding from 
analysis. 
Interval to Revascularisation  
The interval to the repeat revascularisation was calculated as the number of days from the 
index/base elective PCI procedure date to the date of the repeat revascularisation PCI or 
CABG procedure.  
 
=DATEDIF([Index PCI Date], [Repeat Revascularisation Date], “D”) 
Days to Cut-off 
This was calculated in order to censor/exclude patients which had not seen the full time 
period for the outcome. For example, for all patients which did not have a repeat 
revascularisation procedure or die within the three year time period, were excluded if the 
‘Days to cut-off’ exceeded three years. These patients could not be included for analysis 




=DATEDIF(“12/03/15”, [Index PCI Date], “D”) 
Days to Death 
This represented the number of days from the index/base PCI procedure date to the date 
of death (if the patient did indeed die). This was calculated to ascertain whether the 
patient survived the analysis period of three years or not. 






Of the entire 15,865 consecutive PCI procedures performed at the ECTC between July 
2007 and March 2015 there were 3,568 (22.5%) records that remained in the analysis as 
they met the following criteria: (i) elective priority; (ii) determined to be non-staged 
procedures; (iii) the patients' first elective revascularisation procedure at the ECTC; (iv) 
not missing vital details such as vessel attempted; and (v) non censored due to the 
breaking the cut-off period of three years. Figure 6.3.1 shows the number of PCIs 
excluded from analysis and the final number retained. Some of the procedures excluded 
may have been omitted for multiple exclusion criteria; this is why the total figure of the five 
criteria is greater than 12,137. 
 




6.3.1 Three-year Outcomes 
The primary outcome or endpoint of interest was three-year repeat revascularisation or 
death (RRD). Of the 3,568 unique patients that underwent an initial elective PCI at the 
ECTC, there were 522 (14.6%) combined events within three years of the initial elective 
PCI. This figure is broken down into 374 (10.5% overall) repeat revascularisations and 
148 (4.1%) deaths. It should be noted that some of these patients which underwent a 
repeat revascularisation may have also died within the three-year period but the event 
would only be counted as a repeat revascularisation. Figure 6.3.2 displays the breakdown 
of the three-year events by repeat revascularisation type (PCI or CABG), PCI procedure 
priority, and median number of days until the event. The percentages displayed are 
relative to the overall data (i.e. not just the parent node). 
 




The rate at which the RRD events occur by months since the date of the initial PCI is 
shown in Figure 6.3.3. After three years (36 months) the overall rate is at 14.6% (522 
events). 
 
Figure 6.3.3 – Cumulative RRD event rates over three years 
 
The breakdown of the RRD events by each yearly quarter (three month periods) is show 
below in Figure 6.3.4. 
 
Figure 6.3.4 – Breakdown of Time to RRD events by three-month periods 
As shown above the three-month period which shows the highest percentage of RRD 
events is from the fourth to sixth months following the initial elective PCI procedure. The 
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combined total of RRD events within the first nine months is 46.3 % (242 of 522 events). 
The overall rate of RRD within this same time period is 6.8% (252/3,568). 
6.3.2 Univariate Associations with 3-Year RRD 
Table 6.3.1 lists the univariate associations of the three-year repeat revascularisation or 
death (RRD) outcome with the demographic, clinical, and procedural characteristics of 
each of the initial elective PCI included in the ECTC 3,568 valid cohort. The percentage 
values displayed in the table represent the valid percent of non-missing data. The number 
of missing values (if any) is displayed in the final column of the table. 




n = 3046 
(%) 
RRD 






Age Group (years) - - < 0.001  0 
< 50 266 (7.5) 39 (14.7) - Reference  
50-59 664 (18.6) 83 (12.5) 0.378 0.83 (0.55 to 1.25)  
60-69 1227 (34.4) 142 (11.6) 0.163 0.76 (0.52 to 1.11)  
70-79 1095 (30.7) 188 (17.2) 0.326 1.20 (0.83 to 1.75)  
≥ 80  316 (8.9) 70 (22.2) 0.022 1.65 (1.07 to 2.54)  
Gender     1 
Male 2704 (75.8) 403 (14.9)  Reference - 
Female 863 (24.2) 119 (13.8) 0.420 0.91 (0.73 to 1.13) - 
BMI Classification   0.632  1913 
Normal 292 (17.6) 37 (12.7) - Reference  
Overweight 715 (43.2) 109 (15.2) 0.293 1.24 (0.83 to 1.85)  
Obese Class 1 421 (25.4) 58 (13.8) 0.669 1.10 (0.70 to 1.71)  
Obese Class 2 179 (10.8) 20 (11.2) 0.629 0.86 (0.48 to 1.54)  
Obese Class 3 48 (2.9) 7 (14.6) 0.715 1.17 (0.49 to 2.81)  
Smoking Status   0.785  899 
Never Smoked 957 (35.9) 146 (15.3) - Reference  
Ex-Smoker 1364 (51.1) 203 (14.9) 0.804 0.97 (0.77 to 1.22)  
Current Smoker 348 (13.0) 57 (16.4) 0.621 1.08 (0.77 to 1.52)  
Family History of CHD     577 
No 1,398 (46.7) 204 (14.6)  Reference  
Yes 1,593 (53.3) 217 (13.6) 0.447 0.92 (0.75 to 1.1)  
Previous PCI 858 (24.6)    81 
No 2629 (75.4) 372 (14.1)  Reference  
Yes 858 (24.6) 133 (15.5) 0.329 1.11 (0.89 to 1.38)  
Previous CABG     56 
No 3193 (90.9) 440 (13.8)  Reference  
Yes 319 (9.1) 70 (21.9) < 0.001 1.75 (1.32 to 2.33)  
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Previous MI     200 
No 2169 (64.4) 282 (13.0)  Reference  
Yes 1199 (35.4) 212 (17.7) < 0.001 1.43 (1.18 to 1.74)  
Hypertension     137 
No 1286 (37.5) 177 (13.8)  Reference  
Yes 2125 (62.5) 326 (15.2) 0.250 1.12 (0.92 to 1.36)  
Hypercholesterolaemia     137 
No 1258 (36.7) 183 (14.5)  Reference  
Yes 2173 (63.3) 320 (14.7) 0.886 1.01 (0.83 to 1.23)  
Diabetes     111 
No 2800 (81.0) 377 (13.5)  Reference  
Yes 657 (19.0) 122 (18.6) 0.001 1.46 (1.17 to 1.83)  
COPD     137 
No 3308 (96.4) 475 (14.4)  Reference  
Yes 123 (3.6) 28 (22.8) 0.010 1.75 (1.14 to 2.70)  
PVD     137 
No 3280 (95.6) 472 (14.4)  Reference  
Yes 151 (4.4) 31 (20.5) 0.037 1.53 (1.02 to 2.30)  
VHD     137 
No 3384 (98.6) 496 (14.7)  Reference  
Yes 47 (1.4) 7 (14.7) 0.964 1.01 (0.45 to 2.28)  
Cerebrovascular 
disease 
    137 
No 3284 (95.7) 477 (14.5)  Reference  
Yes 147 (4.3) 26 (17.7) 0.289 1.26 (0.81 to 1.95)  
Renal Disease     137 
No 3270 (95.3) 465 (14.2)  Reference  
Yes 161 (4.7) 38 (23.6) 0.001 1.86 (1.27 to 2.71)  
Rotablation     0 
No 3491 (97.8) 500 (14.3)  Reference  
Yes 77 (2.2) 22 (28.6) < 0.001 2.39 (1.44 to 3.95)  
CTO     109 
No 3104 (89.7) 440 (14.2)  Reference  
Yes 355 (10.3) 71 (20.0) 0.003 1.51 (1.14 to 2.00)  
Atorvastatin      0 
No 2804 (78.6) 414 (14.8)  Reference  
Yes 764 (21.4) 108 (14.1) 0.663 0.95 (0.75 to 1.19)  
GP 2b/3a usage     31 
No 3,235 (91.5) 487 (15.1)  Reference  
Yes 302 (8.5) 32 (10.6) 0.036 0.67 (0.46 to 0.98)  
Heparin     491 
No 3,068 (99.7) 440 (14.3)  Reference  
Yes 9 (0.3) 0 (0.0) 0.220 - (N/A)  
Bival usage     491 
No 168 (5.5) 25 (14.9)  Reference  
Yes 2,909 (94.5) 415 (14.3) 0.825 0.95 (0.6 to 1.47)  
Multivessel PCI     74 
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No 2696 (77.2) 382 (14.2)  Reference  
Yes 798 (22.8) 119 (14.9) 0.599 1.06 (0.85 to 1.32)  
Stent Type    < 0.001  113 
None 192 (5.6) 72 (37.5)  Reference  
≥ 1 BMS 1043 (30.2) 175 (16.8) < 0.001 0.33 (0.24 to 0.46)  
DES exclusive 2220 (64.3) 259 (11.7) < 0.001 0.22 (0.16 to 0.30)  
Stent Length (mm)   0.175  0 
< 15 402 (15.1) 43 (10.7) - Reference  
15-19 785 (29.4) 106 (13.5) 0.168 1.30 (0.89 to 1.90)  
20-24 375 (14.0) 60 (16.0) 0.030 1.59 (1.05 to 2.42)  
> 24 1109 (41.5) 142 (12.8) 0.270 1.23 (0.85 to 1.76)  
Stent Diameter (mm)   0.575  0 
2.25 217 (8.1) 20 (9.2) - Reference  
2.50 593 (22.2) 75 (12.6) 0.181 1.43 (0.85 to 2.40)  
2.75 493 (18.5) 70 (14.2) 0.068 1.63 (0.96 to 2.76)  
3.00 772 (28.9) 106 (13.7) 0.080 1.57 (0.95 to 2.59)  
3.50 477 (17.9) 60 (12.6) 0.200 1.42 (0.83 to 2.42)  
4.00 105 (3.9) 17 (16.2) 0.069 1.90 (0.95 to 3.81)  
4.50 8 (0.3) 2 (25) 0.162 3.28 (0.62 to 17.36)  
5.00 6 (0.2) 1 (16.7) 0.545 1.97 (0.22 to 17.70)  
Stent Diameter (mm)     0 
≤ 2.75   1303 (48.8) 165 (12.7)  Reference  
> 2.75 1368 (51.2) 186 (13.6) 0.475 1.09 (0.87 to 1.36)  
Coronary Vessel     0 
Left main 74 (2.1) 17 (23.0) 0.040 1.76 (1.01 to 3.05)  
LCx 949 (26.6) 130 (13.7) 0.343 0.90 (0.72 to 1.11)  
RCA 1222 (34.2) 195 (16.0) 0.105 1.17 (0.96 to 1.42)  
LAD 1877 (52.6) 253 (13.5) 0.040 0.82 (0.68 to 0.92)  
Graft vessel 81 (2.3) 21 (25.9) 0.004 2.08 (1.25 to 3.46)  
 
The characteristics which were identified as having a significant association (p < 0.05) 
with the three-year RRD outcome were: stent type group; glycoprotein inhibitor IIIb/IIa 
usage; rotablator usage; presence of a chronic total occlusion (CTO); renal disease; age 
(≥ 80 years); prior bypass graft surgery (CABG); prior myocardial infarction (MI); diabetes 
mellitus; chronic obstructive pulmonary disease (COPD); peripheral vascular disease 
(PVD); and treatment to the left main stem or a graft vessel.  
Whilst the association was not significant, the body mass index (BMI) classification of the 
'Overweight' group exhibited a higher RRD rate (15.2%) than the highest 'Obese' class 
(14.6%. class 3). However many records were not recorded for height and weight 
therefore the BMI could not be calculated for many procedures. As expected patients that 
were currently smoking had a higher rate of RRD (16.4%) versus the non-smoker 
counterparts (15.3%). 




6.3.3 Stent and Vessel Characteristics 
As shown in Table 6.3.2 the classification of the 3,568 (minus the 113 missing) initial PCI 
procedures by stent type (None used; at least one BMS; DES exclusively) reveals that 
very few procedures occurred without the insertion of a stent (5.6%), almost a third 
(30.2%) involved the insertion of at least one BMS stent, and the majority (64.3%) 
involved exclusive DES usage. As expected the BMS and to a further degree DES seem 
to function as a protective mechanism versus no stent insertion. The drop from the rate for 
no stents (37.5% RRD) to the DES rate (11.7%) is quite large. 
The majority of the initial elective PCIs were single-vessel procedures with this being 
2,973 in total (83.3%). The detailed analysis of these PCIs has been performed in the 
results section 6.3.5. For the multi-vessel procedures, totalling 595 (16.7%), the highest 
overall rate for any combination of vessels treated was only 5.0% (180 PCIs) representing 
almost one third of the multi-vessel PCIs. The vessels representing 5.0% was the LAD 
and LCX arteries. Closely followed were the LAD and RCA vessels for which 145 PCIs 
(4.1%) were performed on this combination. This was followed by the RCA and LCX 
vessels (114 PCIs) for which the rate was 3.2%. 
The stent type group usage across the year of the initial elective PCI procedure is shown 
in Figure 6.3.5, and as expected shows the following: (i) increase across the year of DES 
insertion from 31% in 2007 to 77.5% in 2012; (ii) a general decrease in BMS usage from 
65.5% in 2007 to 18.8% in 2012. The percentage of procedures featuring no stents 




Figure 6.3.5 – Stent usage versus tear of initial elective procedure 
Table 6.3.2 displays the breakdown of stent type against the mean and median (25th and 
75th percentiles) number days to the 3-year RRD. 
Table 6.3.2 – PCI Stent group type versus mean and median days until RRD 
Stent Group Count (%) RRD (%) Mean (SD) Median (25th/75th) 
None 192 (5.6%) 72 (37.5%) 255.4 (301.0) 140 (54.25, 254.25) 
BMS used 1043 (30.2%) 175 (16.8%) 360.9 (290.3) 281 (121, 538) 
DES exclusive 2220 (64.3%) 259 (11.7%) 430.7 (301.4) 370 (168, 665) 
As expected, in addition to a decrease in event rates from the 'no stent' group to the DES 
exclusive group, there is also an increase in both the mean and median number of days to 
the RRD events. For the patients that did not have a stent inserted, of those that 
experienced 3-year RRD, it occurred to half within approximately 4.6 months (140 days), 
and for those that received DES stents exclusively, half of the RRD patients experienced it 




Table 6.3.3 displays the mean stent dimensions for across the cohorts and stent group 
type. This includes the total stent length, minimum stent diameter and longest stent used, 
all measured in millimetres (mm). 
Table 6.3.3 – PCI Stent group type versus total stent length and minimum stent 
diameter 
Characteristic All None BMS DES 
Total Stent Length 
(mm) 
 
All 31.36 (20.63) 27.50(16.16) 26.67 (18.89) 33.60(21.11) 
No-RRD 31.30 (20.58) 29.59(18.58) 26.25 (18.24) 33.54(21.20) 




All 2.88 (0.45) 2.94 (0.67) 3.14 (0.48) 2.76 (0.38) 
No-RRD 2.88 (0.45) 2.86 (0.63) 3.15 (0.48) 2.76 (0.38) 
RRD 2.91 (0.46) 3.06 (0.75) 3.11 (0.50) 2.77 (0.36) 
The dimension values for the 'no stent' group in Table 6.3.3 represent either the intended 
stent dimensions, or if the PCI was a standard balloon angioplasty, then balloon 
dimensions. 
The RRD rate over different years of the initial elective PCI separated by the number of 
native vessels treated is show below in figure 6.3.6. Overall the single-vessel PCIs 




Figure 6.3.6 – RRD rates by year and single/multi-vessel PCI 
6.3.4 Multivariate Predictors of RRD 
The characteristics which exhibited a significant univariate relationship with three-year 
RRD as reported in section 6.3.2 were used candidate variables for entry into the 
multivariate logistic regression model. This was to determine which of reported risk factors 
were still significant when combined with the other significant univariate characteristics 
and after having been controlled for multicollinearity. 
Table 6.3.4 – Multivariate predictors of 3-year repeat revascularisation or death 
(RRD) 
Characteristic Coefficient SE P Value Adjusted OR (95% CI) 
Age ≥ 80 years 0.502 0.16 0.002 1.65 (1.21 to 2.27) 
Prior CABG 0.445 0.16 0.006 1.56 (1.13 to 2.15) 
Prior MI 0.259 0.11 0.017 1.30 (1.05 to 1.60) 
COPD 0.634 0.24 0.007 1.89 (1.19 to 2.99) 
BMS used -1.120 0.19 < 0.001 0.33 (0.23 to 0.47) 
DES used (only) -1.529 0.18 < 0.001 0.22 (0.15 to 0.31) 
Diabetes 0.414 0.12 0.001 1.51 (1.19 to 1.93) 
Intercept -0.797 NA NA NA 
The risk factor with the highest adjusted odds ratio (1.89) was COPD. It is apparent that 
co-morbidities including diabetes and chronic obstructive pulmonary disease (COPD) 
have higher rates of RRD. The type of stent (whether a BMS was used or DES 




The Hosmer-Lemeshow goodness of test (χ2 = 2.622, with 5 degrees of freedom) was 
performed to assess the calibration (match of predicted RRD against actual RRD), this 
was a good fit amongst different risk groups with the p = 0.76, indicating there were no 
significant differences between the observed and estimated groups. The area under the 
ROC curve was 0.65 (95% CI 0.62 to 0.68, SE = 0.015). The value of 0.65 is regarded as 
fairly poor for discriminating between RRD and no RRD, with 0.50 being randomly 
guessing the outcome and 1.0 being a perfect score. This ROC curve is shown in Figure 
6.3.7. 
 




6.3.5 Single-vessel PCI Analysis 
The following analysis was conducted on a subset of the main 3,568 PCI cohort, namely 
that which features the initial PCI to a single vessel only. This was performed to identify 
whether any strong associations exist which were masked, or hidden when multiple 
coronary arteries were investigated in the previous sections. The aim was identify whether 
any particular vessels in isolation are predisposed to the adverse outcome of 3-year 
repeat revascularisation or death (RRD). Another reason for investigating single-vessel 
PCIs was that it is known with certainty which vessel given devices are applied to. For the 
entire cohort of PCIs (3,568) on multiple-vessel PCIs, the data is not available with 
certainty to show which stent is applied to which coronary artery. Obviously, this problem 
does not exist if only a single vessel is being treated. 
There were 2,973 (83.3%) single-vessel PCI procedures amongst the total valid cohort. 
There were 436 (14.7) RRD events. Of the 436 events, 317 (10.7%) of these were repeat 
revascularisations and the remaining 119 (4.0%) died. 
The single-vessel PCIs were defined as planned PCI treatment to a single coronary 
vessel, as broken down into one of the following five categories. 
 right coronary artery (RCA) 
 left circumflex artery (LCX) 
 left anterior descending artery (LAD) 
 left main stem (LMS) 
 graft vessel (from a previous bypass graft surgery) 
Table 6.3.5 lists the breakdown of events by the type of coronary vessel treated in the 
initial elective PCI. The percentage represented by the repeat revascularisation (RR) 
endpoint and death endpoint is relative to the overall event rate. The p value represents 
whether there is a significant difference in RRD rate for whether a specific vessel was 





Table 6.3.5 – Three-Year RRD breakdown by coronary vessel (single-vessel PCIs) 











LAD 1,427 (48.0%) 186 (13.0%) 133 (9.3%) 53 (3.7%) 0.016 0.78 
RCA 904 (30.4%) 149 (16.5%) 112 (12.4%) 37 (4.1%) 0.064 1.23 
LCX 557 (18.7%) 80 (14.4%) 58 (10.4%) 22 (3.9%) 0.823 0.97 
Graft 65 (2.2%) 17 (26.2%) 10 (15.4%) 7 (10.8%) 0.008 2.10 
LMS 20 (0.7%) 4 (20.0%) 4 (20%) 0 (0%) 0.499 1.46 
The most frequently treated coronary vessel was the LAD with almost half of all the single-
vessel PCIs (48%) involving lesions in this vessel. The second most commonly treated 
artery was the RCA (30.4%) followed by the LCX (18.7%), graft vessels (2.2%), and the 
LMS (0.7%) respectively. 
Table 6.3.5 reveals two significant factors relating to the association of coronary vessels 
with the 3-year RRD end-point for single-vessel PCI. Firstly, that if the lesions being 
treated are located in the left anterior descending artery (LAD) it produces a protective 
effect, hence the odds ratio being lower than 1.0, when compared to treatment of any 
other coronary vessel type. Secondly, although the sample size is very small, for 
treatment of lesions in previously grafted vessels, there is a higher risk of RRD, hence the 
odds ratio being 2.1. Whilst treatment to the left main stem shows the highest risk of RRD 
(20%), the sample size is very small, with only four events occurring in the cohort, and is 
not considered statistically significant (p = 0.499). 
Table 6.3.6 shows the RRD rate and the corresponding mean (SD), and median (25th and 
75th percentiles respectively) number of days until the event for each coronary vessel type 
treated. 
Table 6.3.6 – Single-vessel PCI days to RRD versus coronary vessel treated. 








LAD 1,427 (48.0%) 186 (13.0%) 406.9 (306.7) 308.5 152.5, 629.5 
RCA 904 (30.4%) 149 (16.5%) 364.0 (311.0) 238.0 104.5, 634.0 
LCX 557 (18.7%) 80 (14.4%) 406.5 (311.3) 360 140.5, 626.3 
Graft 65 (2.2%) 17 (26.2%) 468.5 (377.4) 427.0 114.5, 885.5 
LMS 20 (0.7%) 4 (20.0%) 270.8 (130.2) 287.5 141.0, 383.8 
Of the five vessel types, the highest median number of days to a repeat revascularisation 
or death outcome within 3-years is graft vessels with 427 days. However, the 25th and 75th 
percentiles for this were 114.5 and 885.5 which shows there is a large difference in time 
for the graft vessel RRD events. The vessel with the lowest median number of days until 
an RRD event was the right coronary artery (RCA). This was 238 days with the 25th and 
75th percentiles being 104.5 and 634 respectively. 
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Of the 317 (10.7%) repeat revascularisation procedures within three years for single-
vessel initial PCIs, Table 6.3.7 lists the initial single-vessel treated and the frequency of 
corresponding repeat revascularisation vessel(s). Those of low frequencies are grouped in 
the 'Other' RR Vessel category. The individual percentage of each vessel(s) in the ‘Other’ 
category is smaller than the percentage of the lowest named vessel. 
Table 6.3.7 – Single-vessel PCI days to RRD versus coronary vessel treated 
 
Target Vessel Revascularisation (TVR) 
Table 6.3.8 displays the repeat revascularisation by vessel type for a single classification 
only. The TVR rates which represent the revascularisation of the initial coronary vessel in 
the repeat revascularisation can be present in multiple categories (e.g. RCA to RCA, RCA 
to LAD and RCA). The rates were as follows in Table 6.3.8. 
Table 6.3.8 – TVR rates by type of coronary vessel treated in the initial PCI 




TVR vessel  
rate (%) 
LAD 84/133 (74.3%) 2.83% 84/1,427 (5.89%) 
RCA 65/112 (58.0%) 2.19% 65/904 (7.19%) 
LCX 30/58 (51.7%) 1.01% 30/557 (5.39%) 
Graft 4/10 (40.0%) 0.13% 4/65 (6.15%) 




6.3.5.1 Stent Characteristics 
Of the 2,973 single-vessel PCIs the breakdown into the stent type group (No stent, BMS 
used, and DES exclusive) is shown in table 6.3.9. Of the 2,973 single-vessel cohort, 96 
PCIs were missing (leaving 2,877) detailed device information on the stent type, so were 
omitted from the following table as it could not be determined if they were under the BMS 
or DES classification. The percentage represented is relative to the non-missing data. 
Table 6.3.9 – Single-vessel PCIs by Stent Type and number of days to an RRD 
event (mean and median) 
Stent Group Count (%) RRD (%) Mean (SD) Median (25th/75th) 
None 181 (6.3%) 67 (37.0%) 240.7 (285.0) 140 (53, 243) 
BMS used 862 (30.0%) 141 (16.4%) 374.7 (291.1) 301 (133, 567) 
DES exclusive 1834 (63.7%) 215 (11.7%) 458.2 (313.9) 392 (175, 714) 
 
As anticipated, the median number of days to a RRD event increases from 140 in the no 
stent group to 392 days in the DES exclusive group. From investigating these rates 
between different stent type groups, it was crucial to ensure that these rates were not 
simply caused by specific vessels being more likely to receive a certain stent type. Tables 
6.3.10 to 6.3.15 display the breakdown of stent type by coronary vessel, RRD events and 
stent dimensions (such as the average minimum stent diameter and average total stent 
length). 
No Stent Group 
Of the valid 2,973 single-vessel PCIs, 6.3% (181) of these procedures did not involve the 
insertion of a stent. This group would include standard balloon angioplasty or procedures 
for which a stent was intending to be used but wasn't inserted. The percentage is relative 
to the overall counts for the group. 
Table 6.3.10 – No Stent PCIs versus coronary vessel 
Vessel Count (%) RRD (%) Mean (SD) Median (25th/75th) 
LAD 67 (37.0%) 26 (38.8%) 257.9 (284.9) 155 (90, 268.8) 
RCA 79 (43.6%) 30 (38.0%) 262.7 (298.5) 140 (51.8, 533.8) 
LCX 31 (17.1%) 10 (32.3%) 144.5 (260.3) 48.5 (40.3, 136.5) 
Graft 3 (1.7%) 0 (0.0%) - - 





Table 6.3.11 –No Stent PCIs versus minimum stent diameter and total stent length 
 
The number of PCIs in the 'No stent' group missing balloon dimension data for the 
coronary vessels was 21, 25, 8, 0, and 1 respectively 
BMS Group 
Table 6.3.12 – BMS PCIs versus coronary vessel 
Vessel Count (%) RRD (%) Mean (SD) Median (25th/75th) 
LAD 346 (40.1%) 51 (14.7%) 402.8 (290.4) 339 (154, 583) 
RCA 307 (35.6%) 51 (16.6%) 333.1 (296.7) 238 (108, 478) 
LCX 172 (20.0%) 26 (15.1%) 421.5 (270.0) 399.5 (178, 614.8) 
Graft 30 (3.5%) 12 (40.0%) 338.9 (331.6) 157.5 (93.8, 698.3) 
LMS 7 (0.8%) 1 (14.3%) 273 (273) 273 (273, 273) 
Table 6.3.13 – BMS PCIs versus minimum stent diameter and total stent length 
Characteristic RRD No RRD P Value 
Total Stent Length 
(mm) 
   
LAD 22.26 (16.96) 21.58 (13.35) 0.749 
RCA 30.80 (24.30) 24.93 (18.86) 0.108 
LCX 19.48 (13.46) 21.76 (12.44) 0.405 
Graft 22.50 (9.53) 27.39 (16.58) 0.365 
LMS 9.00 (-) 11.20 (3.35) 0.581* 
Minimum Stent 
Diameter (mm) 
   
LAD 3.12 (0.42) 3.15 (0.42) 0.652 
RCA 3.20 (0.46) 3.30 (0.47) 0.165 
LCX 2.98 (0.35) 3.13 (0.46) 0.070 
Graft 3.60 (0.85) 3.32 (0.64) 0.304 




The number of missing stent dimensions for the BMS group was 35, 42, 15, 2, and 0 
respectively. 
DES Group 
Table 6.3.14 – DES PCIs versus coronary vessel 
Vessel Count (%) RRD (%) Mean (SD) Median (25th/75th) 
LAD 966 (52.7%) 104 
(10.8%) 
446.7 (309.0) 371 (175, 684) 
RCA 491 (26.8%) 64 (13.0%) 439.5 (313.2) 381.5 (157.3, 717.5) 
LCX 337 (18.4%) 41 (12.2%) 478.5 (320.8) 414 (217, 783.5) 
Graft 30 (1.6%) 5 (16.7%) 779 (310.1) 945 (442.5, 1034) 
LMS 10 (0.5%) 1 (10.0%) 411 (-) 411 (411,411) 
Table 6.3.15 – DES PCIs versus minimum stent diameter and total stent length 
Characteristic RRD No RRD P Value 
Total Stent Length 
(mm) 
   
LAD 30.95 (17.10) 28.71 (16.19) 0.187 
RCA 33.89 (20.36) 37.56 (24.80) 0.267 
LCX 25.46 (11.41) 26.04 (17.94) 0.840 
Graft 27.20 (8.64) 26.84 (13.13) 0.954 
LMS 18.00 (-) 12.89 (4.28) 0.291* 
Minimum Stent 
Diameter (mm) 
   
LAD 2.72 (0.30) 2.77 (0.35) 0.153 
RCA 2.97 (0.42) 2.89 (0.42) 0.172 
LCX 2.70 (0.31) 2.62 (0.30) 0.147 
Graft 3.40 (0.55) 3.06 (0.54) 0.208 
LMS 2.75 (-) 3.58 (0.53) 0.174* 





6.3.5.2 Stenosis Information 
In the available data for this study, information relating to the approximate percentage that 
the lesion occludes a given coronary artery was available. However, this was not 
accessible for graft vessels. This unfortunately was missing from many records because it 
is not a mandatory field. However, an analysis into the data for which stenosis 
percentages was performed. This was also performed to test the hypothesis of whether 
disease severity (% occlusion of the vessel) is highly associated with RRD. 
Table 6.3.16 – PCI procedure stenosis percentages for coronary arteries 
Vessel  Total (%) RRD (%) by 
sub group 
RRD (%) by 
vessel 
LAD (proximal)    
0 to 49% 426 (36.0%) 49 (24.0%) 35.4% 
50 to 74% 125 (17.9%) 16 (12.8%) 11.1% 
75 to 94% 349 (29.8%) 45 (12.9%) 31.2% 
95 to 99% 221 (18.9%) 23 (10.4%) 16.0% 
100% 49 (4.2%) 9 (18.4%) 6.2% 
LAD (other)    
0 to 49% 402 (34.9%) 37 (9.2%) 26.1% 
50 to 74% 124 (10.8%) 20 (16.1%) 14.1% 
75 to 94% 364 (31.6%) 54 (14.8%) 38.0% 
95 to 99% 192 (16.7%) 17 (8.9%) 12.0% 
100% 70 (6.1%) 14 (20.0%) 9.9% 
RCA    
0 to 49% 9 (1.3%) 2 (22.2%) 1.6% 
50 to 74% 29 (3.9%) 5 (17.2%) 4.0% 
75 to 94% 274 (37.2%) 36 (13.1%) 29.0% 
95 to 99% 327 (44.4%) 64 (19.6%) 51.6% 
100% 98 (13.3%) 17 (17.3%) 13.7% 
LCX    
0 to 49% 1 (0.2%) 0 (0.0%) 0% 
50 to 74% 19 (4.0%) 6 (31.6%) 9.0% 
75 to 94% 227 (47.7%) 32 (14.1%) 47.8% 
95 to 99% 196 (41.2%) 21 (10.7%) 31.3% 
100% 33 (6.9%) 8 (24.2%) 11.9% 
LMS    
0 to 49% 2 (13.4%) 1 (25.0%) 25% 
50 to 74% 3 (20.0%) 2 (66.7%) 50% 
75 to 94% 8 (53.3%) 1 (12.5%) 25% 
95 to 99% 2 (13.3%) 0 (0.0%) 0% 





6.3.5.3 Univariate Associations with 3-Year RRD 
An analysis was performed (as with table 6.3.1) on the cohort of single-vessel initial PCIs. 
Whilst not reported here, the list of significant (p < 0.05) characteristics which were 
associated with three-year RRD are displayed in Table 6.3.17 along with the 
corresponding rates, p values, and odds ratios (95% confidence intervals). 
Table 6.3.17 –significant univariate associations with 3-Year RRD 
Characteristic Patients 
(n = 2,973) 
RRD 
(n = 436) 





  < 0.001  0 
< 50 230 (7.7%) 37 (16.1%)  Reference  
50-59 556 (18.7%) 61 (11.0%) 0.050 0.64 (0.41 to 1.00)  
60-69 1,037 (34.9%) 123 (11.9%) 0.082 0.70 (0.47 to 1.05)  
70-79 898 (30.2%) 160 (17.8%) 0.538 1.13 (0.77 to 1.67)  
≥ 80  252 (8.5%) 55 (21.8%) < 0.001 1.46 (0.92 to 2.31)  
Prior CABG 266 (9.1%) 59 (22.2%) < 0.001 1.78 (1.31 to 2.43) 49 
Prior MI 1006 (35.9%) 182 (18.1%) < 0.001 1.50 (1.21 to 1.85) 171 
Diabetes 543 (18.9%) 103 (19.0%) 0.001 1.51 (1.18 to 1.93) 95 
COPD 100 (3.5%) 22 (22.0%) 0.034 1.68 (1.04 to 2.73) 116 
Renal Disease 140 (4.9%) 33 (23.6%) 0.002 1.87 (1.25 to 2.80) 116 
Rotablation 69 (2.3%) 19 (27.5%) 0.002 2.27 (1.32 to 3.88) 0 
CTO 286 (9.9%) 56 (19.6%) 0.017 1.46 (1.07 to 1.97) 90 
LAD vessel 
treated 
1,427 (48.0%) 186 (13.0%) 0.016 0.78 (0.63 to 0.95) 0 
Graft Vessel 
treated 
65 (2.2%) 17 (26.2%) 0.008 2.10 (1.20 to 3.70) 0 
Stent Type    < 0.001  96 
None 181 (6.3%) 67 (37.0%)  Reference  
≥ 1 BMS 862 (30.0%) 141 (16.4%) < 0.001 0.34 (0.23 to 0.47)  
DES exclusive 1,834 (63.7%) 215 (11.7%) < 0.001 0.23 (0.16 to 0.32)  
The single-vessel significant univariate characteristics were similar to those for the entire 
cohort (3,568 initial PCIs including multi-vessel procedures), apart from: the omission of 
treatment to left main stem (LMS) for which the odds ratio and p value were 1.46 and 0.50 
respectively; peripheral vascular disease (PVD) for which the values were 1.28 and 0.320 




6.3.5.4 Multivariate Predictors of 3-Year RRD (Single-Vessel) 
The list characteristics with a significant univariate association (p < 0.05) with 3-Year RRD 
for single-vessel initial PCI procedures were used as candidates for entry into a 
multivariate logistic regression analysis to identify the list of significant multivariate 
predictors, after controlling for multicollinearity. The multivariate predictors are listed below 
in table 6.3.18. 
Table 6.3.18 – Multivariate Predictors of 3-Year RRD for Single-Vessel PCI 
Procedures 
Characteristic Coefficient SE P Value 




Age ≥ 80 years 0.479 0.2 0.008 1.62 (1.14 to 2.30) 2 
Prior CABG 0.412 0.2 0.021 1.51 (1.07 to 2.14) 2 
Prior MI 0.271 0.1 0.022 1.31 (1.04 to 1.66) 1 
COPD 0.597 0.3 0.025 1.82 (1.08 to 3.06) 2 
BMS used -1.112 0.2 < 0.001 0.33 (0.22 to 0.48) 1 
DES used (only) -1.503 0.2 < 0.001 0.22 (0.16 to 0.32) 0 
Diabetes 0.441 0.1 0.001 1.55 (1.19 to 2.03) 2 
Intercept -8.19 NA NA NA NA 
 
The risk factor with highest adjusted odds ratio for the single-vessel PCIs was also COPD. 
The set of multivariate predictors as anticipated was identical to the entire cohort (3,568 
PCIs), the inclusion of multi-vessel PCIs did not 'hide' or mask any potential risk factors 
that were only present for single-vessel prediction of RRD. 
The Hosmer-Lemeshow goodness of fit statistic was χ2 = 2.532 with df = 5, and p = 0.77, 
again indicating a good fit of observed RRD versus estimated RRD across different risk 
groups. The area under the ROC curve was again similar to the entire cohort, with 











6.3.6 BMS and DES Procedures 
The results from the investigation in 6.3.5 reveal that the number of PCIs which did not 
feature the insertion of a stent was low, at 6.3%. A subsequent analysis was performed on 
the single-vessel cohort to investigate the PCIs which featured the insertion of a stent 
(BMS or DES). 
In total, after excluding the ‘no stent’ group, there were 2696 valid PCIs in the remaining 
cohort. The breakdown by type is displayed in Table 6.3.19. 
Table 6.3.19 – PCIs with either a BMS or DES inserted (n=2696) 
Stent Type No RRD (%) RRD (%) Total (%) 
BMS 721 (83.6) 141 (16.4) 862 (32.0) 
DES 1619 (88.3) 215 (11.7) 1834 (68.0) 
The overall rate RRD in for both stent types was 13.2% (356 events). The majority of the 
PCIs (68%) used a drug-eluting stent (DES). The BMS group had the higher rate of RRD 
at 16.4% versus 11.7% in the DES group. The characteristics identified as potential 
candidate variables for multivariate analysis are displayed in Table 6.3.20. 
Table 6.3.20 – Univariate associations of single-vessel PCIs featuring BMS or DES 
insertion, with 3-year RRD 
Characteristic Patients (%) RRD (%) P value Odds Ratio OR 95% CI 
Prior MI 885  148 (16.7%) < 0.001 1.55 1.23 to 1.96 
Prior CABG 238 52 (21.8%) < 0.001 2.01 1.44 to 2.80 
Diabetes 488 91 (18.6%) < 0.001 1.73 1.33 to 2.25 
Renal Disease 120 30 (25.0%) < 0.001 2.30 1.50 to 3.53 
COPD 94 19 (20.2%) 0.042 1.70 1.01 to 2.85 
Rotablator 61 14 (23.0%) 0.023 1.20 1.09 to 3.67 
Age ≥ 80 225 50 (22.2%) < 0.001 2.02 1.44 to 2.83 
Graft treated 60 17 (28.3%) < 0.001 2.68 1.51 to 4.75 
LAD treated 1312 155 (11.8%) 0.038 0.79 0.63 to 0.99 
Age      
< 50 213 30 (14.1) < 0.001 Reference  
50-59 494 47 (9.5) 0.075 0.64 0.39 to 1.05 
60-69 949 98 (10.3) 0.115 0.70 0.45 to 1.09 
70-79 815 131 (16.1) 0.477 1.17 0.76 to 1.79 
>= 80 225 50 (22.2). 0.029 1.74 1.06 to 2.877 
Stent Length      
< 15mm 402 43 (10.7) 0.175 Reference  
15-19mm 785 106 (13.5) 0.168 1.30 0.89 to 1.90 
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20-24mm 375 60 (16.0) 0.030 1.59 1.045 to 2.420 
> 24mm 1109 142 (12.8) 0.270 1.23 0.854 to 1.761 
Stent Diameter      
2.25 217 20 (9.2) 0.575 Reference  
2.50 593 75 (12.6) 0.181 1.43 0.85 to 2.40 
2.75 493 70 (14.2) 0.068 1.63 0.96 to 2.76 
3.00 772 106 (13.7) 0.080 1.57 0.95 to 2.59 
3.50 477 60 (12.6) 0.200 1.42 0.83 to 2.42 
4.00 105 17 (16.2) 0.069 1.90 0.95 to 3.81 
4.50 8 2 (25) 0.162 3.28 0.62 to 17.36 
5.00 6 1 (16.7) 0.545 1.97 0.22 to 17.70 
Stent Diameter      
<= 2.75mm 1303 165 (12.7) 0.475 Reference  
> 2.75mm 1368 186 (13.6)  1.09 0.87 to 1.36 
 
The majority of the candidates exhibiting a significant univariate association with three-
year RRD are the same as those identified in the cohort that included the PCIs with no 
stent. In this analysis however, treatment to the LAD vessel appears to show a lower rate 
of RRD compared to any other vessel treated (i.e. graft, RCA, LCx, LMS). 
The candidates were then used for entry into the multivariate model. The stent type was 
included as a candidate as prior knowledge suggested this was a risk factor (table 6.3.19). 
The variables that remained significant predictors in the final multivariate model are listed 
in Table 6.3.21  
Table 6.3.21 – Multivariate Predictors of 3-Year RRD for Single-Vessel PCI 
Procedures for BMS/DES stent insertion 
Characteristic Coefficient SE P Value 




Age ≥ 80 years 0.561 0.19 0.003 1.75 (1.22 to 2.52) 2 
Prior CABG 0.529 0.19 0.004 1.70 (1.18 to 2.44) 2 
Prior MI 0.312 0.13 0.014 1.37 (1.07 to 1.75) 1 
COPD 0.591 0.27 0.029 1.81 (1.06 to 3.07) 2 
DES used -0.386 0.13 0.002 0.68 (0.53 to 0.87) -1 
Diabetes 0.507 0.14 < 0.001 1.66 (1.26 to 2.19) 1 
Renal Disease 0.472 0.23 0.044 1.60 (1.01 to 3.07) 1 
Intercept -2.026 NA NA NA NA 
The multivariate predictors in Table 6.3.21 are similar to those reported in Table 6.3.18, 




The Hosmer-Lemeshow goodness of fit test was non-significant, χ2 = 1.166, df = 5, and p 
= 0.95, indicating a good fit between observed and estimated 3-year RRD. The calibration 
plot is displayed in Figure 6.3.9. 
 
 
Figure 6.3.9 – Observed versus estimated 3-year RRD for BMS and DES insertion cohort 
Despite a good fit between the observed and estimated rates amongst each group, the 
area under the ROC curve (AUROC) was 0.63 (0.59 to 0.66), indicating a poor ability to 






The primary motivation for this study was to identify which demographic, procedural, or 
clinical characteristics, if any, are highly associated (i.e. statistically significant, p < 0.05) 
with RRD. As documented in Chapter 2 (Literature Review) and identified in the previous 
chapter which investigated 30-day all-cause mortality rates at the ECTC, it has been 
widely established that elective PCI patients (at least any acceptably performing hospital 
or cardiac centre) exhibit low rates of popular outcomes, such as in-hospital major 
adverse cardiac events (MACEs) or mortality, short-term MACE or mortality (i.e. 30 days 
following a procedure). 
This study investigated the rate of the composite endpoint, or outcome of a non-staged 
repeat revascularisation or all-cause mortality (RRD) within three-years of a patient's first 
elective PCI at the Essex Cardiothoracic Centre (ECTC). The repeat revascularisation 
events included any subsequent coronary revascularisation procedure for a given patient, 
whether this is a subsequent PCI or a CABG. 
The overall three-year RRD rate was 14.6% (522 events), as expected the majority of 
these (374) were repeat revascularisations (10.5% overall) and the remaining 148 (4.1%) 
events were deaths. From 2008 (the first full calendar year of procedures at the ECTC) 
onwards, the RRD rate remains similar between single-vessel and multi-vessel initial PCI 
procedures with the largest difference being only 2.9%, occurring in 2012 (single-vessel = 
16.2% and multi-vessel = 13.3% RRD). The majority (81.8%) of the repeat 
revascularisation patients were referred for a PCI in their subsequent procedure resulting 
in only 18.2% undergoing a bypass graft (CABG). Of the 306 patients returning within 
three years for another PCI, most were elective (244, 79.7%) with the remaining 62 
(20.3%) requiring urgent or emergency PCI. Almost half of the events (46.3%) occurred 
within the first nine months following the date of the procedure. 
As expected, the highest rate of RRD is seen in the 'No stent' group with 37.5% of 
patients experiencing RRD, followed by 16.8% in the BMS group, and 11.7% in the DES 
group. These rates were very similar for the single-vessel PCI analysis, at 37.0%, 16.4%, 




6.4.1.1 Univariate Predictors of RRD 
The univariate predictors of RRD which exhibited this highest odds ratios were rotablator 
usage (2.4), treatment to a previously grafted coronary vessel (2.1), renal disease (1.9), 
closely followed by prior CABG, COPD, and LMS treatment with an approximate odds 
ratio of 1.8. The other univariate risk factors were old age (≥ 80 years), diabetes, PVD, 
presence of a CTO, and a prior myocardial infarction. The two characteristics with 
apparent protective effects (i.e. odds ratios below 1.0) were glycoprotein inhibitor usage 
and the BMS/DES stent groups. It should be noted that prior CABG and graft vessel 
treatment are related and therefore would only exhibit univariate associations. T 
multivariate logistic regression process eliminates the multicollinearity from the final 
model. The rate of RRD in PCIs to a previously grafted vessel is high. However, the 
median time to RRD is longer than any other native coronary vessel. None of these 
characteristics are surprising, especially as elderly patients are more likely to have a 
higher chance of dying (one of the two RRD components) as well as having other 
(unrecorded) comorbidities being linked to mortality. The classification of angina, although 
not listed, was analysed, but as anticipated because this cohort were stable, elective 
patients it is not surprising that this would not be identified as a predictor due to unstable 
angina being more associated with urgent patients. 
6.4.1.2 Multivariate Predictors of RRD 
The final set of multivariate predictors, after having controlled for multicollinearity was 
identical for the entire PCI cohort (3,568 procedures) and for the single-vessel cohort 
(2,973). These were in descending order of adjusted odds ratio: COPD (1.9); age ≥ 80 
years (1.7); prior CABG (1.6); diabetes (1.5); prior MI (1.3); and the protective effects were 
BMS (0.33) and DES (0.22) both relative to the 'No stent' group. The single-vessel multi-
vessel predictors exhibited similar values for the corresponding odds ratios. Rotablator 
usage, presence of a CTO, PVD, and renal disease were used as candidates for entry 
into a multivariate analysis as they exhibited a significant univariate relationship with RRD, 
however after controlling for multicollinearity these characteristics were no longer 
significant in the final multivariate model. It could be the case that elderly, diabetic, and 
patients with severe previously documented coronary heart disease exhibit higher rates of 
PVD and renal disease, and similarly those with prior myocardial infarctions and those 
which needed prior bypass grafts also exhibited tougher, more calcified coronary lesions, 
hence having a high multicollinearity. It is also highly likely that CTO or rotablator usage 
was more prominent in the 'No stent' group, such that a stent could not be successfully 
inserted due to a CTO or hard lesions. 
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6.4.1.3 Single-vessel Initial PCI Analysis 
Of the 3,568 initial PCI procedures, 83.3% of these were PCI to either a single native 
coronary vessel or previously grafted coronary vessel. The overall RRD rate was 14.7%, 
broken down into 10.7% repeat revascularisations and 4.0% deaths. These procedures 
were additionally investigated in isolation to determine whether any different significant 
predictors could be identified that was hidden when combined with multi-vessel PCIs. The 
stent group usage (from None, BMS, to DES) was 6.3%, 30.0% and 63.7% respectively 
with the corresponding median days to RRD being 140, 301, and 392 respectively. 
The left anterior descending vessel (LAD) was treated, or at least attempted in 48% of all 
single-vessel PCIs, the next highest rate was the right coronary artery (RCA) which was 
involved in 30.4% of procedures. The treatment of the left main stem (LMS) was not a 
significant univariate risk factor, this is likely to be because of the low sample size (20) 
and the fact the most of the PCIs involving LMS treatment were in the multi-vessel 
procedure cohort. The LAD vessel was involved in 74.3% of the repeat revascularisations, 
closely followed by the RCA in 58%. The RCA showed the lowest median days to RRD 
(238), and the highest as expected was CABG at 427. 
Single-Vessel to Single-vessel Repeat Revascularisation Events 
For procedures featuring a repeat revascularisation to a single vessel, the LAD exhibited 
the highest percentage whereby almost half (45.9%) involved target vessel 
revascularisation of the LAD, however this figure could be high because the proximal and 
other branches are combined within the LAD. 
For most coronary vessels a TVR (same corresponding vessel) was the highest treated 
vessel on the repeat revascularisation as stated above this was 45.9% for the LAD, 38.4% 
for the RCA, and 32.8% for the LCX, therefore there is a higher chance of the same 
vessel needing revascularisation in future than any other vessel when fixing the initial PCI 
to a single vessel only. It is unknown simply whether it is a problem with the stent failing or 
restenosis, such that the conditions which resulted in the specific coronary artery 
becoming stenotic in the first place are simple repeating. 
Stent Type breakdown by Vessel Attempted 
For the 'No stent' group, the vessel with the highest attempted rate was the RCA (43.6%) 
followed by the LAD (37.0%). Interestingly the LCX exhibited the lowest number of median 
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days to a RRD event (49). There were no significant different between any of the balloon 
(or attempted stent, if it indeed failed) dimensions. 
For the PCIs using a BMS stent, the LAD vessel had the highest attempted rate with 
40.1%, closely followed by the RCA (35.6%). Interestingly in this stent group, the LCX had 
the highest median days to repeat revascularisation (400). There were no significant 
differences between any of the stent dimensions for the RRD patients versus the no-RRD 
counterparts. Although not significant (p = 0.07) the mean minimum stent diameter for the 
LCX vessel was larger for the no-RRD group at 3.13mm (SD = 0.46) versus 2.98 mm 
(0.35), thus a very slight increased risk of RRD if a smaller stent diameter is used. The 
logical assumption here would be that the smaller the vessel would become more easily 
occluded. 
The DES cohort (as did the BMS) showed the LAD as the highest vessel attempted rate 
(52.7%) followed by the RCA (26.8%). The lowest median days to RRD was for the LAD 
at 371 days. Also as shown with the BMS group, the DES didn't not have any significant 
differences but the mean minimum stent diameter was higher (2.77mm, SD = 0.35) for the 
no-RRD group versus the RRD group (2.72mm, SD = 0.30), the p value was 0.153.  
Stenosis Percentages for Attempted Vessels 
The treatment of the LAD was identified as a significant univariate predictor of RRD, it 
reported a protective effect (odds ratio 0.78) if this vessel was treated compared to PCIs 
where it was not. A likely reason for this was that, compared to the LCX and RCA arteries, 
the LAD patients were treated for a much lower percentage stenosis in their vessels. For 
example, LCX and RCA had 41.2% and 44.4% of patients with 95-99% stenosis, the LAD 
proximal and other vessels exhibited high rates of 0-49% stenosis, at 36.0% and 34.9% 
respectively. The RCA also exhibited a very high percentage of 100% stenosis (13.3%) 
compared to the LCX (6.9%), LAD proximal (4.2%), and LAD other (6.1%). 
PCIs Including BMS or DES Insertion 
The final analysis within this study excluded the PCIs which did not feature a stent 
insertion (i.e. balloon angioplasty), thus retaining only the BMS and DES procedures. This 
allowed comparisons to be made between the BMS and DES cohort, i.e. to verify whether 
certain predictors reported by others (Wilson et al., 2011; Wang et al., 2012; Taniwaki et 
al., 2014) were useful in predicting three-year RRD in the ECTC cohort. Previously, the 
BMS and DES patients were only compared to the reference variable, ‘no stent group’, 
and not directly with each other. After exclusion of the ‘no stent’ group, an additional risk 
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factor was identified, this being renal disease. The stent diameter and stent length was 
investigated, as existing research reported (Hess et al., 2014) these as predictors for 1-
year target vessel revascularisation (TVR). It was unknown whether this also features as a 
risk factor in the combined outcome of 3-year RRD. Following testing, it was found that 
neither the minimum stent diameter or stent length in the overall BMS and DES cohorts 
were significant predictors of 3-year RRD. The exact reason for this is unknown. It may be 
the case that the significance of the predictor is effectively diluted by the non-TVR PCIs 
for the repeat revascularisation events, because the present study combined the BMS and 
DES cohort, it may be that further investigation into BMS and DES stent dimension 
thresholds, reveals they become significant (e.g. stent type BMS and diameter ≤ 2.75 mm 
versus DES ≤ 2.75), this would have been interesting to investigate had a larger database 
been available. One of the main difficulties in comparing BMS and DES subgroups is that 
the characteristics are changing, and so have the indications as to why each stent was 
used. In modern PCI procedures, a DES will almost always be used. The majority of the 
BMS cohort present was from PCIs performed in earlier years at the ECTC. Therefore 
direct comparisons are problematic. 
The discrimination performance when excluding the ‘no stent’ group was also poor 
(AUROC = 0.63, 0.59 to 0.66). This verifies that the usage of longer-term predictors, such 
as 3-year RRD, are less effective than those identified at the short-term, as identified in 
the 30-day morality prediction model developed in Chapter 5. When the stent type is DES, 
this acts as a ‘protective’ effect relative to BMS, the DES usage is a predictor in the 
multivariate model (OR = 0.68 , p = 0.002), this is consistent with other literature (Wilson 





6.4.2 Other Literature 
Whilst, at the time of conducting this study, no other literature could be found using the 
same endpoint, some similarities were identified in predictors for repeat revascularisation. 
Wu et al. (2004) identified diabetes as a predictor of repeat revascularisation by CABG. 
Their study, however, identified multi-vessel disease as a predictor which, was not found 
to be significant in this study. More interestingly, the total (or 'maximum') stent length (per 
mm longer) was also. Their repeat revascularisation rate was 16.2% compared to 10.5% 
present. Similarly to this study, Wu et al. also identified prior CABG as a predictor 
although their repeat revascularisation outcome for this predictor was limited to PCI only 
(not CABG). When they fixed their outcome to repeat revascularisation by CABG only (i.e. 
excluding PCI) they found that prior CABG and MI were predictors but surprisingly were 
associated with lower outcomes and subsequent risk of CABG.  
In a study by Wang et al. (2012) that focussed on obesity in repeat revascularisation 
within DES PCI patients, they identified hypercholesterolaemia and diabetes as 
multivariate predictors, however their outcome was limited to non-target lesion 
revascularisations, whereas this study identified a rate of target vessel revascularisation 
(TVR) which could be why hypercholesterolaemia was identified as a predictor in this 
cohort. 
In the 4-year study of repeat revascularisation in new-generation DES patients by 
Taniwaki et al. (2014) similar predictors were found. However, their study focussed on 
target lesion revascularisation (TLR) rates amongst different DES stent types. Like this 
study it was found that age, diabetes (insulin-treated however), and although high rates 
were found in this present study but not statistically significant, the treatment of the right 
coronary artery (RCA) was associated with a higher risk of TLR. Interestingly, also 
identified was that treatment to the LAD vessel operates as a protective effect versus 
treatment not involving the LAD. This was identified as a significant univariate predictor, 
offering a similar protective effect (OR = 0.78, p = 0.03), in the ECTC cohort after the ‘no 
stent’ group was excluded, however during the multivariate analysis it was found not to be 
significant. This could be due to other incorporated risk factors having a higher likelihood 
of the LAD being treated relative to other coronary vessels. Treatment to saphenous 
grafts were also identified as a significant predictor however in the available database for 
the present study the breakdown of graft vessel type was not performed. The study by 
Taniwaki et al., in addition to TLR predictors also identified the list of predictors for any 
revascularisation. Younger age was identified as protective (odds ratio 0.98, 95% CI 0.97 
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to 0.99). Diabetes as also found in the ECTC cohort was a predictor (OR = 1.38, 1.08 to 
1.76). Whilst the present study exhibited a non-significant lower minimum stent diameter 
(surrogate for vessel diameter) as having a higher rate of RRD, Taniwaki et al. found that 
a smaller reference vessel diameter was associated with a lower rate (0.76, 0.62 to 0.93). 
It's possible that using the combined outcome of death and repeat revascularisation 
affected this finding and, that if limited to repeat revascularisation only, it may be 
significant.  
6.4.3 Limitations 
Not all of the PCI procedures that were planned, or 'Staged', may have been detected 
during this analysis, and hence some of the 374 (10.5%) repeat revascularisation events 
may have in reality been initially planned by a cardiologist during the time of the patient's 
initial PCI. This possible limitation is due to the PCI procedures not necessarily being 
recorded or identified as such in the CVIS database correctly by operators, or other staff 
following completion of a patient's procedure. If recorded correctly, the information used to 
identify staged procedures can be located in one of four fields within the database: (i) 
'Indication for Intervention'; (ii) 'Test Reason'; (iii) 'Medical Notes'; (iv) discharge letters. 
The adopted solution to detect likely staged procedures not recorded correctly as such, 
was recommended by an experienced interventional cardiologist and CVIS user within the 
ECTC. It was made apparent that all staged procedures would be both elective, and the 
interval in days between the patient's initial PCI discharge and date of entry onto the 
subsequent waiting list would be less than one week. 
As previously discussed in Chapter 6 (The all-cause 30-day mortality study), the cause of 
death for patients was not available, therefore patients that died within three years of their 
initial PCI procedure, may have died from causes completely unrelated to their 
cardiovascular disease. It is therefore not viable to predict whether the initial elective PCI 
had a positive or negative effect on the patient’s survival. 
A minor limitation encountered is that the actual lesion dimensions (i.e. segment length or 
width) are not recorded anywhere in the CVIS database. Only the dimensions of the 
stent(s) and balloon(s) used in the procedure were available, however these act as 
surrogates for the former, and assume that the interventional cardiologists would have 




A possible limitation (although unknown) as that data completeness could be masking out 
comorbidities or diagnosis information. In the earlier years of the ECTC operation detailed 
information is more likely to be missing than compared to modern times. If a field or 
medical history was blank in the past it might not necessarily mean the condition did not 
exist, but simply that is was not known about or tested for. Thus trends in demographic 
and patient characteristics could simply be better explained by data completeness. 
As also previously discussed in the other studies, a limitation exists relating to patients 
that may have relocated outside of the Essex region within the three-year period, and thus 
would have likely undergone a subsequent revascularisation procedure at another cardiac 
centre or hospital, if such a procedure was required. This could also result in mortality 
notifications not being transferred to the CTC. Because of limitations with ethical approval 
and data access, patient primary care records at other hospitals or cardiac centres was 
not available in this study. It is therefore possible that the rates reported in this study are 
underestimated, and this would subsequently impede the performance of risk prediction. It 
may however be argued that given old age (≥ 80 years) is a multivariate risk factor, these 
patients are less likely to relocate than their younger counterparts. 
 
6.4.4 Conclusions 
The final hypothesis in section 1.3 was tested and determined to be true. Certain novel 
risk factors were identified in the construction of the multivariate models for predicting 3-
year RRD. The risk factors, not present in the NWQIP risk model, were: prior CABG; prior 
MI; COPD; BMS or DES insertion; and diabetes mellitus. Additionally, it was discovered 
that as with the 30-day mortality model, treatment to lesions in the LMS or graft vessels, 
were not significant. It might be the case that going forward, these two NWQIP risk factors 
might not be useful predictors of other adverse outcomes either, possibly due to more 
experienced operators knowing how to treat these vessels, than was previously the case 
during the original NWQIP cohort era.  
The discriminatory testing of the multivariate models in this study produced an area under 
the ROC curve considered fairly poor (0.65 and 0.66 respectively), thus limiting the 
usefulness of these predictors in a model that would be accepted elsewhere. Because of 
the composite outcome of repeat revascularisation and death within three years, it is 
anticipated that differing characteristics may limit the predictive accuracy of events, i.e. the 
patient characteristics that experience such events are too different and thus when 
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combined into a single composite outcome the usefulness or accuracy of any one such 
endpoint is diminished. It does however identify certain predictors which allows certain 
subgroups to be given more care and planning to. 
The composite outcome of three-year RRD reported here can be extremely useful for 
interventional cardiologists, care nurses, and patients in terms of planning future 
operations and informed decision making. By knowing the core set of multivariate risk 
factors which exhibit strong relationships with the RRD outcome, it can assist in making 
caring for the most vulnerable patients more efficient, or in simple terms allocate 
resources more effectively. This study also revealed the relationship breakdown between 
stenosis percentage group and RRD rate. The lower rates of RRD seen in procedures 
treating the left anterior descending arteries (proximal or other) can be explained due to 
lower vessel occlusion, or 'stenosis percentage' when compared to other coronary 
arteries, especially the right coronary artery (RCA).  
There may be a cancellation effect occurring relating to the similar RRD rates over the 
years the ECTC has been active. The increase in higher risk elective patients, such as 
those with comorbidities including diabetes, hypertension, hypercholesterolaemia, 
peripheral vascular disease (PVD), and chronic obstructive pulmonary disease (COPD) is 
apparent and would likely increase the risk of both repeat revascularisation and death. 
However, the increased percentage usage of DES stents and corresponding reduction of 
BMS insertion, could act as a preventative measure thus lowering the RRD rates so in 
essence combining these two factors cancels out any differences in the RRD rate over 
time.  
It should be noted that when drawing conclusions from the three-year RRD event reported 
in this study, some patients that underwent a repeat revascularisation may have also died 
following the subsequent procedure but still within the three-year period. Therefore, the 
only event reported in this instance would be the repeat revascularisation procedure. 
 
6.4.5 Future Work 
Other cardiologists at cardiac centres similar to the ECTC could investigate the RRD rates 
in their cohorts in ascertain whether the multivariate predictors as identified in this study 
are also prominent predictors in their cohort of initial elective PCIs. 
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For future investigation into adverse outcomes, including repeat revascularisation and 
long-term mortality, it would be useful to have a framework in place which could track 
patients nationally rather than being limited to a single cardiac centre. This would directly 
address the limitation of patients potentially relocating to a different area and limit the 
chance of event rates being underestimated. 
This study combined PCI procedures regardless of the type of stent embedded, i.e. the 
cohort included procedures featuring (i) standard balloon angioplasty; (ii) bare-metal stent 
(BMS) insertion; (iii) different generations of drug-eluting stent (DES) usage. Due to the 
decreasing percentage of PCIs using BMS, as displayed in this cohort (65.5% in 2007 
falling to 18.8% in 2012), and corresponding increase in DES usage (31% in 2007 rising 
to 77.5% in 2012), it should warrant a prediction model or analysis that looks at DES in 
isolation, or at least separates BMS and DES into different models, the only slight 
negative point would be the complexity of having operators use multiple algorithms to 
estimating risk. It would have been interesting to investigate specific subgroups of DES 
patients, such as those with diabetes, or more specifically, diabetic patients with small 
stent diameters, and whether this subgroup exhibits higher rates versus non diabetic 
patients. Had a larger database of PCIs been available, this would have been 
investigated. As with this study, by utilising a single prediction model that incorporates the 
stent type (none, BMS usage, DES exclusive) it allows all patients to be compared using 
the same risk prediction system. 
It would be beneficial to provide additional training to any staff members, whether this be 
interventional cardiologists, coders, or nurses, to populate patient procedure data into the 
CVIS database. It should be made clear that more complete datasets regarding patient 
demographics, procedural aspects, comorbidities, and other clinical characteristics are 
beneficial for investigating which subgroups of patients are at higher risk of experiencing 
various important clinical outcomes. By not leaving important data fields blank such as 
'Test Reason' or 'Indication for Intervention', it could have perhaps improved upon 
identifying various associations between patients and rates of RRD. As previously 
discussed, identification of whether successive PCI procedures for a given patient were 
staged or not could be addressed rather than having to check in several different 
database fields or manually read thousands of medical notes fields. Clearer labels and 
descriptions could be utilised such “Does this patient need to return for another cardiac 








7.1 Summary of Studies 
The three studies (Chapters 4, 5, and 6) investigated important adverse outcome rates of 
three main endpoints following percutaneous coronary intervention (PCI) at the Essex 
Cardiothoracic Centre (ECTC). In total the number of valid PCIs available for analysis was 
15,865 and these procedures were performed on patients of all priorities (elective, urgent, 
and emergency) between July 2007 and March 2015. 
7.1.1 Main Findings 
From conducting the three studies (Chapters 4, 5, and 6) to meet the thesis objectives 
stated in section 1.5, the following was learned: 
 The NWQIP risk model for predicting in-hospital MACE did not perform as 
effectively as it did in the original study (Grayson et al., 2006), or the external 
validation study (Kunadian et al., 2008), the calibration, which is a measure of 
estimated and observed MACE rates amongst different risk groups exhibited large 
differences and hence the NWQIP model overestimated MACE rates. 
 Treatment to lesions in the LMS or graft vessels is not significant multivariate 
predictors of in-hospital MACE, or 30-day mortality, in the ECTC cohort. 
 The 30-day all-cause mortality rate in the ECTC cohort was 2.1% in the training 
set and 2.0% in the validation set (including all PCI priorities). 
 Multivariate predictors of 30-day mortality in the ECTC cohort were verified using 
an internal validation set. These predictors (odds ratios; and P values) were: ages 
60-69 (3.01; < 0.001); 70-79 (5.17; < 0.001); age ≥ 80 years (11.61; < 0.001); 
female sex (1.57; 0.007); cardiogenic shock (7.31; < 0.001); cerebrovascular 
disease (2.08; 0.013); urgent PCI (2.01; 0.028); emergency PCI (10.23; < 0.001); 
peripheral vascular disease (2.39; 0.004); and pre-operation ventilation (4.97; < 
0.001). 
 The discrimination (AUROC = 0.89, SE = 0.021) and calibration (χ2 = 9.955, p = 
0.27, and df = 8) were verified using the validation set. 
 Some of the 30-day mortality risk factors identified in Chapter 5 have also been 
reported in two recently published risk models for 30-day mortality (McAllister et al, 
2016; Wall et al, 2017), thus verifying their importance as predictors on other 
cohorts within the UK. These were cardiogenic shock, age, PCI priority, and 
cerebrovascular disease (in the McAllister study). 
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 For elective PCI patients, the rate of three-year repeat revascularisation or death 
(RRD) was 14.6% (10.5% were repeat revascularisations and 4.1% were patient 
deaths). 
 Multivariate predictors of 3-year RRD were: age ≥ 80 years (1.65; 0.002); prior 
CABG (1.56; 0.006); prior MI (1.3; 0.017); COPD (1.89; 0.007); BMS insertion 
(0.33; < 0.001); DES exclusive insertion (0.22; < 0.001); and diabetes (1.51; 
0.001). When excluding PCIs that did not use a stent, renal disease was identified 
as a risk factor (OR = 2.29, p < 0.001). When utilising a BMS and DES cohort, the 
stent dimensions (diameter and length) were not significant predictors of 3-year 
RRD.  
 The performance of the 3-year RRD risk model was quite poor in terms of 
discrimination, i.e. the AUROC = 0.65 (SE = 0.015), and the calibration was χ2 = 
2.622 (P = 0.76, df = 5). Therefore suggestion that using such a long endpoint 
(three years) weakens associations of risk factors and that other characteristics 
not currently recorded in the ECTC database may yield better associations with 
the outcome and hence be more useful in a prediction model. Such characteristics 
may include diet, and sedentary lifestyle, or premature cessation of dual anti-
platelet therapies (DAPT). 
 
7.1.2 Hypothesis 
The three hypotheses stated in the Introduction chapter (1.3) in brief were: 
Hypothesis 1: The NWQIP risk model is outdated and will not perform as effectively in a 
modern PCI cohort. 
Hypothesis 2: Not all of the NWQIP risk factors will be significant predictors of in-hospital 
MACE in a modern PCI cohort and hence some would no longer be used in a modern risk 
prediction model. 
Hypothesis 3: Multivariate logistic regression analysis on a modern PCI cohort could 
allow novel risk factors to be identified that have significant associations with adverse 
outcomes following PCI (i.e. in-hospital MACE, mortality, repeat revascularisation). 
These hypotheses were tested in the analysis of each of the three main studies within this 
thesis, and were found to be true, or at least true for the ECTC PCI cohort. Firstly for 
hypothesis 1, it was found in Chapter 4 that the NWQIP model is poorly calibrated and 
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large differences are present between the observed and estimated MACE rates amongst 
different risk groups. For hypothesis 2, it was found that treatment to LMS or graft lesions 
were no longer significant predictors of MACE or 30-day mortality. Lastly, for hypothesis 3, 
two novel risk factors were identified for the outcome of 30-day mortality. These were 
peripheral vascular disease (PVD) and pre-operation ventilation. These two risk factors, in 
addition to several other variables (some of which are present in the NWQIP model) were 





7.2 In-hospital MACE 
In-hospital MACE is a composite endpoint comprising the occurrence of at least one of the 
following: death; Q-wave myocardial infarction; emergency coronary artery bypass graft 
(CABG) surgery; or a cerebrovascular accident (stroke). This composite outcome was 
investigated because it was chosen as the outcome of the UK's first major risk prediction 
model following PCI (Grayson et al, 2006). By investigating this outcome it could be 
determined whether MACE rates had differed over time which also equates to changes in 
intervention technology, by geographical location within the UK (i.e. north-west relative to 
the south-east where the ECTC is located). 
Another reason to externally validate the NWQIP model and the MACE outcome was that 
it had already been externally validated on a PCI cohort a few years after the original 
study (Kunadian et al, 2008), for which this cohort was based in the Midlands (as opposed 
to the north-west of England). They found that the NWQIP risk model performed better for 
predicting MACE in their cohort than it did in the original cohort. The performance metrics 
for these two studies and the analysis using the ECTC cohort are listed below in Table 
7.1.1. 
Table 7.1.1 – summary of NWQIP risk model performance testing across different 
PCI cohorts 
PCI Cohort Patients  Date MACE (%) ROC HL p Value 
NWQIP 
original 9914 01/2001 to 12/2003 
129 
(1.30%) 0.76 0.43 
NWQIP 
validation 1786 01/2004 to 12/2004 N/A 0.72 N/A 
External 




(0.82 to 0.90) 0.95 




(0.79 to 0.96) < 0.01 
 
By revalidating the NWQIP model and the MACE outcome on the ECTC cohort it could 
determine how reliable the model is at estimating MACE rates on a modern cohort despite 
many changes (as mentioned) in technology, demographics, comorbidities etc. The 
discrimination (area under the ROC curve) saw an improvement in both the Kunadian 
(2008) study and in the ECTC cohort. The calibration, i.e. the goodness of fit between 
observed and estimated MACE amongst different risk groups was excellent (p = 0.95) in 
the Kunadian cohort, bearing in mind a p value of 1.0 would indicate a perfect calibration, 
i.e. a 100% match of observed and estimated MACE in every risk group. The calibration in 
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the ECTC cohort however was extremely poor (p < 0.01) indicating there were large 
differences in multiple risk groups. In the eight different risk groups it was found that the 
large differences between observed and estimated MACE were present in the four highest 
risk groups. The exact reason behind this poor calibration could be explained by certain 
NWQIP risk factors such as treatment to left main stem (LMS) lesions or graft lesions no 
longer being such a high-risk during modern PCI procedures. Faster revascularisation, 
especially for emergency patients i.e. those presenting with ST-elevation myocardial 
infarction (STEMI) stemming from more UK PCI centres and operators could mean than in 
modern times critically ill patients have faster door-to-balloon times and whereas 
previously they may have died in the operating theatre (hence the in-hospital death MACE 
component) but now they survive. The study found that in the ECTC cohort, lesions in 
graft vessels no longer exhibited a univariate or hence multivariate relationship with 




7.3 30-Day Mortality 
The outcome of all-cause 30-day mortality following PCI was chosen because the in-
hospital MACE end-point occurs at very low rates in any respectably performing hospital 
or cardiac centre. The rates in the three studies as displayed in Table 7.1.1 were 1.3%, 
2.07%, and 1.46% respectively. This outcome is clearly especially low in stable (elective) 
PCI patients. As reported in Chapter 4, the majority of the MACE events are due to in-
hospital death, for example out of the 193 MACE events identified in the ECTC cohort, 
146 (75.5%) were due to death. Such low rates of the other three MACE components (Q-
wave MI, cerebrovascular accident, and emergency CABG) result in low statistical power 
when performing a univariate analysis with the characteristics in the PCI dataset. Because 
death is such an important component, and is easily recognisable and recorded correctly 
in cardiac centre databases, this outcome was analysed for the second study (Chapter 5). 
The overall in-hospital death rate was 1.11% (146 events from 13,202 PCIs), whilst this is 
an clearly an important outcome, this also occurs at a very low rate. Despite the ability to 
predict in-hospital MACE being useful for operators, consultants, and patients (for 
informed consent of risk), more useful outcomes would be long-term, for example a given 
patient might have a relatively low risk of dying during their hospitalisation, but they may 
have a higher risk of dying three weeks following their discharge. Clearly being able to 
identify longer-term outcomes is of equal importance. As detailed in Chapter 2 
(Theoretical Background), some research has suggested than the 30 day window 
following a PCI procedure is important for assessing recovery from the PCI, i.e. the 
highest risk to those PCI patients comes within the first several weeks of their operation. 
This was largely the justification for the choice of 30-day mortality, and the fact that it is 
robust and easily recognisable. Former ECTC patients which died have their death date 
updated in the PAS database and this is linked to the ECTC CVIS database usually it is 
updated within 30 days. The all-cause mortality outcome had to be used because the 
exact cause of death information was not available or recorded in the CVIS database. 
In Chapter 5 (30-Day Mortality Prediction), a multivariate logistic regression analysis was 
performed to construct a 30-day mortality risk prediction model for PCI patients. The entire 
ECTC cohort of PCIs was divided into a training set, used to develop the risk model, and a 
validation set, used to internally validate the model's performance. The outcomes of 30-
day all-cause mortality and in-hospital MACE are listed in Table 7.1.2 for both the training 




Table 7.1.2 – ECTC training set and validation set outcomes for in-hospital MACE 
and 30-day mortality by priority of PCI 
Outcome Elective (n) Urgent (n) Emergency (n) Total (n) 
Training Set (n = 9279) - - 
  MACE 0.5% (22) 0.6% (15) 3.6% (91) 1.4% (128) 
30-day mortality 0.4% (17) 0.9% (25) 6.1% (155) 2.1% (197) 
     Validation Set (n = 4119) 
    MACE <0.1% (1) 0.9% (10) 2.4% (34) 1.1% (45) 
30-day mortality 0.3% (4) 1.0% (11) 4.9% (69) 2.0% (84) 
 
As expected the rates for both outcomes in elective and urgent patients are very low. It 
can be argued that the MACE (3.6%, 2.4%) and 30-day mortality (6.1%, 4.9%) are still 
very low respectively. The training set performance produced an ROC of 0.88 (0.85 to 
0.91) which suggests very good discrimination, and the Hosmer-Lemeshow goodness of 
fit test produced p = 0.67 indicating little departure of a perfect fit across different risk 
groups for observed versus estimated outcomes. When this prediction model was tested 
on the validation PCI cohort (n = 4119) it produced a similar ROC curve of 0.89 (0.85 to 
0.93) and a goodness of fit of p = 0.26, again both metrics suggest the model performed 
for discrimination and calibration respectively. 
The risk factors in the 30-day mortality risk prediction model incorporated some of those 
present in the NWQIP model for MACE prediction such as age, female sex, cardiogenic 
shock, PCI priority, and cerebrovascular disease however the two novel risk factors were 
pre-operation ventilation, often a surrogate marker of out-of-hospital cardiac arrest, and 
peripheral vascular disease (PVD). 
Comparison with other models 
Since the 30-day mortality model, using the ECTC cohort(Chapter 5), was developed, two 
studies featuring the development of a 30-day mortality logistic regression model have 
been published by other researchers in the UK (McAllister et al, 2016; Wall et al, 2017). It 
is important to consider the similarities and differences between these models and the one 
developed using the ECTC cohort. Following the publication of these studies, it allows 
interesting comparisons to be made within the UK, as previously, the majority of risk score 
models where developed outside of the UK (e.g. United States). The US in particular is 
known to contain differences in population and hence patient characteristics reporting for 
PCI. 
McAllister et al., (2016) utilised a very large database of PCI data for procedures 
performed in the whole of England and Wales from 2007-2011. Scotland and Northern 
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Ireland were excluded due to issues of reliability for 30-day mortality tracking from the 
Office for National Statistics (ONS). In total, their training database featured 336,433 PCI 
procedures. They validated their model using data from 76,804 PCI procedures performed 
in 2012 across England and Wales. The 30-day mortality for training and validation 
cohorts was 1.70% and 2.09% respectively. The increased mortality rate in the validation 
cohort is consistent with increasing proportions of emergency priority PCIs performed over 
recent years. The binary predictors in the final model were: female sex (OR = 1.07 per 
year, 1.07 to 1.08), diabetes (OR = 1.69, 1.56 to 1.83), prior MI (OR=1.17, 1.10 to 1.25), 
cerebrovascular event (OR=1.54, 1.39 to 1.71), cardiogenic shock (OR=45.47, 30.72 to 
67.31). The other predictors were procedure urgency (classified into five groups), age 
(OR=1.07, 1.07 to 1.08), renal disease based on creatinine (OR=2.71, 2.38 to 3.09) and 
dialysis (OR=3.09, 2.56 to 3.73). Two predictors based on age-shock and age-diabetes 
interaction were also incorporated into their regression equation. 
In 2017, Wall et al., developed and validated a model using a cohort of 6522 patients from 
the South Yorkshire Cardiothoracic Centre between January 2007 and September 2013, 
in the north of England. Their model was validated both internally and externally, at 
Manchester Royal Infirmary, using a database of 3290, and 3239 PCIs respectively. The 
external validation cohort comprised PCIs from January 2012 to December 2014. The 30-
day mortality rates were for training, internal validation, and external validation cohorts 
were 2.3%, 2.3%, and 2.0% respectively. Five risk factors were identified in their 
univariate analysis and used their model, the odds ratios and corresponding 95% CIs 
were: cardiogenic shock (OR =20.1, 11.6 to 35.1), emergency PCI (OR=10.5, 5.8 to 19.0), 
history of renal disease (OR=5.0, 2.6 to 9.5), diabetes (OR=1.6, 1.1 to 2.4), and age 
(OR=1.1 per year, 1.0 to 1.1). 
The reported characteristics of the training set for each of the three studies are displayed 




Table 7.1.3 – Characteristics for the ECTC, McAllister, and Wall training cohorts 
used to develop their respective 30-day mortality models 
Characteristic ECTC McAllister (2016) Wall (2017) 
Mean age (SD) 65.4 (11.8) 64.7 (N/A) 62.5 (11.6) 
Male sex 74.9% 74.19% 71.8% 
Cardiogenic shock 2.5% 1.4% 0.9% 
PCI Priority 
   
Elective 44.1% 41.73% 31.9% 
Urgent 29.0% 35.64% 32.0% 
Emergency 26.9% 22.42% 36.1% 
Diabetes 17.4% 17.73% 14.3% 
Prior CABG 7.0% 8.24% N/A 
Prior MI 27.1% 25.2% 27.4% 
Prior PCI 20.1% 20.63% N/A 
Cerebrovascular 
event 
3.9% 3.67% N/A 
History of Renal 
Disease 
12.5% 2.19% 1.6% 
Whilst there is some variation in the date ranges of each training cohort, all of the PCIs 
began in 2007. The latest date was featured in the Wall cohort, ending in 2013. As seen 
from Table 7.1.3, the ECTC cohort featured the highest percentage (2.5%) of patients with 
cardiogenic shock, which is known to be one of, if not, the strongest predictors of adverse 
events (MACE and 30-day mortality) following PCI. There was also a large difference 
between renal disease in the ECTC cohort compared to both external cohorts. This was 
12.5%, 2.19%, 1.6%. The reason for this is unknown. It may be the case that district 
hospitals send renal disease patients to the ECTC for PCI at an earlier stage in the 
patients’ cardiovascular disease than other PCI centres. Hence, the patients may get 
treated as elective whereas other centres treat renal disease patients with emergency PCI 
at a later stage instead. It could also be an issue of data reliability at the ECTC. The 
ECTC cohort had similar rates to the cohort used by McAllister (national England and 
Wales PCIs), and/or Wall across several characteristics, these were: mean age, male 






Each of the three models retains three of the NWQIP risk factors, as predictors, these are 
age, cardiogenic shock, and procedure priority. The presence and strength of cardiogenic 
shock as a major predictor in all models, is no surprise, given that patients exhibiting this 
are considered critically ill. The ECTC and McAllister models also included female sex and 
cerebrovascular events as predictors. The omission of female sex from the Wall model is 
surprising, however because this risk factor exhibits the lowest odds ratios (of any binary 
independent predictor) in the ECTC and McAllister models (1.57 and 1.12 respectively), it 
may be the case that the Wall cohort (based in Sheffield) perform treatment on a higher 
proportion of younger female patients, which could explain the lower association with 30-
day mortality. The univariate odds ratio however, for female sex and 30-day mortality was 
not reported by Wall, so the degree of the relationship with the outcome cannot be 
verified. The female patients in the Wall cohort represented 28.2% of all PCIs, whereas 
this was only 25.1% (ECTC) and 25.8% (McAllister) in the other studies. The omission of 
cerebrovascular events as a predictor in the Wall cohort should also be noted. The reason 
for this not being a risk factor in their cohort is unknown, it may be the case that this 
subgroup are less likely to undergo PCI, and instead be given pharmacological therapy to 
treat their symptoms. All three models were consistent with the omission of two of the 
NWQIP risk factors, these being treatment to graft lesions and to the left main stem 
(LMS). The reason for this, as described in Chapters 4 and 5, may simply be due to 
increasing operators and PCI Centres, or by operators having more experience with these 
vessels. By having an increased number of PCI centres performing primary PCI, it may be 
the case that faster transport to the centres for emergency patients exists now than did 
previously. 
The ECTC model, unlike both the McAllister and Wall models, did not incorporate renal 
disease or diabetes as predictors in the final model. Given the inclusion in both external 
models and some other published literature (external to the UK), it is important to consider 
why they were not present in the ECTC model. A possible explanation is that they 
exhibited high multicollinearity with other predictors in the model, such as age, hence why 
they were dropped. It may also be that their presence in the model did not increase the 
amount of explained statistical variance in the relationship with 30-day mortality, and 
hence include did not increase the discrimination or calibration performance. 
Another possible explanation is that the older PCI records in the ECTC cohort are less 
likely to contain medical history for the patients, especially emergency. The ECTC is a 
tertiary cardiac centre, meaning elective patients are referred there by hospitals in the 
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local county, this means the patients’ medical history (e.g. diabetes and renal disease) 
may not correctly be linked and recorded at the ECTC. This is especially more likely for 
older PCI records. However, given the importance in recent years for submission to the 
national audit body, the data completion and accuracy rates are likely to improve. For 
emergency patients especially, access to their medical history may be limited, especially if 
the patient has never undergone a prior PCI or CABG at the ECTC. This could be a 
possible explanation as diabetes and renal disease information may simply be recorded 
as negative, rather than missing, hence affecting the association with 30-day mortality 
during the regression analysis. 
The two external studies did not report data on peripheral vascular disease (PVD), as this 
was identified as a risk factor in the ECTC model. It is difficult to therefore to consider the 
reasons for its omission without looking at the odds ratios. It may be the case that the 
medical history is not easily obtained either from referral hospitals, or that increasing 
proportions of emergency PCI patients means that detailed history was not available and 
hence was not identified as a significant predictor. Pre-operation ventilation patients were 
excluded from the McAllister study, so comparisons cannot be made to their cohort with 
regards to it being a predictor of 30-day mortality in the ECTC model. 
Performance 
Table 7.1.4 displays the performance metrics for each model, including the area under the 
ROC curve (AUROC), and the Hosmer-Lemeshow (H&L) goodness of fit calibration test. 
These values, unless unavailable (N/A), are listed for both the training and validation 
cohorts used for the ECTC and the two recently published models. 
Table 7.1.4 – Performance metrics for the ECTC, McAllister, and Wall cohorts 
Model Dataset AUROC (95% CI) H&L test 
ECTC 
 
Training 0.88 (0.85 to 0.91) P = 0.67 
validation 0.89 (0.85 to 0.93) P = 0.27 
McAllister et al (2016) 
Training 0.84 (N/A) N/A 
Validation 0.85 (N/A) N/A 
Wall et al (2017) 
 
Training 0.82 (0.79 to 0.85) P = 0.32 
Validation 
(internal) 
0.81 (0.76 to 0.86) P = 0.39 
Validation 
(external) 
0.90 (0.87 to 0.93) P = 0.07 
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The calibration in the model developed by Wall, when applied on an external cohort, was 
p = 0.07, although considered non-significant, this is close to exhibiting large differences 
between observed and predicted 30-day mortality. 
When visually inspecting the calibration plots of observed versus estimated risk for each 
of the three models, they all exhibit a similar characteristic whereby clustering amongst 
the lower several risk groups is seen, i.e. the percentages of both estimated and observed 
30-day mortality, for these groups are very close. Despite the omission of both diabetes 
and renal disease, the ability to discriminate and the fit of observed versus estimated 30-
day mortality remains similar. The similarities in performance despite the differences in 
which risk factors are used, could be due to the fact that the certain risk factors (present in 
all), e.g. cardiogenic shock, PCI priority, and increasing age, carry a strong association 
with the 30-day outcome, and risk factors that are not present in the ECTC (e.g. diabetes 
and renal disease), carry weaker ones that their inclusion does not necessarily increase 
performance by a large amount. 
Future Recommendations 
Clearly all three models can discriminate well between those patients that die within 30 
days of PCI and those which did not, as evident by the range of the AUROC values (0.81 
to 0.90). When each model was validated, whether this is using an internal or external 
cohort, the ability to discriminate well was maintained. The calibration of observed and 
estimated 30-day mortality rates was also verified on their respective validation cohorts. 
As previously mentioned, for the outcome 30-day mortality, across all three of these UK 
models, the lower risk groups are clustered closely together, i.e. there are only small 
percentage differences between for example, a patient in risk 2 and a patient in risk group 
3. This is especially a problem for such models because the frequency of adverse rates in 
these groups is low, and hence overestimation or underestimation during model 
construction is more likely. 
The outcome of 30-day mortality across each model was classified as all-cause, i.e. those 
including both cardiac and non-cardiac death. It may be the case that many patient deaths 
are not related to patient’s cardiovascular disease and hence this would weaken any 
associations for risk factors. In an ideal scenario, it would be beneficial to obtain the cause 
of death for each patient, to determine if it was cardiac related in origin. The multivariate 
regression analysis could then be performed again to yield useful insights for risk factors 
associated with cardiac death in the UK. The risk factors associated with cardiac death 
may exhibit stronger relationships and hence allow patients to be classified into risk 
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groups more appropriately, thus allowing better risk prediction to be achieved. Currently, 
access to the cause of death is not available for analysis, unless the patient experienced a 
complication resulting in death during their index procedure. 
In the future, using ECTC data, it would beneficial to test the performance of both the 
McAllister and Wall models. To verify whether the selection of risk factors identified in their 
models, aid in increasing discrimination or calibration performance. The McAllister model 
was developed using a large database of PCI from across England and Wales, and hence 
could reveal interesting information about how closely the national average PCI 









7.4 Three-Year RRD 
Three-Year Repeat Revascularisation or Death (RRD) is defined as all-cause death or 
any unplanned/non-staged coronary revascularisation, whether this be a PCI or CABG 
within three years of a patient's initial elective PCI at the ECTC. The justification for this 
outcome was that even 30-day mortality following PCI occurs at low rates, i.e. in the 
ECTC training set and validation set these rates were 2.1% and 2.0% respectively. Most 
importantly these rates were very low (as one would expect) in elective patients for which 
the rates were 0.4% and 0.3% respectively. What cardiology consultants, interventional 
operators and patients would be more interested in are the prediction of important 
outcomes following elective PCI procedures, knowing the risk for an emergency patient 
may in most cases be irrelevant for two main reasons (1) the patient is in a critical state 
and cannot effectively make decisions about whether to have the procedure and (2) the 
alternative to a patient not having a PCI make be death 
The end-points of the first two studies (Chapters 4 and 5), whilst important outcomes to 
investigate, are very short-term and do not provide useful information for the elective 
patient's prognosis over longer periods of time. Whilst the 30-day period may be useful for 
identifying whether a patient has recovered from the PCI procedure it says nothing about 
the risks of future adverse events. These factors favoured investigating two other 
important outcomes which were reportedly known to occur at higher rates as described in 
Chapter 2 (Theoretical Background), and anticipated to occur at much higher rates for 
elective patients than simply analysing in-hospital MACE and 30-day mortality. The 
outcomes were combined into a composite end-point that was investigated in the third 
study within this Thesis (Chapter 6, Three-Year Repeat Revascularisation or Death), 
these were the occurrence death or repeat revascularisation within three years. The three 
year time period is useful because it extended the analysis window for mortality from 30 
days and the repeat revascularisation component was important because it allows 
informed consent to patients, i.e. elective patients may opt against going through with a 
PCI if they know there is a high risk of death, or high risk that they might require another 
PCI within three years. This outcome also allows operators, consultants and cardiology 
staff to better allocate their resources to the patients at the highest risk, and also plan 
future workload. By looking at past repeat revascularisation rates it can provide 
expectations of how many patients they would expect to see back at the ECTC for another 
revascularisation procedure. Identifying these end-points with anticipated high rates in the 
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PCI cohort, would allow a higher statistical power and hence strong univariate and 
multivariate association analysis. 
The event rates in the three-year RRD analysis that featured 3,568 valid PCIs are listed 
below in Table 7.1.5. 
Table 7.1.5 – Three-Year RRD outcome rates (n = 3,568) following elective PCI at 
the ECTC 
Outcome Patients (n) Patients (%) 
RRD 522 14.6% 
Repeat 
Revascularisation 374 10.5% 
Death 148 4.1% 
Overall 14.6% (522 patients), almost one elective patient in every seven experienced 
either death or a return to the ECTC for subsequent coronary revascularisation procedure. 
Not surprisingly the majority of the repeat revascularisations (10.5%, 374 patients) were 
subsequent PCI procedures (8.6%, 306 patients). Of these 306 PCIs the majority were 
elective (79.7%, 244), which is important an important point to consider, because the vast 
majority are elective it would suggest that the patient's initial elective PCI could have been 
protective, i.e. if an elective patient had been previously seen by cardiology consultants 
and subsequently underwent elective PCI it would be extremely detrimental if that elective 
patient then went on to have a subsequent myocardial infarction, because treating an 
elective patients cardiovascular disease it clearly the primary aim so they are free from 
such adverse outcomes as future heart attacks. 
It was discovered that when investigating the time-to-event for Three-Year RRD, 57.4% of 
these events occurred within one year following the initial elective PCI. To further break 
down the 12 months, 35% of the events occurred within six months. Investigating the 
differences in events over time was an important consideration from the beginning of this 
study as it can identify whether the typical cessation period of 12 months where patients 
usually stop taking dual-antiplatelet therapy (DAPT) yields any sudden clustering of death 
or repeat revascularisation events, this was identified in this study. 
The multivariate predictors for 3-Year RRD were advanced age (i.e. ≥ 80 years), prior 
CABG, prior MI, COPD and diabetes. Two 'protective' characteristics (i.e. odds ratios 
below 1.0) were incorporated in the model, these being BMS insertion and DES insertion, 
clearly the insertion of DES acts as the biggest protective effect (i.e. lower risk) relative to 
BMS. The BMS characteristic was incorporated because this is relative to either standard 
balloon angioplasty or a failed PCI, such as where the lesions were too calcified to 
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penetrate and hence the coronary vessel was not treated effectively. Both of these factors 
suggest BMS/DES usage in the risk model act as surrogates for failed PCI/balloon 
angioplasty which can be seen as beneficial especially in cardiac databases where failed 
PCIs are difficult to determine. The other factors are not surprising, firstly elderly patients 
are clearly more at risk of dying than their younger counterparts, and also are likely to 
have more frail coronary vessels and weaker hearts. Diabetes and COPD have been 
linked to adverse outcomes and higher rates of death for many years (as identified in 
Chapter 2, theoretical background) so it is not surprising these comorbidities are 
considered significant risk factors. Patients with prior CABGs were found to have higher 
risks of 3-Year RRD, the exact reasoning behind this may be difficult to prove but it is 
hypothesised that CABG patients would have undergone the graft surgery because their 
cardiovascular disease was complex (i.e. multi-vessel, complex lesion characteristics 
such as location within the artery), the CABG may have effectively provided complete 
revascularisation and hence blood flow to the coronary vessel but the patient's lifestyle, 
diet, lack of exercise which predisposed them to cardiovascular disease in the first place 
may not have change since their CABG and hence the reformation of lesions may have 
occurred, or another explanation is that other coronary vessels not treated by the CABG 
have become occluded and they are the causative reason behind the repeat 
revascularisation. 
Prior myocardial infarction was also a risk factor incorporated into the risk model, the likely 
explanation behind this again relates to the patient’s susceptibility to cardiovascular 
disease manifestation, myocardial infarction patients may be more likely to develop 
lesions faster and these lesions may be more complex relative to stable patients. 
The 3-Year RRD risk model developed in Chapter 6 utilised to entire utilised the entire 
ECTC PCI (not counting exclusion criteria) and hence there was only a training set. The 
three-year end-points of mortality and repeat revascularisation would have meant that the 
training and validation sets if both were used, would be very small. Therefore it was 
decided to use the entire available cohort for development of the risk model, and in the 
future test it with subsequent ECTC PCI after a sufficient time period has occurred, 
additionally it would be beneficial for external PCI centres to test the model on their PCI 
cohorts. The discrimination, i.e. area under the ROC curve was 0.65 (0.62 to 0.68) 
indicating a fairly poor performance level especially relative to the NWQIP model for 
MACE (ROC = 0.83) and the 30-day mortality risk model (ROC = 0.88). The model was 
however calibrated well with the Hosmer-Lemeshow goodness of fit test producing p = 
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0.76, indicating an excellent fit of observed versus predicted 3-Year RRD across different 
risk groups. 
The reduction in discriminatory power as described above, relative to the original NWQIP 
model and the 30-day mortality model developed in Chapter 5 could be explained by the 
fact that all the multivariate predictors in the logistic regression model exhibit much lower 
estimated odds ratios and hence regression coefficients compared to the other two 
models for the MACE and 30-day mortality outcomes. Because this model uses a three-
year window and the others use in-hospital and 30-day (respectively) it is likely that time 
weakens these associations and other characteristics either not currently recorded in the 
database, or not easily/economically measured be responsible. One of these 
characteristics is likely to be diet, i.e. cholesterol/fat intake can affect the rate and 
probability of plaque/lesions building up in either the same coronary arteries or other non-
treated coronary arteries. Secondly, lack of exercise and sedentary lifestyle which results 
in a weaker heart as opposed to an athletic individual with a strong heart is an important 
factor to consider. Currently genetic predisposition and DNA sequencing is expensive and 
a very low number of patients would have ever had their DNA analysed, in the future with 
cheaper sequencing technology and more available testing methods it may be the case 
that genetic single nucleotide polymorphisms (SNPs) be identified relating to the formation 
of lesions in coronary vessels, however this is just a hypothesis at this stage, and clearly it 





An important point to consider during the analysis of the ECTC PCI data in all three of the 
studies incorporated in this Thesis was that it was unknown how accurate the recorded 
data is, this is especially important for the end-points, i.e. in-hospital complication data 
fields, and mortality. For example the two factors to consider are: (1) are complications 
(most notably Q-wave MI, and cerebrovascular accidents) accurately recognised by 
hospital staff, and if they are do the staff input into the CVIS database for every patient 
PCI procedure in which they occur; (2) Do the patients which die out-of-hospital all 
correctly get reported in the CVIS/ECTC database, or are the some patients that have 
died (e.g. within three years) that the CVIS database does not know about. These two 
factors could result in an underestimation of actual outcomes and hence mean the risk 
models developed exhibit regression coefficients and odds ratios that have weaker 
associations than they truly should be. It is anticipated that because the UK centres are 
under a homogeneous structure, i.e. the National Health Service (NHS), any such 
limitation in this area would at the very least be consistent across different cardiac centre 
databases and thus would have little overall effect on the risk model if used in another UK 
centre. Given more stringent data completion policies, especially those created by the 
British Cardiovascular Intervention Society (BCIS), it is anticipated that going forward this 
type of limitation would be less of a problem, especially with better staff training and 
diagnosis equipment. 
A limitation related the 30-day mortality and 3-Year RRD risk models is that the death 
outcome component was all-cause, hence not only would this outcome comprise of 
patients that died from a cardiac cause, but could also include patients that died from a 
completely unrelated cause such as a car crash, or non-related disease such as cancer. 
Because tracking patients after they have left hospital is extremely difficult and beyond the 
ethical clearance of this Thesis, cause of death information was not available. Many other 
studies and risk models, not just limited to outcomes following PCI but many other types 
of procedures and surgeries, still use all-cause death. But clearly it would be useful to 
cardiology consultants, PCI operators, and patients to identify the rate of total deaths that 
responsible related to the patient's cardiovascular disease state. High rates of cardiac-
related deaths could indicate a failure in treating the patient effectively, as obviously the 
primary aim of coronary intervention is to reduce mortality and morbidity amongst 
cardiovascular disease patients. If it was found that despite a PCI procedures, patients 
were still dying from their cardiovascular disease this could cause ramifications for 
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nationally funding PCI procedures, i.e. why would the NHS spend money on these 
procedures if it did not make patient's cardiovascular disease state improve. 
Similarly to tracking the patient’s death after they have been discharged from the ECTC, it 
is also not known if the patient relocates to an area outside of Essex that they have 
undergone a subsequent coronary revascularisation (PCI or CABG) at another cardiac 
centre. Because of this a possible underestimation of three-year RRD rates could be 
present.  
Relating to data accuracy, it is also unknown how well certain patients have been 
previously diagnosed for certain comorbidities known to be risk factors of adverse 
complications (e.g. PVD, COPD, diabetes etc.). Patients in the CVIS database which do 
not have anything present for the Medical History data field may not necessarily be free 
from known medical issues, it may just be the case that they have not been diagnosed at 
that current stage, if in the future they are diagnosed with any such comorbidity, the prior 
PCI procedure record is not updated retrospectively, they would only have their medical 
history data field updated with such a comorbidity in future PCI procedures. It is unknown 
how accurately patients are diagnosed and hence the strength of various univariate and 





7.6 Final Conclusions 
The five objectives specified in section 1.5 were completed during the undertaking of the 
three studies. Objective 1 was completed by investigating the outcomes following PCI in 
all three studies. Objective 2 was completed in the Chapter 4 study. Objectives 3 and 4 
were completed in Chapters 4 and 5. Objective 5 was completed in Chapter 6. In 
completing these objectives, all three of the specified hypotheses were tested and 
determined to be true. 
The three research studies within this thesis (Chapters 4, 5, and 6) provide a useful 
insight into important adverse event rates in PCI patients within the south-east of England. 
It was found than changing demographics, stenting technology, and comorbidities in a 
modern era all seem to play a role in the worsening performance of the established 
NWQIP risk model for predicting in-hospital MACE. It was found that NWQIP 
overestimated these adverse outcome rates and the ECTC cohort was no longer at as 
high risk for patients who exhibited the NWQIP risk factors. 
The more robust outcome of 30-day mortality was investigated which previously, to the 
Author's knowledge had not been done, or even reported by Grayson et al. (2006) or 
Kunadian et al. (2008). As previously discussed in Chapter 7.3, two new models were 
published in the UK by other researchers (McAllister et al, 2016; Wall et al, 2017), 
featuring the outcome of 30-day mortality, this allowed findings to be compared between 
the three models. The model developed in Chapter 5 identified two additional risk factors 
(not present in the NWQIP model) that were pre-operation ventilation (a surrogate for out-
of-hospital cardiac arrest), and peripheral vascular disease (PVD), the latter of which was 
also determined to be a predictor by Peterson et al. (2010). This risk model was internally 
validated by a PCI cohort of 4119 patients and was shown to be stable, i.e. produce a 
similar performance to the training set used to construct it. The discrimination and 
calibration performance was similar compared to the other two UK 30-day mortality 
models recently developed. 
It was found that even extending in-hospital death to 30 days following the date of the PCI 
procedure, the rates were still very low relatively speaking, and this was even more 
apparent for elective patients. The findings in this study provided the justification for 
investigating outcomes for elective (low risk) patients that would be useful to operators, 
consultants, and patients, such outcomes were repeat revascularisation or death within 
three years of the patients PCI. Previous studies as detailed in the Theoretical 
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Background (Chapter 2) used either repeat revascularisation or death but they were not 
used as composite outcomes over a period of three years. In addition to these, all of these 
studies were conducted outside of the UK national health care setting and thus the 
findings and rates are questionable when applied to a UK PCI cohort. 
It was found that COPD, diabetes, age, stent insertion (BMS or DES), prior CABG, and 
prior MI were all predictors of 3-Year RRD, and that the majority of these events (57.4%) 
occurred within the first year following a patient's initial elective PCI at the ECTC. The 
discrimination performance however was weaker than that found using the NWQIP model 
(for in-hospital MACE) or the 30-day mortality risk model (Chapter 5). Such weakening of 
associations and hence discrimination performance could suggest that these recorded risk 
factors diminish over time and over characteristics either not currently known or recorded 
come into play and explain the associated variance. Despite this reduction in 
performance, along with the 30-day mortality risk model it would be beneficial to validate 
these for: (1) future PCI patients at the ECTC – to test how stable the model is, and how it 
adapts to trends in comorbidities and stent types; (2) external PCI cohorts to the ECTC 
but still within the UK. If such validation certifies the stability of the risk models as useful 
predictors of their associated outcomes, then the models could further be tested in clinical 
settings external to the UK. Because of the PCI dataset specification (BCIS dataset 5.6.2), 
it is known that UK based cardiac centres will have data fields for all of the risk factors 
within both the 30-day mortality model, and the 3-Year RRD model. So it is not anticipated 
this model would be too complex for any external entity to validate. 
Overall these three studies contribute to the prediction of outcomes following PCI in UK 
cardiac centres. Apart from the two recent studies described, there has been limited, 
published, peer-reviewed studies conducted in a UK setting, and the combination of the 




7.7 Summary of Original Contributions 
At the time of writing this and to the knowledge of the author, the research within this 
thesis provides three main original contributions to the field of adverse outcomes following 
PCI procedures performed in the UK, and more specifically, in the county of Essex. 
This was the first UK study (Chapter 4) to assess the performance of the NWQIP risk 
prediction model (for in-hospital MACE following PCI) in a modern era which features 
many differences as described in Chapter 1, compared to the original NWQIP study era 
(Grayson et al., 2006) and the external validation study era (Kunadian et al., 2008). It was 
found that NWQIP no longer performs as well as it did in its original setting over a decade 
ago. The model overestimates the risk of in-hospital MACE in the ECTC PCI cohort, and 
exhibits prominent differences between the observed and estimated risk amongst different 
risk groups. This suggested that the model should be recalibrated and/or investigation into 
novel risk factors should be performed. It was discovered that treatment to the LMS and 
graft lesions were no longer significant predictors and hence their usage in modern 
prediction models should be reconsidered. 
Secondly, a multivariate prediction model for 30-day mortality (Chapter 5) following PCI 
was developed. Several of the predictors were also present in the NWQIP model (age, 
female sex, cardiogenic shock, cerebrovascular disease, and PCI priority) thereby 
reconfirming their importance as predictors in the modern era. Additionally, peripheral 
vascular disease (PVD) and pre-operation ventilation were identified. The prediction 
model was internally tested using a validation cohort to verify the stable discrimination and 
calibration performance. Comparisons to the recent UK studies were made and similar 
predictors were featured in all models (namely age, cardiogenic shock, and PCI priority). 
The third study within this thesis (Chapter 6) was the first to investigate the outcome of 3-
year repeat revascularisation or death (RRD) in elective patients following PCI in the UK. 
Elective patients have very low rates for short-term adverse outcomes such in-hospital 
MACE and 30-day mortality. Investigation into risk factors for these patients over a longer 
time period was therefore warranted. The multivariate predictors identified were: age, prior 
CABG; prior MI; stent type (BMS/DES); and diabetes. This confirmed that certain 
comorbidities over time, e.g. diabetic patients will have increased risk of adverse events. 
The performance of the model was poor however. It is hypothesised that other 
characteristics not currently available in the PCI database, such as sedentary lifestyle, 
diet, and cessation of dual anti-platelet therapy (DAPT) could enhance risk prediction. 
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7.8 Recommendations for Future 
Research 
Clearly an important point to consider with data analysis studies that have a primary aim 
to identify the strength of relationships between certain characteristics/risk factors and 
adverse outcomes is data completeness. Having high data completeness rates would 
allow a better analysis to be performed and yield more accurate relationships amongst the 
data. It is anticipated that with more effective staff training and data completion policies 
put forward by national bodies (e.g. BCIS) that better data analysis could be undertaken 
on adverse outcomes following PCI in the future. 
With regards the database/dataset available for analysis in these three studies, it would 
be beneficial to make staff more aware of what to input into certain data fields. For 
example when analysis the vessels attempted during the PCIs at the ECTC it was 
discovered that some procedures on lesions inside previously grafted vessels were simply 
listed as 'Graft(s)' in this field, and did not have the name of the coronary vessel that had 
been grafted, this had to be located under a more difficult process of analysing an 'Event' 
data field manually (which was obviously time consuming and not very efficient). Some of 
these PCIs did have the correct graft vessel listed in addition to the 'Graft(s)' value in the 
vessels attempted field. The discrepancy between these two is that they do not mean the 
same, for example, a procedure with PCI to a RCA graft vessel may in one record be 
listed as 'RCA, Graft(s)', but in another simply Graft(s). In addition to this other PCI 
records indicated that the RCA vessel and the graft vessel were separate, i.e. multi-vessel 
PCI, when in reality the graft vessel may have been the left circumflex (LCx) artery. 
Modifications and more efficient and clear PCI procedural characteristics such as graft 
vessel vein type, and the native vessel it was grafted onto could better recorded. Not all 
procedures were correctly marked when they failed, for example, some basics fields 
indicate the number of lesions attempted and number of lesions treated yet when 
manually reviewing the Events data field, it was noticed that some of these PCIs failed 
and it would not be known from looking at the former fields. These instances were 
manually corrected however this was time consuming and obviously not efficient for future 
analysis especially in a digital age. 
Due to the inability to track patients once they were discharged from the ECTC, unless 
they returned to the ECTC for any type of cardiac procedure, the true rates of adverse 
outcomes were difficult to know and hence underestimation of rates could occur. Whilst 
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such a framework may be expensive, in future it would be extremely beneficial to have a 
better patient tracking mechanism in place so that various UK cardiac centres and 
hospitals can follow a patient's future care, i.e. future revascularisations (at different 
cardiac centres), future visits to general practitioners (GPs) for chest pain and other 
indicators of cardiovascular disease. Currently, it is not known how these patients lives 
are affected after their PCI, i.e. are they able to resume activities such as walking, 
running, cycling they the manifested disease previously prohibited them from doing, or 
does the PCI provided not have any effect of their quality of life (QoL), or worst of all does 
make their life worse, i.e. are they confined to their home for the rest of their life. A 
possible solution to tracking their QoL would be for cardiac rehabilitation teams to request 
questionnaires to be completed (e.g. the Short-Form 36 QoL). 
Another interesting line of research for future work would be to distinguish outcomes rates 
between the different generations of drug-eluting stents (i.e. 1st, 2nd, and 3rd generation 
DES) and identify whether the additional costs to the NHS of successive generations is 
justified by any reduction in adverse event rates. In the future further analysis of 
bioabsorbable and biodegradable stents, following the current development of the second 
generation by Abbot Laboratories, if adopted for commercial usage, could then be 
compared to the various DES generations at the ECTC. A small point related to DES PCIs 
especially relevant to the 3-Year RRD study is that despite recommendations being 
provided to patients about taking dual antiplatelet therapy (DAPT) or aspirin alone, the 
exact period of time the patients continue to these pharmacological therapies us unknown 
and may have an effect of 3-Year RRD rates. It was identified that a lot of the 
pharmacological therapy information was stored in a free text 'Patient Notes', perhaps in 
the future a more efficient medicine component could be built into PCI/patient databases 
that tracks all known medicines a patient is taken along with the start/end periods. 
As detailed in the Theoretical Background (Chapter 2) some researchers have focussed 
on developing multiple risk models to better assess strengths of certain relationships. For 
example separate risk models for BMS and DES PCI procedures, or separate risk models 
for different priorities or indications, i.e. one model for stable/elective patients and another 
model for emergency/STEMI patients. This could be beneficial but also has the drawback 
of increased complexity, i.e. operators, audit reports, consultants, and patients would have 
to juggle multiple risk models instead of just one which incorporates these differences as 
risk factors, i.e. single models would typically have emergency PCIs as a predictor, and 
indeed the 3-Year RRD model developed (Chapter 6) uses the stent types (BMS, or DES) 
as 'protective' risk factors. 
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The final point relating to datasets or how the data is recorded is the identification of 
staged PCIs, in the 3-Year RRD analysis especially, staged procedures were not easily 
identified and multiple data fields were interrogated, along with free-text notes fields to 
determine whether a procedure was truly staged. The aim was to identify unplanned/non-
staged procedures so a lot of the records had to be manually assessed by eye for whether 
or not they were staged. A simple data field rather than having to consult four separate 
fields and a discharge letter document would be highly beneficial for future analysis. It is 
unknown how effectively staged procedures are recorded at other UK cardiac centres, but 
there is no reason to believe the ECTC would be any different to them. 
As for future work to be conducted by other research utilising PCI cohort databases 
external to the ECTC, the two risk models developed (Chapter 5, 30-day mortality and 
Chapter 6, 3-Year RRD) should be externally validated to assess how well they perform 
using other patient populations, if such external validation provides a good performance 
for discrimination and calibration this could would indicate that the risk models could be 
adopted for usage at UK PCI centres for predicting such adverse outcomes or at least be 
used as an audit tool for comparing operators or hospitals with each other. The two 
recently published UK models could also be verified on new ECTC PCI procedures to 
assess how stable their discrimination and calibration performance is, and how this 
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Bootstrap Resampling Code 
% [Script: Bootstrap Resampling for ROC AUC value] 
% [Author: L Webster] 
% [Last updated: 20/02/14] 
Clc 
clear 
I = load('bstrap-NWQIPMACE.txt'); 
p = I(:,1); % probabilities 
y = I(:,2); % real 30-day mortality outcome 
n_rows = size(I,1); % get number of rows. 
n_replacement = round(n_rows * 0.7); % no. of picks for each sample 
disp(['Total rows: ' num2str(n_rows) ', replacement: ' num2str(n_replacement)]); 
AUC_samples = []; 
randomz = []; 
for bSample=1:200 % iterate 10 samples (change to 200) 
iSamples = []; 
for i=1:n_replacement 
r = randi([1,n_rows]); 
iSamples(end+1,1) = p(r); 
iSamples(end,2) = y(r); 
end 
[X,Y,T,AUC] = perfcurve(iSamples(:,2), iSamples(:,1),1); 
AUC_samples(end+1) = AUC; 
plot(X,Y); 
hold on 
disp(['Finished generating sample: ' num2str(bSample)]); 
end 






Cardiovascular Database Fields 
This section lists the variables available and subsequently considered for analysis as 
significant risk factors for predicting various outcomes (in-hospital MACE, 30-day 
mortality, repeat revascularisation, and target vessel revascularisation). The exact field 
names have been removed because they are confidential. It should be noted that the 
‘Example Types’ column of a specific variable may not necessarily list all types 
represented in the database. For example, the variable ‘Test Reason’ features 607 unique 
values and therefore many are omitted, and only the most frequently populated values are 
displayed here. ‘D/T’ represents ‘Date and Time’. Some of the fields are calculated, for 
example there is a field ‘History of neurological disease’ which lists specific 
diseases/disorders, and another field ‘History of neurological dysfunction’ which is a 




Appendix B1: PCI Fields from the BCIS Dataset 
Field Example Types/Description/Units 
Sex Male, female, unknown 
Referral source Ambulance, DGH, CTC internal, GP, other, ward 
Test Reason STEMI-acute (possible PPCI), stable angina, chest pain, NSTEMI-
stabilised on medical therapy, ACS, CAD, NSTEMI – on going 
instability, inferior MI, MI, unstable angina, …etc. 
Intended Procedure Left Heart Catheter +/- PCI, PCI standard, Pressure Wire +/- PCI, 
PCI Rotablation, Left Heart Catheter with LV angiogram, …etc. 
Priority Elective in-patient, planned inter-hospital transfer, emergency 
direct admission (PPCI), elective daycase, emergency 
interhospital transfer (PPCI), emergency PPCI admission, Day 
Case, Elective New, …etc.  
Actual Procedure Aortogram, Coronary graft angiography, LV Angiogram, 
percutaneous coronary intervention, coronary angiogram and LV 
study, …etc. 
Operation Date and Time [date and time of procedure] 
Consultant Responsible - 
Primary Operator - 
Primary Operator Status - 
Second Operator - 
Previous MI Yes, No, Unknown, Missing 
Previous CABG Yes, No, Unknown, Missing 
Previous PCI Yes, No, Unknown, Missing 
History: Renal Disease Acute failure (dialysis), chronic failure: 
dialysis/haemodialysis/peritoneal dialysis, missing, unknown, 
normal, GFR 30 to 50 ml/min, transplant, abnormal creatinine 
levels (3) 
LVEF Category Good (>50%), Moderate (30-50%), Poor (<30%), Unknown, 
Missing 
Diabetes Not Diabetic, Type 2 (oral/insulin/diet controlled), Type 1, 
Unknown, Missing, Unknown – data awaited, impaired glucose 
tolerance, newly diagnosed diabetes. 
Medical History Asthma, cerebrovascular event, COPD, Diabetes, 
Hypercholesterolaemia, hypertension, non-coronary cardiac 
surgery, PVD, renal problems, valvular heart disease, unknown, 
missing. 
Cardiogenic shock [pre-procedure] 
LMS stenosis Unknown/missing, 0%, 1-49%, 50-74%, 75-94%, 95-99%, 100% 
LAD proximal stenosis Unknown/missing, 0%, 1-49%, 50-74%, 75-94%, 95-99%, 100% 
LAD other stenosis Unknown/missing, 0%, 1-49%, 50-74%, 75-94%, 95-99%, 100% 
RCA stenosis Unknown/missing, 0%, 1-49%, 50-74%, 75-94%, 95-99%, 100% 
Cx stenosis Unknown/missing, 0%, 1-49%, 50-74%, 75-94%, 95-99%, 100% 
Num. grafts present  
Num. grafts patent  
IRA Flow Grade TIMI 0, TIMI 1, TIMI 2, TIMI 3, missing, unknown 
D/T symptom onset [PCI; ACS only] 
D/T arrival first hospital [ACS only] 
D/T arrival at PCI hospital [ACS only] 
D/T of first balloon 
inflation 
[PCI] 
Clinical syndrome Acute Coronary Syndrome (ACS/AMI), Stable, Unknown, Missing 
Indication for Intervention Stable – angina, ACS – UA/NSTEMI/convalescent STEMI, ACS – 
Primary PCI for AMI (no lysis), Staged procedure, ACS – Rescue 
PCI for AMI, …etc. 
Procedure Urgency Elective, Urgent, Emergency, Salvage, Unknown, Missing 
Arterial access Arterial, Venous, Arterial & Venous, Missing 
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Vessel(s) attempted Graft(s), LADother, LADprox, LCX, LMain, RCA, Missing 
Num. vessels attempted [Not epicardial territories] 
Num. Chronic occlusions [Number of chronic occlusions attempted] 
Num. lesions attempted [Number of lesions attempted] 
Num. lesions successful [Number of lesions successfully treated] 
Largest balloon/stent [Largest balloon/stent used] 
Indication for stent Stent used – elective/sub optimal result/bail out, not applicable, 
stent not used – other/lesion too long/small vessel/side branch or 
bifurcation/danger of losing side branch/tortuous artery  
Left main stem protected Yes, No, Missing 
Num. restenoses  [Number of restonoeses attempted] 
Num. Instent stenoses [Number of instent stenoses attempted] 
Num. stents used  
Num. DES used [Number of Drug-eluting stents used] 
Longest stented/treated [Longest stented/treated segment] 
Procedural complications None, missing, coronary dissection, cardiac arrest/arrythmia – VF, 
…etc. 
Arterial complications None, missing, haemorrhage, arterial dissection, unlised, …etc. 
Post-proc complications None, missing, in-hospital death, access site haematoma, 
unlisted, …etc. 
PCI Hospital Outcome No complications, missing, death, unlisted, arterial complication, 
…etc. 
GP IIb/IIIa drug(s) used Abciximab,tirofiban,eptifibitide,unlisted/missing/none [during 
procedure] 
Date Discharge  
Status at discharge Alive, Dead, missing, unknown 
Drugs Lignocaine, Heparin, Isoket, Verapamil, Diazemuls, …etc. 
Devices [Make and dimensions of balloon/catheter/BMS/DES, and other 
used] 
Presenting ECG (ACS 
only) 
ST elevation/LBBB, T wave changes, Normal Sinus Rhythm, ST 
depression, no acute changes, unknown, other acute changes, 
missing 
Cardiac enzymes/marker [Cardiac Enzymes/Markers Raised: yes/no] 
Angina Status Class [CCS – Canadian Cardiovascular Society classification, pre-proc 
and stable] 
Dyspnoea Status Class [NYHA classification] 
ECG ischaemia On resting ECG, No, Unknown/missing, On nuclear perfusion, 
…etc. 
Discharged To [Hospital DGH], Home, Referring Centre, Carers home, ward, 
surgery, …etc. 
Arterial management LBA, LFA, LFV, LRA, Other, RBA, RFA, RFV, RRA, missing 
Ventilated pre-op [Pre-operation ventilator usage] 
Consultant  
Age at procedure  
D/T Arrival  
D/T Admission  
D/T Waiting list  
Angiogram Yes/No 
Pressure Wire Yes/No 
IVUS  
Unprotected LMS  
Rotablation  
CTO [Chronic total occlusion] 
Graft PCI  
Multivessel PCI  
Primary PCI admission  
Primary PCI procedure  
NWQIP risk score  
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NWQIP risk %  
Epicardial territories [Epicardial territories stented] 
Height  
Weight  
Smoking Status Ex smoker, Unknown, Smokes, Never Smoked, 5-10 per day, 
…etc. 
Family History of CAD Yes, No, Unknown, Missing 
Radiation dose  
Fluoroscopy time  
Contrast Medium Visipaque, ultravist, omnipaque, optiray, omnipaque 350, iomeron, 
(blank) 
Contrast Medium Dose  
Drugs at Procedure Lignocaine, Heparin, Isoket etc. 
Ethnic Group White British, Bangladeshi, Black African, Not known, …etc. 
Post Op Medicine Aspirin, Atorvastatin, Clopidogrel, Ramipril, …etc. 
Drug therapy PreOp  
Why no IIb/IIIa given [during procedure] recent lysis, good result in low risk patient, 
…etc. 
History of Hypertension No history of hypertension, history of hypertension, blank 
Event notes [Balloon, stent inserted, details and location etc.] 
Mechanical ventilation Yes, No, Blank 
Thrombolysis Yes, No, Unknown, Yes - < 1 day, Yes – 1-7 days, Yes > 7 days 
LVEF (Percentage)  
Recent lysis (ACS only) Yes, No, Unknown, Yes - < 1 day, Yes – 1-7 days, Yes > 7 days 
Num. grafts post-op  
Q Wave on ECG Yes, No, Unknown, Blank 
D/T call for help (STEMI)  
Admission route Interhospital transfer, direct to cardiac centre, out patient referral, 
…etc.  
Cholesterol  





Appendix B2: Cardiac Surgery Fields from the SCTS 
Dataset 
Field Example Types/Description/Units 
Test Reason CAD, ACS, IHD, aortic valve disease, breathlessness, 
STEMI, NSTEMI, …etc. 
Priority Emergency (Interhospital transfer/inpatient), elective, 
…etc. 
D/T admission  
Referral Urgent via wards, elective, emergency via 
(wards/ITU/A&E), ..etc.  
Operation Type CABG, CABG + Valve, Valve, blank 
D/T Surgery Start [Two separate fields representing (1) Date, and (2) Time] 
D/T Surgery Finish [Two separate fields representing (1) Date, and (2) Time] 
D/T Leave Theatre [Two separate fields representing (1) Date, and (2) Time] 
Cardiac procedure CABG alone, CABG + valve, CABG + other, CABG + 
valve + other, …etc. 
Sex Male, Female 
History of hypertension Treated/BP > 140/90 on > 1 occasion prior to admission, 
None, Unknown 
Ventilated Pre-Op Yes, No, Blank 
Cardiogenic shock  [Pre-Op] Yes, No, Blank 
Intended procedure CABG, aortic valve replacement and CABG, mitral valve 
replacement, …etc. 
Haemoglobin  






Pre-op cardiac massage Yes, No, Blank 
Pump Yes, No, Blank 
D/T return to ITU  
Oxygenator Avant, Eos, Affinity, ECC.O, RX 15, blank 
Arterial pump Roller, centrifugal, blank 
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Num. previous MIs One, two or more, none, unknown, blank 
D/T last PCI [Date of last PCI performed, includes non-CTC PCIs, i.e. 
pre 2007] 
Interval surgery & last 
MI 
No previous MI, 1-30 days, 31-90 days, 6-24 hours, < 6 
hours, blank 
Diabetes management Not diabetic, oral therapy, insulin, diet 
Smoking status Current smoker, ex smoker, never smoked, blank 
[H] neuro dysfunction [History of neurological dysfunction] Yes, No, blank 
[H] neuro disease None, TIA/RIND, CVA full recovery, Parkinson’s, 
multiple sclerosis, …etc. 
D/T last catheterisation  
Pre-op heart rhythm Sinus rhythm, atrial fibrillation, ventricular 
fibrillation/tachycardia, …etc. 
Status at discharge Alive, Died in cardiac unit/ward/theatre 
Discharge destination Home, same hospital (other spec.), other hospital, 
convalescence, blank 
D/T discharge/death [Combined field of either discharge date of date of death 
in hospital] 
Graft site “RCA-PDA, OM1, Mid LAD”, “Mid LAD”, “Mid LAD, 
OM1, RCA-PDA”, …etc. 
Euroscore additative 0-20, blank 
Euroscore logistic 0-100%, blank 
Cardiopulmonary 
bypass 
Yes, No, Blank 




Operative urgency Elective, Urgent, Salvage, Emergency, Blank 
D/T Anaesthetic  




LVEF percentage  
Carotid Bruits Yes, No, blank 
Angina Status pre-op [Canadian Cardiovascular Society classification] 
Dyspnoea status pre-op [NYHA classification] 
Renal disease (surgery) None, CKD stage 3, creatinine > 200 micro mol/l, 
unknown, …etc. 
Pulmonary disease None, COAD/emphysema, asthma, long term 
bronchodilator, …etc. 
Primary incision Median/right sternotomy, left/right thoracotomy 
D/T Procedure  
Sub procedure name CABG, aortic valve replacement and CABG, mitral valve 
repair, …etc. 
Theatre bloods 1-13, blank 
Theatre FPP 1-9, blank 
Theatre platelets 1-7, blank 
OIR ITU bloods 1-33, blank 
ITU FPP bloods 1-19, blank 
ITU platelets bloods 1-14, blank 
L/R heart catheterisation This admission, previous admission, No, blank 
PA systolic  30-85, blank 
Creatinine (pre-op) 18-1320, blank 
Multisystem failure Yes, no, Blank 
Other risk factors No, until operation, within one week of operation, blank 
Extent of vessel disease 2 vessels > 50% stenosis, 3 vessels > 50% stenosis, 1 
vessel > 50%, …etc. 
LMS Disease Not investigated, LMS > 50% stenosis, no LMS or LMS < 
50% stenosis 
Claudication Yes, No, blank 





Yes, No, blank 
Active endocarditis Yes, No, blank 
Creatinine  
IV nitrates/heparin Until operation, No, blank, within one week of operation 
IV inotropes prior 
anaes. 
No, Yes, Blank, 
Any Complications Recovery without post op complication, complications 
occurred, blank 
D/T Discharge Surgery  
No CABG  
D/T Death  
Other cardiac 
procedures 
Other not listed, no other, blank, …etc. 
Infection complications None, chest infection, superficial sternal wound infection, 
…etc. 
Other vascular complic. [complications] None, deep venous thrombosis, other, 
…etc. 
Aorta details Blank, asc. Aneurysm interposition tube graft, …etc. 
Valve details [Uniques] aortic stenosis replace mechanical, …etc. 
Other Thor. Vasc. 
Procs. 
[thoracic vascular procedures] None, aortic or peripheral 
vascular, …etc. 
GI tract None, other, hepatic failure, jaundice, prolonged ileus, 
…etc. 




No, blank, pre-operation, intra-operation 
Reason for ^ IAB pump Unstable angina, haemodynamic instability 
Category CTC inpatient, CTC out patient, DGH, DGH outpatient, 
ECTC surgery, …etc. 
Graft conduit Long SV, free LIMA, pedicle LIMA, …etc. 
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Bypass Time  
Mitral Aortic Aortic, Mitral, Both, Neither 
Length of Stay (LOS)  
Waiting Days  
Waiting Working Days  
Time in minutes (ward)  
Appendix B3: Myocardial Infarction Fields from the 
MINAP Dataset 
Field Example Types/Description/Units 
Gender Male, Female, Unknown 
Ethnic Group White British, White, Not Known, Black African, 
Pakistani, …etc. 
Pickup Postcode  
D/T Test  
Smoking Status Current smoker, never smoked, ex smoker, unknown, non 
smoker ?, …etc. 
Diabetes Diabetes (dietary/insulin/oral medicine), not diabetic, 
insulin + oral, …etc. 
D/T symptom onset  
D/T call for help  
D/T arrival 1
st
 responder  
Serum gluclose [Get measurement from John/Stewart] 
D/T arrival ambulance  
D/T arrival hospital  
Statin use Yes, No, Unknown, Blank 
Ejection Fraction % 0-100, -1 
Cardiac enzymes raised Yes, No, Unknown, Blank. 
Place 1
st




D/T reperfusion treat. [treatment] 
Delay before treatment No, awaiting cath lab team, cath lab compromised, 
unexplained delay, other, cardiac arrest, ambulance 
procedural delay, …etc. 
Cardiac rehabilitation Yes, No, Not indicated, unknown, patient declined 
Smoking cessation 
advice 
Yes, no, unknown, planned in rehab, not applicable 
Dietary advice given Yes, no, unknown, planned in rehab, not applicable 
D/T Procedure  
Source Paramedic ambulance, IHT A&E (DGH), CTC clinic, IHT 
ward (DGH) 
Cardiac arrest location A&E, no arrest, CCU, cath lab, ward, elsewhere hospital, 
after arrival, …etc. 
Intervention Not performed, angioplasty, CABG, planned after 
discharge, blank, …etc. 
D/T discharge  
D/T arrival non 
intervent. 
[interventional hospital] 
Death in hospital Blank, unknown, from MI, other cardiac/non-cardiac, 
…etc. 
Initial diagnosis ACS, definite MI, other initial diagnosis, chest pain, blank 




Not given, unknown, out of hospital, after arrival in 
hospital, already on drug, contraindicated  
Peak troponin  
Discharged Beta blocker Yes, no, not indicated, unknown, …etc. 
ACE inhibitor or ARB Yes, no, not indicated, unknown, …etc. 
Discharged on statin Yes, no, not indicated, unknown, …etc. 
Discharged ACE/ARB Yes, no, not indicated, unknown, …etc. 




Initial reperfusion treat. [treatment] Primary PCTA, reperfusion not attempted, 
…etc. 
Discharge diagnosis MI (ST-e), ACS/NSTEMI, PCI related MI, MI 
(unconfirmed), …etc. 
Presentation comments [Unique details on case presentation] 
Ambulance trust East of England, East Midlands, London ambulance, north 
west, blank 
Angio performed Blank, N/A, other, patient died, diagnosis not ACS, …etc. 
Coronary angiography N/A, blank, not performed, symptom driven this hospital, 
…etc. 
Bleeding complications None, unknown, intracranial bleed, …etc. 
Outcome of interest Blank, unknown, discharged (no neurologic deficit), 
another hospital, …etc. 






Appendix C: Excel VBA 
Reintervention Code 
The following code was developed to identify the repeat revascularisation and target 
vessel revascularisation index PCI records, and there subsequent valid procedure. The 
main purpose of this code is to identify the revascularisation procedure (PCI or CABG) 
and obtain the procedure ID number and date so that subsequent analysis can be 
performed. 
Private Sub findRevascularisations(SEARCHTYPE As Integer, PRIORITY_FILTER 
As String) 
' Main procedure to search for RR/TVR procedures (PCIs or CABGs) 
' SEARCHTYPE 0 = RR (any) 
' SEARCHTYPE 1 = TVR (only) 
' PRIORITY_FILTER = text to filter if we want to ignore records 
' ...added handling of PCI to Graft vessels. 
' Last updated: 02/11/15 
 
Dim numRowsBCIS, numRowsSCTS, i, j, numFound As Integer 
Dim dictPCI As Dictionary ' hold PCI IDs/row numbers 
Dim dictCABG As Dictionary ' hold CABG SCTS IDs/row numbers 
Dim startTimer As Double 
Dim xxxx As String 
 
Dim secondsElapsed As Double 
Dim str_VesselAttempted As String 
Dim str_NextVesselsAttempted As String 
Dim date_operation, date_operation_nested, date_operation_scts, 
date_waiting_nested As Date 
Dim str_BasePriority, str_graftsite, str_LPI_bcis, str_lpi_bcis_nested, 
str_previousLPI, str_SurgeryType, str_NextTestReason, 
str_NextStagedLookup, strTVRcheck As String 
Dim col_NextRevascDate, col_NextProcID, col_NextRevascType, 
col_NextPriority, col_Interval2Revasc, col_Interval2Death As Integer 
Dim col_scts_graftsite, col_stagedNext, col_LPI_bcis, col_PROCID_bcis, 
col_LPI_scts, col_PROCIID_scts, col_Date_bcis, col_Date_scts, 
col_NextDate, col_Staged, col_SurgeryType, col_VesselAttempted, 
col_priority_bcis, col_priority_scts, col_waitingdate, 
col_NextTestReason, col_priorRevasc, col_StagedLookup As Integer 
Dim str_BaseGraftVessels As String 
Dim str_NextGraftVessels As String 
Dim str_CABGvessels As String 
Dim filterElectiveOnly As Boolean 
Dim index As Integer 
filterElectiveOnly = False 
' Increase performance by temporarily disabling some features... 
Application.ScreenUpdating = False 
Application.DisplayStatusBar = False 
Application.EnableEvents = False 
 
 
Worksheets("BCIS Data").Activate ' load the PCI/BCIS worksheet 
numRowsBCIS = ActiveSheet.Range("A65536").End(xlUp).Row 




Set dictPCI = New Dictionary 
Set dictCABG = New Dictionary 
 
' ***[Set Column Lookup Numbers]*** 
col_priorRevasc = ColumnNum("PriorRevasc", "BCIS Data") 
col_LPI_bcis = ColumnNum("1_02 Local Patient Identifier", "BCIS Data") 
col_PROCID_bcis = ColumnNum("PROC_ID", "BCIS Data") 
col_LPI_scts = ColumnNum("1_02 Local Patient Identifier", "SCTS Data") 
col_PROCID_scts = ColumnNum("PROC_ID", "SCTS Data") 
col_Date_bcis = ColumnNum("3_01 Date and time of operation", "BCIS Data") 
col_Date_scts = ColumnNum("0_63 Surgery Start Date", "SCTS Data") 
col_Staged = ColumnNum("2_02 Indication for Intervention", "BCIS Data") 
col_SurgeryType = ColumnNum("0_39 Operation Type", "SCTS Data") 
col_VesselAttempted = ColumnNum("3_09 Vessels attempted", "BCIS Data") 
col_priority_bcis = ColumnNum("2_03 Procedure Urgency", "BCIS Data") 
col_priority_scts = ColumnNum("2_35 Operative urgency", "SCTS Data") 
col_waitingdate = ColumnNum("0_1 Waiting List Date", "BCIS Data") 
col_NextTestReason = ColumnNum("0_2 Test Reason", "BCIS Data") 
strPreviousLPI = "Nothing" ' dummy value 
col_stagedNext = ColumnNum("StagedNext", "BCIS Data") 
col_StagedLookup = ColumnNum("StagedLookup", "BCIS Data") 
col_scts_graftsite = ColumnNum("3_15 Graft Site", "SCTS Data") 
col_graftvesselsattempted = ColumnNum("Graft Vessels attempted", "BCIS 
Data") 'get PCI to which graft vessels 
col_GraftMappingCustom = ColumnNum("Graft Mapping Custom", "SCTS Data") ' 
SCTS grafts to native names 
 
' ***[END]*** 
colx_RunTime = ColumnNum("RunTime", "BCIS Data") 
colx_RRType = colx_RunTime + 1 
colx_LPI = colx_RunTime + 2 
colx_BaseProcID = colx_RunTime + 3 
colx_NextProcID = colx_RunTime + 4 
colx_BaseDate = colx_RunTime + 5 
colx_NextRevascDate = colx_RunTime + 6 
colx_NextRevascType = colx_RunTime + 7 
colx_NextPriority = colx_RunTime + 8 
colx_Interval2Revasc = colx_RunTime + 9 
colx_Interval2Death = colx_RunTime + 10 
colx_BaseVessels = colx_RunTime + 11 
colx_NextVessels = colx_RunTime + 12 
colx_NextIndication = colx_RunTime + 13 
colx_NextTestReason = colx_RunTime + 14 
colx_VesselDetails = colx_RunTime + 15 ' Stores info such as S:S, S:M, 
M:S, M:S etc. 
colx_NextWaitingDate = colx_RunTime + 16 
 
If SEARCHTYPE = 0 Then 
    Debug.Print "Search: Repeat Revascularisation (any)" 
ElseIf SEARCHTYPE = 1 Then 
    Debug.Print "Search: Target Vessel Revascularisation (TVR only)" 
End If 
 
If PRIORITY_FILTER = "Elective,Urgent,Emergency" Then 
    Debug.Print "Filter: None - including all base PCI priorities" 
    filterElectiveOnly = False 
ElseIf PRIORITY_FILTER = "Elective" Then 
    Debug.Print "Filter: Elective PCI priorities only" 





'....::::[Begin PCI Dictionary]::::.... 
startTime = Timer 
last_PCI = "" ' set to blank first time... 
 
For i = 2 To numRowsBCIS 
    str_LPI_bcis = ActiveSheet.Cells(i, col_LPI_bcis).Value 
    str_BasePriority = ActiveSheet.Cells(i, col_priority_bcis).Value 
     
     
    If str_LPI_bcis = last_PCI Then 
        'already loaded first into dictionary so skip 
     
    Else 
        ' Might need to change this if want all priorities [!?] 
        If filterElectiveOnly = True And str_BasePriority = "Elective" 
Then 
            dictPCI.Add str_LPI_bcis, i 
            last_PCI = str_LPI_bcis 
         
        ' Handle if we include ALL first PCI priorities, NOT just 
elective. 
        ElseIf filterElectiveOnly = False Then 
            dictPCI.Add str_LPI_bcis, i 
            last_PCI = str_LPI_bcis 
        End If 
    End If 
Next i 
 
Debug.Print "Unique PCI Patients: " + Str(dictPCI.count) 
'....::::[END PCI dictionary]::::.... 
 
'....::::[Begin CABG Dictionary]::::.... 
Debug.Print "Loading PCIs into Dictionary..." 
 
last_CABG = "" ' set to blank first time... 
 
For i = 2 To numRowsSCTS 
    str_LPI_scts = Worksheets("SCTS Data").Cells(i, col_LPI_scts).Value 
     
    If str_LPI_scts = last_CABG Then 
        'already loaded first into dictionary so skip 
    Else 
        dictCABG.Add str_LPI_scts, i 
        last_CABG = str_LPI_scts 
    End If 
     
Next i 
 
Debug.Print "Unique CABG Patients: " + Str(dictCABG.count) 
'....::::[END PCI dictionary]::::.... 
 
' Iterate through PCI patients 
Debug.Print "Looking for next PCI records..." 
For Each patient In dictPCI.Keys 
 
    str_BasePriority = ActiveSheet.Cells(dictPCI.Item(patient), 
col_priority_bcis).Value 
    nextFound = False 
        ' proceed to analyse code. 
        exclusionReason = "" ' string for holding exclusion reason 
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        excludeRecord = False ' string for deciding if record should be 
excluded 
        isVesselLAD = False ' for combining LAD other and proximal 
vessels into single LAD later on! 
        str_LPI_bcis = ActiveSheet.Cells(dictPCI.Item(patient), 
col_LPI_bcis).Value ' get LPI value of row, have as key name anyway 
        nextFound = 0 
        str_VesselAttempted = ActiveSheet.Cells(dictPCI.Item(patient), 
col_VesselAttempted).Value 
        str_priorRevasc = ActiveSheet.Cells(dictPCI.Item(patient), 
col_priorRevasc).Value 
        ActiveSheet.Cells(dictPCI.Item(patient), colx_RunTime).Value = 
Now() 
        If SEARCHTYPE = 0 Then 
            ActiveSheet.Cells(dictPCI.Item(patient), colx_RRType).Value = 
"Any" 
        ElseIf SEARCHTYPE = 1 Then 
            ActiveSheet.Cells(dictPCI.Item(patient), colx_RRType).Value = 
"TVR" 
        End If 
         
        If str_VesselAttempted = "" Or str_VesselAttempted = "##" Then 
            ActiveSheet.Cells(dictPCI.Item(patient), 
colx_BaseVessels).Value = "Missing" 
            excludeRecord = True 
            GoTo SkipToNextRow 
        End If 
                     
        samePatient = True ' check if same patient 
        str_LastLPI = str_LPI_bcis 
        index = 1 ' hold increment for while loop 
        Do While str_LastLPI = str_LPI_bcis 
            str_lpi_bcis_nested = ActiveSheet.Cells(dictPCI.Item(patient) 
+ index, col_LPI_bcis).Value ' Get LPI of nested (next PCI + 1) 
            If str_lpi_bcis_nested <> str_LPI_bcis Then 
                ' Next Patient 
                GoTo SkipToNextRow 
            Else 
                ' Same Patient 
                ' Amend so checks if valid before populating other revasc 
columns 
                isTVR = False ' identify whether a TVR 
                isTVRgraft = False ' if PCI to graft lesion(s) 
                ' Verify whether procedure is staged or not... 
                str_NextStagedLookup = 
ActiveSheet.Cells(dictPCI.Item(patient) + index, col_StagedLookup).Value 
                If str_NextStagedLookup <> "Staged" Then 
                    str_NextVesselsAttempted = 
ActiveSheet.Cells(dictPCI.Item(patient) + index, 
col_VesselAttempted).Value 
                    ' set TVR to false if base/next vessels are missing 
                    If str_NextVesselsAttempted = "" Or 
str_NextVesselsAttempted = "##" Or str_VesselAttempted = "##" Or 
str_VesselAttempted = "" Then 
                        ' cannot consider TVR because we do not know at 
least one of base/next vessels being treated 
                        excludeRecords = True 
                        exclusionReason = exclusionReason + 
";BaseOrNextVesselMissing" 
                        GoTo SkipToNextRow 
                    Else 
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                        ' Both the Base/Next vessels ARE known 
                        ' Combine LADprox and LADother into single LAD 
vessel 
                        If InStr(str_VesselAttempted, "LADprox") <> 0 
Then 
                            str_VesselAttempted = 
Replace(str_VesselAttempted, "LADprox", "LAD") 
                        End If 
                        If InStr(str_VesselAttempted, "LADother") <> 0 
Then 
                            str_VesselAttempted = 
Replace(str_VesselAttempted, "LADother", "LAD") 
                        End If 
                        If InStr(str_NextVesselsAttempted, "LADprox") <> 
0 Then 
                            str_NextVesselsAttempted = 
Replace(str_NextVesselsAttempted, "LADprox", "LAD") 
                        End If 
                        If InStr(str_NextVesselsAttempted, "LADother") <> 
0 Then 
                            str_NextVesselsAttempted = 
Replace(str_NextVesselsAttempted, "LADother", "LAD") 
                        End If 
                        ' /END LAD proximal and other unification. 
                         
                        strTVRcheck = "" 
                        ' Check if both base/next NOT grafts = easy to 
handle 
                        If InStr(str_VesselAttempted, "Graft") = 0 And 
InStr(str_NextVesselsAttempted, "Graft") = 0 Then 
                            strTVRcheck = 
CheckVessels(str_VesselAttempted, str_NextVesselsAttempted) 
                            If InStr(strTVRcheck, "TVR") <> 0 Then 
                                'TVR detected! 
                                isTVR = True 
                            End If ' /END TVR check 
                        End If ' /END non-graft both check 
                         
                       ' Handle if base OR next has graft(s) being 
treated with PCI 
                        If InStr(str_VesselAttempted, "Graft") <> 0 Or 
InStr(str_NextVesselsAttempted, "Graft") <> 0 Then 
                            str_BaseGraftVessels = 
ActiveSheet.Cells(dictPCI.Item(patient), col_graftvesselsattempted).Value 
                            str_NextGraftVessels = 
ActiveSheet.Cells(dictPCI.Item(patient) + index, 
col_graftvesselsattempted).Value 
 
                            ' check if the graft vessels are missing or 
present 
                            ' [Update: 16/11/15] Fix graft vessel not 
being detected for TVR, e.g. base LCX (non-graft) and next LCX Graft 
                           
                            ' Allow base to be missing and just raw-
vessel but next is graft 
                            ' Only check if graft vessel missing is being 
treated 
                 
                            Dim combinedNextVessels As String 
                            Dim combinedBaseVessels As String 
                            combinedNextVessels = "" 
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                            combinedBaseVessels = "" 
                            '[1] Permutation: Base not-graft but valid, 
and next has graft. 
                            If InStr(str_VesselAttempted, "Graft") = 0 
And str_VesselAttempted <> "-1" And str_VesselAttempted <> "##" And 
InStr(str_NextVesselsAttempted, "Graft") <> 0 Then 
                                ' Base is valid but not graft, but next 
is graft! 
                                ' combine next VA/graft... 
                                 
                                combinedNextVessels = 
str_NextVesselsAttempted + "," + str_NextGraftVessels 
                                strGraftTVRcheck = 
CheckVessels(str_VesselAttempted, combinedNextVessels) ' instead of base 
graft 
                                 
                                If InStr(strGraftTVRcheck, "TVR") <> 0 
Then 
                                    'TVR detected - strange because base 
not listed as graft but revasc IS 
                                    isTVRgraft = True 
                                End If 
                             
                            ElseIf InStr(str_VesselAttempted, "Graft") <> 
0 And InStr(str_NextVesselsAttempted, "Graft") = 0 Then 
                                combinedBaseVessels = str_VesselAttempted 
+ "," + strBaseGraftVessels ' new variable 
                                strGraftTVRcheck = 
CheckVessels(combinedBaseVessels, str_NextVesselsAttempted) 
                                If InStr(strGraftTVRcheck, "TVR") <> 0 
Then 
                                    ' TVR detected! 
                                    isTVRgraft = True 
                                End If 
                             
                            ElseIf str_BaseGraftVessels = "##" Or 
str_BaseGraftVessels = "-1" Or str_NextGraftVessels = "##" Or 
str_NextGraftVessels = "-1" Then 
                                isTVR = False 
                                strTVRcheck = "MissGraft" 
                                strGraftTVRcheck = "MissGraft" 
                            Else 
                                 
                                If InStr(str_VesselAttempted, "Graft") <> 
0 And (str_BaseGraftVessels <> "##" And str_BaseGraftVessels <> "-1") 
Then 
                                    ' populate base graft vessel column 
                                    combinedNextVessels = "" ' hold 
vessel attempted + graft vessel info 
                                    combinedNextVessels = 
str_NextVesselsAttempted + "," + str_NextGraftVessels 
                                    strGraftTVRcheck = 
CheckVessels(str_BaseGraftVessels, combinedNextVessels) 
                                     
                                    If InStr(strGraftTVRcheck, "TVR") <> 
0 Then 
                                        ' TVR detected on graft 
                                        isTVRgraft = True 
                                    End If 
                                End If '/END Graft validation check 
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                            End If '/END Base/Next vessel validation 
check 
                        End If '/END at least one graft base OR next 
present 
                     
                        ' Handle whether RR or TVR 
                        If SEARCHTYPE = 0 Or (SEARCHTYPE = 1 And isTVR = 
True) Or (SEARCHTYPE = 1 And isTVRgraft = True) Then 
                            ' It is a valid revascularisation record so 
populate/extract necessary data 
                                str_indication = 
ActiveSheet.Cells(dictPCI.Item(patient), col_Staged).Value ' termed 
staged but set to indication for intervention 
                                str_indication_nested = 
ActiveSheet.Cells(dictPCI.Item(patient) + index, col_Staged).Value 
                                str_NextTestReason = 
ActiveSheet.Cells(dictPCI.Item(patient) + index, 
col_NextTestReason).Value 
                         
                                date_operation = 
ActiveSheet.Cells(dictPCI.Item(patient) + index, col_Date_bcis).Value 
                                ActiveSheet.Cells(dictPCI.Item(patient), 
colx_NextRevascDate).Value = date_operation            'next date 
                                ActiveSheet.Cells(dictPCI.Item(patient), 
colx_NextVessels).Value = str_NextVesselsAttempted     'next vessels 
                                ActiveSheet.Cells(dictPCI.Item(patient), 
colx_BaseVessels).Value = str_VesselAttempted          'base vessels 
                                ActiveSheet.Cells(dictPCI.Item(patient), 
colx_NextPriority).Value = ActiveSheet.Cells(dictPCI.Item(patient) + 
index, col_priority_bcis).Value   'next priority 
                                ActiveSheet.Cells(dictPCI.Item(patient), 
colx_NextProcID).Value = ActiveSheet.Cells(dictPCI.Item(patient) + index, 
col_PROCID_bcis).Value 'next Proc ID 
                                ActiveSheet.Cells(dictPCI.Item(patient), 
colx_NextIndication).Value = str_indication_nested 'next indication 
                                Worksheets("BCIS 
Data").Cells(dictPCI.Item(patient), colx_Interval2Revasc).Value = 
ActiveSheet.Cells(dictPCI.Item(patient) + index, col_waitingdate).Value 
                                ActiveSheet.Cells(dictPCI.Item(patient), 
colx_NextWaitingDate).Value = ActiveSheet.Cells(dictPCI.Item(patient) + 
index, col_waitingdate).Value 'next Waiting Date 
                                ActiveSheet.Cells(dictPCI.Item(patient), 
colx_LPI).Value = str_LPI_bcis ' LPI 
                                ActiveSheet.Cells(dictPCI.Item(patient), 
colx_BaseDate).Value = ActiveSheet.Cells(dictPCI.Item(patient) + index, 
col_Date_bcis).Value 'base Date 
                                ActiveSheet.Cells(dictPCI.Item(patient), 
colx_NextRevascType).Value = "PCI" 
                                ActiveSheet.Cells(dictPCI.Item(patient), 
colx_Interval2Death).Value = strTVRcheck + ";" + strGraftTVRcheck 
                                ActiveSheet.Cells(dictPCI.Item(patient), 
colx_BaseProcID).Value = ActiveSheet.Cells(dictPCI.Item(patient), 
col_PROCID_bcis).Value 
                                 ActiveSheet.Cells(dictPCI.Item(patient), 
colx_BaseDate).Value = ActiveSheet.Cells(dictPCI.Item(patient), 
col_Date_bcis).Value 
                     
                                strPreviousLPI = str_LPI_bcis ' not sure 
if correct... 
                                nextFound = 1 
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                                '''''''''''''''Exit For ' not sure if 
Exit For or do nothing! 
 
                        End If '/END TVR/RR SEARCHTYPE filter check 
                    End If '/END blank/missing vessel check for base 
                End If '/END Staged lookup check! 
            End If '/END LPI, same patient match! 
             
             
            index = index + 1 
        Loop 
SkipToNextRow: 
            If nextFound = 0 Then 
                ' No new PCI detected 
                ActiveSheet.Cells(dictPCI.Item(patient), 
colx_BaseDate).Value = ActiveSheet.Cells(dictPCI.Item(patient), 
col_Date_bcis).Value 'base Date 
                ActiveSheet.Cells(dictPCI.Item(patient), 
colx_NextRevascDate).Value = "No new Identified" 
            End If 
         
'    End If '/END Priority filter 
Next 
Debug.Print "Finished PCI Dictionary While" 
 
'....::::[CABG Inbetween PCI-PCI]::::..... 
' Iterate through first CABG records and see if falls inbetween PCI-PCI 
date 
Dim counterCABGreplacePCI As Integer 
Dim filter As String 
counterCABGreplacePCI = 0 
strPreviousLPI = "blar" 
index = 0 ' start from zero instead of 1 this time, because want to test 
first CABG, not from 2nd 
For Each patient In dictCABG.Keys 
 
    nextFound = 0 
    ' [1] Check if CABG Patient exists in BCIS PCIs (first elective 
only!) 
    If dictPCI.Exists(patient) Then 
        ' Only proceed to check IF a next PCI has populated the base PCI 
record. 
        filter = ActiveSheet.Cells(dictPCI.Item(patient), 
colx_NextRevascDate).Value 
         
        If filter <> "No new Identified" And filter <> "" Then ' changed 
to blank! 
            ' Patient exists in BCIS/PCI so iterate through all CABGs of 
same patient (if multiple exist) 
            index = 0 
            Do While patient = Worksheets("SCTS 
Data").Cells(dictCABG.Item(patient) + index, col_LPI_scts).Value 
                date_operation = ActiveSheet.Cells(dictPCI.Item(patient), 
colx_BaseDate).Value  ' Base date 
                date_operation_nested = 
ActiveSheet.Cells(dictPCI.Item(patient), colx_NextRevascDate).Value ' 
Next PCI date 
 




                str_LPI_scts = Worksheets("SCTS 
Data").Cells(dictCABG.Item(patient) + index, col_LPI_scts).Value 
 
                date_operation_scts = Worksheets("SCTS 
Data").Cells(dictCABG.Item(patient) + index, col_Date_scts).Value 
                str_SurgeryType = Worksheets("SCTS 
Data").Cells(dictCABG.Item(patient) + index, col_SurgeryType).Value 
                str_graftsite = Worksheets("SCTS 
Data").Cells(dictCABG.Item(patient) + index, col_scts_graftsite).Value 
                str_CABGvessels = Worksheets("SCTS 
Data").Cells(dictCABG.Item(patient) + index, 
col_GraftMappingCustom).Value ' September - load  CABG vessels mapped to 
native names. 
                isTVRgraft = False 
                 
                ' Check if date inbetween base PCI and next PCI 
                If date_operation_scts > date_operation And 
date_operation_scts < date_operation_nested And (str_SurgeryType = "CABG" 
Or str_SurgeryType = "CABG + Valve") Then 
                   ' Date IS inbetween the base PCI and next PCI so 
replace the PCI with the current CABG 
                    str_VesselAttempted = 
ActiveSheet.Cells(dictPCI.Item(patient), col_VesselAttempted).Value 
                    str_BaseGraftVessels = 
ActiveSheet.Cells(dictPCI.Item(patient), col_graftvesselsattempted).Value 
                    ' Combine the LADother and LADproximal into single 
LAD vessel 
                    If str_VesselAttempted = "##" Or str_VesselAttempted 
= "" Then 
                        ' Cannot consider TVR... 
                    Else 
                        If InStr(str_VesselAttempted, "LADprox") <> 0 
Then 
                            str_VesselAttempted = 
Replace(str_VesselAttempted, "LADprox", "LAD") 
                        End If 
                        If InStr(str_VesselAttempted, "LADother") <> 0 
Then 
                            str_VesselAttempted = 
Replace(str_VesselAttempted, "LADother", "LAD") 
                        End If 
 
                    End If 
                    '/END Combine... 
                     
                    str_VesselAttempted = Replace(str_VesselAttempted, 
"Graft(s)", "") 
                    If str_BaseGraftVessels <> "##" And 
str_BaseGraftVessels <> "-1" Then 
                        ' Graft Vessel Known... 
                        str_VesselAttempted = str_VesselAttempted + "," + 
str_BaseGraftVessels 
                    End If 
                    If str_CABGvessels <> "-1" And str_VesselAttemped <> 
"##" And str_VesselAttempted <> "" Then 
                        strTVRcheck = CheckVessels(str_VesselAttempted, 
str_CABGvessels) 
 
                        If InStr(strTVRcheck, "TVR") <> 0 Then 
                            ' We have TVR 
                            isTVRgraft = True 
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                           ' MsgBox ("TVR graft Detected") 
                        End If 
                    End If 
 
                    If SEARCHTYPE = 0 Or (SEARCHTYPE = 1 And isTVRgraft = 
True) Then 
                        ActiveSheet.Cells(dictPCI.Item(patient), 
colx_NextRevascDate).Value = date_operation_scts 
                        ActiveSheet.Cells(dictPCI.Item(patient), 
colx_NextProcID).Value = Worksheets("SCTS Data").Cells(dictCABG(patient) 
+ index, col_PROCID_scts).Value 
                        ActiveSheet.Cells(dictPCI.Item(patient), 
colx_NextPriority).Value = Worksheets("SCTS 
Data").Cells(dictCABG(patient) + index, col_priority_scts).Value 
                        ActiveSheet.Cells(dictPCI.Item(patient), 
colx_NextTestReason).Value = "-" 
                        ActiveSheet.Cells(dictPCI.Item(patient), 
colx_NextWaitingDate).Value = "-" 
                        ActiveSheet.Cells(dictPCI.Item(patient), 
colx_NextIndication).Value = "-" 
                        ActiveSheet.Cells(dictPCI.Item(patient), 
colx_NextVessels).Value = str_CABGvessels 
                        nextFound = 1 
                        counterCABGreplacePCI = counterCABGreplacePCI + 1 
                         
                        If str_SurgeryType = "CABG" Then 
                            ActiveSheet.Cells(dictPCI.Item(patient), 
colx_NextRevascType).Value = "CABG replace" 
                        ElseIf str_SurgeryType = "CABG + Valve" Then 
                            ActiveSheet.Cells(dictPCI.Item(patient), 
colx_NextRevascType).Value = "CABG + Valve replace" 
                        End If 
                    End If '/END SEARCHTYPE check TVR check 
                     
                    GoTo SkipToNextCABGPatient 
                Else 
                        ' No intermediate match for this CABG so skip – 
Do not goto because another CABG with SAME patient may exist 
                End If '/END date operation match inbetween 
         
            index = index + 1 ' increment next CABG record. 
            Loop 
        End If '/END Patient exists but does have PCI check 
    End If '/END patient does not exist. 
     
SkipToNextCABGPatient: 
Next 
Debug.Print "Finished CABG Intermediate search" 
'....::::[END CABG between PCI-PCI]::::.... 
 
'....::::[Start CABG no PCI search]::::.... 
Debug.Print "Starting CABG no PCI search" 
 
For Each patient In dictCABG.Keys 
    nextFound = 0 
    ' [1] Check if CABG patient exists in BCIS/PCIs (first elective only) 
    index = 0 
    If dictPCI.Exists(patient) Then 
        ' Patient exists in BCIS, only proceed if no PCI/CABG exists. 




        ' check if set to 'No new Identified'! 
        If filter = "No new Identified" Then 
            ' Loop through multiple, could be that first CABG is before 
PCI 
            Do While patient = Worksheets("SCTS 
Data").Cells(dictCABG.Item(patient) + index, col_LPI_scts).Value 
                date_operation = ActiveSheet.Cells(dictPCI.Item(patient), 
colx_BaseDate).Value 
                date_operation_scts = Worksheets("SCTS 
Data").Cells(dictCABG.Item(patient) + index, col_Date_scts).Value 
                str_SurgeryType = Worksheets("SCTS 
Data").Cells(dictCABG.Item(patient) + index, col_SurgeryType).Value 
                ' check date of CABG is after the base PCI date... 
                If (str_SurgeryType = "CABG" Or str_SurgeryType = "CABG + 
Valve") And date_operation_scts > date_operation Then 
                    str_VesselAttempted = 
ActiveSheet.Cells(dictPCI.Item(patient), col_VesselAttempted).Value 
                    str_BaseGraftVessels = 
ActiveSheet.Cells(dictPCI.Item(patient), col_graftvesselsattempted).Value 
                    isTVRgraft = False 
                    str_LPI_scts = Worksheets("SCTS 
Data").Cells(dictCABG.Item(patient) + index, col_LPI_scts).Value 
                    str_graftsite = Worksheets("SCTS 
Data").Cells(dictCABG.Item(patient) + index, col_scts_graftsite).Value 
                    str_CABGvessels = Worksheets("SCTS 
Data").Cells(dictCABG.Item(patient) + index, 
col_GraftMappingCustom).Value 
                    ' Combine LADother and LADproximal into single LAD 
vessel... 
                    If InStr(str_VesselAttempted, "LADprox") <> 0 Then 
                            str_VesselAttempted = 
Replace(str_VesselAttempted, "LADprox", "LAD") 
                    End If 
                    If InStr(str_VesselAttempted, "LADother") <> 0 Then 
                        str_VesselAttempted = 
Replace(str_VesselAttempted, "LADother", "LAD") 
                    End If 
                    If InStr(str_NextVesselsAttempted, "LADprox") <> 0 
Then 
                        str_NextVesselsAttempted = 
Replace(str_NextVesselsAttempted, "LADprox", "LAD") 
                    End If 
                    If InStr(str_NextVesselsAttempted, "LADother") <> 0 
Then 
                        str_NextVesselsAttempted = 
Replace(str_NextVesselsAttempted, "LADother", "LAD") 
                    End If 
                    '/END LAD other and proxminal unification 
 
                    str_VesselAttempted = Replace(str_VesselAttempted, 
"Graft(s)", "") 
                    If str_BaseGraftVessels <> "##" And 
str_BaseGraftVessels <> "-1" Then 
                        ' Graft Vessel Known... 
                        str_VesselAttempted = str_VesselAttempted + "," + 
str_BaseGraftVessels 
                    End If 
                    If str_CABGvessels <> "-1" And str_VesselAttemped <> 
"##" And str_VesselAttempted <> "" Then 





                        If InStr(strTVRcheck, "TVR") <> 0 Then 
                            ' We have TVR 
                            isTVRgraft = True 
                            'MsgBox ("TVR graft Detected") 
                        End If 
                    End If 
                    ' Check TVR/SEARCHTYPE 
                    If SEARCHTYPE = 0 Or (SEARCHTYPE = 1 And isTVRgraft = 
True) Then 
                        ActiveSheet.Cells(dictPCI.Item(patient), 
colx_NextRevascDate).Value = date_operation_scts 
                        ActiveSheet.Cells(dictPCI.Item(patient), 
colx_NextProcID).Value = Worksheets("SCTS 
Data").Cells(dictCABG.Item(patient) + index, col_PROCID_scts).Value 
                        ActiveSheet.Cells(dictPCI.Item(patient), 
colx_NextPriority).Value = Worksheets("SCTS 
Data").Cells(dictCABG.Item(patient) + index, col_priority_scts).Value 
                        ActiveSheet.Cells(dictPCI.Item(patient), 
colx_NextTestReason).Value = "-" 
                        ActiveSheet.Cells(dictPCI.Item(patient), 
colx_NextWaitingDate).Value = "-" 
                        ActiveSheet.Cells(dictPCI.Item(patient), 
colx_NextIndication).Value = "-" 
                        ActiveSheet.Cells(dictPCI.Item(patient), 
colx_NextVessels).Value = str_CABGvessels 
                        nextFound = 1 
 
                        If str_SurgeryType = "CABG" Then 
                            ActiveSheet.Cells(dictPCI.Item(patient), 
colx_NextRevascType).Value = "CABG no PCI" 
                        ElseIf str_SurgeryType = "CABG + Valve" Then 
                            ActiveSheet.Cells(dictPCI.Item(patient), 
colx_NextRevascType).Value = "CABG+Valve no PCI" 
                        End If 
 
                    End If '/END SEARCHTYPE TVR check 
                End If '/END surgerytype/date check 
                 
            index = index + 1 
            Loop 
 
             
     
        End If '/END filter no new identified 
    End If '/END patient check exists in BCIS 
     
     
Next 
 
Debug.Print "Finished CABG no PCI search" 
'....::::[END CABG no PCI search]::::.... 
 
secondsElapsed = Round(Timer - startTime, 2) 
Debug.Print "...finished in: " + Str(secondsElapsed) 
 
Application.ScreenUpdating = True 
Application.DisplayStatusBar = True 





Appendix D: Excel VBA Devices 
Extraction Code 
The purpose of the following code is to extract the list of BMS and DES stents from the 
Devices field, so that the exact stent dimensions (length and diameter) can be identified 
for subsequent analysis. This code makes use of two separate BMS and DES tables 
featuring all stents used and their details such as name, manufacturer, diameter, and 
length. 
Private Sub cmdExtractDevices_Click() 
' Procedure: extracts all BMS and DES stents from the Devices field by 
using 
' ...a table of BMS and DES stents on their own sheets. 
' 
' Last Updated: 24/6/15 
Application.ScreenUpdating = False 
 
Dim numRows As Integer 
Dim numStentsBMS As Integer 
Dim numStentsDES As Integer 
Dim numRowsBMS As Integer 
Dim numRowsDES As Integer 
 
Dim TEMPstrDevices As String ' temp var for replacement call 
 
Dim lengthTotalBMS As Double 
Dim lengthTotalDES As Double 
Dim widthSmallestBMS As Double 
Dim widthSmallestDES As Double 
Dim widthLargestBMS As Double 
Dim widthLargestDES As Double 
 
Dim i As Integer ' main BCIS looping variable 
Dim j As Integer ' loop through stents fields 
Dim k As Integer ' loop through devices array 
 
Dim colDevices As Integer ' hold col num of Devices 
Dim colProcID As Integer 
 
Dim DEVICES() As String ' main devices array *obsolete 
Dim strDevices As String ' main devices string 
Dim strProcID As String 
Dim xLength As Integer 
 
Worksheets.Add.Name = "VBA_Devices" 
 
Worksheets("BCIS Data").Activate 
numRows = ActiveSheet.Range("A65536").End(xlUp).Row 
numRowsBMS = Worksheets("Stents BMS").Range("A65536").End(xlUp).Row 
numRowsDES = Worksheets("Stents DES").Range("A65536").End(xlUp).Row 
 
colDevices = ColumnNum("DEVICES", "BCIS Data") 
colProcID = ColumnNum("PROC_ID", "BCIS Data") 
 
' [Loop thru BCIS rows/Device] 
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For i = 2 To numRows 
    numStentsBMS = 0 
    numStentsDES = 0 
    lengthTotalBMS = 0 
    lengthTotalDES = 0 
    widthSmallestBMS = 0 
    widthSmallestDES = 0 
    widthLargestBMS = 0 
    widthLargestDES = 0 
     
    strDevices = ActiveSheet.Cells(i, colDevices).Value ' main devices 
string 
    strProcID = ActiveSheet.Cells(i, colProcID).Value 
     
    ' [Loop thru BMS stent table] 
    For j = 2 To numRowsBMS 
        If InStr(strDevices, Worksheets("Stents BMS").Cells(j, 1).Value) 
Then 
            ' [Check if same stent (dimensions) used more than once! copy 
as original destroyed] 
            TEMPstrDevices = ActiveSheet.Cells(i, colDevices).Value 
            xLength = Len(TEMPstrDevices) - Len(Replace(TEMPstrDevices, 
Worksheets("Stents BMS").Cells(j, 1).Value, "")) 
            yLength = Len(Worksheets("Stents BMS").Cells(j, 1).Value) 
             
            If (xLength / yLength) > 1 Then 
                If (xLength / yLength) > 2 Then 
                    'MsgBox "Proc ID: " & strProcID & ", has same BMS 
multiple times: " & (xLength / yLength) 
                End If 
                numStentsBMS = numStentsBMS + (xLength / yLength) 
                ' (add dimension information) 
                lengthTotalBMS = lengthTotalBMS + ((xLength / yLength) * 
Worksheets("Stents BMS").Cells(j, 5).Value) 
                '[largest width] 
                If widthLargestBMS = 0 Then 
                    widthLargestBMS = Worksheets("Stents BMS").Cells(j, 
4).Value 
                Else 
                    ' replace if smaller 
                    If widthLargestBMS < Worksheets("Stents 
BMS").Cells(j, 4).Value Then 
                        widthLargestBMS = Worksheets("Stents 
BMS").Cells(j, 4).Value 
                    End If 
                End If 
                '[end largest width] 
                '[smallest width] 
                If widthSmallestBMS = 0 Then 
                    widthSmallestBMS = Worksheets("Stents BMS").Cells(j, 
4).Value 
                Else 
                    'replace if larger 
                    If widthSmallestBMS > Worksheets("Stents 
BMS").Cells(j, 4).Value Then 
                        widthSmallestBMS = Worksheets("Stents 
BMS").Cells(j, 4).Value 
                    End If 
                End If 
                '[end smallest width] 
            Else 
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            ' stent exists in Devices only once (same dimensions) 
                numStentsBMS = numStentsBMS + 1 
                ' [add dimension information] 
                lengthTotalBMS = lengthTotalBMS + CDbl(Worksheets("Stents 
BMS").Cells(j, 5).Value) 
                If widthSmallestBMS = 0 Then 
                    widthSmallestBMS = CDbl(Worksheets("Stents 
BMS").Cells(j, 4).Value) 
                Else 
                    'replace if smaller 
                    If widthSmallestBMS > CDbl(Worksheets("Stents 
BMS").Cells(j, 4).Value) Then 
                        widthSmallestBMS = CDbl(Worksheets("Stents 
BMS").Cells(j, 4).Value) 
                    End If 
                End If 
                ' [largest width] 
                If widthLargestBMS = 0 Then 
                    widthLargestBMS = CDbl(Worksheets("Stents 
BMS").Cells(j, 4).Value) 
                Else 
                    ' replace if smaller 
                    If widthLargestBMS < CDbl(Worksheets("Stents 
BMS").Cells(j, 4).Value) Then 
                        widthLargestBMS = CDbl(Worksheets("Stents 
BMS").Cells(j, 4).Value) 
                    End If 
                End If 
                ' [end largest width] 
            End If 
        End If 
    Next j 
    ' [... END Stents BMS loop] 
     
    ' Write  Devices sheet headers 
    Worksheets("VBA_Devices").Cells(1, 1).Value = "PROC_ID" 
    Worksheets("VBA_Devices").Cells(1, 2).Value = "BMS Stents" 
    Worksheets("VBA_Devices").Cells(1, 3).Value = "DES Stents" 
    Worksheets("VBA_Devices").Cells(1, 4).Value = "BMS Total Length (mm)" 
    Worksheets("VBA_Devices").Cells(1, 5).Value = "BMS Smallest diameter 
(mm)" 
    Worksheets("VBA_Devices").Cells(1, 6).Value = "BMS Largest diabeter 
(mm)" 
    Worksheets("VBA_Devices").Cells(1, 7).Value = "DES Total Length (mm)" 
    Worksheets("VBA_Devices").Cells(1, 8).Value = "DES Smallest diameter 
(mm)" 
    Worksheets("VBA_Devices").Cells(1, 9).Value = "DES Largest diameter 
(mm)" 
    ' end  devices headers 
     
    ' Write BMS details to new Devices sheet 
    Worksheets("VBA_Devices").Cells(i, 1).Value = ActiveSheet.Cells(i, 
colProcID).Value 
    Worksheets("VBA_Devices").Cells(i, 2).Value = numStentsBMS 
    Worksheets("VBA_Devices").Cells(i, 4).Value = lengthTotalBMS 
    Worksheets("VBA_Devices").Cells(i, 5).Value = widthSmallestBMS 
    Worksheets("VBA_Devices").Cells(i, 6).Value = widthLargestBMS 
    ' end BMS details 
     
    ' [*] Same calculations again for DES stents 
    For j = 2 To numRowsDES 
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    If InStr(strDevices, Worksheets("Stents DES").Cells(j, 1).Value) Then 
        TEMPstrDevices = ActiveSheet.Cells(i, colDevices).Value 
        tmpDevice = Worksheets("Stents DES").Cells(j, 1).Value 
         
        xLength = Len(TEMPstrDevices) - Len(Replace(TEMPstrDevices, 
Worksheets("Stents DES").Cells(j, 1).Value, "")) 
        yLength = Len(Worksheets("Stents DES").Cells(j, 1).Value) 
         
        If (xLength / yLength) > 1 Then 
 
            numStentsDES = numStentsDES + (xLength / yLength) 
            lengthTotalDES = lengthTotalDES + ((xLength / yLength) * 
Worksheets("Stents DES").Cells(j, 5).Value) 
            '[largest width] 
            If widthLargestDES = 0 Then 
                widthLargestDES = Worksheets("Stents DES").Cells(j, 
4).Value 
            Else 
                ' replace if smaller 
                If widthLargestDES < Worksheets("Stents DES").Cells(j, 
4).Value Then 
                    widthLargestDES = Worksheets("Stents DES").Cells(j, 
4).Value 
                End If 
            End If 
            ' end largest width 
            If widthSmallestDES = 0 Then 
                widthSmallestDES = Worksheets("Stents DES").Cells(j, 
4).Value 
            Else 
                ' replace if smaller 
                If widthSmallestDES > Worksheets("Stents DES").Cells(j, 
4).Value Then 
                    widthSmallestDES = Worksheets("Stents DES").Cells(j, 
4).Value 
                End If 
            End If 
        Else 
        ' Stent exists only once 
        numStentsDES = numStentsDES + 1 
         
        lengthTotalDES = lengthTotalDES + CDbl(Worksheets("Stents 
DES").Cells(j, 5).Value) 
        If widthSmallestDES = 0 Then 
            widthSmallestDES = CDbl(Worksheets("Stents DES").Cells(j, 
4).Value) 
        Else 
            ' replace if smaller 
            If widthSmallestDES > CDbl(Worksheets("Stents DES").Cells(j, 
4).Value) Then 
                widthSmallestDES = CDbl(Worksheets("Stents DES").Cells(j, 
4).Value) 
            End If 
        End If 
        ' largest width 
        If widthLargestDES = 0 Then 
            widthLargestDES = CDbl(Worksheets("Stents DES").Cells(j, 
4).Value) 
        Else 
            ' replace if smaller 
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            If widthLargestDES < CDbl(Worksheets("Stents DES").Cells(j, 
4).Value) Then 
                widthLargestDES = CDbl(Worksheets("Stents DES").Cells(j, 
4).Value) 
            End If 
        End If 
        ' end largest width 
    End If 
    End If 
     
    Next j 
     
    ' Write DES details to new Devices sheet 
    Worksheets("VBA_Devices").Cells(i, 3).Value = numStentsDES 
    Worksheets("VBA_Devices").Cells(i, 7).Value = lengthTotalDES 
    Worksheets("VBA_Devices").Cells(i, 8).Value = widthSmallestDES 
    Worksheets("VBA_Devices").Cells(i, 9).Value = widthLargestDES 
    ' end DES details 
     
    Debug.Print (i) 
     
Next i 




Application.ScreenUpdating = True 
End Sub 
 
 
 
 
 
 
 
